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Background and Aims 
The application of hypertrophic cardiomyopathy (HCM) genetics in clinical practice has been 
limited by an incomplete knowledge of the genetic background and a poor understanding of 
genotype-phenotype relationships. The aims of this study were to study genotype-phenotype 
relationships in HCM, expand the knowledge on the genetic architecture of the disease, 
explore genetic modifiers of the phenotype and develop a methodology for interpretation of 
variants detected by high-throughput sequencing platforms.  
 
Methods 
The study population consisted in consecutive and unrelated HCM patients. In order to analyze 
coding, intronic and regulatory regions of 41 cardiovascular genes, solution-based sequence 
capture was followed by massive parallel resequencing. Single-nucleotide variants, small 
insertion/deletions and copy number variants (CNVs) were called. For the analysis of variants 
in the coding region, rare, non-synonymous, loss-of-function and splice-site variants were 
defined as candidates. These variants were tested for associations with clinical phenotype and 
survival. For the analysis of non-coding variation, variants located in known transcription factor 
(TF) binding sites and 3’UTR miRNA targets were identified. The performance of an insilico 
pathogenicity prediction strategy incorporating structural features was explored for MYH7 




Eight-hundred-and-seventy-four patients (49.6±15.4 years, 67.8% males) were studied; likely 
disease-causing sarcomere protein (SP) gene variants were detected in 383 (43.8%). Patients 
with SP variants were characterized by younger age and higher prevalence of family history of 
HCM, family history of sudden cardiac death, asymmetric septal hypertrophy, higher maximal 
wall thickness (P-values<0.0005) and increased cardiovascular death (P-value=0.012).  Similar 
associations were observed for individual SP genes. Patients with ANK2 variants had greater 
maximum wall thickness (P-value=0.0005). Associations at a lower level of significance were 
demonstrated with variation in other non-SP genes. Four CNVs were detected in MYBPC3, 
PDLIM3, TNNT2 and LMNA. Fourteen percent carried non-coding variants mapping to TF 
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binding sites. The pathogenicity prediction for MYH7 missense variants had an accuracy of 0.93; 
the phenotype predictor had an accuracy of 0.79 and novel genotype-phenotype associations 
were suggested. Three families were studied using WES; in two of these families the main 
candidate variants were in OBSCN and TTN.  
 
Conclusions 
Patients with SP variants differed from those without with respect to age, family history, 
ventricular morphology and prognosis. Novel associations were demonstrated between 
individual sarcomeric genes and several phenotype traits and for the first time, associations 
between rare variants in non-SP genes and phenotype were described. CNVs and non-coding 
variation in SP genes can additionally contribute to the genetic architecture of HCM. 
Pathogenicity prediction incorporating structural features revealed additional genotype-
phenotype associations. Whole-exome sequencing suggested new causal genes.  
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HF: heart failure 
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HGMD: Human Gene Mutation Database 
HTS: high-throughput sequencing 
ICD: implantable cardioverter-defibrillator 
ICH: Institute of Child Health 
Ig: immunoglobulin 
IGV: Integrative Genomics Viewer 
Indel: insertion-deletion 
IQR: interquartile range 
LA: left atrium  
LGE: late gadolinium enhancement 
LMM: : myosin heavy chain’s light meromyosin 
LOF: loss-of-function 
LV: left ventricle 
LVEDV: left ventricular end-diastolic volume 
LVEF: left ventricular ejection fraction 
LVESV: left ventricular end-systolic volume 
LVH: left-ventricular hypertrophy 
LVNC: left ventricular non-compaction 
LVOT: left ventricular outflow tract  
LVOTO: left ventricular outflow tract obstruction  
MAF: minor allele frequency 
MAPK: mitogen-activated protein kinase 
MLP: muscle LIM protein 
MLVWT: maximal left ventricular wall thickness  
MPLA: multiplex ligation-dependent probe amplification 
Murf: Muscle specific Ring Finger  
MyBPC: myosin bind protein C 
NCBI: National Center for Biotechnology Information 
ncSNV: non-coding single nucleotide variant 
NFAT: nuclear factor of activated T-cells 
NGS: next‐generation sequencing  
NHLBI: National Heart, Lung and Blood Institute 
NIHR: National Institute for Health Research  
NRSF : neuronrestrictive silencer factor 
nsSNP: non-synonymous single nucleotide polymorphism 
NSVT: non-sustained ventricular tachycardia 
NYHA: New York Heart Association  
OMIM: Online Mendelian Inheritance in Men 
PDB: protein database 
PKA: protein kinase A 
PKC: protein kinase C 
PICP: C-terminal propeptide of type I procollagen  
QC: quality control 
RAAS: renin-angiotensin-aldosterone system 
RCM: restrictive cardiomyopathy 
RFLP: restriction fragment length polymorphism 
RHYME:Ranolazine for the Treatment of Chest Pain in HCM Patients 
RLC: regulatory light chain 
RNA: ribonucleic acid 
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ROC: receiver operating characteristics 
RVH: right ventricular hypertrophy 
SAAP:Single Amino Acid Polymorphism  
SAAPbd:Single Amino Acid Polymorphism database 
SAAPdap: Single Amino Acid Polymorphism data analysis pipeline 
SAM: systolic anterior movement  
SCD: sudden cardiac death  
SERCA2: sarcoplasmic/endoplasmic reticulum calcium ATPase 2  
SIFT: sorting intolerant from tolerant 
SNP: single nucleotide polymorphism 
SP: sarcomeric protein 
SPB: systolic blood pressure 
SRF: serum response factor 
SSCP: single-strand conformation polymorphism 
STAT3: signal transducer and activator of transcription 3 
SV: systolic volume 
TF: transcription factor 




TnT: troponin T 
UCL: University College London 
UTR: untranslated region 
UPS: ubiquitine-proteosome system 
VUS: variant of unkown significance 
WES: whole-exome sequencing 
WEKA: Waikato Environment for Knowledge Analysis 
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1. DEFINITION, PHENOTYPE AND EPIDEMIOLOGY OF HYPERTROPHIC 
CARDIOMYOPATHY 
 
Cardiomyopathies (heart muscle diseases) are defined as myocardial disorders that are not 
solely explained by coronary artery disease or abnormal loading conditions [1]. They are 
classified according to ventricular function and morphology into four main subtypes: 
hypertrophic cardiomyopathy (HCM); dilated cardiomyopathy (DCM); restrictive 
cardiomyopathy (RCM) and arrhythmogenic (right) ventricular cardiomyopathy (ARVC). Figure 
1.  Diseases that do not fit into these categories are termed unclassified cardiomyopathies and 
include left ventricular (LV) noncompaction (LVNC) and Tako-Tsubo cardiomyopathy [1]. All 




Figure 1. Schematic showing the different main cardiomyopathy phenotypes. Reproduced with 
permission from [2]. 
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Hypertrophic cardiomyopathy (HCM) is defined as left ventricular hypertrophy in the absence of 
abnormal loading conditions, such as severe hypertension or valve disease, sufficient to provoke 
the observed phenotype. It occurs in approximately 1 in every 500 adults [3],[4],[5],[6],[7],[8].   
The histopathology of HCM is characterized by cardiomyocyte hypertrophy and disarray, 
interstitial and replacement fibrosis and dysplastic arterioles [9]. 
Ventricular hypertrophy frequently develops during periods of rapid somatic growth, but can 
appear de novo at any time from infancy to old age. Presentation in infancy is associated with 
symptoms of heart failure and failure to thrive. In older children and adults the most common 
symptoms are dyspnoea, syncope and chest pain [3].  
HCM is generally considered the commonest cause of sudden cardiac death (SCD) below 35 
years of age, but SCD can happen at any age, with a peak incidence in adolescence and young 
adulthood, often in minimally symptomatic individuals [6],[7],[8]. The disease is associated 
with a lifelong risk of atrial fibrillation (AF) and stroke [3],[10],[11]. In the long‐term, a 
significant proportion of patients (5-10%) develop progressive symptoms caused by gradual 
deterioration in left ventricular function [11]. This so‐called “end‐stage” is characterised by 
severe impairment of contractile performance and is associated with an annual mortality rate 
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2. GENETIC BACKGROUND AND MECHANISMS OF DISEASE 
 
In approximately half of adolescents and adults with the disease, HCM is inherited as an 
autosomal dominant trait, caused by mutations in cardiac sarcomere protein genes. This disease 
is characterized by a high locus and allelic diversity. More than 1000 mutations have been 
identified [13],[14],[15],[16],[17],[18], the majority of which (75% to 80%) involve cardiac 
myosin heavy chain (MYH7) and cardiac myosin binding protein C (MYBPC3). Mutations in 
cardiac troponin T (TNNT2), troponin I (TNNI3), alpha‐tropomyosin (TPM1), myosin light chains 
(MYL2, MYL3) and cardiac actin (ACTC1), account for 15-20% of the identified sarcomere 
mutations. Mutations in other sarcomere or related genes, including alpha-myosin heavy chain 
(MYH6), titin (TTN), Z‐disc protein genes like muscle LIM protein (CSRP3) or calcium-handling 
genes such as phospholamban (PLN), account for less than 1% of cases each. A further 5% of 
unexplained left ventricular hypertrophy (LVH) cases are caused by metabolic or storage 
disorders (for example, Anderson-Fabry disease, mitochondrial disorders, glycogen storage 
disorders), neuromuscular disorders, chromosome abnormalities and genetic syndromes such 
as cardio-facial-cutaneous disorders, including Noonan and LEOPARD syndrome.  When all 
these disorders are excluded, approximately 30‐40% of HCM remains unexplained [13], 
[14],[15],[16],[17],[18],[19, 20],[21, 22],[23]. 
 
2.1. NORMAL SARCOMERE STRUCTURE 
Each cardiac myocyte is composed of a parallel arrangement of myofibrils that run 
longitudinally along the cell and are transversely sub-divided into contractile units called 
sarcomeres. [24]. The sarcomere is a highly specialized cytoskeletal structure, which 
constitutes the fundamental motor unit of the cardiomyocyte [25]. Each sarcomere is 
comprised of thin and thick myofilaments. The thick filament is composed of around 300 
molecules of myosin, each made up of two protein units of beta- or alpha-myosin heavy chain 
and four myosin light chain molecules – two essential and two regulatory [25]. Figure 2. The 
thin filament is composed of repeating actin molecules, closely associated with the regulatory 
troponin complex  (troponin T, troponin I and troponin C) which exerts its function in 
coordination with alpha-tropomyosin [26]. The protein cardiac myosin binding protein C also 
contributes to the regulation of actin-myosin interactions  
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The regular arrangement of the myofilaments delineates a number of discrete topographic 
zones in each sarcomere: the M-band in the middle of the sarcomere; the A-band which is 
made up of multiple and parallel thick filaments and includes a central region, the H-zone, 
devoid of cross-bridges and consisting only of myosin tails; the I-band in which there are only 
aligned thin filaments with no overlap with thick filaments; and finally, the Z-discs which 
constitute the lateral boundaries of the sarcomere [25]. Figure  3. 
 
Myosin heavy chain is divided into three main domains: the globular head (the “motor 
domain”), which includes the adenosine triphosphate (ATP) and the actin binding sites; the 
neck, an alpha-helical domain where the light chains bind and which is further subdivided in a 
converter region and a lever arm involved in the amplification of mechanical energy required 
for the power-stroke of myosin along actin; and the tail or rod region, a helical coiled-coil 
protein that intertwines with the tail of another heavy chain molecule to form the thick 
filament [27]. There are two highly homologous isoforms of the myosin heavy chain, encoded 
sequentially by two genes located in tandem on chromosome 14: MYH6 encodes alpha-myosin 
heavy chain and MYH7 encodes beta-myosin heavy chain. MYH7 is the dominantly expressed 
gene in the adult human ventricular cardiomyocytes (around 70-80% of beta-myosin heavy 
chain mRNA), while MYH6 is expressed at higher levels in the developing heart, particularly in 
the atria [28],[27, 29]. 
 
Myosin light chains are part of the EF-hand family of calcium binding proteins. Their function is 
believed to be essentially mechanical, providing support to the heavy chain neck and possibly 
regulating the interaction of myosin head with actin and consequently the force and velocity of 
contraction. The essential light chain (ELC), encoded by MYL3, is located closer to the myosin 
head and the regulatory light chain (RLC), encoded by MYL2, binds to the neck closer to the 
rod domain [25]. 
 
Myosin-binding protein C (MyBPC) is made up of 11 domains (8 immunoglobulin-like and 3 
fibronectin-like) numbered C0-C10; it also includes a proline/alanine-rich linker sequence 
between C0 and C1 and a regulatory motif between domains C1 and C2, that contains protein 
kinase A phosphorylation sites [27]. MyBPC interacts with the thick filament through 3 
domains at its C terminus, which bind to both myosin and titin. The molecular stoichiometry is 
believed to be 2 - 4 MyBPC molecules per myosin. At the N-terminus, MyBPC may exert a 
regulatory role through its interaction with the myosin neck and actin [27].  
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The cardiac thin filament is composed by multiprotein complexes made of 7 actin monomers, 1 
troponin complex - troponin I (TnI), troponin T (TnT) and troponin C (TnC) - and 1 alpha-
tropomyosin (TM) coiled-coil dimer [26]. The overall structure of the troponins is similar, as 
they are composed by helical domains separated by linker sequences of varying lengths that 
confer a high degree of flexibility to the molecule [26]. Alpha-tropomyosin is an alpha-helical 
coiled coil dimer, which runs along the length of the actin filament and plays a key role in 
regulating contraction. Alpha-cardiac muscle actin is one of the isoforms of actin, a group of 
highly conserved proteins involved in cell motility. Globular actin (G-actin) polymerizes to form 
filament actin (F-actin), which is structurally organized as a two-stranded helix [30].  
 
2.2. MECHANISM OF CONTRACTION – THE CROSS-BRIDGE CYCLE 
 
The fundamental principle governing muscle contraction is that of the sliding filament theory, 
in which the sliding of actin past myosin generates muscle tension. The interaction between 
myosin and actin, in which the globular head of the myosin molecule bends towards and then 
binds to actin, contracts, releases actin, and then initiates a new cycle is known as myosin-
actin cycling. The links between the myosin head and actin are called cross bridges; the 
contraction of the myosin S1 region is called the power stroke, which requires the hydrolysis of 
ATP to release energy.  
 
Electrical activation of the heart and contraction are coupled through the intracellular 
movement of calcium. Depolarization of the cardiomyocyte cell membrane during the action 
potential activates the L-type voltage-dependent calcium channels in the T tubule; the influx of 
calcium into the cell then leads to the opening of ryanodine-receptor channels in the adjacent 
sarcoplasmic reticulum with a rapid increase in cytosolic calcium [31]. Calcium binds to TnC, 
inducing an allosteric conformational change in TnI and TnT that is transmitted to tropomyosin. 
This causes a transition from a  “blocked” to a “closed” state, which then exposes the myosin 
binding sites of actin, which allows the cross-bridges to occur (“open” state) [26],[31]. The 
myosin heavy chain head, with ADP and inorganic phosphate bound to its nucleotide binding 
pocket, then interacts with the exposed actin binding sites. This is followed by the release of 
ADP and inorganic phosphate, which occurs concomitantly to the power stroke, resulting in 
force development via shortening of the sarcomere and the I-band and the approximation of 
the Z-discs. Following this, ATP binds to the nucleotide binding pocket of the myosin heavy 
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chain head, which detaches from actin. The myosin then hydrolyzes the ATP into ADP and 
inorganic phosphate once again [31], re-starting the cycle. 
 
 
Figure 2. Schematic representation of the main eight sarcomere proteins and their interactions in the 
sarcomere. cMyBP-C: cardiac myosin binding protein C - domains are numbered C0 to C10, starting at 
the N terminus of cMyBP-C; m: regulatory motif between domains C1 and C2 that contains protein 
kinase A (PKA) phosphorylation sites; PA, a proline/alanine-rich linker sequence between C0 and C1; ELC: 
essential myosin light chain; LMM: myosin heavy chain’s light meromyosin; RLC: regulatory myosin light 








Section I – Introduction: 2. Genetic background and mechanisms of disease 
 24 
 
Figure 3. Schematic representation of the discrete topographic zones in each sarcomere. The M-band 
constitutes the middle of the sarcomere; the A-band is made up of multiple and parallel thick filaments 
and includes a central region, the H-zone, devoid of cross-bridges and consisting only of myosin tails; the 
I-band in which there are only aligned thin filaments, with no overlap with thick filaments; and finally, 




2.3. CONTRACTILE PROTEIN GENE MUTATIONS  
 
Mutations in proteins of the cardiac sarcomere comprise the main cause of hypertrophic 
cardiomyopathy (HCM). With the exception of the myosin light chains, genetic variation in all 
of these proteins can also cause dilated cardiomyopathy (DCM), although a larger percentage 
of cases remain genetically unsolved in DCM [32]. A proportion of restrictive cardiomyopathy 
(RCM) is also caused by mutations in sarcomere protein genes [33]. Table 1 summarizes the 
sarcomeric and associated proteins, encoding genes, interactions, associated disease 
phenotypes and their respective prevalence.  
 
Genetic mechanisms of disease 
 
Two different basic pathogenic mechanisms are thought to account for disease associated with 
mutations in cardiac sarcomere proteins. Missense single nucleotide variants (a nucleotide 
change and hence codon change that results in an aminoacid being substituted by another 
aminoacid in the protein) predominantly lead to a dominant negative effect (described as a 
“poison peptide” mechanism) in which the mutated protein is not destroyed but rather 
Section I – Introduction: 2. Genetic background and mechanisms of disease 
 25 
integrates into the sarcomere, leading to the disease phenotype. This is thought to be 
characteristic of MYH7 variants [18]. Alternatively, nonsense single nucleotide variants or small 
frameshift insertion-deletions can introduce a premature stop codon and hence result in 
haploinsufficiency, due to nonsense mRNA mediated decay or proteolysis of a truncated (just 
partially translated) protein [34]. This mechanism is believed to be typical of the majority of 
MYBPC3 disease-causing mutations [35]. 
 
Myosin heavy chain 
The first cardiomyopathy-causing mutation was described in MYH7 in 1990 in a large family 
with hypertrophic cardiomyopathy [13]. Since then more than 400 mutations have been 
reported in patients with HCM, DCM, RCM and LVNC, most of which affect residues in the 
head and neck regions of the molecule [27],[36]. The various effects of individual variants on 
fibre contractile velocity, force and calcium-sensitivity have been proposed as an explanation 
for the existence of dramatically different phenotypes arising from genetic variation in the 
same molecule [27],[36]. A paradigm has been proposed, whereby mutations that increase 
motor activity and power output lead to HCM, while those that diminish motor function and 
decrease power output lead to DCM[27],[36].  
 
Myosin light chains 
Mutations in both MYL2 and MYL3 were first associated with HCM in 1996 [16]. A small 
number of disease-causing mutations are located in two of the four EF-hand domains for MYL3. 
For MYL2, the reported variants are mostly located in two regions: a) an EF-hand domain that 
has the ability to bind calcium and magnesium or b) around the phosphorylated serine-15 
residue. In vitro and in vivo functional studies predominantly show an increase in motor 
activity and power output and are consistent with the ‘gain of function’ hypothesis for HCM 
pathogenesis caused by  mutations in these proteins [27]. There is no report associating MYL2 
or MYL3 mutations with phenotypes other than HCM. 
 
Cardiac myosin-binding protein C 
Mutations in cardiac myosin-binding protein C were first associated with HCM in 1995 in two 
separate reports [37],[14]. Since then, more than 300 variants have been described in 
association with HCM and variation in this protein is reported as the most common cause of 
the disease in large cohorts of unrelated patients [38]. Most of the DNA variants result in 
potentially truncated proteins (nonsense or frameshift insertion-deletions) and are believed to 
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lead to haploinsufficiency [27]. Others (around 40%) are missense variants, of more 
unpredictable effect. Possible mechanisms of disease for missense mutations include protein 
misfolding–which can lead to a poison-peptide mechanism (dominant-negative effect)–or 
haploinsufficiency through activation of protein surveillance/degradation systems [27] that 
destroy the misfolded proteins.  
 
Troponin-Tropomyosin complex and Actin 
Alpha-tropomyosin (encoded by TPM1) and troponin T (encoded by TNNT2) were the first thin 
filament proteins to be linked to HCM [15]. This discovery was rapidly followed by reports of 
mutations in troponin I (encoded by TNNI3) in 1997 [17] and actin (ACTC1) in 1999 [39] and 
later troponin C (TNNC1) in 2008 [40]. Troponin T variation has been associated with HCM 
(around 50 mutations) and also with DCM and RCM phenotypes. Troponin I mutations have 
been linked to HCM, RCM and, more recently, to DCM. Around 40 mutations have been 
published to date. A homozygous troponin C variant was first described in a family with DCM 
[41] but suggested associations with HCM [40] are unproven. Genetic variation in both alpha-
tropomyosin and actin is associated with HCM and DCM.  
 
2.4. ROLE OF THE NON-CONTRACTILE SARCOMERE PROTEINS IN DISEASE 
 
Mutations in the non-contractile elements of the sarcomere may also result in a 
cardiomyopathy phenotype. Some of the most important are as follows: 
 
2.4.1. TITIN 
Titin is a giant macromolecule that consists almost entirely of hundreds of immunoglobulin 
and fibronectin-like domains, which interact with sarcomeric proteins at the Z-disc, the myosin 
filament and the M-band, while other specific domains provide the elastic spring connection to 
myosin and actin filaments in the I-band [42], [43], [44, 45]. Figures 3 and 4.  It spans an entire 
half-sarcomere, bound at the N-terminus to the Z-disc and at the C-terminus to myosin and 
myosin-binding protein C. Titin has a major role in determining the mechanical properties of 
the heart through its effects on passive tension during myocardial stretch and restoring forces 
during early ventricular filling and is an important biomechanical sensor and organisational 
element within the sarcomere [44].  
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The protein is encoded by the TTN gene on chromosome 2, which undergoes complex 
differential splicing, resulting in isoforms with variable elastic properties [46]. The two main 
isoform classes of the adult cardiac muscle are N2B and N2BA, which have different I-region 
lengths. N2BA contains an additional and unique N2A element and a larger spring-like PEVK 
(rich in proline, glutamic acid, valine, and lysine) element. Isoform switches, with increased 
expression of longer and more compliant isoforms (increasing the ratio N2BA:N2B), have been 
reported in heart failure associated with either reduced or preserved ejection fraction [46]. 
 
Titin stiffness can be regulated even faster by phosphorylation of the PEVK element by protein 
kinase C-alpha (activated by the alpha-1 adrenergic pathway), which results in increased 
passive tension or the N2B by protein kinases A (activated by the beta-adrenergic pathway) 
and G, which results in decreased passive tension [46].  
 
Titin also has a serine/threonine kinase domain, in the transition of the M to the A-band [47]. 
Some of its targets include ubiquitin ligases that act on pathways relevant to cell survival and 
autophagy, such as Nbr, p62 or Murf.  
 
Variation in TTN was linked to DCM for the first time in 2002 [48],[49]; ten years later 
truncating titin mutations were reported to be the most common genetic cause of dilated 
cardiomyopathy [50]. Although more debatable, there are also published reports of an 
association with HCM [51], RCM [52] and arrhythmogenic cardiomyopathy [53]. 
 
2.4.2. Z-DISC AND ASSOCIATED PROTEINS 
The Z-disc corresponds to the lateral borders of the sarcomere. Besides its mechanical function, 
this structure is composed of proteins that have signaling functions related to the 
transcriptional regulation of muscle growth and mechano-transduction [24], [54]. Mutations in 
Z-disc associated proteins (figure 4) are predominantly associated with DCM rather than HCM: 
 Alpha-actinin (encoded by ACTN2) is composed of four spectrin repeats at its centre as 
well as an actin-binding domain (ABD) at its N-terminus and two EF hands (calmodulin 
homology domains) at the C-terminus, which enable α actinin to cross-link actin 
filaments within the Z-disc [24]. Figure 4.  It seems to serve an important role in actin 
localization and forms the principal cross-links at the Z-disc between actin filaments of 
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opposite polarity, originating from contiguous sarcomeres. Alpha-actinin mutations 
have been described in both HCM and DCM [55], [56]. 
 Muscle LIM protein (MLP, encoded by CSRP3) is a LIM-domain protein that interacts 
with α actinin, calcineurin, and telethonin.  It is also localized in the nucleus and has 
been implicated in various pathways, including mechano-sensation and mechano-
transduction, calcium metabolism, myofibrillogenesis and actin polymerization. 
Genetic variation is associated with HCM and DCM [56],[57]. 
 
 Telethonin (encoded by TCAP) binds the N-terminal domain of two adjacent titin 
molecules and is a substrate of titin kinase; it interacts with various proteins such as 
ankyrin repeat protein 2, T-tubular system components, and ion channels. It is also 
implicated in regulation of myocardial hypertrophy by interacting with calsarcin-1 
(myozenin-2), and myostatin. Variation in this gene has been observed in HCM and 
DCM [58]. 
 
 Calsarcin 1 or Myozenin 2 (encoded by MYOZ2) is involved in the transcriptional 
regulation of muscle growth. Variation in this gene has been proposed as a cause of 
HCM [59]. 
 
 Four-and-a-half-LIM-domains-1 (encoded by the X-chromosome gene FHL1) localizes 
to the sarcomeric Z-disc/I-band area and the nucleus. This protein is important in 
sarcomerogenesis, structural maintenance of the sarcomere and transcriptional 
regulation.  Both HCM and DCM phenotypes have been described, in isolation or in 
association with neuromuscular disease (e.g. Emery-Dreifuss muscular dystrophy) [60]. 
 
 Cypher/ZASP or LIM domain binding protein 3 (encoded by LDB3) has an amino-
terminal PDZ domain that interacts with alpha-actinin; it also interacts with protein 
kinase C at the C-terminal. Mutations in LDB3 were reported in DCM and LVNC [61] 
and also HCM [62], although evidence for the latter is debated. 
 
 Actinin-Binding LIM Protein (ALP) or PDZ/LIM domain protein 3, encoded by PDLIM3, 
belongs to the ALP family of proteins, characterized by an N- terminal PDZ domain and 
a C-terminal LIM domain. It has been proposed as a candidate gene for HCM, but no 
convincing evidence has been found as yet [63]. 
Section I – Introduction: 2. Genetic background and mechanisms of disease 
 29 
 
 Desmin (encoded by DES) is an intermediate filament, which connects to desmosomes 
and interacts with the Z-disc. Pathological variation in this gene leads to a number of 
phenotypes, including muscular disease, RCM with conduction abnormalities [64] and 
DCM [65]. An arrhythmogenic cardiomyopathy phenotype has also been described 
[66], [67]. 
 
 Myopalladin (MYPN) interacts with several proteins including α-actinin, titin, nebulette 
and cardiac ankyrin repeat protein (CARP). Variation in this gene has been described in 
association with DCM, HCM and RCM [68]. 
 
 Nexilin (NEXN), which contributes to maintain the integrity of the Z-discs against the 
tension generated within the sarcomere, interacts with actin and mutations have been 
associated with HCM [69] and DCM [70]. 
 
 Ankyrin repeat domain 1 (ANKRD1)-encoded cardiac adriamycin responsive protein, or 
cardiac ankyrin repeat protein (CARP) is a protein localized in the I-band, that interacts 
with the N2A domain of titin and the N-terminal region of myopalladin. It can also be 
found in the nucleus, where it functions as a transcription co-factor in the embryonic 
and fetal heart; an increased expression was detected in advanced heart failure. 
Genetic variation has been associated with HCM [51] and DCM [71],[72]. 
 
2.4.3. M-BAND AND ASSOCIATED PROTEINS 
The M-band is located in the centre of the A-band (figure 3 and 4) and is important in 
distributing tension along the sarcomere. The two main proteins of the M-band are myomesin 
and M-protein.  Both myomesin and M-protein interact with other sarcomere proteins, such as 
titin and myosin and with M-band associated structural proteins, such as obscurin and 
regulatory proteins, for example Nrb1 or FHL1. A mutation in myomesin has been associated 
with the development of HCM [73].  
 
Obscurin (encoded by OBSCN) is a giant muscle-specific protein that contains multiple 
structural motifs, including hundreds of immunoglobulin-like and fibronectin-like domains and 
a GTP-GDP exchange factor (GEF) domain that can interact with two serine/threonine protein 
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kinase domains. Alternative splicing of OBSCN results in different isoforms. Additionally, 
obscurin interacts at the M-band with ankyrin-1 (involved in sarcolemma-cytoskeleton 
interactions) and interacts with the sarcoplasmic reticulum [24],[74]. A single report suggested 




Figure 4. Schematic representation of the sarcomere, focusing on the Z-disc and the M-band proteins 
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Table 1. Summary of the sarcomeric and associated proteins, encoding genes, interactions, associated 
disease phenotypes and respective prevalence.  For HCM: only percentages for the strongest 
established genes are shown. OMIM: Online Mendelian Inheritance in Men. DCM: dilated 
cardiomyopathy; HCM: hypertrophic cardiomyopathy; RCM: restrictive cardiomyopathy; LVNC: left 
ventricular non-compaction.X means that mutations in the gene have been associated with the 
phenotype.  
Gene OMIM Protein Interactions DCM HCM RCM LVNC 
Sarcomere  - 
contractile 
proteins 
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2.5. DOWNSTREAM MECHANISMS OF DISEASE AND POSSIBLE DRUG TARGETS 
 
It is striking that while the first sarcomeric protein gene mutations were reported over 20 
years ago, the treatment of patients with cardiomyopathy is still largely palliative. Fortunately, 
greater understanding of the biological consequences of sarcomere mutations is leading to 
new ideas on the treatment of genetic heart muscle diseases. Downstream disease pathways 
and possible drug targets are illustrated in figure 5. 
 
2.5.1. CROSS-BRIDGE KINETICS  
Much research has focused on an exploration of the consequences of sarcomeric protein gene 
mutations on myofilament contraction, mostly using recombinant proteins or 
cellular/molecular studies from engineered animal models and less frequently, patient tissue 
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from myectomies or explanted hearts. Based on these findings, it has been hypothesized that 
small molecule inhibitors or activators of acto-myosin cross-bridge formation might be able to 
correct one of the fundamental pathophysiological mechanisms in cardiomyopathy [74] 
[76])[77], however acknowledging that other mechanisms may account for low force 
generation, including lower myofibril density and higher cardiomyocyte area, which are 
aspects of cardiomyocyte remodeling that vary between mutated genes [78].  
 
2.5.2. CALCIUM SENSITIVITY AND CYCLING  
Based on a hypothesis in which the differential effects of mutations on calcium homeostasis 
explain phenotypic variation [36],[27], manipulation of myofilament calcium sensitivity is being 
explored as a potential therapy. A recent paper, using a knock-in rodent model of a 
tropomyosin mutation, demonstrated that correction of increased calcium sensitivity, by co-
expressing a pseudo-phosporylated troponin I, prevented the development of the phenotype, 
including a correction of diastolic dysfunction [79].  
 
Deranged calcium cycling is a feature of heart failure of various aetiologies and is the 
consequence of changed expression or post-translational modifications of 
sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) and the ryanodine receptor 2 
(RYR2) [80]. Altered calcium cycling has been proposed as a fundamental aspect of HCM at the 
cellular level, possibly as a consequence of calcium being retained at the sarcomere [81, 
82],[83]. Altered calcium cycling in HCM and other cardiomyopathies may also be explained by 
reduced uptake into the sarcoplasmic reticulum by the SERCA2 pump due to a cellular 
energetic defect [84]. The main clinical consequences of altered calcium dynamics are early 
and delayed after-depolarizations, arrhythmia and diastolic dysfunction [85], [86].   
 
Animal models have shown that de-sensitization to calcium corrects the arrhythmogenic 
phenotype [86] and in a recent study using induced pluripotent stem cells as a model for HCM 
[87], pharmacological inhibition of calcium and sodium entry attenuated the arrhythmogenic 
cellular phenotype.  
 
In two rodent models of HCM, an alpha- myosin heavy-chain missense mutant mouse and a 
transgenic mouse model expressing a cardiac troponin T mutation, inhibition of plasma 
sarcolemmal L-type calcium channel by diltiazem prevented fibrosis and improved LV diastolic 
function [81, 88]. Another recent paper focused on altered electro-mechanical coupling, using 
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cardiomyocytes from HCM patients undergoing myectomy. In a comparison with 
cardiomyocytes from non-hypertrophic non-failing tissue, the authors demonstrated that late 
sodium current inhibition with ranolazine improved a cellular phenotype provoked by 
increased calmodulin kinase II activity and increased phosphorylation of its targets, resulting in 
a reduction in early and delayed after-depolarisations [89]. A clinical trial of ranolazine in HCM 
is in progress (Ranolazine for the Treatment of Chest Pain in HCM Patients (RHYME); 
NCT01721967; clinicaltrials.gov). 
 
2.5.3. SIGNALING PATHWAYS AND PROTEIN DEGRADATION PATHWAYS 
Protein phosphatases and kinases 
Many of the sarcomere, Z-disc and M-band proteins, as well as titin, are linked to 
cardiomyocyte survival/growth pathways, via nuclear factor of activated T-cells (NFAT) 
transcription factor, mitogen-activated protein kinases (MAPKs) and other protein kinases and 
transcription/co-transcription factors. This places the contractile and associated proteins as 
intermediaries between these downstream pathways and the mechanical processes of 
muscular tension, contractility and energy consumption [24],[74], [80]. These downstream 
pathways are also being considered in the search for new therapies. Possible targets include 
protein kinases, enzymes that catalyze the phosphorylation of various substrates (the most 
frequent post-translational modification of proteins) and that are key-mediators of cell activity 
via signal transduction pathways vital for metabolism, cell cycle, motility, survival/apoptosis 
and cell-cell communication [90]. Protein phosphatases have the opposite role; by 
dephosphorylating the same substrates as the kinases, they contribute to the regulation of the 
same pathways, as the activity of a signal transduction protein depends on the ratio between 
phosphorylated and dephosphorylated state [91].  
 
Calcineurin, co-localized with MLP at the Z-disc, is a Ser/Thr phosphatase involved in the 
pathways leading to maladaptive remodeling/hypertrophy and heart failure. It acts through 
transcription factors such as NFAT, which also localizes at the Z-disc, but can translocate into 
the nucleus [74], [24]. Other Z-disc proteins described previously, such as MLP or FHL1, can 
also act in the nucleus as cofactors of transcription. 
 
MAPKs, such as Erk2, are also localized at the Z-disc and interact with co-factors such as FHL1 
[24]. They are involved in cardiomyocyte hypertrophy-promoting pathways. 
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Protein kinase C epsilon is a Ser/Thr kinase localized at the Z-disc; it can translocate into the 
nucleus, activating pathways leading to physiological hypertrophy [24]. 
Protein degradation and autophagy pathways 
There is a growing interest in protein degradation pathways including the ubiquitine-
proteosome system (UPS) and degradation by lysosomes via autophagy [92]. The ubiquitine-
proteosome system has the task of flagging misfolded /truncated proteins, by adding poly-
ubiquitin chains on them. Proteins become marked for degradation by the proteasome, an ATP 
consuming process. This system is also importantly involved in the control of cell 
growth/survival [74]. 
 
Calpain 1, a protease involved in cell-cycle regulation and apoptosis pathways, together with 
caspases, is also located at the Z-disc and M-band [74], [24]. 
 
Ubiquitinated proteins that are not disposed by the proteasome can form aggregates, that are 
then marked for autophagy by p62 (SQSTM1) and Nbr1, proteins present at the Z-disc and M-
band. Autophagy can also dispose of entire damaged organelles [74]. 
 
Others, such as the TRIM (“tripartite motif”) proteins, including Murf (Muscle specific Ring 
Finger proteins) 1 and 3 localize to the Z-disc and Murf 1 and 2 to the M-band. Murf1 
ubiquitylates and degrades sarcomeric proteins such as myosin heavy chain or troponin I.  
Murf1 also inhibits the protein kinase C (PKC) dependent hypertrophy pathway and has been 
described as having a transcription repressor activity of c-jun in the heart. Finally, Murf2 can 
also have a developmental role in myofibrillogenesis [74],[24]. Mutations in Murf1 have been 
associated with HCM [93], but this was recently contested [94]. 
 
The presence of these proteins at the Z-disc and M-band, their ability to concomitantly interact 
with ubiquitin and autophagosome-associated proteins, together with the fact that they are 
targets for titin-kinase, strongly suggests a link between contractile function / mechano-
sensing and the processes that regulate cell survival and growth; they can therefore eventually 
be involved in the pathogenesis of cardiomyopathy at the cellular level and therefore 
constitute ideal candidate targets for pharmacological intervention. 
 
2.5.4. CARDIOMYOCYTE-FIBROBLAST CROSS-TALK: FIBROSIS  
Interstitial fibrosis is one of the defining histological characteristics of cardiomyopathy [9] and 
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is thought to contribute to arrhythmia and LV diastolic and systolic dysfunction. In an animal 
(mouse) model of HCM, sarcomere protein gene mutations activated proliferative and pro-
fibrotic signals in fibroblasts to produce pathologic remodelling; fibroblasts also demonstrated 
increased expression of TGF-beta and other pro-fibrotic proteins, like periostin [95]; 
administration of neutralizing antibodies or losartan attenuated fibroblast proliferation and 
fibrosis, and in the case of losartan, hypertrophy in mutation-positive pre-hypertrophic mice 
was prevented [95].   
 
In human HCM, an increased level of C-terminal propeptide of type I procollagen (PICP), a 
biomarker of type I collagen biosynthesis, has been described in mutation carriers without left 
ventricular hypertrophy and in patients with overt HCM [96].  
 
2.5.5. CARDIOMYOCYTE ENERGETICS  
The myocardium depends on oxygen for high-energy phosphate production by oxidative 
phosphorylation. In the normal heart, adenosine triphosphate (ATP) is produced primarily by 
the metabolism of free fatty acids (FFAs) and carbohydrates, with FFAs accounting for 
approximately 70% of total ATP production. Importantly, FFAs are less efficient as a source of 
myocardial energy, as they require approximately 10% more oxygen than glucose in order to 
produce an equivalent amount of ATP [97]. Evidence from animal and human studies suggest 
that HCM (and perhaps other cardiomyopathies) is characterised by a reduction in the 
concentration of high-energy phosphates in the myocardium [98]. This might be partly 
explained by myocardial ischaemia caused by microvascular dysfunction, but may also be a 
direct consequence of sarcomere protein gene mutations on myocardial contractile efficiency 
[99]. A trial of perhexiline, that acts by inhibiting carnitine palmitoyl transferase (CPT-1/2), 
involved in mitochondrial uptake of long-chain fatty acids, versus placebo, showed an 
improvement of diastolic function and increased exercise capacity [100]. A number of other 
studies are evaluating the effect of drugs that stimulate glucose oxidation and reduce fatty 
acid oxidation and thereby improve myocardial efficiency and lower oxygen demand in 
patients with HCM and DCM. 
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Figure 5. Mechanisms of disease in hypertrophic cardiomyopathy and possible drug targets. Reproduced 
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3. COMPLEXITY AND CHALLENGES IN HYPERTROPHIC CARDIOMYOPATHY GENETICS 
 
Mutations in the main sarcomeric proteins, that constitute the motor unit of the 
cardiomyocyte, are well established as causes of cardiomyopathy [18]. Animal models and 
functional studies have provided sound evidence of causality for some of the increasingly large 
number of variants associated with these diseases. However, there are still a considerable 
number of unsolved issues that merit research. 
 
3.1. GENETIC TESTING STRATEGIES, HIGH-THROUGHPUT SEQUENCING AND INTERPRETATION OF RARE VARIATION 
 
Most clinical guidelines [101, 102] recommend routine molecular genetic testing of HCM 
probands. Given the high level of biological discrimination afforded by genetic testing, the 
finding of an established disease-causing mutation adds weight to the diagnostic confirmation, 
and allows differentiation of geno- and phenocopies that could benefit from specific 
therapeutic strategies [103]. Genetic testing is also justified by the assumption that genotype 
information can be used to guide therapy and counselling strategies for families and to provide 
pre-symptomatic diagnosis of family members and thereby offer clinical surveillance, early 
medical intervention and reproductive advice [101],[102].   
 
In clinical practice, the use of genetic testing has been limited by the cost and complexity of 
conventional sequencing technologies. The yield of genetic testing is also relatively limited, 
with the identification of a causal variant in less than 50% of the cardiomyopathy cases. The 
emergence of high-throughput sequencing (HTS) technologies has promised to tackle both 
limitations.  
 
HTS or massively parallel sequencing is able to sequence substantially larger genomic regions 
at the same or lower cost compared to conventional Sanger (capillary) sequencing [104]. These 
also called next‐generation sequencing (NGS) platforms allow the interrogation of many genes 
simultaneously – an improvement from the existing strategy of examining a fixed subset of 
genes (e.g. sarcomeric). This is relevant given the increasingly recognized overlap between the 
genetic background of different cardiomyopathy phenotypes and the locus heterogeneity that 
characterizes these diseases.  
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A pilot study exploring the use of targeted NGS in ten patients with cardiomyopathy (five HCM 
and five DCM patients) has demonstrated accuracy equivalent to conventional sequencing 
[105], with a sensitivity of 96%, which was comparable with other reports focussing on non-
cardiac inherited diseases [106].  
 
Limitations of HTS accuracy are mainly related to the sequencing of repetitive regions - which 
are prone to create false positives - and insertion-deletions, for which HTS can have limited 
sensitivity [107]. However HTS can have increased sensitivity compared with conventional 
screening strategies such as denaturating high pressure liquid chromatography (DHPLC), when 
variants are homozygous [108] or can be even superior to Sanger sequencing when variants 
occur in specific locations such as close to the end of analysed segments or untranslated 
regions [109]. 
 
As technological advances facilitate faster and more complete genetic testing, there arise new 
challenges regarding the interpretation of genetic variants. The establishment of pathogenicity 
of a new variant classically rests on the demonstration of co-segregation of the variant with 
disease in affected families. However, in most instances, families are too small to establish 
causality beyond reasonable doubt. High throughput sequencing technologies have amplified 
this problem through the sequencing of large panels of genes or even entire exomes  - the 
coding part of the genome - and genomes, i.e. the entire DNA sequence [107]. These 
sequencing strategies generate large numbers of potentially pathogenic variants, only some of 
which are obviously related to the phenotype of patients undergoing testing [107]. In silico 
prediction tools are frequently used to determine pathogenicity of novel variants in this 
situation, but these are known to have poor accuracy and have not been developed or 
validated for specific diseases. [110].  
 
Large-scale population studies, designed to explore the scope of genetic variation in humans, 
have recently been published, after the beginning of my research. The 1000 genomes project 
(http://www.1000genomes.org), published as a pilot report [111] and phase I data [112], 
studied the genomes of 1,092 non-phenotyped individuals from 14 populations, reporting that 
each individual carries approximately 250 to 300 loss-of-function variants in annotated genes 
and 50 to 100 variants previously implicated in inherited disorders. Another report on data 
generated by the 1000 genomes project confirmed that human genomes contain 
approximately 100 genuine loss-of-function variants, with around 20 genes being completely 
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inactivated [113]. Other projects aimed at building a database of variation from phenotyped 
disease populations and healthy controls were meanwhile launched. The NHLBI exome 
sequencing project completed the exome sequencing of 6503 individuals (data is publicly 
availble at http://evs.gs.washington.edu/EVS/) and a report based on part of these data 
showed similar findings to the ones from the 1000 genomes project [114]. A similar UK based 
project was launched in 2011, the UK10K project, that generated sequencing data for 
approximately 10000 individuals from the UK, including disease and control cohorts 
(www.uk10k.org). 
 
Studies that described this previously unexplored and unexpected complexity in the inherited 
cardiac disease context have meanwhile been published. In a study [115] focussed on 
arrhythmogenic right ventricular cardiomyopathy (ARVC) associated genes, radical mutations 
were present in 0.5% of a control population versus 43% of ARVC cases, while 16% of controls 
carried missense mutations versus a similar 21% of ARVC cases. In another study, 33 missense 
variants previously associated with long-QT syndrome were identified in 1 of every 31 
individuals in the population of the NHLBI Exome Sequencing Project [116].  
 
3.2. GENOTYPE-PHENOTYPE ASSOCIATIONS  
 
HCM is characterized by a highly heterogeneous phenotype, a highly variable intra and inter-
familial expressivity and incomplete and age-dependent penetrance [117]. This genotype-
phenotype plasticity is largely unexplained [118].  
 
As stated in the previous section, patients are routinely offered genetic testing in order to 
provide them with information about the likely impact of disease on their lives and to facilitate 
lifestyle and medical interventions that improve prognosis [101]. However, for this strategy to 
succeed, there must be a predictable relation between specific genotypes and disease 
expression. One of the factors that still dramatically hampers the use of genetics in daily 
clinical decisions is the poor understanding of such genotype-phenotype relationships.  
 
In clinical practice, the most robust associations between mutation and phenotypes are still 
relatively crude. This lack of knowledge is partly explained by the locus and allelic 
heterogeneity of all cardiomyopathies [32] and the small size of most reported patient cohorts. 
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In addition, novel variants with no established clinical phenotype information are increasingly 
common in the literature.  
 
Following the identification of the first sarcomeric protein gene mutations, studies of large 
families explored the relationships between genetic variants and different sub-phenotypes. 
Specific associations were reported between individual mutations in ß-myosin heavy chain 
(MYH7) and troponin T (TNNT2) [119, 120, 121], [122, 123], [124] and prognosis and then 
some general correlations between particular genes and clinical phenotype were suggested. 
For example, a later onset and more benign prognosis for cardiac myosin binding protein C 
(MYBPC3) carriers [125], [126], [127], [128] and  mild hypertrophy and higher risk of sudden 
cardiac death for TNNT2 carriers [129],[130]. However, subsequent work [131],[132],[133] in 
large cohorts of mostly unrelated and consecutive probands [134, 135, 136] [137], [138], [139] 
yielded contradictory and inconsistent findings. 
 
It has been hypothesized that the impressive genotype-phenotype plasticity and the challenge 
in finding reproducible genotype-phenotype associations could be explained by modifier 
genes, epigenetics, post-transcriptional and post-translational modifications and 
environmental effects [140, 141], [142]. Previous work looking for common 
variants/polymorphisms acting as modifiers has proven to be relatively unhelpful [143], [144], 
[145], [146]. A paper [147] explored the role of renin-angiotensin-aldosterone system (RAAS) 
in the phenotypic expression of HCM. The authors did not find major effects of genetic 
variation within the genes of the RAAS system on the phenotypic expression of HCM. Similar to 
that report, several studies have examined the role of common genetic variants on the 
expression of sarcomere mutations using GWAS or more commonly a candidate gene 
approach, but have failed to show any major effect on disease expression 41, 42 [143], [144], 
[145], [146] [147].  
 
Given the substantial genetic overlap between different cardiomyopathies and knowledge 
from other genetic diseases, other authors have predicted the possible modifier effect of 
genes acting in common downstream pathways (e.g. other cardiomyopathy genes), but this 
has not been systematically explored before my studies [32], [142].  
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3.3. STRUCTURAL VARIATION 
 
Copy-number variants (CNVs), usually defined as genomic deletions and duplications greater 
than 1 K base pairs, are an important cause of genetic variation in the general population [112, 
148] and contribute to both simple Mendelian and complex genetic traits [149, 150]. 
Hypertrophic cardiomyopathy (HCM) is predominantly caused by missense mutations in 
cardiac sarcomeric protein genes [117]. Small insertion-deletions (denoted as indels, which are 
usually less than 10 base pairs) in sarcomeric protein genes are also relatively common [117], 
but the importance of major structural variation as a cause or modifier of the HCM phenotype 
is unknown.  
 
This deficiency is important, as most diagnostic genetic laboratories have used Sanger 
sequencing strategies when screening patients with the disease and are, therefore, unable to 
detect this type of genetic variation. Even with the introduction of high-throughput sequencing, 
variant calling pipelines are usually directed for the detection of single nucleotide variants or 
small insertion-deletions. 
 
Recently, bioinformatic algorithms have been developed to allow the detection of structural 
variation from high‐throughput short-read sequencing data [151]-[152]. While several 
analytical approaches are available [152], read depth based strategies are most effective for 
targeted sequencing because they do not require the sequencing of the DNA region 
surrounding the CNV breakpoints.  
 
3.4. NON-CODING VARIATION 
 
Current genetic diagnostic strategies in hypertrophic cardiomyopathy and other Mendelian 
diseases are based on the screening of the exons and intron-exon flanking regions of the most 
commonly associated genes, looking for potentially pathogenic mutations. This approach is 
based upon the fact that the coding region, corresponding to 1% of the genome, is considered 
to harbour the pathogenic variation responsible for Mendelian disease. Nevertheless, recent 
estimates from the ENCODE (“Encyclopedia of DNA Elements”) project suggest that around 
80% of the genome has a biochemically relevant role [153]. Importantly, it has already been 
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demonstrated that variation in the non-coding regions can be the cause in a proportion of 
other genetic diseases, such as nonsyndromic intellectual disability [154].  
 
It seems very likely therefore that a proportion of cardiomyopathies may also result from 
regulatory gene mutations. Additionally, through a putative interference in epigenetic and 
other regulatory mechanisms, non-coding variation could potentially modify the phenotype 
when added to the effects of a “main” coding variant, and partially explain the extremely 
variable expressivity that has contributed to a poor understanding of genotype-phenotype 
relationships in HCM.  
 
However, prediction of the functional consequence of non-coding variation is more difficult 
than that of coding variation, due to the unknown function of the great majority of the non-
coding DNA. The recent efforts of the ENCODE project [153] allowed a significant amount of 
experimentally validated data to be generated and made available, including ChIP (chromatin 
immunoprecipitation) -sequencing [155],[156] data for TF binding sites, that helps predict the 
possible consequences of non-coding variants.  
 
These challenges of interpretation are increased by the growing awareness that a large 
amount of variation is present in the general population. This was recently shown for coding 
variation [111],[113, 114], but also for non-coding variation, as reported in the publication of 
phase 1 results from the 1000 genomes project project [112]. According to these report, 
individuals carry between 18 and 69 rare variants in conserved TF binding motifs. 
 
3.5. IN SILICO PREDICTION OF THE PATHOGENICITY OF A CODING VARIANT 
 
The high genetic heterogeneity that characterizes HCM makes determination of the 
pathogenicity of individual genetic variants problematic [157]. These variants are often novel 
and missense variants with uncertain effects on gene function. The effects of a missense 
variant on molecular function, phenotype, and organism fitness can be extremely diverse 
[158]. The use of high-throughput sequencing approaches is likely to result in even greater 
complexity, by identifying multiple variants in individual patients. Given the almost impossible 
task of developing massively parallel functional studies to match massively parallel sequencing 
platforms, new interpretative tools are needed.  
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Among some of the tools that can be used to estimate the effect of a variant and prioritize 
further analysis are in silico prediction software. The best known are PolyPhen (“Polymorphism 
Phenotyping”), PolyPhen2 and SIFT (“Sorting Intolerant from Tolerant”) [159],[160]. More 
recently, Condel (“Consensus Deleteriousness Score”) [161] a tool developed by combining 
Polyphen and SIFT algorithms, was reported to achieve increased accuracy. These software 
packages can be used to predict the damaging effect of a missense variant based on features 
that include species conservation and the physicochemical difference between the aminoacids. 
Nevertheless, the accuracy is largely unknown, because they were not designed for clinical use 
or for specific diseases and have not been validated against thoroughly annotated locus-
specific databases or phenotype datasets [110]. Moreover, they frequently give conflicting 
results that limit their clinical utility [162].  
 
Another major drawback of existing prediction softwares is the fact that they make use of 
limited structural information. SAAPdb (“Single Amino Acid Polymorphism” database) and 
SAAPdap (“Single Amino Acid Polymorphism” data analysis pipeline), developed by Martin et al 
[163],[164],[165],[166] uses a combination of rule-based structural measures to assess 
whether a modification is likely to alter or destroy the function of the protein. This software 
has already been used to study structural differences between disease-causing mutations and 
neutral polymorphisms [163], to analyse mutations in glucose-6-phosphate dehydrogenase 
[167] and in tumour suppressor p53 [168].  
 
In HCM, different functional consequences have been suggested to depend on the specific 
domain/region where the variant is localized [169]. Nevertheless, the hypothesis that the 
structural impact of a missense variant could influence phenotype and disease severity and 
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4. SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS OF GENOTYPE-
PHENOTYPE ASSOCIATIONS  
 
As part of the background preparation for my PhD thesis, I summarised and critically reviewed 
the current literature on genotype–phenotype associations in patients with HCM and 




The methodology and presentation of the review is based on the recommendations of the 
PRISMA statement [170].  
 
4.1.1. STUDY SELECTION AND ELECTRONIC SEARCH METHODS  
I searched PubMed/Medline up to December 2012, for the terms “genotype” or “genetics” 
combined with either “phenotype”, “age”, “family history”, “histology”, “wall thickness”, 
“geometry”, “morphology”, “left ventricular function”, “heart failure”, “stroke”, “risk factor”, 
“sudden cardiac death”, “syncope”, “abnormal blood pressure response”, “implantable 
cardioverter-defibrillator”, “myectomy”, “alcohol septal ablation”, “death”, “prognosis” or 
“outcome”, each combined either with “hypertrophic cardiomyopathy” or “HCM”. Duplicates 
were eliminated. References from the retrieved original articles and reviews were searched for 
missing studies.  
 
I selected observational English language human studies, with a cross-sectional or prospective 
design, that compared phenotypic features in patients with and without sarcomere mutations 
and between specific genes or individual mutations. The first selection was made by reading 
abstracts and the final selection by reading full articles.  
 
In order to reduce ascertainment biases, the pooled analysis was confined to studies reporting 
on cohorts of unrelated and consecutive patients, where at least two sarcomere genes were 
sequenced. Some of these studies also included data on relatives; those data were excluded 
from the pooled analyses. Studies that compared specific individual mutations, data that 
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incorporated relatives and publications in which patients were selected on the basis of a 
certain phenotypic/clinical feature were excluded from the pooled analysis but were used to 
inform the narrative review. 
 
4.1.2. STATISTICAL ANALYSIS 
I extracted data on the following phenotypic features to a table: age; family history of HCM; 
histology; morphology and function evaluated by cardiac imaging (extent and pattern of 
hypertrophy, late gadolinium enhancement, atrial and ventricular dimensions and function, 
left ventricular outflow tract obstruction, mitral valve abnormalities); clinical risk factors for 
sudden cardiac death (maximum left ventricular wall thickness ≥ 30mm, abnormal exercise 
blood pressure response, non-sustained ventricular tachycardia, family history of sudden 
cardiac death, syncope); interventions, outcome and prognosis (all death, cardiovascular death, 
SCD, non-fatal heart failure, AF, non-fatal stroke, implantable cardioverter-defibrillator (ICD) 
implantation, myectomy and alcohol septal ablation). 
 
A random effect meta-regression model [171] was used to combine the data and to obtain the 
pooled (overall) estimate for a set of clinical features that were most frequently reported in 
the final selected studies: age at presentation, gender, family history of HCM, family history of 
sudden cardiac death (SCD) and maximum left ventricular wall thickness (MLVWT). Other 
clinical parameters, including the majority of the risk factors for SCD, were inconsistently 
reported or not rigorously defined in the great majority of the selected studies. 
 
The overall prevalence was the weighted average of the prevalence across different studies. 
The pooled estimate is the weighted average of study specific estimates, where weights were 
calculated using measures of precision (inverse of the variance). Intra- and inter-study 
variances were used in the calculation of precision. The intra-study variance was the variance 
of the prevalence/proportion/mean obtained for each study. The between study variance, a 
parameter of the random effects meta-regression model, was estimated using method of 
moments. The inter-study variance was used to adjust for the heterogeneity in 
prevalence/proportion/mean between studies. Heterogeneity between studies was further 
assessed using I2 statistic, which represents the proportion of total variability in the 
prevalence/proportion data attributable to the heterogeneity between the studies. This 
statistical analysis was conducted in collaboration with Dr. Shafiqur Rahman, Institute of 
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The initial search resulted in a total of 242 studies after removing duplicates. Twenty-two 
additional studies were added after reviewing the references of the retrieved articles. Reviews 
(n=29) and editorials (n=6) were excluded from the systematic review and publications that did 
not fulfil the pre-specified inclusion criteria were excluded from the meta-analysis. In 
particular, 53 family based studies were judged to be unsuitable for pooled analyses (table 2) 
as they included small numbers of patients and were characterised by marked variability in the 
methods and scope of genetic testing, the extent of family screening and the definition of 








The 18 studies [23],[173],[174],[21, 175, 176, 177],[178],[179],[180],[181],[182],[22],[183, 
184],[185],[186] selected for the pooled analyses (corresponding to 13 distinct cohorts and a 
Section I – Introduction: 4. Systematic review and meta-analysis of genotype –phenotype associations 
 48 
total of 2459 patients)  are described in table 3. The pooled analysis for the percentage of 
individuals that are sarcomere mutation-positive (42.5%, 95% CI: 35.2%-46.7%) is shown in 
figure 7. Different publications were used in the analysis of individual clinical parameters, 
according to the completeness of the required data
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Table 2. Family-centred studies reporting on penetrance, severity and prognosis. Reproduced with permission from [172]. SCD: sudden cardiac death (in some studies this includes 





















SCD in the 
famlily 
Mutations Design 
MYBPC3          
Niimura  et al 1998 [125]  16 228 137 60% - 36 34 12 CS 
Charron et al 1998  [187] 2 33 23 69% - 7 4 1 (SASint20 or 
IVS20-2A>G) 
CS 
Charron et al 1998 [126]  9 69  49* 71% (adults) - 9 4 7 CS 
Moolman et al 2000 
[133] 
1 27 10 
(excluding 
deaths) 
- - 5 2 1 CS 
Konno et al 2003 [188] 7 16 16 100% (above 50y) - NR NR 1(R820G) CS 
Kubo 2005  [189] 15 39 30 77% (100% above 
50y) 





Konno et al 2006 [190] 5 15 11 73% (90% above 
30y) 
- NR 4 1 (IVS21+1G>A) CS 
Saltzman et al 2010 
[191] 
34 77 60* 78% - - 18 1 (R502W) CS 
Oliva-Sandoval et al 2010 
[192] 
18 65 40 61.5% - 9 17 (+2 
appropriate 
shocks) 
1 (IVS23+1G>A) CS 
Choi et al 2010 [193] 1 7 6 86% - - 2 1 (L1238P) CS 
Hirota et al 2010 [194] 2 9 8 89%* NR 0 0 1 (S297X) CS 
Page et al 2012 [138] 57 167 95 56.9% (34.5% 
relatives) 
7.9±4.5 5 3 42 L 
MYH7          
Watkins et al 1992 [121] 12 121  121 100% - 47 24 7 CS 
Epstein et al 1992 [119] 
+ Fananapazir et al 1994 
[120] 
4 108 73 68%* - NR 13 4 CS 
Anan et al 1994 [195] 6 75 75 100% - 37 24 3 CS 
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Consevage et al 1994 
[196] 
1 4 4 - - NR 0 1(R719G) CS 
Marian et al 1994 [197] 2 10 # 21 86% - 11 8 1 (G1208A) CS 
Marian et al 1995 [131] 3 23 # 33 - - 14 10 2 CS 
Posen et al 1995 [198] 2 42 - 60% for R403W  
80% for R249Q 
(adults) 
- NR 0 2 CS 
Ko et al 1996 [199] 1 NR 11 NR - 5 3 1 (R453C) CS 
Tesson et al 1998 [195] 4 25 15 * - NR 4 4 CS 
Charon et al 1998 [187] 5 35 (adults) 23 (adults) 66% (adults) - 9 4 5 CS 
Charron et al 1998 [126]  7 45 (adults) 32 71% (adults) - 12 8 7 CS 
Hwang et al 1998 [200] 1 5 # 13 100% - 8 7 1 (G716R) CS 
Enjuto et al 2000 [201] 3 30 NR NR - 9 6 1 (R723G) CS 
Hvandrup et al 2001 
[202] 
1 5 5 100% - NR 3 1 (V606M) CS 
Huang et al 2001 [203] 1 1 1 - - NR 2 1 (R719G) CS 
Brito et al 2003 [204] 2 16 14 100% in one of 
the families and  








NR 2 1 (I263T) L 
Liu et al 2005 [205] 1 9 4 44% - NR 2 1 (A26V) CS 
Perrot et al 2005 [206] 5 17 11 65%* - NR 0 5 CS 
Choi et al 2010 [193] 1 15 15 100% - NR 8 1 (G716R) CS 
TNNT2          
Watkins et al 1995 [123] 11 112 - 75% (above 16) - 50 39 8 CS 
Moolman et al 1997 
[130] 
2 22 17* 80% (above 16) - 7 7 1(R92W) CS 
Nakajima-Taniguchi et al 
1997  [207] 
1 4 4 (excluding 
deaths) 
NR - 2 2 1 (A104V) CS 
Anan et al 1998 [208] 6 16 # 13 81% - 2 2 1 (F110I) CS 
Varnava et al 1999 [209] 1 - 5 - - NR 4 1 (R94L) CS 
Torricelli et al 2003 [210] 5 10 # -  - NR 2 5 CS 
Theopistou 2004 [211] 1 5 # - - - NR 5 1 (R278C) CS 
Gimeno et al 2009 [212] 4 16 # 24 - - 11 7 3 CS 
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TNNI3          
Kokado et al 2000 [132] 7 25 - 96% (above 20) 8.7±2.5  7 1 (K183 del) L 
Shimizu et al 2002 [213] 10 46 - - - NR 4 1 (K183 del) CS 
Mogensen et al 2004 
[137] 
23 100 48 48% - 12 6 13 CS 
Doolan et al 2005 [214] 4 15 11 73% * - NR 4 4 CS 
Choi et al 2010 [193] 1 12 12 100% - 8 2 1 (R145G) CS 
MYL2          
Flavigny et al 1998 [215] 3 17 # 16 
(excluding 
deaths) 
- - NR 2 2 CS 
Kabaeva et al 2002 [216] 2 8 # 7 - - NR 2 2 CS 
MYL3          
Lee et al 2001 [217] 2 14 - 78% (adults) - NR 2 1 (A57G) CS 
Choi et al 2010 [193] 1 12 5 63% (adults) - 2 1 1 (A57G) CS 
TPM1          
Yamauchi-Takihara et al 
1996 [218] 
3 - 8 (excluding 
deaths) 
- - 7 6 3 CS 
Coviello et al 1997 [219] 3 - 21 - - 2 2 1 (D175N) CS 
Karibe et al 2001 [220] 1 14 # 26 53% - 13 11 1 (V95A) CS 
Jongbloed et al 2003 
[221] 
1 - 12 - - 9 9 1 (E62Q) CS 
Makhoul et al 2011 [222] 1 4 4 100% -  1 (+2 
appropriate 
shocks) 






Table 3. Studies selected for pooled analyses. Frequency of mutations in each sarcomere gene and sequencing methodology for each study. Reproduced with permission from 




























Richard et al 2003 [23] 197 9 63 26.4 25.4 4 4 2.5 0.5 0 0 SSCP+DS 
Morner et al 2003 [173] 46 8 28 20 2.2 * 0 2.2 2.2 0 0 0 SSCP / DHPLC 
Erdmann et al 2003 [174] 108 6 33.3 18.5 13 * 0.9 0.9 - - - 0.9 
SSCP+DS or 
RFLP 
Van Driest et al 2003-2005 
[21, 175, 176, 177] 389 8 37.7 18.2 14.9 2.3 1.3 1.8 0 0.3 0.8 DHPLC+DS 
Olivotto et al 2008 [178] 203 8 62 34 17 3.5 0.49 3.5  0.49 0.99 DHPLC+DS+RFLP 
Garcia-Castro et al 2009 [179] 120 5 26.7 16 8 0.8 0    0.8 DS 
Andersen et al 2009 [180] 90 11 36 10 10 2.2 2.2  1.1 1.1 1.1 SSCP+DS 
Laredo et al 2006 + Rodriguez-
Garcia et al 2010 [181],[182] 130 2 23 15 8 - - - - - - SSCP+DS+RFLP 
Millat et al 2010 [22] 192 4 48 25 12 3.1 3.1 - - - - DHPLC+DS 
Waldmuller et al 2011 [183] 236 2 41 24 17 - - - - - - DS 
Brito et al 2012 [184] 77 5 53 35 11.7 6.5 2.6 0 - - - DS 
Gruner et al 2012 [185] 471 8 35 14.9 13.6 2.3 0.85 0.2 0.6 0.4 0.64 DS 
Yobau Zou et al 2013 [186] 200 8 51 18 26 4 3.5 1 1.5 1.5 1.5 DS 
 
 





Figure 7. Pooled analysis for the proportion of individuals that are sarcomere gene mutation-positive. 
The overall proportion was 42.5% (95% CI 35.2% to 49.7%). The analysis shows significant 
heterogeneity. Reproduced with permission from [172]. 
 
4.2.1. DEMOGRAPHIC CHARACTERISTICS AND FAMILY HISTORY 
Age  
Younger age at presentation in carriers of sarcomere protein gene mutations is a common 
finding in many studies [185] [174],[21, 183, 184] and [186]. The presence of multiple 
sarcomere gene mutations (double or triple heterozygosity, compound heterozygosity or 
homozygosity) was associated with a younger age compared to a single mutation or to the 
absence of mutations in a single report [21]. In contrast, some other publications have 
reported a non-significant association between age and the presence of sarcomere mutations 
[178], [179], [182] and [22].  
 
In the pooled analysis (figure 8), the presence of a sarcomere gene mutation was associated 
with a younger age at presentation. The age for sarcomere-positive individuals was 38.4 years 
(95% CI of 28.1-48.7). The age for sarcomere-negative individuals was 46.0 years (95% CI  35.6-
56.4). The overall mean difference was statistically significant  (p <0.0005). There were no 
significant heterogeneity effects (I2= 45.4% with P-value=0.07) between studies.  
 




Figure 8. Forest plot from random effect meta-analysis showing that the presence of a sarcomere gene 
mutation was associated with a younger age at presentation. The age for sarcomere-positive individuals 
was 38.4 years (95% CI 28.1 to 48.7 years). The age for sarcomere-negative individuals was 46.0 years 
(95% CI 35.6 to 56.4 years) (P-value<0.0005). There were no significant heterogeneity effects (I
2
 = 45.4% 
with P-value=0.07) between studies. Reproduced with permission from [172]. 
 
Some studies reported that patients with mutations in MYH7 present earlier than MYBPC3 
mutation patients: [126], [22], [223],  but others have failed to show such a difference [174], 
[183], [184]  [176], [179], [182] or even describe a younger age at diagnosis for patients with 
truncating mutations in MYBPC3 [174]. 
 
The pooled analysis (figure 9) showed no statistically significant difference in the age at 
presentation between the MYBPC3 (37.6 years, 95% CI: 27.1- 48.2) and MYH7 (35.3 years, 95% 
CI: 22.1 - 48.5) sub-cohorts, P-value=0.316. 
 




Figure 9. Forest plot from random effect meta-analysis showing no statistically significant difference 
regarding the age of presentation between MYBPC3 (37.6 years, 95% CI 27.1 to 48.2 years) and MYH7 
(35.3 years, 95% CI 22.1 to 48.5 years) sub-cohorts, p = 0.316. There was no significant effect of 
heterogeneity between studies (I
2
 = 50.0% with p = 0.062). Reproduced with permission from [172]. 
 
 
Three studies have compared age at presentation between patients harbouring MYH7 
mutations and patients without mutations in this gene. In one [177], patients with a MYH7 
mutation presented earlier than patients without a mutation (with or without mutations in 
other genes), but this was not replicated in two other studies [224],[181]. One study [9] 
reported a younger age at presentation in TNNT2 patients than other patients with HCM. One 
further publication [225] reported that patients with mutations in MYBPC3 were older at 
presentation than individuals harbouring mutations in MYH7 or TNNT2.  
 
Gender 
A higher frequency of male patients is reported in the great majority of HCM cohorts. An 
association between the absence of a sarcomere mutation and an even higher proportion of 
males is reported in two studies [185] [182], but not in others [174], [21], [178], [179], [183]. 
 
The pooled analysis (figure 10) showed no statistically significant difference in the proportion 
of males in patients with sarcomere gene mutations compared with those without (57.5% vs 
61.5% respectively, P-value=0.422). 
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There is no reported difference in the proportion of males between MYH7 and MYBPC3 
mutation patients [126], [174], [176] [195], [179], [182],[223], except for a single study that 
reported  a higher frequency of male patients with MYBPC3 truncating mutations compared to 
MYH7 [174]. There was no difference in the prevalence of males in two studies that compared 
MYH7-positive to MYH7-negative patients [177], [181]. 
 
 
Figure 10. Forest plot from random effect meta-analysis showing the absence of a statistically significant 
difference between the proportion of males in sarcomere-positive (57.5%, 95% CI 53.4 to 61.6) 
compared with sarcomere-negative patients (61.5%, 95% CI 58.2 to 64.8, P-value=0.422). No significant 
heterogeneity effect was observed (I
2
 = 51.7%, p = 0.082). Reproduced with permission from [172]. 
 
 
Family history  
A family history of HCM has been associated with the presence of a sarcomere mutation [185], 
[174], [21], [183], [178], [226], [180]. The pooled analysis (figure 11) showed a significantly 
higher proportion of a family history of HCM within the mutation-positive subgroup (50.6%, 
95% CI of 46.8%-54.4%) compared to mutation-negative individuals (23.1%, 95% CI of 20.6%-









Figure 11. Forest plot from random effect meta-analysis showing a significantly higher proportion of a 
family history (FH) of hypertrophic cardiomyopathy (HCM) within the sarcomere-positive subgroup 
(50.6%, 95% CI 46.8% to 54.4%) compared to the sarcomere-negative individuals (23.1%, 95% CI 20.6% 
to 26.6%) (P-value<0.0005). There were significant heterogeneity effects (I
2
=73.1%, P-value=0.001) 
between studies. Reproduced with permission from [172]. 
 
 
MYH7-positive patients are more likely to present with a family history of HCM, compared 
with patients without mutations in this gene [177],[181],[179]. The last study [179] compared 
against sarcomere-negative patients. 
 
No study has reported a significant difference in the proportion of a positive family history in 
patients harbouring MYBPC3 versus MYH7 mutations [174], [176], [182], [183]. The pooled 










Figure 12. Forest plot from random effect meta-analysis showing no difference between the proportion 
of family history (FH) of hypertrophic cardiomyopathy (HCM) in patients with MYPBC3 mutations 
(46.5%, 95% CI 38.6% to 54.3%), compared to the frequency of FH of HCM in patients with MYH7 
(50.9%, 95% CI 41.8% to 59.9%) (P-value=0.284). There were no significant heterogeneity effects 
between studies (I
2
= 54.7%, P-value=0.085).  Reproduced with permission from [172]. 
 
 
In one study, patients carrying mutations in the thin myofilament genes – troponin T (TNNT2), 
troponin I (TNNI3), actin (ACTC1) and alpha-tropomyosin (TPM1) -  had a similar frequency of a 
family history of HCM compared to the rest of rest of the cohort [175]. 
 
Arterial hypertension 
Four studies in three different cohorts reported on the prevalence of arterial hypertension in 
sarcomere-positive versus negative individuals [180],[181],[182],[185]. Only one of those 
studies found a significant association [185], reporting a higher prevalence amongst 
sarcomere-negative individuals. The pooled analysis showed an overall proportion of 
hypertensive patients amongst sarcomere-positive individuals of 22.8% (95% CI 17.3-28.2%), 
compared with a proportion of 41.7% amongst sarcomere-negative (95% CI  37.2, 46.2%, p = 
0.004) (figure 13). 
 
 




Figure 13. Forest plot from random effect meta-analysis showing that the proportion of patients with 
hypertension among sarcomere-positive individuals (22.8%, 95% CI 17.3% to 28.2%) is significantly less 
than the proportion among sarcomere-negative patients (41.7%, 95% CI 37.2% to 46.2%) (P-
value=0.004). There were no significant heterogeneity effects (I
2
=46.3%, P-value=0.155) between 
studies. Reproduced with permission from [172]. 
 
 
4.2.2. MORPHOLOGY AND FUNCTION  
Maximum left ventricular wall thickness 
The presence of any sarcomere gene mutation was associated with a greater maximum LV wall 
thickness (MLVWT) in several studies [185], [21], [184], [182]. Complex genotypes (multiple 
mutations in sarcomere genes) were associated with an even greater wall thickness compared 
to sarcomere negative patients in some but not all studies [21], [227], [186] [174], [178, 195], 
[179], [183]. 
 
The pooled analysis (figure 14) showed a greater MLVWT for patients carrying any sarcomere 
mutation (21.0 mm, 95% CI of 16.9-25.1 mm) compared to sarcomere-negative individuals  
(19.3 mm, 95% CI of 15.7-22.8 mm), P-value=0.03. The heterogeneity effects between studies 
were not significant  (I2=40.8%, P-value=0.133). 
 
Differences in the prevalence of a maximum wall thickness ≥ 30 mm between sarcomere-
positive and sarcomere-negative individuals were explored in two studies, that found no 
significant associations [21], [178]. 




Figure 14. Forest plot from random effect meta-analysis showing a greater maximum left ventricular 
wall thickness (MLVWT) for patients carrying any sarcomere mutation (21.0 mm, 95% CI 16.9 to 25.1 
mm) compared to sarcomere-negative individuals (19.3 mm, 95% CI 15.7 to 22.8 mm) (P-value=0.03). 
There were no significant heterogeneity effects (I
2




Patients carrying mutations in MYBPC3 seem to have a similar degree of hypertrophy when 
compared to MYH7 patients [182], [184], [179], [176], [174], [126] with the exception of a 
single study [183], that described an increased average LV wall thickness for MYBPC3 patients. 
The pooled analysis showed no difference in MLVWT between the MYBPC3 and MYH7 sub-








Figure 15. Forest plot from random effect meta-analysis showing no difference in maximum left 
ventricular wall thickness (MLVWT) between the MYBPC3 (21.0 mm, 95% CI 17.1 to 24.8 mm) and MYH7 
(19.2 mm, 95% CI 15.6 to 22.9 mm) sub-cohorts (P-value=0.574). No significant effects of heterogeneity 
between the studies were observed (I
2
=50.3%, P-value=0.074). Reproduced with permission from [172]. 
 
 
In a single study, there was no difference between the LV wall thickness of patients with thin 
filament mutations and the rest of the cohort [175]. 
 
In two studies that focus on the presence or absence of a MYH7 mutation, a higher degree of 
hypertrophy in MYH7 patients compared to the negative individuals is reported in one but not 
the other (40)[181]. Additionally, MYH7-head mutations were reported to be associated with 
increased wall thickness when compared to rod region mutations in another publication [223]. 
 
Ventricular morphology 
Few studies have analysed the distribution of LV hypertrophy.  Sarcomere protein mutations 
are reported to be much more frequent in patients with a reverse septal curvature phenotype 
compared with those with sigmoidal septum in two studies [228] [185], where this 
morphology was described as an independent predictor of genotype-status. Another 
publication [62] described an association between Z-disc mutations and sigmoidal septum. 
One study [224] did not find a significant difference in the prevalence of asymmetrical 
hypertrophy versus other sub-phenotypes in patients harbouring MYH7 mutations. 
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Two studies have examined the genetic background of apical HCM. One [229] reported the 
absence of an association between genotype and apical HCM, with some of the mutations 
giving rise to different hypertrophy patterns within the same family. In the second study [230] 
there was a lower percentage of mutation-positive patients in apical HCM (13%) compared to 
non-apical HCM (40%). 
 
LV dimensions and function 
Most studies have not demonstrated an association between genotype and LV end-diastolic 
diameter, fractional shortening (FS) and ejection fraction [178], [185], [186]. One publication 
[224] reported a higher FS for MYH7-positive versus negative patients and another [181] 
reported an increased ejection fraction in patients harbouring MYH7 mutations. In a single 
longitudinal study [178], patients with a sarcomere protein mutation were more likely to 
develop LV systolic or diastolic dysfunction during follow-up. 
 
Microvascular function and myocardial fibrosis 
One study [231] has reported reduced myocardial blood flow in patients carrying a sarcomeric 
mutation, compared with mutation-negative patients. Mutation-positive status was also 
associated with a higher prevalence of late gadolinium enhancement [231]. Another recent 
publication [96] described an increased level of C-terminal propeptide of type I procollagen, a 
biomarker of type I collagen biosynthesis, in MYH7 carriers compared to MYBPC3 carriers 
without hypertrophy; this association was not present in patients with LV hypertrophy.  
 
Left ventricular outflow tract obstruction and mitral valve abnormalities 
Most studies have shown no significant association between left ventricular outflow tract 
obstruction and genotype status [126], [173], [21], [175, 176, 177], [178], [179], [181], [182], 
[223], [184]. One study [185] reported an increased prevalence of left ventricular outflow tract 
obstruction in genotype-negative patients (48% vs 37%), but it was not an independent 
predictor of genotype-status. 
 
The only study to report on the association between genetic background and mitral 
regurgitation found an increased prevalence of mitral regurgitation in MYH7 patients 
compared to genotype-negative patients [183]. 
 
 




Very few studies have analysed the correlation between genotype and histologic findings. One 
study [9] described less fibrosis and more severe myocyte disarray in patients with TNNT2 
mutations; but no difference between genotype-positive and negative patients was found in a 
series of genotyped patients undergoing septal myectomy [195, 232]. In a study [219], 
reporting on a TPM1 missense mutation, histopathological features were indistinguishable 
between the reported family and patients with mutations in other genes. Another report [233] 
described an association between the presence of a sarcomere mutation and the severity of 
cardiomyocyte hypertrophy, but not with other histologic features of HCM. 
 
4.2.3. RISK FACTORS FOR SUDDEN CARDIAC DEATH 
Syncope  
Two studies described an association between the presence of MYH7 mutations and an 
increased prevalence of syncope in comparison to carriers of MYBPC3 mutations [225] or 
MYH7-negative patients [224]. 
 
Abnormal blood pressure response to exercise 
Two studies report an association between genotype and an abnormal blood pressure 
response to exercise (ABPRE). In one [182], sarcomere-positive patients had a higher 
prevalence of ABPRE (32% in MYBPC3 and 61% in MYH7) than sarcomere-negative patients 
(11%). In a second, [234] patients with the TNNT2 R92W mutation had a lower exercise blood 
pressure response compared to patients with any mutation in MYH7.  
 
Family history of SCD 
Patients carrying sarcomere mutations have a higher proportion of family history of SCD in 
some cohorts [178], [22], [185], but not others [21], [179], [182], [184]. Pooled analysis (figure 
16) showed a significant difference in the proportion of patients with a family history of SCD 
between sarcomere-positive (27.0%, 95% CI of 23.5%-30.3%) and sarcomere-negative 
individuals (14.9%, 95% CI of 12.6%-17.2%, P-value<0.0005). Heterogeneity effects between 
studies were not significant (P-value=0.650). 
 




Figure 16. Forest plot from random effect meta-analysis showing a significant difference for the 
proportion of a family history (FH) of sudden cardiac death (SCD) between sarcomere-positive (27.0%, 
95% CI 23.5% to 30.5%) and sarcomere-negative individuals (14.9%, 95% CI 12.6% to 17.2%) (P-
value<0.0005). There were no significant heterogeneity effects (I
2
=0%, P-value=0.650). Reproduced with 
permission from [172]. 
 
 
In studies comparing MYBPC3 and MYH7 mutations, only one described an increased 
frequency of a family history of SCD in MYH7 patients [223]; this was not the case in others 
[176], [179], [182], [184]. The pooled analysis (figure 17) showed no difference between MYH7 
and MYBPC3 sub-groups regarding family history of SCD (P-value=0.651). 
 




Figure 17. Forest plot from random effect meta-analysis showing that the proportion of a family history 
(FH) of sudden cardiac death (SCD) is not different between MYBPC3 (31.6%, 95% CI 24.7% to 38.5%) 
and MYH7 patients (31.0%, 95% CI 22.5% to 39.5%) (P-value=0.651). No significant heterogeneity effects 
were observed (I
2
=0%, P-value=0.598). Reproduced with permission from [172]. 
 
 
Patients harbouring mutations in MYH7 had an increased family history of SCD compared to 
MYH7-negative individuals in one publication [181], although the same association was not 
described in another [177].  
 
4.2.4. INTERVENTIONS AND PROGNOSIS 
Implantable cardioverter-defibrillator (ICD) implantation 
Data on the frequency of ICD implantation in mutation carriers are contradictory, with some 
reporting an increased prevalence of implanted ICDs in sarcomere-positive patients compared 
to sarcomere-negative [21] and others no association with mutation status [178], [179],[184]. 
As studies reporting ICD implants are very heterogeneous with respect to design and data 
presentation, a pooled analysis was not possible. 
 
In the majority of studies comparing MYBPC3 and MYH7 mutation carriers, there were no 
differences in the frequency of ICD implantations [176], [179], [183].  One study, [174] 
reported an increased frequency of ICD implantation in patients with MYBPC3 truncating 
mutations and another [223] a higher number of ICD implantations in MYH7 mutations. Finally, 
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a study [177] reported an increased implantation of ICDs in MYH7-positive patients compared 
to MYH7-negative individuals, which was not observed in another report [224]. 
 
Septal myectomy and alcohol septal ablation  
A higher frequency of sarcomere mutations is reported in patients undergoing invasive septal 
reduction therapies alone in one study [183] and in another that combined treatment for left 
ventricular outflow tract obstruction with ICD implantation [174]. In contrast, three studies 




The majority of studies have found no association between genetic background and the 
prevalence of atrial fibrillation –[184], [185], [179], [224]. In one [178], chronic atrial fibrillation 
was significantly more prevalent at baseline evaluation in genotype-positive patients.  
 
Severity of disease, prognosis and outcome 
The great majority of genotype-phenotype correlation studies reporting on outcome are family 
focussed, analyse fewer than 100 individuals and are cross-sectional in design (table 2). A 
pooled analysis of outcomes was not performed. 
 
Four studies provided longitudinal follow-up data. One was confined to individuals with 
MYBPC3 mutations [195] (57 families and 167 genotype-positive individuals) and one to 
families with TNNT2 mutations [195] (20 families and 92 genotype-positive individuals). 
Another, reporting on unrelated probands, described a poorer prognosis in sarcomere 
mutation-positive patients, with an increased incidence of a combined endpoint of 
cardiovascular death, evolution to NYHA class III or IV heart failure and non-fatal stroke [178]; 
a fourth study [223] reported an increased incidence of SCD in MYH7 probands compared to 
MYBPC3 patients. 
 
Some familial studies describe a particularly severe phenotype and poor prognosis in 
individuals with multiple mutations (homozygous or compound and double heterozygous) 
[235], [236], [237], [238], [239], [240], [241]. An increased burden of risk factors for SCD and 
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higher likelihood of an evolution to a dilated phenotype was also reported in a series of triple 
mutation carriers [242]. 
 
Clinical Penetrance 
Penetrance is very variably reported in family studies. Some describe penetrance for the whole 
family, while others only for adults. Some examples of general associations between genotype 
and penetrance are reported for MYBPC3 [195], [243] (late onset and higher rate of 
incomplete penetrance in females), MYH7 [206], (age-dependent penetrance) and TNNI3 (high 
rate of incomplete penetrance) [195]. One study [126] reported later penetrance in MYBPC3 
families compared to MYH7 families, but another [133] described a higher than expected 
penetrance for a MYBPC3  mutation that generated a cryptic donor splice site. 
 
4.3. SUMMARY OF RESULTS 
 
Given the genetic and clinical heterogeneity that characterise HCM, it is not surprising that 
very few genotype-phenotype relationships have been shown to be reproducible. As the great 
majority of mutations are private (unique to each family) [195], studies lack statistical power 
to demonstrate correlations between individual mutations and phenotype. The variable 
expression of the same or similar mutations with respect to age at presentation, severity of 
hypertrophy and prognosis is another important confounder [204],[195] [140].  
 
As this systematic review shows, this genetic complexity has led to an exploration of genotype-
phenotype effects based on the affected gene rather than individual mutations.  The 
advantage of this approach is that it increases the sample size and power to detect 
associations, but as we show in this review, there are still substantial differences with respect 
to study design, case ascertainment and the depth of clinical phenotyping. In addition, the 
assignment of pathogenicity to genetic variants varies considerably and there is little 
consideration of other factors that might influence disease expression such as comorbidity and 
ethnic background. 
 
In spite of these limitations, the meta-analysis of pooled data does show that a small number 
of clinical variables are consistently associated with genotype; specifically, age at presentation, 
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maximum left ventricular wall thickness, and family history of HCM or SCD. For each of these 
parameters, the pooled association is significant for the comparison between sarcomere 
mutation-positive and negative patients, but not when comparing the two most frequently 
affected genes, MYBPC3 and MYH7. Patients carrying a sarcomere mutation seem to present 
earlier, have more severe hypertrophy, and have higher prevalence of a family history of the 
disease and SCD. Although data are limited, it does seem that patients with more than one 
sarcomere mutation also present earlier or with a more severe phenotype [21],[186, 227] and 
a higher likelihood of an evolution to a dilated phenotype [242], but this last observation 
requires further study.  
 
The consistent differences observed between sarcomere-positive and sarcomere-negative 
patients suggest that, in spite of heterogeneity across different genes and mutations, 
sarcomeric protein disease might be characterised by a class-effect. The corollary would be 
that HCM not caused by sarcomeric protein mutations has different clinical characteristics, 
natural history and prognosis, reflecting the large number of potential genetic and non-genetic 
mimics of HCM. The pooled data showing an increased prevalence of hypertension in 
sarcomere-negative individuals provides some circumstantial evidence for this hypothesis. 
 
The clinical value of the associations demonstrated in this meta-analysis is probably confined 
at present to the general counselling of families, and in particular relatives that are considering 
predictive genetic testing or parents seeking reproductive advice. Specific advice on 
therapeutic interventions requires more robust data than exist at present, particularly in 
relation to the natural history of individual mutations. This requires large-scale genotyping 
combined with new bioinformatic approaches that take into account the mutation type (e.g. 
missense versus truncating mutations) and the biological effect of the mutation on protein 
structure and function, including the functional domain [169]. The relatively high frequency of 
rare sarcomeric variation in general population databases [244],[245],[246],[247],[248] also 
makes attribution of causality extremely challenging. Finally, more sophisticated phenotyping 
tools that can detect early disease manifestations (intermediate phenotypes) are required to 










1- Improve understanding of genotype-phenotype relationships in patients with 
hypertrophic cardiomyopathy. 
2- Identify novel genetic causes and modifiers of the disease phenotype, using a high-
throughput sequencing approach. 
3- Develop methodologies for the interpretation of variants called by high-throughput 
technologies.  
6. HYPOTHESES 
 Distinct individual rare candidate variants in sarcomere and associated genes are 
associated with specific  sub-phenotypes 
 Distinct sarcomeric genes are associated with specific sub-phenotypes; 
 Non‐sarcomeric genes associated with other cardiomyopathies or channelopathies act 
as modifiers of the phenotype;  
 Copy-number variation explains some  “genotype-negative” cases; 
 Evaluation of the structural impact of missense variants improves the accuracy of in 
silico prediction of pathogenicity; 
 Sarcomere gene expression can be modified by variation in the non-coding regulatory 
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1. STUDY COHORT AND ETHICAL APPROVAL 
 
The study cohort comprised unrelated and consecutively evaluated patients with HCM 
referred to an inherited cardiovascular disease unit at The Heart Hospital, University College 
London (UCL), London, U.K.   
 
HCM was diagnosed in probands when the maximum left ventricular wall thickness (MLVWT) 
on two dimensional echocardiography measured 15 mm or more in at least one myocardial 
segment or when MLVWT exceeded two standard deviations corrected for age, size and 
gender in the absence of other diseases that could explain the hypertrophy. In individuals with 
unequivocal disease in a first degree relative, a diagnosis was made using extended familial 
criteria for HCM [249]. 
 
The project was approved by the UCL/UCLH Joint Research Ethics Committee (ethical approval 
is included in Appendix B). Before enrolment and venesection, all patients provided written 
informed consent (consent form is included in Appendix B) and received genetic counselling in 
accordance with international guidelines [101]. Blood samples were collected at routine clinic 
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2. TARGETED GENE ENRICHMENT AND HIGH-THROUGHPUT SEQUENCING OF 41 
CARDIOVASCULAR GENES 
 
The library design, capture protocol and sequencing platform development and optimization were 
coordinated by Dr. Mike Hubank, UCL Genomics, UCL Institute of Child Health, in collaboration with Dr. 
Petros Syrris, UCL Institute of Cardiovascular Science. Dr. Syrris conducted all the protocolized laboratory 
work from DNA extraction to the preparation of plates for the sequencing platform (phases I and II) at 
Paul O’Gorman building laboratory, UCL and Dr. Hubank coordinated the sequencing platform tasks at 
Institute of Child Health. My role consisted in: a) confirming that each individual sample already 
longitudinally collected for sequencing was from a case that strictly complied with diagnostic criteria for 
hypertrophic cardiomyopathy (as described above); b) prospectively selecting new samples while 
checking for those criteria and organizing the consent, counselling and sample collection at the 
outpatient clinic; b) prospectively organizing the collection of new samples in the outpatient clinic for 
Sanger confirmation, whenever the patient carried a variant that had criteria for confirmation (as 
described below); c) consenting and participating in genetic counselling for all the prospectively collected 
samples. I did not directly participate in the protocolized laboratory activities, i.e. DNA extraction, plate 
construction and sequencing platform tasks, but the methodology is included here for completion. 
 
The study was designed to screen 2.1Mb of genomic DNA sequence per patient, covering coding, 
intronic and selected regulatory regions of 20 genes known to be associated with HCM and 
dilated cardiomyopathy (DCM), 17 genes implicated in other inherited cardiomyopathies and 
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Table 4. Name of the targeted genes, Ensembl accession number, chromosomal position and size. 
(Ensembl: Feb 2009 (GRCh37/hg19). The total size of genomic sequence for 41 loci was approximately 
3Mb, which was reduced to 2.1Mb of capture sequence following the exclusion of repetitive DNA 
regions in the custom RNA bait library design with eArray (Agilent). Reproduced with permission from  
[251]. 
Gene Ensembl no 
Location 
Chromosome: base range 
Dimension 
(base-pairs) 
MYBPC3 ENSG00000134571 chr11:47352958-47374253 21,295 
MYH7 ENSG00000092054 chr14:23881948-23904870 22,922 
TNNI3 ENSG00000129991 chr19:55663137-55669100 5,963 
TNNT2 ENSG00000118194 chr1:201328143-201346805 18,662 
TPM1 ENSG00000140416 chr15:63334838-63364111 29,273 
MYL2 ENSG00000111245 chr12:111348626-111358404 9,778 
MYL3 ENSG00000160808 chr3:46899357-46904973 5,616 
ACTC ENSG00000159251 chr15:35080297-35087927 7,630 
TNNC1 ENSG00000114854 chr3:52485108-52488057 2,949 
MYH6 ENSG00000197616 chr14:23851199-23877482 26,283 
TTN ENSG00000155657 chr2:179390720-179672150 281,430 
PDLIM3 ENSG00000154553 chr4:186422852-186456712 33,860 
CSRP3 ENSG00000129170 chr11:19203578-19223589 20,011 
DES ENSG00000175084 chr2:220283099-220291459 8,360 
LMNA ENSG00000160789 chr1:156084461-156109878 25,417 
LDB3 ENSG00000122367 chr10:88428426-88495822 67,396 
VCL ENSG00000035403 chr10:75757872-75879912 122,040 
TCAP ENST00000309889 chr17:37821599-37822806 1,207 
PLN ENSG00000198523 chr6:118869442-118881586 12,144 
RBM20 ENSG00000203867 chr10:112404155-112599227 195,072 
JUP ENSG00000173801 chr17:39910859-39942964 32,105 
DSP ENSG00000096696 chr6:7541870-7586946 45,076 
PKP2 ENSG00000057294 chr12:32943682-33049780 106,098 
DSG2 ENSG00000046604 chr18:29078027-29128813 50,786 
DSC2 ENSG00000134755 chr18:28645944-28682388 36,444 
RYR2 ENSG00000198626 chr1:237205702-237997288 791,586 
TMEM43 ENST00000306077 chr3:14166440-14185180 18,740 
TGF-beta3 ENST00000238682 chr14:76424442-76448092 23,650 
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KCNQ1 ENSG00000053918 chr11:2466221-2870339 404,118 
KCNH2 ENSG00000055118 chr7:150642050-150675014 32,964 
SCN5A ENSG00000183873 chr3:38589554-38691164 101,610 
KCNE1 ENSG00000180509 chr21:35818989-35828063 9,074 
KCNE2 ENSG00000159197 chr21:35736323-35743440 7,117 
ANK2 ENST00000394537 chr4:113970785-114304894 334,109 
CASQ2 ENSG00000118729 chr1:116242628-116311426 68,798 
CAV3 ENSG00000182533 chr3:8775496-8788450 12,954 
KCNJ2 ENSG00000123700 chr17:68165676-68176181 10,505 
PLEC1 ENSG00000178209 chr8:144989321-145025044 35,723 
GJA1 ENST00000282561 chr6:121756745-121770872 14,127 
PKP4 ENSG00000144283 chr2:159313476-159537938 224,462 




2.1. PHASE I – LIBRARY DESIGN AND CAPTURE AND SEQUENCING PROTOCOL OPTIMIZATION  
 
A web-based design tool, eArray (Agilent Technologies, Santa Clara, CA, USA) was employed to 
design an initial SureSelect (Agilent) capture library of oligonucleotides (RNA bait groups) 
based on the target gene sequences using the following parameters: library size 1x55K; length 
120; tiling 1x.  
 
Control samples from patients with HCM who were known to carry disease-causing sequence 
variants, previously detected with conventional Sanger sequencing, were used in pilot studies 
to validate the method (data not shown, as this was an integral part of another Ph.D. thesis 
supervised by Dr. Mike Hubank, UCL Genomics). The library was used to capture the target 
regions from 8 patients, which were then sequenced (single end) on an Illumina GAIIx platform 
with 35 base-pair (bp) read length. Single-end sequencing of control samples with known 
HCM-related variants identified regions of low coverage possibly associated with suboptimal 
sample processing steps or low capture efficiency. The pilot study was used to optimise the 
protocol and to redesign the capture library, introducing double density cover to regions of 
low coverage and increase cover at the 5’ regulatory ends of genes. The following steps were 
adopted: single-end adapters were replaced with paired-end adapters; sequencing read length 
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was increased from 35 bp to 75 bp and the capture RNA bait library was redesigned with 
eArray to enrich regions with low coverage. The new design included an additional 965 RNA 
baits at 2x tiling for all <30 read depth regions, 2x tiling for 20 genes associated with HCM and 
DCM and redesigned sequence regions were extended 5-10Kb upstream of all genes. As a 
result 23,637 120 bp RNA baits were redesigned to target a total of 2.1Mb of genomic DNA.  
 
In order to increase efficiency and reduce costs, we adopted a 75 bp paired-end multiplexed 
sequencing method which allowed us to pool 12 samples into a single lane of an Illumina GAIIX 
flow cell and thus, taking into account internal controls, sequence a total of 84 samples in a 
single instrument run. The multiplex sequencing protocol was also tested using control 
samples. In early sequencing test runs, a total of 21 samples from HCM patients were sequenced 
as part of developing and optimising the method (data not shown – Dr. Mike Hubank, UCL 
Genomics).  
 
2.2. PHASE II – SEQUENCING OF THE STUDY COHORT  
 
For phase two, sample preparation was carried out as recommended by Agilent and initially 
based on the SureSelect Target Enrichment for Illumina paired-end multiplexed sequencing 
method. Genomic DNA shearing (3µg) per patient was performed on a Covaris E220 
instrument in 96-well plates. Fragmented DNA was end-repaired and “A” base addition was 
performed using the NEBNext DNA Sample Prep Master mix Set 1 (New England BioLabs). 
Ligation of indexing-specific paired-end adapters to DNA samples was performed using the 
Illumina Paired-End Genomic DNA Sample Prep Kit and the subsequent amplification of the 
adapter-ligated library was carried out with Herculase II Fusion DNA Polymerase (Agilent). 
Hybridization of amplified libraries to the SureSelect biotinylated RNA library (baits) was 
performed at 65ºC for 24 hours on a GeneAmp PCR System 9700 (AppliedBiosystems). 
Addition of index tags to the library preparation was achieved by PCR using the Illumina 
Multiplex Sample Preparation Oligonucleotide Kit and Herculase II Fusion DNA Polymerase 
(Agilent). Following the introduction of the SureSelectXT Target Enrichment protocol, all the 
above steps were performed with Agilent reagents as recommended by the manufacturer. 
Clean-up of DNA samples was performed according to the protocol using Agencourt AMPure 
XP beads and Dynal MyOne Streptavidin T1 magnetic beads (Invitrogen, hybridisation step). 
Quality of DNA samples throughout the protocol was assessed with Agilent 2100 Bioanalyzer 
DNA assays. All steps were performed manually using individual PCR tubes or 96-well plates 
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except the incubation of the hybrid-capture/bead solution (hybridisation step) on 96-well 
plates, which was carried out on the Bravo Automated Liquid Handling Platform (Agilent) using 
an Agilent instrument protocol with small modifications. Samples were subjected to standard 
Illumina protocols for cluster generation and sequencing. Paired-end multiplexed sequencing 
was performed on an Illumina GAIIX with twelve samples tagged with different index 
sequences (Illumina) combined in each lane. 
 
From plate 4 (234th patient) onwards, successive updated versions of the Agilent sample 
preparation protocol were used according to the manufacturer’s instructions. The latest version 
of SureSelect Target Enrichment for Illumina paired-end multiplexed sequencing protocol was 
v1.6 released in October 2013. (SureSelectXT Target Enrichment for Illumina paired-end 
sequencing library. Illumina HiSeq and MiSeq multiplexed sequencing platforms. Protocol. 
Agilent. version 1.6; October 2013). The main scientific principles of the updated versions 
remained the same but they contained a number of improvements in sample preparation 
compared to the initial protocol. The main changes referred to smaller initial quantities of 
genomic DNA (200ng to 3µg), use of Agilent enzymes and reagents throughout the protocol, 
optimisations of hybridisation steps and replacement of in-solution PCR procedure with an on-
bead PCR method. Introduction of additional SureSelect indexes allowed multiplexing of 16 
samples in a single pool. The resulting index-tagged sample pools were sequenced on the 
Illumina HiSeq 2000 system, a more powerful sequencer compared to GAIIX, which can 
generate up to 200Gb of sequencing data per run. (HiSeqTM 2000 sequencing system. 
Specification sheet: Illumina sequencing. Pub. No. 770-2009-036. 17 June 2010). Cluster 
generation on Illumina cBot was carried out according to the manufacturer’s protocol. A total 
of 128 HCM samples (16 multiplexed samples x 8 lanes) were sequenced (100bp, paired end) 
per instrument run, using standard methods (Illumina). 
 
2.3. SEQUENCING AND ANALYSIS OF UK10K CONTROL SAMPLES  
 
The UK10K project was designed to study the scope of rare genetic variation in longitudinally 
followed-up U.K. general population cohorts (e.g. the Avon Longitudinal Study of Parents and 
Children - ALSPAC), cohorts of individuals with neurodevelopmental disorders and rare disease 
cohorts. Details regarding the selection of the study samples can be found at www.uk10k.org. 
None of the UK10K control samples was recruited on the basis of a cardiac phenotype. 
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Sequencing results for the first 223 patients were compared with a set of 1,287 UK controls 
with exome sequence data generated by the UK10K project. These samples are the subset of 
UK10K whole-exomes for which ethics enabled their use as control samples as of November 
2012.  
 
The sequencing protocol for the UK10K project is available through its website (www.uk10k.org).  
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3. SEQUENCE DATA ANALYSIS FOR TARGETED EXONIC REGIONS 
 
The alignment and variant calling steps from the raw sequencing data, that generated initial datasets of 
variants, as well as the data extraction from UK10K and UCLexome and the related case-control 
analyses, were all developed and conducted by Dr. Vincent Plagnol, UCL Genetics Institute. The detailed 
methodology for Dr. Plagnol’s bioinformatic work is included in this thesis for completion (chapters 3.1, 
3.4, 3.5). My work consisted in all the downstream manual filtering, manual annotation, in silico 
prediction of pathogenicity and further analysis of each individual variant (part of chapter 3.1 and all 
chapter 3.2). At each time a new dataset of variants was generated through the bioinformatic pipeline, I 
checked the data for quality, discrepancies and errors, based in clinical judgment and results from the 
Sanger confirmation. I also confirmed the annotated frequency at available databases, i.e. 1000 
genomes and exome sequencing server. My close interaction and continuous guiding of the 
bioinformatic work led to several improvements of the pipeline during the development of my thesis, 
leading to a higher accuracy of the generated data.  
 
3.1. BIOINFORMATIC ANALYSIS PIPELINE 
 
For the case samples, paired-end reads were aligned using the Novoalign software v2.7.19 on 
the human reference genome build hg19 using quality score calibration, soft clipping and 
Illumina adapter trimming.  
 
On an initial stage (for the first 233 samples), following the exclusion of PCR duplicate reads 
(Picard MarkDuplicate tool), insertion-deletions (indels) and single-nucleotide polymorphisms 
(SNPs) were called using the software SAM (“Sequence Alignment/Map”) tools (version 0.1.18) 
[252]. Variants were filtered on the basis of the SAMtools Phred scale quality score greater 
than 20. 
 
At a later stage (for all samples), our calling strategy followed closely the Genome Analysis 
Toolkit (GATK) best practices as of January 2014 [253]. Following BAM file (defined as a binary 
version of a SAM file) compression using the GATK ReduceReads module [254], multi-sample 
calling was performed on all probands jointly with a set of 1,492 unrelated whole exomes 
(“UCL-exomes consortium”) using the GATK Unified Genotyper [254]. After GATK variant 
recalibration (separately for SNPs and indels) calls were annotated using the ANNOVAR 
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software (with the Ensembl gene definitions) [255]. For all association tests, we filtered 
variants for the GATK recalibration PASS filter. 
Candidate variants for further analysis were defined using frequency and predicted functional 
effect. For the functional filter, exonic non-synonymous, loss-of-function and splice-site 
variants were included.  
 
Initially, we used the allele frequency estimates from the 1,000 genomes project database 
[111] and we used a 0.5% minor allele frequency cut off (based on the November 2010 and 
May 2011 releases).  
 
All sequence data were later filtered using a minor allele frequency threshold of ≤ 0.2%, based 
on the National Heart, Lung and Blood Institute (NHLBI) exome variant server data (computed 
through the ANNOVAR annotations). To provide a more accurate estimate of variant frequency 
in controls that is not affected by potential differences in calling strategy in the NHLBI dataset, 
we randomly selected 25% of the 1,492 UCL-exomes samples as an “external control set” and 
removed variants that appeared more than twice in these 372 “external controls”. These 
samples were only used to define a variant frequency and were not included in the subsequent 
case-control test to avoid a previously noted statistical issue, where variant frequency is 
defined in the same set that is used for case-control testing [256].  
 
3.2. MANUAL ANNOTATION OF THE VARIANTS AND IN SILICO PREDICTION OF PATHOGENICITY 
 
I identified all variants present in the dbSNP build 137 database [257], published in the 
literature and includd in general and locus-specific genetic databases using ClinVar 
(http://www.ncbi.nlm.nih.gov/clinvar/), Human Gene Mutation Database – trial version 
(http://www.hgmd.org) and Health in Code Inc. mutation database (access allowed for the 
purpose of this research, courtesy of Dr. Lorenzo Monserrat, 
https://mutaciones.healthincode.com). The latter is a curated and annotated database of 
inherited cardiovascular disease genes, built within a genetic testing laboratory and to be used 
as a tool for reporting, that includes a review of the available literature on most of the 
published mutations.  
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In silico prediction of pathogenicity for novel missense variants was performed using 
Polyphen2, SIFT and Condel [159],[160],[161]. A variant was predicted to be pathogenic if: a) 
classified as “damaging” by SIFT and simultaneously “possibly” or “probably damaging” by 
Polyphen2, or b) predicted to be damaging by Condel.  
 
When a variant was not confirmed by Sanger sequencing or the quality of the call was in doubt, 
I used Integrative Genomics Viewer [258] (http://www.broadinstitute.org/igv/UserGuide) 
software to visualize the genomic region in detail (BAM files containing SNP and indels calls) to 
ascertain the veracity of the call.  
 
I plotted all the rare variants (MAF ≤ 0.5%) encountered in the 8 main sarcomere genes 
(MYBPC3, MYH7, TNNT2, TNNI3, MYL2, MYL3, ACTC1, TPM1) in a 2D graphic representation for 
better visualization, using the Plot Protein software (https://sites.google.com/site/plotprotein/) 
[259]. 
 
3.3. TITIN VARIANTS - MANUAL ANNOTATION AND PREDICTION OF PATHOGENICITY 
This part of the work was done in collaboration with Professor Mathias Gautel, King’s College London, 
who helped to generate a list of prioritized variants based in in-house built tools, including homology 
modelling for some of titin domains and prediction of interference with ligand binding. Prof. Gautel also 
coordinated the case-control comparison of the frequency of titin variants to look for enrichment. My 
role consisted in: a) providing and organizing the initial lists of rare/candidate titin variants; b) manually 
annotating those lists as to an initial prediction of the probable impact of the variants, including in silico 
prediction of pathogenicity of the missense variants and flagging potentially truncating vs others; c) 
checking for the frequency of the variants in general population variation databases; d) exploring the 
distribution of the variants along titin; e) organizing the collection of samples that allowed the 
confirmation of prioritized titin variants with Sanger sequencing. 
 
Due to the complexity of TTN structure and the number of encountered variants, the absence 
of adequate in silico pathogenicity prediction tools and the scarcity of pathogenicity 
annotation in the literature/ genetic databases, we opted for a strategy of prioritizing missense 
variants for further analysis, based on the physicochemical difference of the amino acid 
change, domain location, predicted structural effect and possible impact on interaction with 
titin ligands.  
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Titin variants that were predicted to cause degradation or a truncated form of the protein 
were also flagged. These included splice-site disrupting, frameshift insertion-deletions and 
stop-codon variants.   
The MAF of each individual titin variant was also compared with the MAF of the same variant 
in the 1000 genomes database [111], to calculate an enrichment score, and thereby define a 
sub-population of enriched variants for further analysis. 
 
3.4. ANALYSIS OF UK10K CONTROL SAMPLES AND CASE-CONTROL COMPARISON OF CANDIDATE NSSNPS 
Work done in collaboration with Dr. Vincent Plagnol, UCL Genetics Institute, as described above. 
 
For the UK10K samples, alignment was performed using Bowtie [260] and the calling algorithm 
merged the output of SAMtools (version 0.1.17) and GATK Unified Genotyper (version 1.3-21).  
 
To limit the technical difficulties associated with comparing sets of variants in controls and 
cases generated using different protocols and analyzed in different laboratories, we restricted 
our comparison to non-synonymous single nucleotide polymorphisms (nsSNPs), hence 
excluding insertion-deletions (indels) and larger copy number variants. We retrieved the data 
from the UK10K project and annotated nsSNPs as candidates using the same protocol and 
thresholds that were applied to the set of HCM cases.   
 
This analysis was restricted to the first 180 Caucasian HCM cases, which could be matched to 
the 1,287 UK10K control samples. All computations were performed using the statistical 
software ‘R’. Frequencies of candidate nsSNPs were compared between cases and controls. 
We then used the case-control data to infer the proportion of HCM cases explained by rare 
nsSNPs variants in each gene. We used a profile likelihood approach to estimate this 
parameter of interest (Appendix C - additional statistical methods).  
 
For genes showing a significant excess of rare nsSNPs, point estimates for the probability that 
a rare nsSNP is causal for HCM were estimated using the formula: (proportion of carriers of 
rare nsSNPs in cases - proportion of carriers of rare nsSNPs in controls)/ proportion of carriers 
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3.5. CASE CONTROL COMPARISON OF CANDIDATE NSSNPS WITH UCL-EXOMES COHORT 
Work done in collaboration with Dr. Vincent Plagnol, UCL Genetics Institute, as described above. 
 
Using a similar statistical approach, we compared the frequency of rare variants in each of the 
41 genes in the total HCM cohort of 874 individuals with the frequency of rare variants in each 
gene in the UCL-exomes cohort. 
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4. CLINICAL VALIDATION AND ASSESSMENT OF THE ACCURACY OF THE HIGH-
THROUGHPUT SEQUENCING PLATFORM AND ANALYSIS PIPELINE 
 
Work done in collaboration with Dr. Petros Syrris, who performed the laboratory work related to Sanger 
sequencing. My role consisted in: a) prospectively organizing the collection of new samples in the 
outpatient clinic for Sanger confirmation, whenever the patient carried a variant that had criteria for 
confirmation (as described below); b) consenting and participating in the genetic counselling for sample 
collection; c) analysing the results from the Sanger confirmation and comparing with the high-
throughput sequencing data to assess accuracy. This process led to improvements of the pipeline during 
the development of my thesis, allowing a higher accuracy of the generated data. 
 
Following improvement of coverage using the pilot control samples (Phase I as described 
above, chapter 2.1.), I designed a two-step continuous clinical validation of the HTS sequencing 
platform and analysis pipeline, mainly directed at the clinical exclusion/detection of false 
positives (specificity). However, in exons with a low mean coverage, Sanger sequencing was 
still performed because of the possibility of low sensitivity.  
 
4.1. STEP 1 –SYSTEMATIC VALIDATION OF ACCURACY FOR PLATES 1-3 (FIRST 223 PATIENTS) 
 
The following variants were submitted to conventional dideoxy sequencing using BigDye 
Terminator v3.1 sequencing chemistry (AppliedBiosystems) on a 3130xl capillary sequencer 
(AppliedBiosystems):  all variants with a read depth below 15; potentially pathogenic variants in 
sarcomeric and associated genes as well as published and potentially disrupting ion-channel and 
ARVC-associated variants.  
 
We also sequenced, using conventional dideoxy sequencing, those exons with an average read 
depth below 15: MYBPC3 exons 5 and 13; TNNI3 exon 1; KCNH2 exons 1 and 13.  All MYH6 
variants present in the first three plates were also confirmed using dideoxy sequencing, due to 
the high homology between MYH7 and MYH6 at DNA level, which could potentially generate 
false positive results. TTN variants judged to be relevant for further study (as described under 
chapter 3.3) were also confirmed by Sanger sequencing.  
 




4.2. STEP 2 – APPLICATION -  VALIDATION OF CLINICALLY ACTIONABLE VARIANTS (ALL PATIENTS) 
 
We carried out confirmations by conventional dideoxy sequencing using BigDye Terminator v3.1 
sequencing chemistry (AppliedBiosystems) on a 3130xl capillary sequencer (AppliedBiosystems) 
on the following:  potentially pathogenic rare variants in sarcomeric and associated genes as well 
as published and potentially disrupting ion-channel and ARVC-associated variants. Accuracy was 
calculated according to conventional formulae.  
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5. PHENOTYPE DATA COLLECTION AND GENOTYPE-PHENOTYPE ANALYSIS 
 
An observational, retrospective, longitudinal cohort study design was used. Initial evaluation 
and follow-up data were collected prospectively and registered in a relational database. All 
patients were evaluated every 6–12 months or earlier if there was a clinical event.  Follow-up 
data was collected until the 31st September 2013.  
 
The initial/baseline observation and physical examination of the patients, performance of the diagnostic 
tests and collection of the data into the database were prospectively conducted by various clinicians and 
researchers. I reviewed all the data, collected missing values, re-coded the variables as needed for the 
analyses, collected follow-up clinical, imaging and survival data, and collected and coded new 
parameters that were not present in the original database.  I designed and performed all the statistical 
analyses. 
 
5.1. DEMOGRAPHIC DATA AND SYMPTOMS 
 
Dyspnoea was coded according to the New York Heart Association (NYHA) classification. Chest 
pain was classified as exertional, if precipitated by physical activity and relieved by rest, or 
atypical. Palpitations were coded as a binary variable. Unexplained syncope was defined as 
unexplained transient loss of consciousness at or prior to first evaluation, suggestive of 
arrhythmic origin. 
 





All patients underwent 12 lead electrocardiography (ECG). Standard 12-lead ECG was 
performed in the supine position during quiet respiration. The following data was recorded 
and analysed for this work: heart rate, rhythm, QRS axis, PR interval and QRS duration.  
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5.3. CARDIO-PULMONARY EXERCISE TESTING  
 
Patients were exercised on a treadmill using the Bruce or modified Bruce protocols or on an 
upright bicycle ergometer using an incremental ramp protocol. Simultaneous 12-lead 
electrocardiography was performed throughout. Blood pressure was measured by auscultation 
of the brachial artery during deflation of a mercury sphygmomanometer at rest, every minute 
during exercise and for the first 5 min of recovery. Simultaneous respiratory gas analysis was 
performed using previously published methods [261]. Recorded heart rate and systolic blood 
pressure at rest and peak exercise was used in this work, as well as the blood pressure 
response (difference between maximal and rest systolic blood pressure). An abnormal 
response is defined below.  
 
5.4. AMBULATORY ECG MONITORING 
 
Patients underwent two or three channel 24 to 48 h ambulatory electrocardiogram 
monitoring, while performing unrestricted daily activities. The presence or absence of non-





Two-dimensional and M-mode echocardiography were performed using standard methods for 
chamber quantification [262], [263]. All dimensions were analysed as continuous variables. 
The end-diastolic dimension of the left ventricle was re-coded as a binary variable for analysis 
(dilated versus non-dilated), using a cut-off of 55mm. Fractional shortening was also analysed 
as both a continuous and a binary variable; a FS ≤ 25% was used to define systolic left 
ventricular dysfunction. 
 
End-diastolic LV wall thickness was recorded at mitral valve and papillary muscle level in the 
anterior and inferior septum and in the anterior, lateral, inferior and posterior LV wall using 
short-axis two-dimensional echo images. Wall thickness at the apex was measured in the two-
chamber, four-chamber and short-axis apical views. The pattern of hypertrophy was classified 
as asymmetric septal, predominantly apical or concentric [262].  The definitions of the pattern 
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and severity of the left ventricular hypertrophy (LVH) were as previously published [6]. 
 
Left ventricular outflow tract velocities were measured using continuous wave Doppler, and LV 
outflow tract gradients were calculated using the modified Bernoulli equation. A maximal left 
ventricular outflow tract gradient (LVOT) ≥ 30 mmHg at rest was used to define obstructive 
HCM and allowed re-coding of this continuous parameter into a binary variable (obstructive 
versus non-obstructive). When the maximal LVOT was ≥ 50 mmHg, the phenotype was 
recoded as severely obstructive. 
 
Quantification of diastolic function and valvular regurgitation followed established guidelines 
[264], [265]. The severity of diastolic dysfunction and mitral regurgitation were re-coded as 
binary variables, with a cut-off of ≥ moderate to define the sub-groups. 
 
The presence of right ventricular hypertrophy was defined as a right ventricular free wall 
thickness ≥ 6mm measured at the parasternal or subcostal view [266].  
 
5.6. DEFINITION OF THE CLINICAL RISK FACTORS FOR SUDDEN CARDIAC DEATH 
 
Major risk factors for SCD [5, 139],[267],[261] were defined as:  family history of sudden 
cardiac death at an age ≤ 40 years or SCD in a relative with confirmed HCM at any age;  
unexplained syncope (defined above); NSVT during ambulatory ECG monitoring, defined as 3 
or more ventricular premature complexes at a rate of ≥ 120 bpm, lasting <30 s [268]; 
maximum left ventricular wall thickness ≥ 30 mm; an abnormal blood-pressure response 
during symptom limited upright exercise testing, defined as a failure of systolic blood pressure 
to rise by > 25 mm Hg from baseline values or a fall of > 10 mm Hg from the maximum blood 
pressure during upright exercise [269]. 
 
5.7. CARDIAC MAGNETIC RESONANCE PROTOCOL 
 
Approximately one-third of the cohort (N=271, 31%) was submitted to cardiac magnetic 
resonance imaging as part of the clinical assessment. Standard clinical scans (localizers, three 
long-axis views, black and white blood images, full LV short-axis stack) were performed using a 
1.5-T magnet (Avanto, Siemens Medical Solutions, Erlangen, Germany). CMR short-axis 
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volumetric studies [270] were acquired from retrospectively-gated, breath-held, balanced, 
steady-state free-precession cines. LV volumes, ejection fraction (EF) and LV mass were 
determined according to standardized CMR methods [271] (papillary muscles were included in 
the LV mass). LV wall thickness was calculated for the septum and posterior wall on end-
diastolic and end-systolic short-axis cine frames. End-systolic left atrial areas were measured 
by planimetry on 4-chamber view. AMVL length was measured using the method described in 
[272]. Presence of rest LV outflow tract obstruction and systolic anterior motion of the mitral 
valve leaflet were noted. Breath-held, delayed contrast enhancement images acquired through 
an inversion recovery sequence were obtained 7-15 min after injection of 0.1 mmol/kg 
gadolinium-DTPA.  
 
5.8. STATISTICAL ANALYSIS 
 
R (version 3.0.0) and IBM SPSS (version 22.0.0.0) were used for the analyses. 
 
5.8.1. DESCRIPTIVE STATISTICS AND COMPARISON OF MEANS AND PROPORTIONS BETWEEN GROUPS 
Clinical phenotype data are presented as frequency (and percentage) for non-continuous 
variables and mean +/- standard deviation or median and interquartile range (IQR) for 
continuous variables where appropriate. Normally distributed continuous variables were 
compared using unpaired two-tailed Student t test.  Multiple groups were compared using 
analysis of variance (ANOVA). Categorical variables were compared using Chi-squared or Fisher 
exact tests. When appropriate, non-parametric tests were used.  
 
Group comparisons were made for the prevalence and severity of each phenotypic trait (at 
baseline and final follow-up) and for survival (see below) in patients with versus without a 
candidate rare (MAF≤0.2%) variant in one or more of the eight most common sarcomeric 
protein (SP) genes (MYH7, MYBPC3, TNNI3, TNNT2, MYL2, MYL3, ACTC1, TPM1). We also 
compared the prevalence and severity of each phenotypic trait between patients carrying only 
one compared to more than one variant in SP genes. The same comparisons were made for 
the presence versus absence of rare variation in each SP-associated gene and non-SP gene. 
 
All the above was done 1) for the whole cohort and 2) only within in the subgroup of 
sarcomere-positive individuals.  This was based on the hypothesis that by selecting a more 
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homogeneous group in terms of biological cause, additional genotype-phenotype associations 
could be discovered, namely regarding possible modifier effects of non-SP genes. 
 
Direct comparisons were also made between the four most frequent SP genes- MYBPC3, 
MYH7, TNNT2 and TNNI3 for each phenotypic trait. Additionally, I repeated all the above 
comparisons, only using the variants in silico predicted to be pathogenic, to test the relevance 
of such tools for genotype-phenotype association discovery, hypothesizing that such a filtering 
would generate a dataset of variants with an increased biological effect, that could reveal 
additional correlations, despite the slightly decreased statistical power (due to a lower number 
of variants). 
 
For TTN variants, additional genotype-phenotype analysis were conducted using linear 
discriminant analysis and multivariate logistic regression (stepwise backward selection and an 
alpha-value of 0.05 for model retention). 
 
5.8.2. MULTIPLE COMPARISON CORRECTION STRATEGY 
For each clinical trait of interest we tested the effect of variants in several genes: 8 SP genes 
and 28 non-SP genes (excluding the 4 candidate genes GJA1, PKP4, PNN and PLEC1 - and TTN). 
Therefore, a nominal P-value of 0.05 was not appropriate. In addition, the Bonferroni 
correction for the number of phenotypes multiplied by the number of genes is too stringent, 
because it tests the global null of no association between any pair of gene/trait. We therefore 
took an intermediate approach, correcting for each phenotype for the number of gene tests.  
For SP genes, we performed 9 tests (one per SP gene, plus an additional test for all SP 
mutations combined). Therefore, we used P < 0.0056, which is 0.05/9. For non-SP genes, we 
corrected for 28 tests, which translates into P < 0.0018 = 0.05/28. Data on associations that did 
not fulfil these thresholds but met a nominal P-value of < 0.05 are also presented in the results 
section. 
 
5.8.3. LOGISTIC REGRESSION ANALYSIS AND CONSTRUCTION OF A MODEL AND SCORE TO PREDICT THE PRESENCE 
OF A SARCOMERE PROTEIN GENE MUTATION 
The parameters that were found to be significantly associated with the presence of a 
candidate variant in any of the 8 main SP genes were used to build a model and a score for 
prediction of genotype status. Continuous variables were transformed in categorical binary 
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variables, by applying cut-off values based on receiver operating characteristic (ROC) curve 
analysis. Logistic regression used a stepwise backward selection and an alpha-value of 0.05 for 
model retention. The weights of each parameter in the final model / genotype prediction score 
were calculated by dividing each regression coefficient by the lowest regression coefficient and 
rounding to the nearest integer. Hosmer-Lemeshow goodness-of-fit statistic was used to 
evaluate model precision and the diagnostic accuracy was analysed by ROC curve analysis. 
 
5.8.4. SURVIVAL ANALYSIS 
Survival from cardiovascular death (combining sudden cardiac death, heart failure related 
death and stroke related death) and sudden cardiac death (SCD)/appropriate implantable 
cardioverter-defibrillator (ICD) shocks was modelled using Kaplan-Meier analysis and log-rank 
test, from the first clinical evaluation at The Heart Hospital and from birth. Definition of the 
endpoints and outcome was performed as previously published [6],[261]. Sudden cardiac 
death was defined as witnessed sudden cardiac death with or without documented ventricular 
fibrillation or death within 1 h of new symptoms; nocturnal deaths with no antecedent history 
of worsening symptoms were included in this category. Progressive heart failure was defined 
as death preceded by signs and/or symptoms of heart failure, including cardiogenic shock. 
Heart transplantation was defined as orthotopic heart transplantation performed for end-
stage disease with systolic impairment and refractory congestive symptoms. Other 
cardiovascular death was defined as stroke, pulmonary or systemic embolism and myocardial 
infarction. Non-cardiovascular death was defined as death secondary to non-cardiovascular 
events and of unknown cause. 
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6. SCREENING FOR COPY NUMBER VARIATION  
 
Work done in collaboration with Dr. Vincent Plagnol, UCL Genetics Institute, who developed the read-
depth methodology for CNV calling that was here applied to the HCM samples and also analysed the 
aCGH data using R software (snapCGH). My work consisted in: a) visual analysis and filtering of the 
initial results from read-depth analysis; b) selection of the CNVs for confirmation with aCGH; c) 
contribution to the design of the CGH array; d) analysis of the aCGH validation results with Cytosure 
Software; e) search publicly available databases (e.g. dbVar) for the presence of the validates CNVs and 
f) clinical characterization of patients carrying CVNs.  
 
Given the recent development of bioinformatic algorithms that allow the detection of 
structural variation from high‐throughput short-read sequencing data [151]-[152] and 
considering my hypothesis that structural variation could explain at least part of the 
sarcomere-negative cases, we have screened the available HTS data with the aim of detecting 
CNVs in cardiac sarcomeric protein genes. 
 
6.1. STUDY POPULATION  
 
The population comprised the first 505 unrelated and consecutively evaluated patients of the 
studied cohort. 
 
6.2. BIOINFORMATIC ANALYSIS FOR THE DETECTION OF COPY-NUMBER VARIATION – EXOMEDEPTH 
 
Raw sequence reads in fastq format were aligned against the National Center for 
Biotechnology Information (NCBI) build 37 of the human reference genome using Novoalign 
(v2.08.03). We used a custom bed file summarizing the exons of the 41 targeted genes and the 
R package ExomeDepth v0.97 to count the reads overlapping each exon. ExomeDepth [273] 
uses a read depth approach, and compares the observed number of reads mapping to each 
exon with its expectation based on a comparison set (called the “aggregate reference set”) 
built based on other samples processed within the same experiment and designed to 
technically match the test sample as closely as possible. For each test sample, we used 
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ExomeDepth to build this aggregate reference set and called CNVs using the default 
ExomeDepth parameters. 
 
I focused my analysis in 19 genes previously associated with cardiomyopathy – MYBPC3, MYH7, 
TNNT2, TNNI3, MYL2, MYL3, TPM1, ACTC1, TNNC1, MYH6, LDB3, PDLIM3, CSRP3, DES, TCAP, 
VCL, PLN, LMNA, RBM20.  
 
For further confirmation, we prioritized CNVs found in these genes for which the statistical 
evidence was convincing (log likelihood ratio in favour of a CNV event, as determined by 
ExomeDepth, greater than 7). 
 
6.3. ARRAY COMPARATIVE GENOMIC HYBRIDIZATION 
An aCGH was designed to validate the ExomeDepth called CNVs and to verify that its algorithm 
identified all CNVs. This was done via the Agilent eArray server 
(https://earray.chem.agilent.com/earray/). This was designed to cover 2.1Mbp of sequence 
across the target genes, with 3 probes per exon.  
 
To determine if the aCGH called any CNVs in the selected samples, results were first analysed 
using the Cytosure Interpret software  
(http://www.ogt.co.uk/products/246_cytosure_interpret_software). 
 
Additionally, the Log2 ratios were processed in R, using the package snapCGH [274], which uses 
a Hidden Markov Model based segmentation algorithm for the aCGH intensity data. An 
experiment without measurement or normalization errors run on a normal copy number 
variant null clone would yield a Log2 aCGH probe intensity ratios of 0 because the test and 
reference sample would be equivalent. The Log2 ratio of a heterozygous deletion is Log2(1/2) = 
-1 and a heterozygous gain is Log2(3/2)= 0.58. To limit the background noise, we used the 
"minimum" snapCGH method which simply subtracts the background value from that of the 
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7. ANALYSIS OF THE NON-CODING REGIONS 
 
The available non-coding sequence data from the targeted genes have been screened for 
putative functional variants, with the aim of testing the hypotheses that sarcomere gene 
expression could be changed by variation in the non-coding regulatory regions of the DNA and 
that this variation could be the direct cause of at least a proportion of the unexplained familial 
cases. 
 
The bioinformatic steps of variant alignment and calling, that generated an initial raw list of non-coding 
variants, were done by Dr. Vincent Plagnol, UCL Genetics Institute. My work consisted in all the 
methodology developed and described in 7.2, including downstream filtering, manual annotation, in 
silico analysis of the non-coding variants and generation of a list of putative functional non-coding 
variants. 
 
7.1. STUDY COHORT  
 
This analysis was performed in the first 233 patients of the cohort. 
 
7.2. ANALYSIS OF THE NON-CODING VARIANTS  
 
The noncoding regions of the 8 sarcomere genes most commonly associated with HCM (MYH7, 
MYBPC3, TNNT2, TNNI3, MYL2, MYL3, ACTC1, TPM1) were analysed. Variants present in the 
dbSNP build 135 database [257] were identified. 
 
I buildt the candidate regulatory variant dataset by mapping non-coding variants onto known 
transcription factor (TF) binding sites, identified by ChIP-seq as part of the ENCODE project 
[155],[156] using the UCSC genome browser (http:/genome.ucsc.edu/) [275]. RegulomeDB 
(http://regulome.stanford.edu/) was used to assess the level of evidence supporting those 
transcription factor binding sites, according to available datatypes [276]. Targetscan 
(http://www.targetscan.org/) [277] and miRTar (http://mirtar.mbc.nctu.edu.tw/human/) were 
utilized to identify predicted 3’UTR miRNA target regions. I assessed cardiomyocyte expression 
levels of potentially relevant transcription factors and miRNAs using BioGPS annotation portal 
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(http://biogps.org/#goto=welcome) [278],[279] and mimiRNA 
(http://mimirna.centenary.org.au/mep/formulaire.html)  [280] respectively.  Evolutionary 
conservation of the variant position at the DNA was analysed using genomic evolutionary rate 
profiling (GERP) conservation score [281].  
 
Transcription factors previously experimentally proven to be involved in relevant pathways for 
cardiomyocyte hypertrophic signaling, were then identified through a literature search. I used 
a Pubmed search that combined the name of each transcription factor with either “heart”, 
“cardiac”, hypertrophy”, “cardiomyocyte” or “cardiomyopathy”.  
 
7.3. EXPRESSION STUDY IN PATIENT SAMPLES VERSUS CONTROLS 
 
The laboratory work for this chapter, consisting in RNA extraction from the selected samples, followed by 
array quantification, was done by Dr. Mike Hubank, UCL Genomics, Institute of Child Health, following 
the protocol described below. I identified the samples carrying potentially functional non-coding 
variants; data analysis for comparison with controls was done as part of my own work, in collaboration 
with Dr. Hubank. 
 
Paraffin embedded cardiac tissue samples were available for two patients with potentially 
functional (Results Section, chapter 8) non-coding variants, that had undergone surgical septal 
myectomy for relief of left ventricular outflow tract obstruction. Local ethical approval had 
been obtained from University College London Hospitals/UCL joint ethical committee for 
collection of tissue samples.  
 
Total RNA was prepared from 8 x 10 um sections from paraffin blocks using the ReliaPrep FFPE 
total RNA mini prep kit (Promega, cat Z1001). Following RNA quality check on an Agilent 
Bioanalyser, 50 ng was amplified and labelled using the SensationPlus FFPE amplification and 
labelling module (Affymetrix, 902042) before hybridising to Affymetrix HuGene 1.0 ST arrays.  
 
Labelling and scanning was performed following standard Affymetrix protocols to generate .cel 
files. Data analysis was performed in Genespring 12. Briefly, cel file data from experimental 
material was combined with data from cel files from GEO submission GSE22253 (Gene 
expression and genotype in normal heart; samples  GSM954999_VC_A1.cel-
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 GSM955004_VC_A6.cel; available at 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22253) [282] and re-normalised 
using RMA to generate comparable expression profiles. Individual genes were then compared 
for normalised expression values against the control database samples.   
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8. WHOLE-EXOME SEQUENCING AND DATA ANALYSIS OF SARCOMERE-NEGATIVE 
FAMILIES 
 
High-throuhgput capture platforms that allow the sequencing of the entire coding region of 
the genome (the “exome”) have been applied both in the research and clinical contexts and 
advocated as a possible alternative to targeted gene sequencing for diagnostic purposes 
and/or novel causal gene discovery. We have applied a whole-exome sequencing strategy to 
three sarcomere-negative families with 2 or more relatives affected, to test the hypothesis 
that novel causal genes could be the genetic cause of the disease in HCM sarcomere-negative 
families. The preliminary results are presented as part of this thesis.  
 
8.1. SAMPLES 
Three families with at least two affected members without any candidate sarcomere candidate 
variants from the targeted HTS were selected for whole-exome sequencing. 
 
8.2. GOSGENE APPLICATION AND COLLABORATION 
 
The Centre for Translational Genomics-GOSgene initiative funded by the Great Ormond Street Hospital 
(GOSH) Biomedical Research Centre (BRC) of the National Institute for Health Research (NIHR) offers 
clinicians and PIs at the joint GOSH, ICH and UCL collaborators a comprehensive service to facilitate gene 
identification in uncharacterised genetic disorders. Due to the nature of this project, an application to 
GOSgene was submitted and approved by the GOSgene Access Committee in November 2012. The 
collaborative agreement was for GOSgene to perform exome next generation sequencing in 6 samples, 
two affected individuals from each of 3 families.  
 
The steps described in 8.3 to 8.5, from sequencing to variant calling, that allowed a raw dataset of 
whole-exome variants to be generated, were conducted by GOS gene; the methodology, which followed 
established protocols, is briefly described below.  
 
My work consisted in all the downstream filtering, prioritization, annotation and analysis of the detected 
variants, as well as the initial selection and clinical phenotyping of the enrolled families.  
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8.3. DNA QUANTIFICATION AND QUALITY 
 
DNA from peripheral blood of the patients was received and the GOSgene team run quality 
controls (QCs) measurement required for next generation sequencing technologies. DNA 
concentration and purity was assessed by a Thermo Scientific NanoDrop™ 1000 
spectrophotometer according to the manufacturer’s protocol. DNA concentration from all 
individuals sequenced was also assessed by fluorometric assay using a Qubit® 2.0 Fluorometer 
(Life Technologies) following manufacturer’s instructions. Exome sequencing was performed 
by Beckman Coulter Genomics (Danvers, MA, USA). As per Beckman Coulter Genomics’ 
requirements, 3ug of DNA at 100ng/µl according to Qubit reading were prepared in 30µl of 
H2O. Only samples with an A260/A280 ratio of 1.8-2.0 were sent. To assess DNA integrity, 1µl of 
diluted DNA (100ng/µl) was run on a 1% agarose gel with 1Kb ladder alongside.  
 
8.4. EXOME CAPTURE AND SEQUENCING 
 
Samples were processed using Agilent 51Mb SureSelect Target Enrichment, Human All Exon 
version 4 (Agilent Technologies). The SureSelect Human All Exon kit design covers 1.22% of 
human genomic regions corresponding to the NCBI Consensus CDS database (CCDS). Samples 
were processed according to the SureSelect target Enrichment System for Illumina Paired-End 
Sequencing Library Protocol and run on an Illumina HiSeq2000 sequencer, paired end 2x100bp 
read length with an aimed median coverage of 89x. Samples were multiplexed 4 per lane on 
the HiSeq2000 flowcell to aim for 89x coverage. FASTQ files generated from the sequencing 
run were shipped back from Beckman Coulter Genomics to UCL on an external hard drive. 
 
8.5. EXOME ANALYSIS 
 
The sequencing reads resulting from the HiSeq2000 were aligned by the GOSgene 
Bioinformatics team to the human reference genome (GRCh37 release, downloaded from the 
ENSEMBL database, corresponding to Hg19 NCBI built 37.1) with BWA (Burrows-Wheeler 
Alignment Tool) software [283]. The GATK tool suite was used to further process the 
alignments (base quality score recalibration, indels realignment, duplicate removal, using 
standard hard filtering parameters). Variant calling was also performed using GATK Unified 
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Genotyper multi-sample SNP caller [253]. A summary of the sequencing coverage produced by 
GATK DepthOfCoverage profiler is shown in Results, chapter 9. 
 
8.6. FILTERING AND PRIORITIZATION OF VARIANTS 
 
BAM files containing SNP and indels calls were visualised using the Integrative Genomics 
Viewer IGV (http://www.broadinstitute.org/igv/UserGuide).  
 
SNPs and small insertions/deletions (indels) annotation and interpretation analysis were 
generated through the use of Ingenuity Variant AnalysisTM software 
(www.ingenuity.com/variants) from Ingenuity Systems.  
 
In summary, starting with 7259895 variants spanning 21421 genes, variants were kept with call 
quality at least 20.0 in cases or at least 20.0 in controls.  
 
Initial downstream variants analysis included the assessment of the quality of the reads from 
the BAM files, existing structural variations in the chromosomal region, assessment of the 
novelty against internal GOSgene databases (for common currently not submitted variants), 
details of gene functions (review of databases and literature), affected domains and prediction 
of the biological impact (SIFT, Polyphen and Mutation Taster), amino acid conservation, 
expression pattern, existing animal models and any other relevant information (including 
phenotype indications via OMIM and HGMD). 
 
Variants were then prioritised by predicted frequency starting from “novel” variants (i.e. not 
annotated in databases including dbSNP, NHLBI Exome Sequencing Project (ESP) and 
1000genomes) and predicted effect (starting from essential splice site, stop gained, stop lost, 
frameshift indels and non-synonymous variants).   
 
Parameters used in the Ingenuity Variant Analysis software for filtering of the variants, in order 
to generate an initial candidate dataset for each family, were: 
- MAF ≤ 1% in the 1000 genomes database AND exome sequencing project 
- absent from dbSNP 
- absent from controls 
- absent from in-house GOSgene database 
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- in common for the family members affected 
- non-synonymous, splicing, frameshift 
- localization in genes previously related to cardiomyopathy 
  
I used the detailed script, as follows: 
 
“Excluded those variants that are observed with an allele frequency greater than or equal to 1.0% of the 
genomes in the 1000 genomes project OR greater than or equal to 1.0% of the public Complete 
Genomics genomes OR greater than or equal to 1.0% of the NHLBI ESP exomes (All) OR present in dbSNP. 
 
Kept those variants that are experimentally observed to be associated with a phenotype: Pathogenic, 
Possibly Pathogenic, Unknown Significance, Possibly Benign, Benign OR established gain of function in 
the literature OR gene fusions OR inferred activating mutations by Ingenuity OR predicted gain of 
function by BSIFT OR in a microRNA binding site OR Frameshift, in-frame indel, or stop codon change OR 
Missense OR disrupt splice site upto 10.0 bases into intron OR deleterious to a microRNA OR structural 
variant 
 
Kept those variants which are associated with gain of function OR compound_heterozygous OR 
hemizygous OR heterozygous_alt OR homozygous OR heterozygous_amb OR heterozygous OR 
haploinsufficient AND occur in at least 2 of the case samples at the gene level in the Case samples AND 
not which are associated with gain of function OR compound_heterozygous OR hemizygous OR 
heterozygous_alt OR homozygous OR heterozygous_amb OR heterozygous OR haploinsufficient AND 
occur in at least 1 of the control samples at the variant level in the Control Samples 
 
Kept those that are within 2 hops upstream and that are known or predicted to affect: cardiomyopathy, 
cardiomyocyte abnormalities, cardiomyocyte acidosis, cardiomyocyte activation (activation of 
cardiomyocytes), cardiomyocyte adhesion (adhesion of cardiomyocytes), cardiomyocyte aging, 
cardiomyocyte apoptosis, cardiomyocyte area, cardiomyocyte atrophy, cardiomyocyte autophagy, 
cardiomyocyte beat, cardiomyocyte beating, cardiomyocyte binucleation (binucleation of 
cardiomyocytes), cardiomyocyte chemoinvasion (chemotaxis of cardiomyocytes), cardiomyocyte 
cleavage, cardiomyocyte content, cardiomyocyte contractility, cardiomyocyte contraction (contraction of 
cardiomyocytes), cardiomyocyte coupling, cardiomyocyte cytokinesis, cardiomyocyte cytonecrosis, 
cardiomyocyte damage, cardiac abnormality, cardiac abnormality (organismal abnormalities of heart), 
cardiac activation, cardiac anterior wall hypertrophy, cardiac apoptosis, cardiac arrhythmia, cardiac 
arrhythmia of cardiac ventricle, cardiac arrhythmia of heart atrium, cardiac atrophy, cardiac beating, 
heart abnormality, heart abnormality (organismal abnormalities of heart), heart activation (activation of 
heart), heart apex hypertrophy, heart apoptosis, myocardial cells activation, myocardial cells adhesion, 
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myocardial cells binucleation, myocardial cells chemoinvasion, myocardial cells contraction, myocardial 
cells degeneration, myocardial cells desensitization, myocardial cells differentiation, myocardial cells 
division, myocardial cells dysfunction, myocardial cells function, myopathy, myopathy of heart, ZASP-
related myofibrillar myopathy (myofibrilliar myopathy ZASP-related) or diseases consistent with these 
phenotypes” 
 
All candidate genes in the obtained list were checked for cardiac expression using GeneCards 
(http://www.genecards.org) and BioGPS (www.biogps.org) [278]. 
 
Prioritised candidates variants were confirmed by PCR and Sanger sequencing using the 
methodology previously described in chapter 4. 
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9. IN SILICO ANALYSIS AND STRUCTURAL IMPACT PREDICTION OF MISSENSE VARIANTS 
IN  MYH7 
 
My work consisted in:  a) manually curating a list of MYH7 variants detected in this cohort and extracted 
from the mentioned databases; b) assessing the degree of evidence for the pathogenicity of these 
variants and the frequency of the variants in general population databases; c) annotating the associated 
phenotypes; d) manually introducing each variant at the SAAPdap software and annotating the 
predicted impact in protein structure; e) manually analysing the relationship between the obtained 
impact and the phenotype.  The results and data generated from the manual analysis inspired a 
machine-learning work developed by  Dr. Andrew Martin, Structural and Molecular Biology, UCL. The 
methodology developed and applied by Dr. Martin is described below for completion and the results 
presented in the Results section. During the development of the machine learning work, I continuousy 
discussed the obtained results and data with Dr. Martin, which lead to several optimizations of the 
algorithm  
 
9.1. DATASET OF MYH7 VARIANTS  
 
I built a dataset of beta-myosin heavy chain variants detected in this cohort of consecutively 
evaluated unrelated HCM patients (as described in previous chapters). To increase the number 
of variants analysed, I enriched this dataset with other established disease-causing or likely 
pathogenic variants in MYH7, for which limited phenotypic data was available from a genetic 
testing company database (Health in Code, Inc. - courtesy Dr. Lorenzo Monserrat) and from 
the Human Gene Mutation Database (free trial version, accessed Abril 2012). These additional 
variants were associated not only with HCM but also with dilated cardiomyopathy (DCM), left 
ventricular non-compaction (LVNC), various skeletal myopathies and congenital heart disease. 
All selected variants were rare as defined by a minor allele frequency (MAF) ≤ 0.5% in the 
Heart, Lung and Blood Institute (NHLBI) exome sequencing project database. 
 
I analysed the distribution of the mutations throughout the different domains of the protein 
(P12883), based on the boundaries for the different domains and sub-domains available at 
UniProtKB/SwissProt (http://www.uniprot.org) and Pfam (http://pfam.xfam.org) 
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The expected number of mutations for each residue (Ea) was calculated based on Ea =Na x 
Mt/Nt, where: Ea is the expected number of mutations for amino acid a, Na is the total 
number of amino acids of type a in the protein, Mt is the total number of mutations observed 
and Nt is the total number of residues.  
 
9.2. PREDICTION OF IN SILICO PATHOGENICITY  
 
Prediction was performed using Polyphen2 [160], SIFT [159] and SAAP (single amino acid 
polymorphism) data analysis pipeline (SAAPdap) [166] (http://www.bioinf.org.uk/saap/dap/), 
which indicates whether a mutation is likely to have a detrimental effect on structure using 
cutoff values, and also provides continuous values for each of the analyses. SAAPdap-based 
evaluated features were: a) Interface: Residue is in an interface according to difference in 
solvent accessibility between complexed and un-complexed  forms;  b) Binding: Residue makes 
specific interactions with a  different protein chain or ligand; c) SProtFT: Residue is annotated 
as functionally relevant by UniProtKB/SwissProt; d) Clash: Mutation introduces a steric clash 
with an existing residue; e) Void: Mutation introduces a destabilizing void in the protein core; 
f) CisPro: Mutation from cis-proline,  introducing an  unfavorable  ω torsion angle;  g) Glycine: 
Mutation from glycine, introducing unfavorable  torsion angles; h) Proline: Mutation to proline, 
introducing unfavorable  torsion angles;  i) HBond: Mutation disrupts a hydrogen bond;  j) 
CorePhilic: Introduction of a hydrophilic residue in the protein core; k) SurfacePhobic: 
Introduction of a hydrophobic residue on the protein surface; l) BuriedCharge: Mutation 
causes an unsatisfied charge in the protein core; m) SSGeom: Mutation disrupts a disulphide 
bond; n) Impact: Residue is significantly conserved. 
 
9.3. MANUAL ANALYSIS OF ASSOCIATIONS BETWEEN STRUCTURAL CONSEQUENCES AND PHENOTYPE  
 
I tested the association between each of three available phenotype parameters (maximum 
wall thickness (MLVWT), age at presentation and HCM versus other phenotypes) and: a) effect 
of each of the SAAPdap predicted structural features; b) effect of any of the predicted 
SAAPdap structural features versus absence of any structural effect; c) number of SAAPdap 
structural features affected; d) in silico prediction by SIFT, Polyphen2 or both; e) functional 
domain affected.  
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I also tested for associations between functional domain affected and: a) the presence of each 
of the predicted structural features; b) presence of any of the predicted structural features 
versus none; c) number of SAAPdap structural features affected. 
 
All these associations were tested using Chi-square tests. 
 
9.4. MACHINE LEARNING ANALYSIS TO PREDICT PATHOGENICITY AND PHENOTYPE 
 
Initial pathogenicity prediction was performed using the SAAPpred (predictor), trained on 
HumVar, which is constituted by all human disease-causing mutations from UniProtKB, 
together with common human nsSNPs (MAF>1%) without annotated involvement in disease, 
which were treated as non-damaging [166]. SAAPpred makes use of the analyses from 
SAAPdap to make a prediction of pathogenicity; thus a mutation with no analyses individually 
expected to be damaging can still be predicted to be pathogenic as a result of the accumulation 
of a number of more subtle effects. Ten pre-built models were used and the performance 
results were averaged.  
 
The same approach was used in phenotype prediction for separating mutations associated with 
HCM and DCM. As a starting point, any mutations associated with multiple phenotypes or 
causing phenotypes other than HCM or DCM (i.e. restrictive cardiomyopathy, left ventricular non-
compaction, congenital heart disease, distal myopathies) were discarded. The major problem 
encountered was the unbalanced nature of the dataset; many more mutations existed for 
HCM than for DCM. Perl code was written to limit the size of each class by selecting examples 
at random. For example, if the class size was limited to 21, the complete DCM class was retained 
while 21 mutations were selected at random from the HCM class.  This random selection 
process was repeated 10 times to provide a representative sample of the HCM class and the 
results were averaged. Because the available dataset was limited in size, it was desirable to use 
mapping to multiple structure. For that a Perl program was written to split the HCM and DCM 
unique mutations with available PDB (Protein Data Bank, 
http://www.rcsb.org/pdb/home/home.do) structures into 10 sets of approximately the same 
size. Each of these 10 sets in turn was chosen as a test set and enlarged with all the available 
PDB/chain structures. The remaining 9 sets were used for training by randomly drawing 
balanced datasets of different sizes from the mutations as mapped to protein chains. Results 
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were averaged across the 10 models built using all DCM and different subsets of HCM.  
 
Mutations were represented by a total of 47 ‘features’ from the structural analysis. Of these, 
13 were found to be redundant (i.e. they had the same value for all examples in the dataset), 
thus reducing the number to 34 features. These data were then used to train Random Forest 
models in WEKA. Then, a simple cut-off for each of the 14 major features was used to suggest 
whether they were damaging using SAAPdap results. Chi-square tests were performed to 
investigate which features were most informative. 
 
After determining the optimum number of features and trees, together with exploration of the 
most informative feature subsets, different numbers of models were also investigated (5, 10 
and 20 models).  
 
Addition of the ‘clustering’ feature (see Results Section, chapter 10.3) was also explored.  To 
use this information in machine learning, the centroid of each cluster was calculated and the 
feature vector for each mutation was expanded by the addition of the distances from the C-
alpha of the mutated residue to each of the three centroids. 
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1. STUDY COHORT CHARACTERIZATION 
 
Eight-hundred-and-seventy-four unrelated and consecutive patients with HCM were studied.  
Mean follow-up time was 4.8±3.5 years. Table 5 summarizes the demographic and clinical 
characteristics of the patients. 
 
 
Table 5. Demographic and clinical characteristics of the study cohort. HCM: hypertrophic 
cardiomyopathy; SCD: sudden cardiac death; NYHA: New York Heart Association; ECG: 
electrocardiography; CPEX: cardiopulmonary exercise test; SBP: systolic blood pressure; LVH: left-
ventricular hypertrophy; RVH: right ventricular hypertrophy; FS: fractional shortening; LVOT: left 
ventricular outflow tract; NSVT: non-sustained ventricular tachycardia. 
 
 
Frequency (percentage) or mean ± standard deviation (range) 
or median (IQR) 
DEMOGRAPHICS  
Age at initial evaluation (years) 49.6±15.4 (6-87) 
Male 590/874 (67.8%) 
Ethnicity 
– Caucasian 













Family history of HCM 226/853 (26.5%) 
Family history of SCD 182/872 (20.9%) 
NYHA class III or IV  100/850 (11.8%) 
Syncope  140/856 (16.4%) 
Chest pain 205/854 (24.0%) 
INITIAL ECG  
Atrial fibrillation 43/874 (4.9%) 
PR interval (msec) 174.8±32.4 (108-320) 
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QRS duration (msec) 101.0±25.5 (64-238) 
INITIAL CPEX  
SBP rest (mmHg) 128.8±21.0 (80-210) 
SBP difference (mmHg) 48.5±24.2 (-5 - 150) 
Abnormal systolic blood pressure 
response to exercise  
92/662 (13.9%) 
INITIAL ECHOCARDIOGRAPHY  
Maximal left ventricular wall thickness  
(mm) 
18.5±4.4 (9-38) 
Severe LVH (≥30mm) 17/601 (2.8%) 
Right ventricular hypertrophy (>5mm) 184/864 (21.3%) 
Asymmetric septal hypertrophy 
pattern 
643/850 (75.6%) 
Left atrial diameter (mm) 44.0±7.5 (18-90) 
Left ventricular end-diastolic diameter 
(mm) 
45.9±5.9 (29-65) 
Left ventricular dilatation (> 55 mm) 38/851 (4.5%) 
Left ventricular end-systolic diameter 
(mm) 
28.5±5.6 (9-50) 
Fractional shortening  (%) 38.3±8.2 (16-70) 
Systolic dysfunction (≤ 25% FS) 29/829 (3.5%) 
E wave Deceleration time (ms) 221.0 (184-268) 
Mitral regurgitation – 
moderate/severe 
163/851 (19.2%) 
Peak LVOT gradient (mmHg) 12.0 (4.0-60.0)  
LVOT gradient > 30 mmHg 328/812 (40.4%) 
NSVT – Holter  127/566 (22.4%) 
FOLLOW-UP   
New-onset atrial fibrillation  216/874 (24.7%) 
Implantable cardioverter-defibrillator 177/874 (20.3%) 
Myectomy 130/874 (14.9%) 
Alcohol septal ablation 46/874 (5.3%) 
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Myectomy and/or alcohol septal 
ablation and/or pacemaker 
implantation for LVOT gradient 
reduction 
182/874 (20.8%) 
Cardiovascular death 25/874 (2.9%) 
Sudden cardiac death 16/874 (1.8%) 
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2. TARGETED GENE ENRICHMENT AND HIGH-THROUGHPUT SEQUENCING – COVERAGE 
AND READ DEPTH DATA 
 
The mean value of the per-sample average read depth in the exonic target region across the 
samples was 472.27±127.68. Thirty-four samples had an average read depth lower than 40, 
with a minimum of 8.  Combining all samples and taking the mean value across all samples, 
93.5% of the target region was covered to a read depth of 15 or more.  
 
2.1. ANALYSIS PER PLATE  
 
Considering that there were differences in sequencing platform, multiplexing methodology 
and sample preparation between different plates, particularly from plate 4 onwards compared 
to the previous plates (see Methods Section, chapter 2), it is informative to analyse the 
average read depth per plate, which was: 73.39±108.0 for plate 1, 203.0±223.95 for plate 2, 
351.86±222.17 for plate 3, 494.13±84.21 for plate 4, 480.02±112.64 for plate 5, 486.13±104.56 
for plate 6, 495.34±80.09 for plate 7, 40.12±53.14 for plate 8, 500.30±67.50 for plate 9. Figure 
18, A-G.  
 
When analysing the percentage of acceptable coverage (>15x) per plate, I obtained an average 
of 89.79% in plate 1; 85.78% in plate 2; 87.55% in plate 3; 97.09% in plate 4; 97.90% in plate 5; 
96.35% in plate 6; 97.05% in plate7; 88.39% in plate 8; 98.06% in plate 9. 
 
The significantly lower average read depth for plate 8 was due to sub-optimal clustering, prior 
to the sequencing process. However, the coverage is similar to the first three plates, from 
which the calls were submitted to a process of systematic validation as described on the 
Methods Section, chapter 4; results are presented in the next chapter. From that validation 
process we concluded that even for low read depths the accuracy was acceptable. Therefore, 
even with lower read depth, the calls from plate 8 were considered of adequate quality and 
are under continuous clinical validation.  
 
 





















Figure 18. Box-and-whisker plots, representing the read-depths across the targeted genes, for A: plate 1-
3, B: plate 4, C: plate 5, D: plate 6, E: plate 7, F: plate 8, G: plate 9. The horizontal line on each graph 
represents the read-depth=15 cut-off. Panel A is adapted with permission from [251]. 
 
 
2.2. ANALYSIS PER GENE 
 
The read depth for each gene, across all plates/samples and subdivided in plates 1-3 and 4-9 -
due to differences in the sequencing platform and multiplexing - is shown in table 6. 
 
 
Table 6. Pooled analysis of read depth per gene, across all plates and subdivided in plates 1-3 and 4-9. 
Plate 8 was excluded from this analysis due to a significant lower average read depth caused by sub-
optimal clustering prior to the sequencing process, as explained in the previous sub-chapter.  
Gene 
Read depth (mean±standard 
deviation) – total cohort 
Read depth 
(mean±standard 
deviation) – plates 1-3 
Read depth 
(mean±standard 
deviation) – plates 4-9 
excluding 8 
CASQ2 276.86±163.48 126.95±99.70 391.11±82.55 
LMNA 116.34±86.23 32.50±46.02 173.85±56.23 
TNNT2 234.43±153.91 81.56±85.81 341.91±84.69 
RYR2 311.07±171.42 153.40±106.43 433.83±72.35 
PKP4 268.08±150.95 131.27±93.27 374.64±70.35 
TTN 376.94±178.59 218.07±116.64 505.87±60.86 
DES 185.88±132.31 61.02±77.34 274.28±82.96 
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CAV3 117.82±86.32 33.68±52.06 174.66±55.85 
TMEM43 170.76±117.21 61.48±67.04 249.40±72.92 
SCN5A 142.33±102.01 48.86±60.92 209.05±67.06 
MYL3 213.23±151.42 69.19±85.89 314.77±95.05 
TNNC1 198.68±132.39 64.44±75.64 292.00±69.31 
ANK2 313.00±170.80 157.36±105.40 435.29±71.96 
PDLIM3 309.38±161.18 159.17±98.17 426.44±61.34 
DSP 283.53±159.19 141.66±102.65 394.43±77.07 
PLN 331.15±156.14 194.99±104.16 441.72±62.00 
GJA1 350.13±171.19 196.60±121.24 471.72±63.13 
KCNH2 75.90±57.41 19.28±29.25 114.22±37.88 
PLEC 64.98±52.40 13.73±24.94 99.22±36.94 
VCL 319.27±171.78 159.17±105.74 442.56±72.44 
LDB3 201.48±131.64 75.29±75.99 292.39±74.02 
RBM20 280.49±165.02 122.52±104.01 397.17±77.90 
KCNQ1 121.80±92.20 32.27±47.45 183.22±60.97 
CSRP3 320.32±179.02 149.94±110.10 448.48±78.68 
MYBPC3 130.06±96.00 35.44±51.90 194.83±60.43 
PKP2 264.55±150.21 122.76±90.03 372.11±67.03 
MYL2 287.29±186.78 102.85±106.25 418.70±98.32 
MYH7 250.14±163.68 90.86±98.35 364.02±87.74 
PNN 300.39±171.86 135.88±98.53 423.83±78.38 
MYH6 247.17±163.90 84.89±95.16 361.91±87.46 
TGFB3 215.83±137.01 87.01±78.46 310.46±76.79 
ACTC1 260.42±152.83 118.23±91.69 367.46±77.61 
TPM1 274.76±149.64 141.47±100.48 378.85±70.43 
TCAP 115.25±87.35 31.47±44.98 172.66±59.65 
JUP 100.27±75.15 28.12±40.50 149.81±50.35 
KCNJ2 286.38±168.03 118.36±88.90 408.33±77.16 
DSC2 310.41±164.50 152.45±96.81 430.88±61.82 
DSG2 297.71±162.81 147.85±99.22 414.17±70.51 
TNNI3 153.16±101.62 49.77±54.90 225.15±53.44 
KCNE2 317.72±191.15 144.69±118.00 448.93±104.02 
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3. CLINICAL VALIDATION AND ASSESSMENT OF THE ACCURACY OF THE HIGH-
THROUGHPUT SEQUENCING PLATFORM AND ANALYSIS PIPELINE 
 
3.1. STEP 1 – SYSTEMATIC VALIDATION OF ACCURACY FOR PLATES 1-3 (FIRST 223 PATIENTS) 
 
We successfully validated by Sanger sequencing: 
- all novel and/or potentially pathogenic variants in desmosomal or ion-channel disease 
genes;  
- 48 out of 50 variants with a sufficient quality score but a read depth lower than 15; the 
two exceptions were one missense variant in LDB3 and one frameshift deletion in 
KCNH2;  
- all the MYH6 and MYH7 variants;  
- 45 out of 46 TTN variants were confirmed (one insertion-deletion was wrongly 
annotated).  
In total, 123 out of 126 variants were confirmed, including 16 insertions and deletions and 110 
single base-pair substitutions. This indicated that the approach has a very low false positive 
rate even with a lower read depth.  
 
Regarding the screening of exons with low average read depth (Methods Section, chapter 4), 
only one false negative was found, c.459delC, p.P153fsX5 in MYBPC3. This indicated that the 
sequencing protocol has a very low rate of false negatives, even for lower read depths.  
 
3.2. STEP 2 – APPLICATION -  VALIDATION OF CLINICALLY ACTIONABLE VARIANTS (ALL PATIENTS) 
 
As part of the application phase, we obtained the results for 117 of the variants flagged for 
validation, counselling and clinical use, for which 85 were confirmed and 28 were already 
known from clinical Sanger sequencing conducted in other laboratories. This is equivalent to 
113 true positives (positive predictive value of 96.58%); four variants (2 from the same patient) 
were not confirmed. 
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4. CODING SEQUENCE DATA ANALYSIS 
 
Initial genotype calling generated 90551 exonic and splice-site calls distinct from the reference 
sequence, that corresponded to a total of 7261 distinct variants present in the 874 patients. 
After exclusion of synonymous substitutions, we found 37913 non-synonymous exonic and 
splice-site calls (4105 distinct variants). 
 
After filtering for frequency (for a minor allele frequency (MAF) ≤ 0.5%), we selected 1555 
distinct rare variants (2502 calls); when excluding titin, 826 distinct rare non-synonymous 
exonic or splice-site variants (1236 calls) were obtained as candidates for further analysis. The 
list of candidate variants is provided in Appendix D. In total, 830 patients (95.0%) carried at 
least one variant in the targeted genes, 701 patients (80.2%) when excluding TTN. Six-
hundred-and-thirty-eight (73.1%) patients carried multiple variants, 392 when excluding TTN 
(44.8%).  
 
4.1. SARCOMERE PROTEIN GENE VARIANTS 
 
Using a cut-off MAF of 0.5%, 411 patients (47.03%) carried 272 rare distinct variants in one or 
one or more of the eight sarcomeric protein genes most commonly associated with HCM 
(MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, ACTC1 and TPM1) (table 7). One-hundred-and-
forty-five (53.3%) of these variants were previously published 
[20],[23],[284],[285],[128],[173],[176],[286],[125],[287],[288],[289],[188],[123],[130],[218],[17
],[16],[290],[291],[121],[292],[293],[294],[169],[174],[196],[224],[295],[250],[296],[297],[126],[
298],[227],[181],[299],[178],[300],[212]. Forty-five (16.5%) were novel missense variants 
predicted in silico to be pathogenic and 43 (15.8%) were novel potential loss-of-function 
variants. As such, a majority (85.6%) of these variants are strong candidates for pathogenicity 
and were present in 394 patients (45% of the cohort).  
 
At a cut-off for rarity of minor allele frequency (MAF) ≤ 0.2%, three-hundred-and-eighty-three 
patients (43.8%) had 265 distinct rare variants in the same eight main sarcomere protein genes. 
One-hundred-and-forty-two (53.5%) of these rare variants were previously published as 
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disease-causing mutations, 44 (16.6%) were novel missense variants predicted in silico to be 
pathogenic and 40 (15%) were novel potential loss-of-function variants.  
 
 
Table 7.  Prevalence of rare variants in the eight main sarcomere genes. The number and proportion of 
individuals for each individual gene excludes patients carrying more than one variant, who are grouped 
under “multiple”. MAF: minor allele frequency. 
Gene 
Number of 




individuals (MAF ≤ 
0.2%) 
Number of 




individuals (MAF ≤ 
0.5%) 
ACTC1 3 0.8 3 0.73 
MYBPC3 191 49.9 199 48.4 
MYH7 99 25.9 104 25.3 
MYL2 6 1.6 5 1.2 
MYL3 4 1.0 5 1.2 
TNNI3 15 3.9 15 3.7 
TNNT2 20 5.2 20 4.9 
TPM1 8 2.1 12 2.9 
Multiple 37 9.7 48 11.7 
Total 383 100 411 100 
 
 
Thirty-four patients (3.9%) carried multiple candidate variants in these sarcomere protein 
genes, if considering a MAF cut-off of 0.2%. Forty-eight (5.5%) carried multiple candidate 
variants for a MAF cut-off of 0.5%. The distribution of sarcomere variants in patients with 
multiple variants considering a MAF ≤ 0.5% is shown in Figure 19. Thirty-two (66.7%) of the 
compound, double and triple heterozygotes carried a cardiac myosin binding protein C 
(MYBPC3) variant as one of the candidate sarcomere variants. Twelve patients were 
compound heterozygotes for MYBPC3, one patient was homozygous for a MYBPC3 variant and 
seven patients were compound heterozygotes for MYH7.  
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Figure 19. Number of patients with different combinations of multiple sarcomere variants (MAF≤0.5%). 
Adapted with permission from [251]. 
 
 
In order detect possible clustering of rare variation in certain domain/regions of the sarcomere 
proteins, I plotted the tabulated variants (≤0.5% MAF) in simple models (Plot Protein 









































Figure 20.  Illustrations of the distribution of mutations across the domains of seven of the eight main 
sarcomeric proteins. ACTC1 is not represented due to the very low number of variants in that gene 
(three). For MYBPC3 and MYH7, sub-panels are used in order to cover the entirety of the protein, given 
the high number of variants and the larger size of those two proteins.  CC: coiled-coil; EF: EF-hand 
domain; IG: immunoglobulin domain; FN: fibronectin domain.   
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For MYBPC3, MYH7, MYL2 and MYL3 variants tended to be located in functionally annotated 
domains rather than inter-linker regions. In MYH7 the great majority of variants reside in the 
myosin-head region and neck compared with the coiled-coil rod domain. For TNNT2 and TNNI3, 
a clustering of variants was observed at the C-terminal region. 
 
4.2. OTHER SARCOMERE AND ASSOCIATED GENES 
 
Expanding the analysis to 19 sarcomeric and related / cytoskeletal genes previously associated 
with HCM or DCM – excluding the highly variable titin – resulted in the detection of 446 
distinct rare variants in 549 patients (62.8%) at a 0.5% MAF cut-off. At a 0.2% MAF cut-off, 432 
distinct variants were detected in 457 patients (52.3%). The number of variants found in each 
gene, as well as the predicted functional consequence, is summarised in table 8.   
 
From the 446 variants, 163 (36.6%), present in 322 patients (36.9%), have been previously 
published as pathogenic mutations [297], [295], [296]. Ninety-eight (22.0%) were novel 
missense variants predicted in silico to be pathogenic and 57 (12.8%) were novel nonsense, 
frameshift insertion-deletions or splice-site variants predicted to cause loss-of-function (table 
8). In total, a majority (71%) of these variants are strong candidates for pathogenicity and were 
present in 515 patients (58.9% of the cohort). 
 
Fifty-nine rare (MAF≤0.5%) variants in MYH6, six previously published as disease-causing 
mutations [301], 5 predicted to cause loss-of-function and 26 predicted insilico to be 
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Table 8 Number of distinct rare variants in sarcomeric, Z-disc and calcium-handling genes (MAF cut-off 




Total number of distinct 






predicted in silico to 
be pathogenic  
Nonsense, frameshift or 
splice- site variants 








MYBPC3 126 64 14 32 
MYH7 78 48 15 3 
TNNI3 12 9 2  
TNNT2 20 13  4 
MYL2 7 4 3  
MYL3 5  5  
ACTC1 3 1 1  
TPM1 13 3 4 1 
Subtotal  264 142 44 40 





   
MYH6 53 6 23 5 
TNNC1 4  2 1 
PLN 7  2 2 
CSRP3 9 1 4 2 
TCAP 7 1   
LDB3 13 5 2 1 
VCL 20 3 4 1 
PDLIM3 9  1  
DES 3  1 1 
LMNA 9  1 1 
RBM20 33 1 10  
Subtotal 167 17 49 14 
TOTAL 432 159 93 54 
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Table 9 shows the distribution of patients according to the strength of the evidence supporting 
causality for the detected candidate variants. 
 
 
Table 9.  Level of evidence for the pathogenicity of the distinct variants (“others” – novel missense 
variants not predicted to be pathogenic insilico) . Adapted with permission from [251]. 
 N of patients (%) 
Sarcomere genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, ACTC1, 
TPM1) 
411 (47.03%) 
Published mutation  291 (33.3%) 
Loss of function / insilico predicted to be damaging  103 (54/49) (11.79%) 
Others  17 (2.0%) 
Other sarcomere and sarcomere-associated genes (titin excluded): TNNC1, 
MYH6, VCL, CSRP3, DES, LDB3, LMNA, RBM20, TCAP, PLN, PDLIM3 
138 (15.8%) 
Published mutation  31 (3.6%) 
Loss of function/ insilico predicted to be damaging 90 (18/72) (10.3%) 
Others 17 (1.9%) 
Total 549 (62.8%) 
 
 
4.3. FIRST CASE – CONTROL ANALYSIS: COMPARISON OF NSSNPS BETWEEN THE FIRST 223 HCM CASES AND 
UK10K CONTROLS 
 
For the first 223 patients we combined non-synonymous single nucleotide polymorphims 
(nsSNPs) to test for an overall enrichment in HCM cases compared to the general population. 
For the control set and in a first phase, we used the UK10K exome sequence dataset (see 
Methods Section, chapter 3).  To avoid technical artefacts associated with indel calling, and to 
properly match cases and controls, we restricted this analysis to nsSNPs and the first 180 HCM 
Caucasian HCM cases. Data for the 19 sarcomere and associated genes is summarised in table 
10 and for the eight sarcomere genes most commonly implicated in HCM in figure 21.  
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Four of the sarcomere genes (MYH7, MYBPC3, TNNI3, TNNT2) and also PLN showed an excess 
of rare nsSNP in cases compared to controls (two-tailed Fisher exact P < 0.05), which is 
consistent with the established causal role of rare nsSNPs in these genes. We used these case-
control data to extrapolate the proportion of HCM cases in the general population explained 
by variants in each of these genes (see Methods Section, chapter 3 and table 10). Rare nsSNPs 
in MYH7 explained the largest fraction, with between 9.6 and 20.7% of HCM cases (95% 
confidence interval (CI)). MYBPC3 harbours a significant number of loss-of-function indels that 
are excluded in this first case-control analysis, therefore underestimating the contribution of 
MYBPC3. 
 
Assuming that an excess of candidate variants in HCM cases reflects their disease-causing 
potential, these data can be used to estimate the probability that a candidate nsSNP found in a 
HCM case is disease causing (see Methods Section, chapter 3 and table 10). We found that 
these estimates are largely dependent of the genetic variability for each gene in the general 
population. As an example, nsSNPs in MYH7 explain between 9.6 and 20.7% of HCM cases and 
a rare nsSNP in MYH7 found in a HCM case is estimated to have 86% probability to be causal 
for HCM (table 10). Higher estimates are obtained for rare nsSNPs in the genes TNNT2 and 
TNNI3, even though the contribution of these genes to HCM cases is lower. This is a 
consequence of the much lower presence of nsSNPs in these genes in the control population 
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Table 10.  Rare nsSNPs frequency comparison between my sequencing results and a set of 1,287 UK 
controls with exome sequence data generated by the UK10K project (www.uk10k.org) for 19 HCM/DCM 
associated genes. To avoid technical artefacts associated with indel calling, and to properly match cases 
and controls, we restricted this analysis to nsSNPs and the first 180 HCM UK Caucasian HCM cases. The 
columns show: the proportion of the 1,287 UK controls with exome sequence data generated by the 
UK10K project (www.uk10k.org) and 180 HCM cases that carry rare nsSNPs (rare defined by frequency 
less than 0.5% in the 1000 Genomes dataset), a Fisher exact test P-value to quantify the case-control 
difference, the 95% confidence interval for the estimated proportion of HCM cases explained by rare 
nsSNPs variants in each gene (Appendix C - additional statistical methods), and (in the rightmost column) 
the estimated probability that a rare nsSNP found in a HCM case in each gene is disease causing 
(Appendix C - additional statistical methods). nsSNP: nonsynonymous single nucleotide polymorphism; 
CI: confidence interval. Significant P-values in bold. Adapted with permission from [251]. 
 
Gene 
Rare nsSNPs – 
Frequency in 
controls 




95% CI for the 
proportion of cases 
explained 
Probability that 
a nsSNP is causal 
MYH7 0.025 0.172 3.86E-13 [0.0964-0.207] 0.856 
TNNT2 0.003 0.044 8.41E-05 [0.0136-0.0708] 0.930 
TNNI3 0.000 0.017 0.002 [0.00333-0.0415] 1.000 
MYBPC3 0.045 0.106 0.007 [0.014-0.104] 0.570 
PLN 0.001 0.022 0.001 [0.006-0.0498] 0.965 
MYL2 0.007 0.022 0.065 [0-0.044] NA 
MYL3 0.004 0.011 0.208 [0-0.0301] NA 
ACTC1 0.001 0.006 0.230 [0-0.0167] NA 
TPM1 0.000 0.006 0.123 [0-0.0167] NA 
CSRP3 0.012 0.028 0.168 [0-0.0467] NA 
MYH6 0.053 0.056 0.608 [0-0.0501] NA 
DES 0.005 0.011 0.256 [0-0.0294] NA 
TNNC1 0.000 0.000 1.000 [0-0] NA 
LDB3 0.012 0.011 1.000 [0-0.0228] NA 
TCAP 0.004 0.000 1.000 [0-0] NA 
LMNA 0.005 0.000 1.000 [0-0] NA 
RBM20 0.061 0.056 0.871 [0-0.0361] NA 
PDLIM3 0.011 0.000 0.241 [0-0] NA 
VCL 0.038 0.028 0.677 [0-0.0244] NA 
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Figure 21 Rare nsSNPs frequency comparison between my sequencing results and a set of 1,287 UK 
controls with exome sequence data generated by the UK10K project (www.uk10k.org) for the 8 
sarcomere genes most commonly associated with HCM. The frequency of MYH7, MYBPC3, TNNT2 and 
TNNI3 candidate nsSNPs is significantly higher in this cohort as also shown in table 10. nsSNP: 
nonsynonymous single nucleotide polymorphism. Reproduced with permission from [251]. 
 
 
4.4. SECOND CASE – CONTROL ANALYSIS: COMPARISON OF ALL TYPES OF VARIANTS BETWEEN ALL THE 874 HCM 
CASES AND UCL-EXOME CONTROLS 
 
In a second phase, we compared the aggregated frequency of all types of rare variation in 
sarcomere and associated genes, between the total HCM cohort and the UCL-exome 
sequencing dataset. Because the sequencing methodology and also the variant calling and 
annotation pipeline are similar for the case and control population, the analysis was not 
restricted to nsSNPs. 
 
The results were similar to the first case-control analysis and are summarized in table 11 and 
figure 22. The same four sarcomere genes showed a significant difference between cases and 
controls, now with MYBPC3 as the most significantly different, which is due to the inclusion of 
missense, splice-site and frameshift variants (and not only missense). In this second phase, 
CSRP3 and PLN also showed a significantly higher prevalence of rare variants compared with 
controls. 
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Table 11. Case-control comparison for the frequency of very rare (MAF<0.2%) variants between the 874 
cases and UCL-exome controls for sarcomere and associated genes, ordered by P-value. Significant P-
values in bold. Adapted with permission from [251]. 
Gene Ensembl ID 
Frequency –  
cases 
Frequency  - 
controls 
P-value 
MYBPC3 ENSG00000134571 0,322 0,058 4,23E-36 
MYH7 ENSG00000092054 0,148 0,030 9,75E-19 
TNNT2 ENSG00000118194 0,038 0,005 0,000000956 
TNNI3 ENSG00000129991 0,025 0,001 0,00000409 
CSRP3 ENSG00000129170 0,016 0,005 0,0151 
PLN ENSG00000198523 0,007 0,001 0,0377 
TPM1 ENSG00000140416 0,011 0,005 0,122 
PDLIM3 ENSG00000154553 0,013 0,007 0,188 
MYL2 ENSG00000111245 0,010 0,006 0,256 
TNNC1 ENSG00000114854 0,005 0,002 0,26 
MYL3 ENSG00000160808 0,007 0,004 0,299 
MYH6 ENSG00000197616 0,075 0,068 0,329 
ACTC1 ENSG00000159251 0,003 0,002 0,427 
RBM20 ENSG00000203867 0,051 0,056 0,7 
DES ENSG00000175084 0,003 0,003 0,766 
LMNA ENSG00000160789 0,011 0,016 0,854 
LDB3 ENSG00000122367 0,021 0,031 0,896 
VCL ENSG00000035403 0,030 0,040 0,909 
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Figure 22. Rare variant (nsSNPs+LOFs+splice-site) frequency comparison between my sequencing results 
and the UCL-exome dataset as controls, for the eight sarcomere genes most commonly associated with 
HCM. The frequency of MYH7, MYBPC3, TNNT2 and TNNI3 candidate variants is significantly higher in 
this cohort, as also shown in table 11. Due to the inclusion of LOF and splice-site variants, the 
prevalence and statistical significance of MYBPC3 variants increased compared to figure 21. Adapted 
with permission from [251]. 
 
 
4.5. RECURRENT VARIANTS IN HCM CASES 
 
We also investigated whether nsSNP variants were found in multiple HCM cases, suggesting 
individual mutations as potentially common genetic causes of HCM.  
 
For the first set of 223 patients, we found 3 rare nsSNPs for which the single SNP case-control 
P-value was less than 0.05 compared with the UK10K population, in MYPC3, MYH7 and TNNT2 
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Table 12. Candidate variants present in the first 223 HCM cases for which the single nsSNP case-control 
P-value between HCM cases and UK10K controls was < 0.05. MAF: minor allele frequency. Adapted with 
permission from [251]. 











MYBPC3 NM_000256:c.G1484A:p.R495Q 3 0.008333333 0 0.001833766 Yes 
TNNT2 NM_001001432:c.C296T:p.A104V 3 0.008333333 0 0.001833766 Yes 
MYH7 NM_000257:c.G1988A:p.R663H 3 0.008333333 0 0.001833766 Yes 
 
 
When analysing the whole cohort of 874 patients vs UCL-exome, four different individual 
variants showed a significant P-value for the difference between cases and controls, all in 
MYBPC3 and all previously published. Table 13.  
 
 
Table 13. Candidate variants present in 874 HCM cases for which the single case-control P-value 
between HCM cases and UCL-exome controls was  < 0.05. MAF: minor allele frequency (results for MAF 
0.2% are the same as for a cut-off of 0.5%). Adapted with permission from [251]. 












MYBPC3 NM_000256:c. C1504T:p.R502W 16 0.01038 0 1.8636 e-06 Yes 
MYBPC3 NM_000256: c.1624+4A>T 15 0.01346 0.00132 0.000206 Yes 
MYBPC3 NM_000256: c.G772A:p.E258K 9 0.00616 0 0.001613 Yes 
MYBPC3 NM_000256: c.G655C:p.V219L 6 0.00442 0 0.009914 Yes 
 
 
4.6. TITIN VARIANTS 
 
Seven-hundred-and-twenty-nine rare (MAF <0.5%) titin variants were identified in 786 
probands (89.9%). The distribution of rare TTN variants is shown in figure 23, illustrating a 
widespread distribution across the different regions. 
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One missense variant was previously described as pathogenic in HCM (R8500H) [51]. Twenty-
seven variants (0.005% of the total number of TTN variants) were predicted to cause loss-of-
function and were detected in 46 patients (5.3%): 6 were small frameshift insertions or 
deletions potentially leading to a truncated protein; 4 were nonsense variants that probably 
lead to the synthesis of a truncated protein and 17 more were splice-site variants predicted to 
cause exon skipping  (list of titin variants provided in Appendix E).  
 
Considering all TTN variants, four-hundred and twenty-eight patients (54% of the patients with 
TTN variants) carried a TTN rare variant in association with a variant in one of the eight main 
sarcomere protein genes. Three hundred and fifty eight patients (46%) had titin candidate 
variants in isolation or only in association with other sarcomere-related, desmosomal or ion 
channel disease associated gene variants.  
 
From the 46 patients carrying potentially truncating variants, 20 patients (43%) carried the TTN 
variant together with a main causal sarcomere variant and 26 patients (57%) isolated or only 
associated with ion-channel/desmosome/sarcomere-associated genes.  
 
Figure 23. Distribution of titin rare variants along the multiple regions/domains of the protein. The N2B 
isoform is represented. Z: Z-disc region; I: I-band region; A: A-band region; M:M-band region. 
 
Prioritization of TTN variants for further analysis  
We prioritized 29 TTN variants, present in 29 patients, based on the physicochemical 
difference of the amino acid change, domain location, predicted structural effect and possible 
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impact on interaction with titin ligands. Table 14. This includes variants in A-band fibronectin 
(Fn3) and immunoglobulin (Ig) domains where homology modelling confidently suggests a 
disruptive effect on the protein fold due to the highly conserved position of the affected 
residues in the beta-barrel fold (e.g. L14984P in A72) or due to involvement of the highly 
conserved proline-rich first beta-strand of A-band Fn3 domains (e.g. P11209L in A34) but also 
such domains where frequent HCM-associated variants (occurrences of up to 9 in the cohort) 
are surface exposed or are unclassifiable due to weak existing homology models (e.g. S14161G 
in A63). One of these domains, A150, carries 2 missense mutations (I22692T and S22701F). In 
this same domain, clearly disrupting mutations have been identified in numerous families with 
the strictly skeletal muscle disease entity Human Myopathy with early Respiratory Failure 
(HMERF) [302, 303, 304]. 
 
Two variants were identified in the activation loop of the catalytic protein kinase domain of 
titin (P24914R and R24899H), suggesting that altered kinase activity might also contribute to 
the HCM phenotype (figure 24). Several clearly disruptive variants were identified in the Ig- 
and Fn3 domains immediately flanking the kinase-domain (e.g. a 4-residue insertion-deletion 
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Table 14. Prioritized TTN variants and predicted effect. 
Variant Predicted effect 
NM_003319:c.C41935T:p.P13979S disruption of protein fold 
NM_003319:c.G20528A:p.R6843H surface exposed- ligand interaction 
NM_003319:c.T68075C:p.I22692T disruption of protein fold (A150 domain) 
NM_003319:c.T44951C:p.L14984P disruption of protein fold 
NM_003319:c.C68102T:p.S22701F disruption of protein fold (A150 domain) 
NM_003319:c.C33626T:p.P11209L highly conserved proline 
NM_003319:c.G35080A:p.E11694K surface exposed- ligand interaction 
NM_003319:c.47401_47403del:p.15801_15801del truncating 
NM_003319:c.A3557T:p.D1186V disruption of protein fold 
NM_133378:c.G19937T:p.R6646I disruption of protein fold 
NM_003319:c.A64742G:p.N21581S surface exposed- ligand interaction 
NM_003319:c.C3910T:p.R1304C surface exposed- ligand interaction 
NM_003319:c.G74696A:p.R24899H kinase domain 
NM_133378:c.30508_30510del:p.10170_10170del truncating 
NM_003319:c.G77056C:p.A25686P disruption of protein fold 
NM_133379:c.C16321T:p.R5441X truncating 
NM_003319:c.G78524A:p.R26175Q phosphorylation site 
NM_003319:c.C26729G:p.T8910S surface exposed- ligand interaction 
NM_003319:c. c.C75076T:p.R25026W kinase domain 
NM_003319:c.C74741G:p.P24914R kinase domain 
NM_003319:c.16639_16644del:p.5547_5548del truncating 
NM_003319:c.T39904C:p.S13302P disruption of protein fold 
NM_003319:exon44:c.9977-4G>A truncating 
NM_003319:c.G23419C:p.A7807P disruption of protein fold 
NM_003319:c.G62231A:p.R20744Q surface exposed- ligand interaction 
NM_003319:c.74120_74121insAGCCTTCAG:p.K24707delinsKPSE disrupting/flanking kinase domain 
NM_003319:c.C26953T:p.R8985C surface exposed- ligand interaction 




Some of the individual titin variants occur with a particularly high frequency in our cohort. We 
have therefore also looked for evidence of enrichment of those variants, as an indirect 
evidence of pathogenicity, comparing with the frequency of the same variants in the 1000 
genomes population, to discard the possibility that the observed high prevalence in the HCM 
cohort could simply be due to high background variation in the general population. Table 15. 
Enriched variants were tested for genotype-phenotype correlations (chapter 5).  
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Table 15. Comparison between the frequency of individual TTN variants in this cohort and the 1000 
genomes population, looking for enrichment. MAF: minor allele frequency.  Variants with enrichment 




874 patients per 1000 
MAF in 1000 
genomes per 1000 Enrichment 
S21937I 6 6.87 0.000459137 0.46 14.95 
V20731M 5 5.72 0.000459137 0.46 12.46 
P11209L 4 4.58 0.000459137 0.46 9.97 
A23700G 4 4.58 0.000459137 0.46 9.97 
A25686P 3 3.43 0.000459137 0.46 7.48 
R6666C 9 10.30 0.00183655 1.84 5.61 
S14161G 10 11.44 0.00229568 2.30 4.98 
R8634H 4 4.58 0.000918274 0.92 4.98 
R23683C 4 4.58 0.000918274 0.92 4.98 
M10083V 2 2.29 0.000459137 0.46 4.98 
R10163H 2 2.29 0.000459137 0.46 4.98 
R19226C 2 2.29 0.000459137 0.46 4.98 
G19307E 2 2.29 0.000459137 0.46 4.98 
M26794T 2 2.29 0.000459137 0.46 4.98 
R6843H 9 10.30 0.00229568 2.30 4.49 
R23522H 3 3.43 0.000918274 0.92 3.74 



















Figure 24. Structural modelling of the two TTN variants located in the activation loop of the kinase 
domain. A: P24914R: this variant is at the end of the activation loop segment and replaces a completely 
conserved proline with arginine (element-coded side chain; N= blue, C= white, O= red). The exchange is 
predicted to disrupt the turn at the position at the proline, and to result in a sterical clash; it is predicted 
to be disruptive (sterical clash shown as red volumes). Key residues in the active site are shown as stick 
models. Image generated using PDB entry 1TKI and PyMOL; B: R24899H: this variant is at the beginning 
of the activation loop segment and replaces a completely conserved arginine with histidine (element-
coded side chain; N= blue, C= white, O= red). The exchanged residue is surface-exposed, and this variant 
is therefore structurally not disruptive; however, arginine 24899 is engaged in local salt bridges and 
hydrogen bonds, a minor destabilising local effect is possible. The loss of positive charge possibly affects 
the interaction with ligands like nbr1. Image generated using PDB entry 1TKI and PyMOL. (courtesy of 
Prof. Mathias Gautel, King’s College London). 
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4.7. NON-SARCOMERE PROTEIN GENE VARIANTS 
 
At a MAF cut-off of 0.5%, 132 rare ARVC associated variants were present in 193 patients 
(22.1%) and 210 ion-channel disease variants were found in 238 patients (27.2%).  Thirty-seven 
(28.0%) of the ARVC associated and 46 (21.9%) of the ion-channel variants were previously 
published. A further 85 (24.9%) of these non-sarcomere variants were novel missense variants 
predicted in silico to be pathogenic and 24 (7%) were potential loss-of-function variants. In 
total, slightly over half of these non-sarcomere variants are predicted to have a biological 
effect. One-hundred-and-fifty-seven of the 371 patients (42.4%) carrying these non-sarcomere 
gene variants also carried variants in sarcomere or related genes. 
 
At a MAF cut-off of 0.2%, one-hundred-and-fourteen distinct rare desmosomal protein gene 
variants were present in 122 (14.0%) patients and one-hundred-and-ninety-two rare ion-
channel disease gene variants were present in 196 patients (22.4%). Twenty-nine (25.4%) of 
the desmosomal variants and 38 (19.8%) of the ion channel variants were previously published 
[305],[66],[306],[307],[308],[309],[310],[311],[312],[313],[314],[315],[316],[115],[317],[318]. A 
further 74 (24.2%) of these non-sarcomere variants were novel missense variants predicted in 
silico to be pathogenic and 20 (6.5%) were potential loss-of-function variants. In total, slightly 
over half these non-sarcomere variants are predicted to have a biological effect.  One-
hundred-and-twenty-two patients (43.0% of 284) with these non-sarcomere protein variants 
also carried a sarcomere protein variant. 
 
Table 16 summarizes the number and type of variant in each non-sarcomere gene, while table 
17 and 18 illustrate the case-control comparison for the same genes, using the same 
methodology as for sarcomere genes. None of the non-sarcomere genes showed a statistically 
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Table 16. Number of distinct rare variants in genes associated with arrhythmogenic cardiomyopathy and 




Total number of 
distinct rare 






predicted in silico 
to be pathogenic  
Nonsense, frameshift or 
splice- site  variants 







   
DSC2 20 8 2 1 
DSG2 20 10 4 1 
PKP2 18 6 3 1 
DSP 38 5 11 1 
JUP 7  2  
TMEM43 6 2   
TGF-beta3 5 1   






   
KCNQ1 15 5 1 1 
KCNH2 15 2 4  
SCN5A 33 19 2 2 
KCNE1 4 1   
KCNE2 6 4  1 
KCNJ2 1    
ANK2 63 5 21 5 
CASQ2 8  1 1 
CAV3 2 1   
RYR2 45 1 20 6 
Subtotal 192 38 49 16 
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Table 17. Rare nsSNPs frequency comparison between my sequencing results and a set of 1,287 UK 
controls with exome sequence data generated by the UK10K project (www.uk10k.org) for genes 
associated with arrhythmogenic right ventricular cardiomyopathy and ion channel disease. To avoid 
technical artefacts associated with indel calling, and to properly match cases and controls, we restricted 
this analysis to nsSNPs and the first 180 HCM UK Caucasian HCM cases. The columns show: the 
proportion of the 1,287 UK controls with exome sequence data generated by the UK10K project 
(www.uk10k.org) and 180 HCM cases that carry rare nsSNPs (rare defined by frequency less than 0.5% 
in the 1000 Genomes dataset) and a Fisher exact test P-value to quantify the case-control difference. 
nsSNP: nonsynonymous single nucleotide polymorphism; CI: confidence interval. Adapted with 
permission from [251]. 
Gene 
Rare nsSNPs - 
Frequency in  
controls 




DSP 0.040 0.061 0.240 
ANK2 0.039 0.044 0.690 
DSG2 0.040 0.044 0.842 
KCNE1 0.004 0.006 0.544 
KCNQ1 0.012 0.011 1.000 
CAV3 0.001 0.000 1.000 
TGFB3 0.002 0.000 1.000 
KCNJ2 0.003 0.000 1.000 
JUP 0.014 0.011 1.000 
SCN5A 0.043 0.039 1.000 
CASQ2 0.006 0.000 0.607 
DSC2 0.034 0.028 0.828 
TMEM43 0.013 0.006 0.716 
KCNH2 0.014 0.006 0.500 
KCNE2 0.019 0.000 0.064 
PKP2 0.049 0.028 0.264 
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Table 18. Case-control comparison for the frequency of rare (MAF<0.2%) variants between the 874 HCM 
cases vs UCL-exome samples as controls for ARVC associated and ion-channel genes, ordered by P-value 
(all non significant).  Adapted with permission from [251]. 
Gene Ensembl ID Frequency cases Frequency  controls P-value 
TGFB3 ENSG00000119699 0,006 0,002 0,144 
SCN5A ENSG00000183873 0,054 0,043 0,168 
ANK2 ENSG00000145362 0,090 0,082 0,318 
KCNE2 ENSG00000159197 0,007 0,006 0,486 
KCNQ1 ENSG00000053918 0,024 0,025 0,613 
PKP2 ENSG00000057294 0,034 0,038 0,723 
KCNH2 ENSG00000055118 0,034 0,040 0,737 
KCNE1 ENSG00000180509 0,005 0,006 0,765 
CASQ2 ENSG00000118729 0,009 0,012 0,784 
CAV3 ENSG00000182533 0,004 0,005 0,795 
TMEM43 ENSG00000170876 0,008 0,012 0,85 
DSG2 ENSG00000046604 0,029 0,037 0,858 
JUP ENSG00000173801 0,011 0,016 0,86 
DSC2 ENSG00000134755 0,036 0,050 0,929 
RYR2 ENSG00000198626 0,059 0,077 0,94 
KCNJ2 ENSG00000123700 0,001 0,006 0,988 
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5. PHENOTYPE DATA AND GENOTYPE-PHENOTYPE ANALYSIS 
Genotype-phenotype associations significant at a more stringent threshold (as defined in the 
Methods Section, chapter 5) are summarised in table 19 and figure 25. Additional pairs of 
traits/genes with P-values < 0.05 are shown in table 20 for sarcomere protein (SP) genes and 
table 21 for non-SP genes. 
 
5.1. EFFECT OF MUTATIONS IN SARCOMERE GENES 
Patients with at least one variant in one of the eight main sarcomere genes were younger at 
diagnosis and had a higher frequency of a family history of HCM or sudden cardiac death 
compared to those without sarcomere variants. Patients with sarcomere protein mutations 
were more likely to have asymmetric septal hypertrophy than apical or concentric patterns 
and had greater maximum LV wall thickness. The prevalence of male sex was lower in 
sarcomere-positive individuals (62.4 vs 72.0%, P-value=0.00213). SP-positive individuals were 
also more likely to have an ICD implanted. Patients with sarcomere mutations had a lower 
resting systolic blood pressure (SBP) (123.1±19.2 vs 133.7±21.3mmHg, P-value=1.54x10-9) and 
a lower systolic blood pressure response to exercise (44.1±21.5 vs 52.2±26.9 mmHg, P-
value=7.61x10-5).  
Similar and additional associations were observed when individual SP genes were considered 
(table 19 and 20). 
The proportion of cardiovascular deaths during follow-up was higher in patients with at least 
one variant in one of the eight main sarcomere genes. The same was true for sudden 
death/aborted sudden cardiac death (figure 26). For individual genes, a decreased survival in 
the presence of MYBPC3 variants was detected, when analysing the SCD end-point modelled 
for time from birth, but not when modelled for time of follow-up from first evaluation. The 
presence of rare variation in MYH7 was significantly associated with an increased incidence of 
cardiovascular death when modelled for time from birth. Carriers of a rare TNNT2 variant had 
a worse prognosis due to an increased incidence of cardiovascular death during follow-up, 
either modelled for age or for follow-up time. Survival curves for significant associations with 
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individual sarcomere genes are shown in Figure 27. 
 
5.2. PATIENTS WITH MULTIPLE SARCOMERE PROTEIN GENE VARIANTS  
Patients that carried more than one sarcomere variant had an increased prevalence of syncope 
when compared to individuals with only one sarcomere variant (35.1% vs 16.6%; 13/37 vs 
56/337, P-value= 0.012). Systolic blood pressure (BP) response to exercise was lower in 
individuals with multiple sarcomere variants compared to a single variant (36.5±21.9 vs 
45.1±21.2 mmHg, P-value=0.012) and there was a higher proportion of patients with an an 
abnormal blood pressure response to exercise (10/29 vs 39/276; 34.5% vs 14.1%, P-
value=0.010). Finally, there was a tendency towards an increased proportion of ICDs implanted 
at baseline and during follow-up, amongst multiple variant carriers (42.3%; 11/26) vs single 
variant carriers (22.9%; 58/253), P-value=0.053. No other phenotype traits were significantly 
different for multiple SP variant individuals. Survival differences between multiple and single 
variant carriers are described in the sub-chapter 5.4 below. 
 
5.3. ASSOCIATIONS WITH RARE VARIANTS IN DESMOSOMAL AND ION CHANNEL GENES  
Seventy-one patients carried rare ANK2 variants (of these, 36 also carried sarcomere protein 
variants). At a significance threshold of P < 0.0018, there was a higher proportion of patients 
with a maximum left ventricular wall thickness ≥30 mm amongst carriers of an ANK2 rare 
variant (Table 19).  
Additional phenotype-genotype correlations for non-sarcomere protein genes were identified 
at a less stringent P < 0.05. These are listed in Table 21, and include an increased mean 
MLVWT in ANK2 variant carriers. 
 
5.4. COMPARISONS BETWEEN SARCOMERIC GENES 
MYH7 patients were characterized by a lower fractional shortening (37.19±8.48%) compared 
with patients harbouring all types of MYBPC3 variants (39.71±8.85%, P-value=0.016) and with 
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the patients carrying MYBPC3 loss-of-function (LOF) variants (40.24±8.87%, P-value=0.010). 
The blood pressure response to exercise was lower in the presence of MYH7 rare variation 
(36.08±19.80mmHg) compared with the effect of any MYBPC3 (46.60±21.60mmHg,P-
value<0.0005) or MYBPC3 LOF variation (48.97±22.19mmHg, P-value=0.008). MYH7 patients 
had a longer QRS duration (103.57±24.03 msecs) compared to patients carrying any MYBPC3 
variant (94.08±14.58 msecs, P-value=0.004) or LOF variants (94.49±14.57 msecs, P-
value=0.008). Left atrial size was larger at last evaluation in MYH7 patients compared to 
individuals carrying any type of MYBPC3 rare variant (45.86±9.13 vs 43.43±7.06 mm, P-
value=0.011) or MYBPC3 LOF variants (43.44±7.30 mm, P-value=0.034).   
There were no other significant differences in the evaluated clinical parameters between 
patients carrying mutations in different sarcomeric protein genes.  
Survival was compared between carriers of MYBPC3 variants, carriers of MYH7 variants, 
carriers of variants in both genes (double heterozygotes) and individuals without candidate 
variants in any of those two genes. Figure 28. No difference was observed between MYBPC3 
and MYH7. However, carriers of variants in both genes had a significantly reduced survival 
compared to none or each of the genes, either for cardiovascular death or for SCD, if modelled 
for time from birth. When survival was modelled for follow-up time, survival analysis showed 
the same significant difference between carrying variants in both genes vs none, but only the 
comparison between double heterozygozity vs MYBPC3 reached statistical significance. 
 
5.5. GENOTYPE-PHENOTYPE ASSOCIATIONS FOR VARIANTS PREDICTED IN SILICO TO BE PATHOGENIC 
When repeating all the above comparisons for the variants that were predicted insilico to be 
pathogenic, no additional genotype-phenotype associations were revealed. 
 
5.6. COMPARISONS WITHIN SARCOMERE POSITIVE INDIVIDUALS ONLY 
By repeating all the above comparisons only within the sub-cohort of individuals that carry 
rare variants in sarcomere protein genes, no additional genotype-phenotype associations were 
found. 
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Figure 25. Comparison between sarcomere gene mutation-positive and negative patients. A. Age at 
initial evaluation (45.78±14.65 vs 53.05±14.94 years). B. Family history of HCM. C. Family history of SCD. 
D. Hypertrophy pattern. E. Maximum wall thickness (18.83±4.42 vs 18.12±4.08 mm). F. Implanted ICDs. 
Key: 0:sarcomere-negative; 1: sarcomere-positive. For B, C, F: red colour and percentages indicate the 
individuals with the trait within each genotype; for D light blue – asymmetric septal hypertrophy; red – 
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Table 19. Genotype-phenotype associations for individual sarcomeric and related protein genes and 
non-sarcomere protein genes, meeting the predefined stringent statistical thresholds for multiple 
testing.  P-values reflect the comparison for proportions or means, between the group of patients with 
versus the group of patients without a rare variant in a given gene (P-value thresholds of  < 0.0056 for 
SP genes and < 0.0018 for non-SP genes). HCM: hypertrophic cardiomyopathy; SCD: sudden cardiac 
death; ASH: asymmetric septal hypertrophy; MLVWT: maximum left ventricular wall thickness; LV: left 
ventricle; LA: left atria; BP: blood pressure; LVOTO: left ventricular outflow tract obstruction. 
 
Phenotype Gene 









Age at initial 
evaluation (years) 
MYBPC3 45.5±14.4 51.0±15.5 8.97 x 10
-6
 
MYH7 43.9±15.4 50.5±15.2 1.91 x 10
−5
 
Family history of 
HCM 
MYBPC3 40.4% (86/213) 21.9% (140/640) 2.7 x 10
−7
 
MYH7 47.4% (54/114) 23.4% (173/740) 3.06 x 10
−7
 
Family history of 
SCD 
MYBPC3 28.7% (62/216) 18.3% (120/656) 0.001 
 MYH7 31.6% (37/117) 19.2% (145/775) 0.003 
ASH pattern MYBPC3 88.0% (184/209) 71.6% (459/641) 3.75 x 10
-6
 
 MYH7 89.2% (99/111) 73.6% (544/739) 0.001 
MLVWT (mm) MYBPC3 19.4±4.7 18.2±4.2 0.0005 
MLVWT >30mm ANK2 12.5% (6/48) 2% (11/553) 0.0005 
LV end-diastolic 
diameter (mm) 
MYBPC3 44.8±5.5 46.3±6.0 0.00089 
LV end-systolic 
diameter (mm) 
MYBPC3 27.4±6.0 28.8±5.4 0.005 
LA diameter (mm) RBM20 40.9±6.8 44.2±7.5 0.00239 
Right ventricular 
hypertrophy 
TNNI3 50% (10/20) 21.6% (174/806) 5.49 x 10
-6
 
BP response to 
exercise (mmHg) 













43.1% (22/51) 20.0% (160/799) 0.005 
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Table 20. Additional genotype-phenotype associations for individual sarcomere protein and related 
genes, with P-values <0.05, but not meeting the predefined threshold for significance, if correcting for 
multiple comparisons. P-values reflect the comparison for proportions or means, between patients with 
and without a rare variant in a given gene. HCM: hypertrophic cardiomyopathy; NYHA: New York Heart 
Association; LA: left atria; MLVWT: maximum left ventricular wall thickness; LV: left ventricular; ASH: 
asymmetric septal hypertrophy; LVOT: left ventricular outflow tract; LVOTO: left ventricular outflow 




mean±standard deviation - 
Variant present 
Frequency or 
mean±standard deviation – 
Variant absent 
P-value 
Age at initial 
evaluation 
(years) 
TNNT2 43.5±14.7 49.8±15.4 0.031 
CSRP3 56.7±8.1 49.5±15.5 0.006 









MYBPC3 39.7±8.9 38.2±8.8 0.026 
LV systolic 
dysfunction 
TNNI3 15.8% (3/19) 3.2% (26/810) 0.020 








TNNI3 13.1±26.6 34.8±41.3 0.002 
Family history 
of SCD 




MYH7 22.5% (20/89) 12.6% (72/573) 0.020 
Syncope MYH7 22.8% (26/114) 15.4% (114/742) 0.045 




















































Figure 26. Kaplan-Meier cumulative incidence curves for cardiovascular death and SCD endpoint (see 
Methods Section), comparing sarcomere positive and sarcomere negative individuals.  Modelled for 
follow-up from first evaluation (years): A: cardiovascular death, log-rank test P-value=0.012 (HR: 2.81; 
95% CI:1.21-6.51); B: SCD/aborted SCD: log-rank test P-value=0.039 (HR: 2.89; 95% CI:1.01-8.33). 
Modelled for time from birth (years): C: cardiovascular death, log-rank test P-value=0.001 (HR: 3.99; 
95% CI: 1.71-9.36); D: SCD/aborted SCD, log-rank test P-value=0.028 (HR: 3.44; 95% CI: 1.19-9.92). Y axis 



















Figure 27. Kaplan-Meier cumulative incidence curves for cardiovascular death and SCD endpoint (see 
Methods Section), comparing individuals with versus without a candidate variant in individual 
sarcomeric genes.  A:  Cumulative incidence of cardiovascular death, modelled for time from birth 
(years), for MYH7 positive vs negative patients, log-rank test P-value=0.022 (HR: 2.80; 95%CI:1.20-7.05). 
B: Cumulative incidence of SCD end-point, modelled for time from birth (years), for MYBPC3 positive vs 
negative patients, log-rank test P-value=0.036 (HR: 2.77; 95%CI:1.03-7.45). C:  Cumulative incidence of 
cardiovascular death, modelled for follow-up from first evaluation (years), for TNNT2 positive vs 
negative patients, log-rank test P-value=0.016 (HR: 3.92; 95%CI:1.17-13.12). D:  Cumulative incidence of 
cardiovascular death, modelled for time from birth (years), for TNNT2 positive vs negative patients,  log-
rank test P-value=0.002 (HR: 5.46; 95%CI:1.62-18.39). 
 
 












Figure 28. Kaplan-Meier cumulative incidence curves for cardiovascular death and SCD endpoint (see 
Methods Section), comparing carriers of rare variants in MYH7, MYBPC3, none or both genes.  A: 
cardiovascular death, modelled for time from birth (years), log-rank test P-value=0.028 for none vs 
MYBPC3; P-value=0.018 for none vs MYH7; P-value<0.0005 for none vs both; P-value=0.693 (NS) for 
MYH7 vs MYBPC3; P-value=0.009 for MYBPC3 vs both; P-value=0.023 for MYH7 vs both. B: 
cardiovascular death, modelled for follow-up from first evaluation, log-rank test P-value=0.139 (NS) for 
none vs MYBPC3; P-value=0.121 (NS) for none vs MYH7; P-value=0.007 for none vs both; P-value=0.815 
(NS) for MYH7 vs MYBPC3; P-value=0.101 (NS) for MYBPC3 vs both; P-value=0.180 (NS) for MYH7 vs 
both.  C: SCD end-point, modelled for time from birth (years), log-rank test P-value=0.074 (NS) for none 
vs MYBPC3; P-value=0.188 (NS) for none vs MYH7; P-value<0.0005 for none vs both; P-value=0.917 (NS) 
for MYH7 vs MYBPC3; P-value=0.045 for MYBPC3 vs both; P-value=0.061 (NS) for MYH7 vs both. D:  SCD 
end-point, modelled for follow-up from first evaluation (years), log-rank test P-value=0.036 for none vs 
MYBPC3; P-value=0.095 (NS) for none vs MYH7; P-value<0.0005 for none vs both; P-value=0.983 (NS) for 
MYH7 vs MYBPC3; P-value=0.005 for MYBPC3 vs both; P-value=0.014 for MYH7 vs both.  
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Table 21. Genotype-phenotype associations for non-sarcomeric protein genes not meeting the 
predefined statistical thresholds for multiple testing.  P-values reflect the comparison for proportions or 
means, between the group of patients with versus the group of patients without a rare variant in a given 
gene. LA: left atria; LVOTO: left ventricular outflow tract obstruction; MLVWT: maximal left ventricular 
wall thickness; E/e´ratio: ratio between the maximal velocity of the E wave from the pulsed wave 
Doppler of the transmitral flow and the maximal velocity of the e’ wave of tissue Doppler at the mitral 












LA diameter at the final 
follow-up (mm) 
SCN5A 46.9±5.4 44.3±7.5 0.0418 
LVOTO  
(>30 mmHg) 
SCN5A 57.5% (23/40) 39.5% (305/772) 0.031 
 Ion-channel 49.2% (89/181) 37.9% (239/631) 
0.00595 
MLVWT (mm)  ANK2 19.7±5.6 18.4±4.2 0.0152 
E/e’ CASQ2 16.4±7.1 11.4±5.9 
0.016 
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5.7. LOGISTIC REGRESSION ANALYSIS AND CONSTRUCTION OF A MODEL AND SCORE TO PREDICT THE PRESENCE OF 
A SARCOMERE GENE MUTATION   
 
Based on the previously described significant associations between phenotype traits and the 
presence of a rare variant in any of the 8 main SP genes, the variables selected to enter the 
model were: age at presentation, gender, family history of HCM, family history of SCD, left 
ventricular hypertrophy pattern (asymmetric septal hypertrophy vs others) and maximal left 
ventricular wall thickness (MLVWT).  
 
Age was transformed into a categorical variable by using ROC curve analysis, which defined a 
cut-off of 50 years of age (AUC 0.643; sensitivity 60%; specificity 62%). MLVWT was also 
transformed into a categorical variable, with a cut-off of 17 mm defined by ROC curve analysis 
(AUC 0.556; sensitivity 60%, specificity 50%). 
 
By multivariate logistic regression analysis, all the variables, with the exception of MLVWT, 
were still significantly associated with a SP-positive genotype and were retained in the model. 
Table 22.  
 
Table 22. Multivariate logistic regression model for the presence of a rare variant in a SP gene. FH HCM: 
family history of hypertrophic cardiomyopathy; FH SCD: family history of sudden cardiac death; MLVWT: 
maximal left ventricular wall thickness; ASH: asymmetric septal hypertrophy; OR: odds ratio; CI: 
confidence interval. 
 B P-value OR 
95% CI for OR 
Lower Upper 
Model 1 Male -.442 0.007 .643 .467 .885 
FH HCM .868 <0.0005 2.382 1.665 3.407 
FH SCD .352 0.071 1.422 .970 2.087 
MLVWT≥17mm .244 0.127 1.276 .933 1.747 
Age≥50 -.723 <0.0005 .485 .356 .661 
ASH 1.004 <0.0005 2.730 1.857 4.013 
Model 2 Male -.434 0.008 .648 .471 .891 
FH HCM .852 <0.0005 2.343 1.640 3.348 
FH SCD .342 0.079 1.408 .961 2.065 
Age≥50 -.739 <0.0005 .478 .351 .650 
ASH 1.046 <0.0005 2.846 1.944 4.167 
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As described in the methods, the weighted score for each variable was calculated from the 
regression coefficients and were as follows: male sex: -1; family history of HCM: 3; family 
history of SCD: 1; ASH: 3; age ≥ 50: -2. 
 
Applying the score to the cohort, ROC curve analysis showed a reasonable AUC of 0.723 for the 
model, with a sensitivity of 77% and specificity of 55%, and a cut-off of 0.5 to predict a positive 
genotype. Figure 29. 
 
 
Figure 29. ROC curve analysis evaluating the diagnostic accuracy of the proposed model to predict the 
presence of a sarcomere variant. 
 
5.8. TITIN GENOTYPE-PHENOTYPE ASSOCIATIONS   
5.8.1. COMPARISON OF MEANS AND PROPORTIONS FOR THE DIFFERENT PHENOTYPIC TRAITS 
Carriers of rare TTN variants were younger than patients without those variants : 49.37±15.27 
vs 54.44±14.31, P-value=0.003 and had an increased incidence of ICD implantation during 
follow-up: 21.2% (162/763) vs 12.1% (12/99), P-value=0.033. 
 
The presence of a potential loss-of-function (LOF) or splice-site variant in TTN was associated 
with poorer left ventricular systolic function (fractional shortening 35.3±7.0% vs 38.5±8.3%, P-
value=0.012). 
There was a higher prevalence of males among carriers of an enriched (as defined by an 
enrichment factor > 3, listed in chapter 4.6, table 15) variant (84.1% vs 66.5%, p = 0.003), 
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which were also characterized by a higher maximal LV wall thickness (19.4 ±4.7 vs 18.4±4.3 
mm, p =0.023). 
 
No other phenotype parameter was significantly different in the presence of a LOF, enriched 
or any TTN rare variant, either analysed for a cut-off of 0.5% or 0.2%. 
 
5.8.2. DISCRIMINANT ANALYSIS AND LOGISTIC REGRESSION ANALYSIS 
To reveal additional genotype-phenotype associations, a linear discriminant analysis and 
logistic regression was conducted to predict whether a patient was a carrier of a titin variant. 
 
All TTN rare variants 
No linear discriminant function was found as being able to significantly discriminate carriers vs 
non-carriers of a rare titin variant. Logistic regression analysis reproduced the previous 
findings regarding age and implantated ICDs. 
 
TTN potentially truncating variants 
A linear discriminant function significantly discriminated carriers of potentially truncating 









































Figure 30. Discriminative ability of function 1 to distinguish between diagnostic groups. 0: non-carriers; 
1:carriers of a TTN truncating variant. 
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The function was 70.4% sensitive and 78.6% specific at predicting carriage of a truncating 
variant.  
 
Multivariate logistic regression analysis demonstrated that a lower fractional shortening (or 
ejection fraction), higher maximal left ventricular wall thickness and the presence of 
hypertrophy of the right ventricle were significant discriminators of carriers of a potentially 
truncating variant vs non-carriers (Table 23).  
 
 
Table 23. Multivariate logistic regression analysis for the presence of a potentially truncating titin 
variant. CI: confidence interval. 
 Coefficient P-value 95% CI for coefficient 
Ejection fraction -0.0578368  0.005 -0.0981445-(-0.0175292) 
Right ventricular 
hypertrophy 
1.000587    0.016 0.1830905 - 1.818084 
Maximal left ventricular 
wall thickness 
0.146069    <0.0005 0.0640364 - 0.2281015 
 
 
TTN enriched variants 
A linear discriminant function significantly discriminated carriers of enriched variants vs non-
carriers of enriched variants, as defined by an enrichment factor > 4 and listed in chapter 4.6, 
table 15.   
 
The function was 70.0% sensitive and 77.5% specific at predicting the presence of an enriched 
variant.  
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Figure 31. Discriminative ability of function 1 to distinguish between diagnostic groups. 0: non-carriers; 
1:carriers of an enriched TTN variant. 
 
Multivariate logistic regression analysis demonstrated that male sex, higher increase in left 
ventricular diastolic dimension between baseline and follow-up, larger left atrial diameter and 
higher maximal left ventricular wall thickness at last follow-up were significantly associated 
with carriers vs non-carriers of an enriched variant (table  24). 
 
 
Table 24. Multivariate logistic regression analysis for the presence of an enriched titin variant. CI: 
confidence interval. LA: left atria. LVEDD: left ventricular end-diastolic dimension. MLVWT: maximal left 
ventricular wall thickness. 
 Coefficient P-value 95% CI for coefficient 
Male 1.376369  0.008      0.3604189 -2.392319 
LA diameter 0.0568337 0.010 0.0138598 - 0.0998077 
Increase in LVEDD from  
baseline to follow-up 
0.1043353 0.009      0.0266105 - 0.18206       
MLVWT at last follow-up 0.0814253    0.033 0.0066106 - 0.1097004 
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6. CARDIAC MAGNETIC RESONANCE IMAGING PHENOTYPE DATA 
 
As described in the methods, approximately one-third of the cohort - 271 patients (31%) - was 
submitted to cardiovascular magnetic resonance (CMR) to further characterize the phenotype. 
The main demographic and clinical characteristics are summarized in table 25 and the main 
CMR parameters in table 26. 
 
 
Table 25. Characterization of the subset of the total cohort studied with CMR (N=271). HCM: 
hypertrophic cardiomyopathy. SCD: sudden cardiac death. NYHA: New York Heart Association.  
N=271 
 
Frequency (percentage) or mean ± standard deviation (range) 
or median (IQR) 
DEMOGRAPHICS  
Age at initial evaluation (years) 49.6±14.2 (13-81) 
Male 185 (68.3%) 
Ethnicity 
– Caucasian 













Family history of HCM 59 (21.8%) 
Family history of SCD 47 (17.3%) 
NYHA class III or IV  31 (11.4%) 
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Table 26. Cardiac magnetic resonance parameters. ASH: asymmetric septal hypertrophy; LVEDV: left 
ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; SV: systolic volume; LVEF: 
left ventricular ejection fraction; LA: left atrium; SAM: systolic anterior movement; LVOTO: left 





LVEDV (ml) 137.5±36.8 
LVESV (ml) 35.7±21.2 
Mass (g) 241.0±94.0 
SV (ml) 100.0±26.5 
LVEF (%) 75.2±9.2 
MLVWT 19.9±5.2 
LA area (cm2) 30.2±7.1 
LVH pattern 
   ASH 
   Apical 





Mitral SAM  138 (49.9%) 
LVOTO 105 (38.7%) 
Late gadolinium enhancement  211 (77.9%) 




Given the previously described genotype-phenotype findings and to optimize the statistical 
power with a reduced sample, we limited the analysis to a comparison between sarcomere 
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Table 27. Comparison between sarcomere gene mutation-positive and negative patients for the 
analysed CMR parameters.  Significant or near-significant P-values are shown in bold. ASH: asymmetric 
septal hypertrophy; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic 
volume; SV: systolic volume; LVEF: left ventricular ejection fraction; LA: left atrium; SAM: systolic 
anterior movement; LGE: late gadolinium enhancement; LVOTO: left ventricular outflow tract 
obstruction.  
 Sarcomere-positive Sarcomere negative P-value 
LVEDV 139.08±40.95 136.32±33.53 0.612 
LVESV 39.23±26.43 33.17±15.95 0.052 
SV 97.95±26.36 101.46±26.61 0.370 
LVEF (%) 73.2±9.5 76.7±8.6 0.009 
Mass (g) 218.0±83.6 257.8±97.9 0.006 
MLVWT (mm) 20.8±6.0 19.4±4.6 0.027 
LVH pattern - ASH 
 
79.2% (84/106) 62.8% (103/164) 0.006 
LA area 30.64±6.82 29.83±7.28 0.433 
Presence of LGE   84.8% (89/105) 75.2% (121/161) 0.066 
AMVL (mm)  
(N=31 vs N=36) 
24.6±4.6 25.7±3.3 0.260 
 
 
Sarcomere-positive patients had a higher maximal left ventricular wall thickness, lower 
ejection fraction, lower mass and a higher proportion of individuals with an asymmetric septal 
hypertrophy pattern. Late gadolinium enhancement tended to be more prevalent in 
sarcomere-positive individuals, without reaching statistical significance. 
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7. SCREENING OF COPY NUMBER VARIATION  
 
At the selected confidence threshold level (see Methods Section, chapter 6), twelve CNVs in 12 
patients (2.4% of the 505 patients screened for CVNs) were identified using ExomeDepth. Four 
of these CNVs in 4 patients (0.8%) were validated by array comparative genomic hybridization 
(aCGH): one large deletion in MYBPC3 (involving 4 exons; figure 32), one large deletion in 
PDLIM3 (involving the first 4 exons; figure 33), one duplication of the entire TNNT2 gene 
(figure 32) and one large duplication in LMNA (involving 5 exons; figure 33).  
 
Eight CNVs were not validated by the aCGH analysis, including three single exon duplications 
and one single exon deletion in MYBPC3, two two-exon deletions and one single exon 
duplication in TNNI3 and one single exon duplication in ACTC1. 
 
Figures 32 and 33 show the ExomeDepth generated graphs for each confirmed CNV 
(sarcomeric genes in figure 32, non-sarcomeric genes in figure 33) and the corresponding 
validation graphs generated from snapCGH.  Figures 34-41 show the non-validated CNVs.  
 
Table 28 summarizes the clinical and genetic characteristics of the four patients with validated 
CNVs. Two did not harbour any rare variant in a potentially causal SP gene. The patient 
carrying the duplication of TNNT2 is a carrier of a variant of unknown significance in the same 
gene. The analysis of the read count data at this variant shows that the rare variant occurs less 














Table 28. Demographic, clinical and genetic characteristics of the patients harbouring CNVs. ASA: alcohol septal ablation; ASH: asymmetrical septal hypertrophy; 
del- deletion; dup – duplication; ICD: implantable cardioverter-defibrillator; MLVWT: maximal left ventricular wall thickness; NSVT: non-sustained ventricular 
















Events Sarcomere variant CNV 
H1 M 40 - - 20 ASH - ASA - MYBPC3 del 
H2 M 41 - - 16 ASH - - TNNT2 N262S (VUS) TNNT2 dup 
H3 M 48 - - 22 ASH - - - PDLIM3 del 
H4 M 43 - - 16 ASH NSVT ICD MYBPC3 R495G LMNA dup 
 
 






Figure 32. Large deletion in MYBPC3 involving 4 exons (patient H1) and duplication of the entire TNNT2 










Figure 33. Large deletion of the first 4 exons of PDLIM3 (patient H3) and large duplication in LMNA 
involving the last 5 exons (patient H4).  Upper figures generated through ExomeDepth analysis and 
lower figures generated through snapCGH. 
 





Figure 34. MYBPC3 duplication of a single exon not confirmed by aCGH. Upper figure generated through 
ExomeDepth analysis and lower figure generated through snapCGH. 





Figure 35. MYBPC3 duplication of a single exon not confirmed by aCGH. Upper figure generated through 
ExomeDepth analysis and lower figure generated through snapCGH. 





Figure 36. MYBPC3 duplication of a single exon not confirmed by aCGH. Upper figure generated through 
ExomeDepth analysis and lower figure generated through snapCGH. 





Figure 37. MYBPC3 deletion of a single exon not confirmed by aCGH. Upper figure generated through 
ExomeDepth analysis and lower figure generated through snapCGH. 





Figure 38. TNNI3 deletion of two exons not confirmed by aCGH. Upper figure generated through 
ExomeDepth analysis and lower figure generated through snapCGH. 





Figure 39. TNNI3 deletion of two exons not confirmed by aCGH. Upper figure generated through 
ExomeDepth analysis and lower figure generated through snapCGH. 





Figure 40. TNNI3 duplication of one exon not confirmed by aCGH. Upper figure generated through 
ExomeDepth analysis and lower figure generated through snapCGH. 





Figure 41. ACTC1 duplication of one exon not confirmed by aCGH. Upper figure generated through 
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8. NON-CODING REGION ANALYSIS 
 
A total of 1562 non-coding single nucleotide variant (ncSNV) calls were identified, distributed 
amongst the eight main sarcomere protein genes, in the first 233 patients of the study cohort.  
 
8.1. VARIATION IN TRANSCRIPTION FACTOR BINDING SITES 
Thirty-three distinct rare variants, present in 32 patients (14%), mapped to transcription factor 
(TF) binding sites localized in the 5’ and 3’ untranslated regions, upstream and downstream 
regions and introns.  The majority of these patients (20, 63%) did not have any coding 
candidate variants in sarcomere genes. Figure 42 illustrates the proportion of patients with 
coding and non-coding rare variants in sarcomeric genes. 
 
Table 29 shows the ncSNVs found in TF binding sites, per gene. Twelve variants were present 
in TPM1 (in 12 patients), six in ACTC1 (in 6 patients), five in TNNT2 (in 5 patients), three in 
MYBPC3 (in 4 patients), three in MYL3 (in 3 patients), two in MYH7 (in 2 patients) and one in 
TNNI3 and MYL2 each. Three patients carried two different TF binding site variants each. 
 
Two of the TPM1 non-coding variants were present in both dbSNP135 and 1000 genomes 
project databases: rs146903018 (MAF of 0.1% in the 1000 genomes project and present in two 
of the patients) and rs188184852 (MAF of 0.2% in the 1000 genomes project and present in 
one of the patients). All the other non-coding variants were absent from those databases. 
 
 
Figure 42. Proportion of patients with coding and non-coding variants in the eight main sarcomeric 





Table 29. List of non-coding variants carried by HCM patients, that map onto transcription factors binding sites (TFBS). In bold, TFs described in the literature as part of 
cardiomyocyte survival/growth/hypertrophy pathways and conserved posititions as per GERP score. Ref: reference allele. Obs: observed allele. GERP: genomic evolutionary rate 
















ACTC1 intronic yes NA NA 15 35084011 G A STAT3, E2F6 -2.7 4 
ACTC1 intronic yes NA NA 15 35084035 T A STAT3 -2.7 4 
ACTC1 intronic yes NA NA 15 35087530 C T CTCF, POLR2A, CCNT2, Ini1, SMARCB1, MAX 1.13 4 
ACTC1 intronic no NA NA 15 35087632 C T CTCF, POLR2A, CCNT2, Ini1, TAF1, JunD, E2F6, MAX, SMARCB1 -4.53 4 
ACTC1 UTR5 yes NA NA 15 35087862 C A SRF 2.85 2a 
ACTC1 upstream no NA NA 15 35088006 G C SRF -1.11 4 
MYBPC3 intronic no NA NA 11 47370591 G A CTCF, Rad21, CEBPB, SMC3 2.07 2a 
MYBPC3 intronic no NA NA 11 47370618 A C CTCF, Rad21, CEBPB, SMC3 2.41 2b 
MYBPC3 intronic no NA NA 11 47370703 A G CTCF, Rad21, CEBPB 2.54 4 
MYH7 upstream yes NA NA 14 23905020 T C p300, SP1, HDAC2,HNF4A, HNF4G -3.29 2a 
MYH7 intergenic no NA NA 14 23910572 T A ELF1 1.35 2b 
MYL2 intronic no NA NA 12 111351152 A G POLR2A, EBF1 -8.05 4 
MYL3 intronic yes NA NA 3 46902080 C T CTCF 1.17 4 
MYL3 intronic no NA NA 3 46902091 G A CTCF -1.33 4 
MYL3 intronic yes NA NA 3 46902110 A C CTCF -5.6 4 
TNNI3 intronic no NA NA 19 55663455 C T SETDB1,ELF1, GABP, SPI1 -5.14 2a 
TNNT2 intronic yes NA NA 1 201330921 A G CTCF, SMC3, Rad21, ZNF143 -3.81 4 
TNNT2 intronic no NA NA 1 201337057 G T CEBPB -1.01 3a 




TNNT2 intronic no NA NA 1 201345940 T C POLR2A -2.06 2b 
TNNT2 intronic no NA NA 1 201346338 G A POLR2A -2.03 4 
TPM1 UTR5 no NA NA 15 63334844 G C 
YY1, CTCF, RAD21,POLR2A, 
TAF1 
2.89 2b 
TPM1 UTR5 no NA NA 15 63334923 C T CTCF, RAD21 POLR2A,TAF1, TBP 5.02 2b 
TPM1 intronic no NA NA 15 63335343 C A TAF7 0.428 4 
TPM1 intronic no NA NA 15 63337778 A T GATA2, SRF 5.25 2a 
TPM1 intronic no 0.0011 
rs1469030
18 
15 63341426 G A 
CDX2, CTCF, STAT1, GATA1, POLR2A, ETS1, E2F6, SIN3A, RAD21, 
MXI1, SMC3 
-0.215 4 
TPM1 intronic yes NA NA 15 63341606 T C CDX2, CTCF, STAT1, GATA1, POLR2A, ETS1 -1.54 2b 
TPM1 intronic no NA NA 15 63348576 C T POLR2A -0.546 5 
TPM1 intronic yes 0.00181 
rs1881848
52 
15 63350150 G A POLR2A -6.1 2b 
TPM1 UTR3 no NA NA 15 63356374 C T POLR2A -2.14 5 
TPM1 UTR3 no NA NA 15 63358153 C G GR (NR3C1) 2.79 4 
TPM1 UTR3 yes NA NA 15 63358197 C T GR (NR3C1) -1.94 4 
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8.2. NORMALIZING THE NUMBER OF DISTINCT NON-CODING VARIANTS FOR THE SIZE OF EACH GENE 
 
To test if the frequency of the variants in each gene reflects background random variation 
dependent on the genomic dimension, we normalized the data with respect to the size of the 
genes. ACTC1 and MYL3 showed an excess of candidate non-coding variants compared to gene 
size, in contrast with the others (shown in figure 43).  
 
 
Figure 43. Comparison between the number of distinct variants in each gene and the gene size. 
 
8.3. EVOLUTIONARY CONSERVATION ANALYSIS OF THE GENOMIC COORDINATES 
 
Eight of the TFBS variants (25%) were localized in conserved positions, defined by a genomic 
evolutionary rate profiling (GERP) conservation score  > 2. One in the 5’UTR of ACTC1 (figure 
44), three in intronic regions of MYBPC3 (which correspond to all the noncoding variants in 
these gene) and four in TPM1 (one is shown in figure 45). Seven (88%) of the variants located 
in conserved positions are carried by patients that do not have coding variants in sarcomere 
genes.  
 
8.4. TRANSCRIPTION FACTORS PREVIOUSLY ASSOCIATED WITH CARDIOMYOCYTE HYPERTROPHY AND 
CARDIOMYOPATHY SIGNALING PATHWAYS 
 
When analysing the TFs that bind to the DNA coordinates where these variants map, we 
identified seven TFs previously experimentally shown to be involved in hypertrophy signaling: 
SRF (serum response factor), C/EBPß (CCAAT/enhancer binding protein beta), p300, STAT3 
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(signal transducer and activator of transcription 3), HDAC2 (histone deacetylase 2), NRSF 
(neuron-restrictive silencer factor) and YY1.  
 
In total, the 12 variants that are predicted to potentially interfere with the binding and 
function of these TFs were distributed in 13 patients, nine of which (69%) do not carry coding 
variants in sarcomere genes. Four are in ACTC1 (in 4 patients), three in MYBPC3 (in 4 patients), 
one in MYH7, two in TNNT2 (in 2 patients) and two in TPM1 (in 2 patients). Six of these 
variants (50%) are localized in conserved positions. Again, ACTC1, compared to its dimensions, 
shows excess in non-coding variants mapping to these potentially relevant TF binding sites. 
 
 
Figure 44. Image from the UCSC genome browser showing the genomic region around the variant 
15:35087862C>A, that occurs in a conserved position in the 5’UTR of ACTC1. GERP score is 2.85. 
PhastCons and PhyloP scores also predict the position as conserved, as shown. This position was 
experimentally demonstrated to be part of an SRF binding site, as illustrated in the track “Transcription 
factor ChIP-seq from ENCODE”. The level of evidence for the transcription factor binding at this position 
is high, reflected by a RegulomeDB score of 2a (datatypes available: TF binding + matched TF motif + 








Figure 45. Image from the UCSC genome browser showing the genomic region around the variant 15: 
63337778A>T, that occurs in a conserved position in an intronic region of TPM1. GERP score is 5.25. 
PhastCons and PhyloP scores also predict the position as conserved, as shown. This position was 
experimentally demonstrated to be part of an SRF and GATA-2 binding site, as illustrated in the track 
“Transcription factor ChIP-seq from ENCODE”. The level of evidence for the transcription factor binding 
at this position is high, reflected by a RegulomeDB score of 2a (datatypes available: TF binding + 
matched TF motif + matched DNase Footprint + DNase peak). 
 
 
8.5. 3’UTR VARIANTS IN MIRNA TARGET SITES 
We identified 119 distinct rare variants in the 3’UTR regions of the eight genes, distributed in 
218 of the 233 patients. Of these, only 2 mapped to predicted miRNA target sites (table 30). 
One was localized in the 3’UTR of MYH7 and predicted to interfere with the binding of miR-
516b and miR-28-5p. It was present in two patients and it is identified in the dbSNP135 
(rs45548631). It is also listed in the 1000 genomes database (MAF 0.5%) and the exome 
sequencing project database (MAF 0.6%). Therefore, it seems to be a low frequency variant, 
most probably a benign polymorphism. The other variant is novel, present in the 3’UTR of 
TPM1 and maps to the binding site of miR-30a, miR-30d and miR-30e. These miRNAs are 
amongst the most abundant in the heart and known to be down-regulated in cardiac 
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Table 30. Rare non-coding variants that map onto predicted miRNA target regions. GERP: genomic 
evolutionary rate profiling.  MAF: minor allele frequency. ESP: exome sequencing project. Ref: reference 
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8.6. EXPRESSION COMPARISON BETWEEN CASES AND CONTROLS 
In two patients with cardiac tissue samples available from myectomy, who carried potentially 
functional non-coding variants and no candidate variants identified in a sarcomere protein 
gene, we conducted an array experiment (see Methods Section, chapter 7.3.) comparing 
expression of sarcomere protein genes between these two patients and controls.  
 
One of the patients carried the ACTC1 upstream variant g.35088006G>C, position predicted to 
be involved in the binding of SRF. The other patient had an intronic variant localized in a highly 
conserved intronic region of TPM1: g.63337778A>T, predicted to bind GATA and SRF as 
illustrated in figure 45. No significant differences were found for the RNA expression levels 
between these patients and the control dataset, either for those two genes or any other 











Table 31. Raw and normalized values of mRNA expression of the two cases (G18_0952059 and G18_1052131) and the controls (GSM954999-GSM955004) for the eight main 






































































ACTC1 6234,69 7083,46 12199,00 11438,16 7761,55 11055,34 8687,72 7658,49 -0,40 -0,21 0,57 0,48 -0,08 0,43 0,08 -0,10 
MYBPC3 3743,24 5471,78 4619,76 3386,49 5110,87 4440,73 4335,28 3831,91 -0,23 0,32 0,07 -0,37 0,22 0,02 -0,02 -0,20 
MYH7 10921,64 11903,40 11668,40 10385,90 13019,74 11708,56 12368,06 10759,60 -0,10 0,03 0,00 -0,17 0,16 0,00 0,08 -0,12 
MYL2 11507,23 11626,74 13894,04 13586,81 12733,31 13669,90 13482,04 11129,54 -0,19 -0,17 0,08 0,05 -0,04 0,06 0,04 -0,24 
MYL3 5095,57 6315,96 7552,22 7337,00 7298,29 7986,41 7581,48 6672,58 -0,52 -0,21 0,05 0,00 0,00 0,13 0,05 -0,13 
TNNI3 6398,24 8289,79 5585,82 4769,70 7149,85 7972,92 7086,78 5802,46 -0,07 0,30 -0,27 -0,50 0,09 0,24 0,07 -0,21 
TNNT2 9256,75 12268,60 7071,69 7345,94 6065,22 7675,37 8404,19 8217,87 0,22 0,63 -0,17 -0,11 -0,39 -0,05 0,08 0,05 
TPM1 1598,93 1796,87 1475,61 1512,29 1367,85 1600,32 1630,88 1695,13 0,00 0,17 -0,12 -0,08 -0,23 0,00 0,03 0,08 
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9. WHOLE-EXOME SEQUENCING FOR SARCOMERE-NEGATIVE FAMILIES 
 
9.1. QUALITY ASSESSMENT OF THE SEQUENCING DATA  
 
Analysis of the mean depth of coverage per sample revealed adequate coverage of the exome, 
with a minimum mean read depth per sample of 77.65 and maximum of 118.62, and a 
minimum coverage of 94.5% (for read depth above 15) and a minimum coverage of 82.4% (for 
read depth above 30), as shown in table 32. 
 
 












Family 1 – patient 1 6071881895 118,62 97,8 95,9 87,7 
Family 1 – patient 2 5258116701 102,72 98,2 96,6 88,8 
Family 2 – patient 1 5184108419 101,27 97,8 96,1 87,6 
Family 2 – patient 2 5063555774 98,92 97,9 96 86,8 
Family 3 – patient 1 4398764419 85,93 97,1 94,6 83,3 
Family 3 – patient 2 3974845771 77,65 97,1 94,5 82,4 
 
 
9.2. CANDIDATE VARIANTS  
Based on the filtering process as described in the Methods Section, chapter 8, we obtained 
datasets of between 34-68 candidate variants per family (supplementary tables in Appendix F). 
Pedigrees are shown in figure 46. 
 
Family 1 
34 unique variants were obtained as candidates. From these, only one was localized in a gene 
previously related to cardiomyopathy (TTN T3713I), which is a variant of unknown significance. 
 
Family 2 
40 unique variants were filtered as candidates. From these, one was localized in a gene 
previously related to cardiomyopathy (OBSCN T7800I). Additionally, four occurred in 
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68 unique variants were candidates. From these, 3 were localized in genes previously related 
to cardiomyopathy (OBSCN A7669T and TTN R26175Q and T8910S). Importantly, the TTN 
variants are also included in the list of prioritized variants; the first is a putative 
phosphorylation site and the second is surface exposed and likely involved in ligand interaction 












Figure 46.  Pedigrees of the families studied with whole-exome sequencing. A: family 1;  B: family 2; C: 
family 3. Arrows point to the proband. Squares – males; circles – females; black-filled shapes – affected; 
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10. IN SILICO ANALYSIS OF MYH7 MISSENSE VARIANTS – PATHOGENICITY AND 
PHENOTYPE PREDICTION BASED IN THE STRUCTURAL IMPACT OF THE MUTATION 
 
10.1. MANUAL ANALYSIS 
  
A total of 401 mutations in the MYH7 gene were used to build the dataset (supplementary 
table in Appendix G). More than two-thirds of the variants were published as disease causing 
(72%), in keeping with the proportion of published mutations if only considering our own 
cohort, and the others were novel variants. Of the total mutations, 235 mapped to at least one 
PDB with a total of 806 mappings to (multiple) PDB structures.  
 
More mutations were associated with HCM (n = 292), whereas all other phenotypes were 
associated with fewer than 50 mutations each, including DCM with the next highest number of 
mutations (n = 46). Since mutations related to these phenotypes were the most abundant, 
further analyses were conducted looking specifically at HCM vs DCM and grouping the 
remaining phenotypes as “others”.  
 
Two additional simple phenotype parameters were also available for the HCM-associated 
variants - maximum wall thickness (20±4 mm) and age at presentation (33±16 years). 
 
Restricting the remaining analyses to the variants that mapped to PDB (Protein Data Bank, 
http://www.rcsb.org/pdb/home/home.do) structure, we analysed the distribution of the 
variants amongst the structural and functionally annotated domains of this protein. All of the 
variants were located in the myosin globular head domain or the neck region. From all 
variants, 51% were located in functionally annotated domains: 18% mapped to the actin-
binding site (residues 655-677); 4% mapped to the ATP-binding region (residues 178-185); 3% 
were located in the essential and regulatory myosin light chain binding regions (residues 788-
801 and 814-827) and 27% mapped to the MYBPC3 binding region (residues 839-964, mapped 
to different PDB ID 2FXM and 2FXO). 
 
The predominantly mutated amino acid was arginine (85 variants, expected around 23.53), 
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followed by methionine (20 variants, expected around 10.84) and Glycine (26 variants, 
expected around 14.73). 
 
The analyses of the dataset with SAAPdap (data analysis pipeline) showed that a total of 175 
variants were classified as likely to be damaging by at least one SAAPdap feature. For 55 
variants, no significant structural effect was detected by SAAPdap analysis and 166 failed to be 
analysed by SAAPdap (i.e. they did not map to a PDB structure). The most frequent features 
affected were: mutation of a highly conserved residue (Impact) occurring in 138 variants; the 
mutation of an interface amino acid (Interface) occurring in 48 of the variants and disrupting 
H-bonds, occurring in 42 of the variants. Other significant mutations effects occurred less 
frequently, with mutations causing voids or disrupting disulphide bonds not occurring at all.  
 
A significant association was detected between the mutation of a highly conserved residue  
(“impact”) and the presence of a DCM phenotype instead of HCM (90% versus 53%, P-
value=0.029). Also, the number of variants with annotated features on UniProt was 
significantly higher in the presence of a DCM phenotype (20% vs 0%, P-value=0.020).  
 
Furthermore, an association was found between the predicted mutation of an “Interface” 
aminoacid and the functional domain to which the residue mapped. A mutation affecting 
“Interface” aminoacids tended to affect the MYBPC3 binding region (56% in MYBPC3 binding 
region affected an interface aminoacid vs 0% in the actin-binding domain, P-value=0.001). 
 
Finally, a tendency was observed for an association between the mutation of an “Interface” 
aminoacid and a higher MLVWT (22±4 vs 19±4mm, P-value=0.051) and the variation of a 
“Binding” aminoacid and a higher MLVWT (25±5 vs 20±4mm, P-value=0.052). 
 
10.2. MACHINE LEARNING ANALYSIS TO PREDICT PATHOGENICITY 
 
The accuracy (Acc) to predict pathogenicity versus neutral variation, when the best PDB 
structure for each mutation was chosen, was: Acc = 0.927 for all mutations, Acc = 0.991 for 
DCM associated mutations and Acc = 0.914 for HCM associated mutations Accuracy for all 
phenotypes was greater when using a single best resolution PDB chain instead of using 
multiple PDB chains. 
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To compare SAAPpred performance with SIFT and Polyphen2 prediction software, 235 of the 
mutations that mapped to at least one PDB structure were analysed, of which 92.7% were 
predicted to be damaging by SAAPpred, 69.51% were predicted to be damaging by SIFT, and 
90% were predicted to be pathogenic by Polyphen-2. 
 
10.3. MACHINE LEARNING ANALYSIS TO PREDICT PHENOTYPE (HCM VS DCM) 
 
Regarding the most informative features, the highest Chi-square values were obtained for 
highly conserved “Impact” mutations, followed by mutations to glycines. These results indicate 
that the mutation of residues affecting these features confers a high probability of a 
pathogenic phenotype. Mutation of “Binding” residues is also associated with pathogenicity, 





MYH7 mutations fall into two distinct regions that map to different PDB files, for DCM and 
HCM mutations. For the more C-terminal structure (PDB ID 2fxm) there are only 2 DCM 
mutations (compared with 35 HCM), indicating that DCM mutations are rare in this domain. 
For the N-terminal structure (PDB ID 4db1), there are 16 DCM and 116 HCM mutations.  
 
The data suggest the presence of clusters of residues that are over/under populated with DCM 
and HCM mutations compared with what is expected. Figure 47 illustrates the 3 clusters on 
PDB ID 4db1, colouring the clusters red, green and blue for HCM and orange, yellow and cyan 
for DCM.  
 
In particular, DCM is highly over-represented in the third (blue/cyan) cluster. DCM mutations 
in clusters 1 and 2 (orange and yellow) are hardly visible and therefore mostly buried. On the 












Figure 47. Clustering mutations on PDB ID 4db1 human myosin structure. Colouring the clusters red, 
green and blue for HCM and orange, yellow and cyan for DCM. Clustering was done on one chain and 
the results are then shown on the two chains in the 4db1 crystal structure. 
 
 
HCM vs DCM predictor 
 
 
Eleven models together with the a set of features (see Methods, chapter 9.2) including 
Clustering in addition to Binding, RelativeAccess, SurfacePhobic, CorePhilic, Voids, Clash, 
Proline, CisProline gave an accuracy of 0.75 and a Mathews correlation coefficient (MCC) of 
0.531. The best predictive performance was achieved by averaging 10 models using this 
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1. TARGETED HIGH-THROUGHPUT SEQUENCING DATA ANALYSIS 
 
1.1. QUALITY ASSESSMENT OF THE SEQUENCING DATA 
 
Our high-throughput sequencing (HTS) protocol achieved adequate coverage of the targeted 
genomic DNA, which was comparable to the few previously published studies [105],[320]. The 
accuracy of a targeted HTS methodology is now well established in the literature, if an 
acceptable mean read-depth and coverage is obtained. The threshold of 15x has been 
reported [105, 109, 321],[108] to be sufficient for diagnostic testing, with a sensitivity of 99%. 
In this cohort, 93.5% of the targeted region was covered to a depth of 15 or more. However, 
the read depth per plate varied widely, from 73.39±108.0 for plate 1 to 500.30±67.50 for plate 
9, which was mainly due to differences on the multiplexing methodology and the sequencing 
platform used, which changed from plate 3 (233th patient) onwards. In each plate, read depth 
also varied from gene to gene, which is also the case in other HTS studies in cardiovascular 
disease or otherwise [105].The GC content is one of the main factors responsible for 
differences in read depth among genes, as it influences the capture efficiency, with regions 
with higher GC content being less efficiently captured [322]. This occurred in our experiment 
with some of the MYBPC3 exons, which needed further validation with Sanger sequencing.  
 
To avoid missing important variation, we screened with Sanger sequencing those exons that 
presented an average read-depth of 15 or lower. Also, in order to eliminate possible false-
positives due to low read-depth, variants called at a read depth of 15 or lower were 
systematically validated with Sanger. Both the number of false positives and false negatives 
detected was very low and similar to published reports [109], [108]. 
 
One paper [109] stated that with a mean read depth of 100±35 the statistical chance that a 
variant is missed in a patient is 0.004%. The mean coverage across all the samples is well above 
this threshold, although the initial three plates had lower values; however, as described 
(Sections Methods and Results), those plates were submitted to a more extensive validation 
step. In later plates, while obtaining higher read depth and actually supra-optimal coverage, 
we increased the number of patients sequenced in the same run (pre-capture multiplexing), 
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optimizing time and throughput.  
 
One current research - and in the near future possibly clinical - alternative to targeted 
sequencing is the use of whole-exome sequencing (WES) platforms, which have been 
suggested as cost-effective, as the coding region corresponds to only 1% of the genome and 
hence should be able to cover most protein disrupting sequence variation, while providing 
additional sequence data in all genes. However, some authors have pointed out some 
disadvantages. WES platforms are generally characterized by lower coverage than targeted 
sequencing for a defined number of genes, given the amount of DNA to be sequenced, which 
could either result in lower sensitivity or allow less multiplexing, at the end compromising the 
throughput [107, 109].  Other limitations are higher costs and more challenges in terms of 
interpretation and data analysis [109]. Finally, the clinical use of whole-exome platforms raises 
growing concern and debate surrounding incidental findings [323], because relevant variants 
in genes not related to the phenotype under study can be discovered (e.g. BRCA mutations). 
Recently, guidelines have been published that address this issue [323]. 
 
1.2. GENOTYPING RESULTS 
 
1.2.1. SARCOMERE AND RELATED GENES 
I identified likely causal variants in 47% of the patients, if considering the sarcomere genes 
most robustly associated with HCM (MYBPC3, MYH7, TNNT2, TNNI3, MYL2, MYL3, ACTC1, 
TPM1) -which is in keeping with the published literature on cohorts of unrelated HCM 
probands [38] and with the meta-analysis presented in the Introduction [172]. Previous studies 
have used conventional genetic sequencing techniques to screen patients with HCM and most 
suggest that approximately 50% of individuals carry mutations in one of eight main cardiac 
sarcomere protein genes [20],[157]. This is also the approximate yield previously described in 
the same referral centre where this study was conducted, using conventional sequencing 
methodology [324],[139].  
 
In this study, the distribution of variants amongst individual sarcomere and related protein 
genes was similar to that reported previously and summarized in my systematic review [172]. 
The major causal genes in this cohort were MYBPC3 and MYH7, with variation in MYBPC3 
being the most prevalent. I applied both a 0.5% and a 0.2% MAF filter, without any significant 
Section IV- Discussion: 1. Targeted high-throughput sequencing data analysis 
 190 
difference in the obtained dataset of variants for sarcomere genes. 
 
As to the distribution of mutations across the domains and regions of each of the sarcomere 
proteins, I observed an interesting overlap between my single centre data and what is 
reported as an aggregate from the literature [27],[26],[25]. This is the case of the more 
prevalent mutations in the beta-myosin head and neck domains, where the functional ATP-
binding and actin binding domains reside, compared to the rod region [27]. The C-terminal 
region is apparently one of the clustering zones for TNNT2 and TNNI3 variants [26]. In troponin 
I, the C-terminal region corresponds to a highly mobile domain, for which experimental 
evidence has attributed a role in translating towards troponin T the conformational changes 
provoked by the binding of calcium to troponin C [26]. This could explain an increased 
pathogenicity for variants occurring in this region. The role and structure of the C-terminal 
region of troponin T is still to be explored. In general, the distribution of the variants in this 
single centre cohort data corroborates the putative biologically relevant roles of the domains 
where the clustering of variants occur. One exception to this overlap is the finding of a 
significant number of variants located in the alpha-tropomyosin C-terminal domain (period 7 
of the coiled-coil structure), whereas the large majority of the published variants reside in 
period 2 (N-terminal region) or period 5 (middle of the molecule) [26]. 
 
Considering other possibly causal but less strongly established sarcomeric and related genes, I 
reported, for the first time, the prevalence of all types of variants (including missense) in TTN 
in an HCM cohort. Several recent studies have focussed attention on the role of this protein in 
heart muscle disease [46],[50],[44] . Titin is found in skeletal and cardiac muscle, where it 
forms an elastic filament, bound at the N-terminus to the Z-disc and at the C-terminus to 
myosin, myosin-binding protein C and M-band proteins. The inextensible A-band region of the 
filament consists of regular patterns of immunoglobulin-like and fibronectin repeats, whereas 
the I band region is composed of multiple extensible segments (or “spring” elements) including 
PEVK, N2A (skeletal and cardiac muscle) and N2B (cardiac only). Titin is encoded by a single 
gene on chromosome 2 that undergoes complex differential splicing to produce isoforms with 
variable elastic properties and has a major role in determining the mechanical properties of 
the heart through its effects on passive tension during myocardial stretch and restoring forces 
during early ventricular filling and appears to be an important biomechanical sensor and 
organisational element within the sarcomere [46]. These multiple and central roles in 
cardiomyocyte biology make this protein an ideal candidate gene for cardiomyopathy. 
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Nevertheless, titin has been difficult to sequence and study due to its size, large number of 
isoforms and mostly unsolved tertiary structure.  
 
In the present study, I identified a large number of novel titin variants, occurring in two thirds 
of the probands, the majority in association with variants in other candidate genes. Twenty-
seven of the titin variants, present in 46 patients (5% of the cohort) are predicted to cause 
loss-of-function, which is more than the proportion of potentially truncating mutations 
recently reported in a sub-cohort of patients with HCM [50]. A slight majority of patients (57%) 
carrying potentially truncating variants do not show any associated rare main sarcomere 
protein gene variant, which is the reverse of what is observed if considering all titin  rare 
variants.  
 
The significance of the large number of missense SNPs is more difficult to assess. All the 
individual variants present in this cohort occurred with a frequency less that 0.5% in the 1000 
genomes project [111], and the great majority with a frequency lower than 0.0%, suggesting 
that a proportion are at the very least modulators of the phenotype. However, the overall 
frequency of variants in the HCM cohort was actually lower than that seen in the control 
exome population. This finding is difficult to interpret because the annotation of titin variants 
is made extremely complex by the large number of possible isoforms/transcripts, which are 
not accounted for in existing databases. Furthermore, some individual variants are enriched in 
my dataset and have significantly increased frequency compared to the 1000 genomes 
population. 
 
While this research was ongoing, truncating mutations in TTN were published as a major cause 
of dilated cardiomyopathy (DCM), in a study that detected this type of variants in 25% of 
familial cases and in 18% of sporadic cases [50].  However, robust evidence for pathogenicity is 
not present for all the variants reported and caution has been advised in another study [325], 
that found a truncating variant in 7 of 17 familial DCM cases; however, two of those families 
also carried novel TTN missense variants that co-segregated with the phenotype and in 2 there 
was no co-segregation. 
 
Further work on understanding the role of titin in cardiomyopathy is clearly necessary. Based 
in homology modelling, conservation, domain location and predicted effect on protein 
structure, I have selected a set of around 30 missense variants for future work, including 
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mechanistic/functional studies and co-segregation.  
 
Rare variation in MYH6 was also found in a higher number of patients than initially expected. 
Alpha-myosin and beta-myosin heavy chain are encoded by the tandemly arranged genes 
MYH6 and MYH7 respectively, situated on chromosome 14. As β-myosin heavy chain is the 
predominantly expressed isoform in human hearts, most studies in patients with HCM have 
not screened the MYH6 gene and evidence that mutations in MYH6 can cause HCM only 
comes from a few case reports [28]. MYH6 has also been implicated in familial atrial septal 
defects [301] and sick sinus syndrome [326]. In this study, the frequency of rare MYH6 variants 
in patients was similar to the control populations, questioning the importance of this gene in 
HCM. Further functional studies and family evaluation needs to be performed to determine 
the pathogenicity of the identified SNPs. 
 
Unlike the main contractile sarcomeric genes, the association between sarcomeric 
cytoskeleton genes and cardiomyopathies have mainly been suggested by candidate-gene 
approaches in index-case or only small families, rather than the more classical linkage 
strategies that established successive contractile proteins as a cause of familial HCM or DCM. 
As such, even more caution must be used when interpreting variation in these genes. 
 
1.2.2. NON-SARCOMERE GENES 
Inclusion of additional genes, implicated in other inherited cardiac diseases, resulted in the 
identification of a large number of non-synonymous rare variants in ARVC related and/or ion 
channel genes in 42% of the cohort. While the overall frequency of these variants was similar 
to the control population, published data and in silico prediction tools suggested the 
hypothesis that some of these have the potential to modify the disease phenotype.   
 
ARVC and ion-channel associated genes showed a significant difference in the number of 
identified variants when the cut-off for rarity was 0.2% instead of 0.5%, contrary to the 
findings for sarcomere and related genes. This fact is probably due to the high level of 
variation in ARVC and ion-channel associated genes in the general population [115], [116], 
[245].  
 
Heterozygous mutations in genes encoding desmosomal proteins have been identified in up to 
70% of patients with non-syndromic autosomal dominant forms of arrhythmogenic right 
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ventricular cardiomyopathy [327] and latterly in up to 15% of patients with dilated 
cardiomyopathy [328]. In this cohort, I identified a large number of desmosomal candidate 
variants, most of which were classified as variants of unknown significance. As with TTN, the 
majority occurred in patients that had at least one sarcomere protein (or related) gene variant, 
making it difficult to determine their pathogenic role. The same was true for the many variants 
detected in ion channel genes. I hypothesized that the previously published and other rare 
variants in ARVC-related and ion channel genes may be potential phenotype modifiers in HCM, 
given the overlap of some of the downstream pathways.  
 
1.3. DETERMINING PATHOGENICITY OF SEQUENCE VARIANTS 
 
Even when using conventional sequencing technology, the genetic heterogeneity of HCM and 
the high frequency of novel variants with uncertain effects on gene function present 
considerable challenges for clinical interpretation. Ideally, novel variants should be subjected 
to functional studies, but these are costly, time consuming and often impractical in the clinical 
setting. Similarly, co-segregation analysis within families can be helpful, but is uninformative in 
small pedigrees –which are increasingly prevalent- and often difficult and time-consuming to 
orchestrate.  
 
The recent availability of sequence datasets from large healthy and disease cohorts- 1000 
genomes project [112], NHLBI exome sequencing project, UK10K - makes it possible to use 
them as controls for which variant frequency can be used to filter the variants detected in a 
disease dataset. In this study, I applied both a threshold of 0.5% and 0.2% based on the 1000 
genomes project dataset (step I) and NHBLI ESP (step II); this strategy eliminated around 90% 
of the calls and halved the number of distinct variants, while retaining the most likely causative. 
A recently published study [329] analysed the presence and frequency of DCM associated 
variants in the NHLBI exome sequencing project database and in the dbSNP build 131. Based 
on their findings, the authors proposed a preliminary allele frequency cut-off of 0.04%. 
However, the majority of the studies published since my own work have used cut-offs of 0.5% 
or 1% for rare variation [108]. Some of the relevant variants might be lost if a too stringent 
threshold is applied. For example, if applied to this dataset, the threshold of 0.04% would 
exclude some clinically important variants, including five disease-causing published sarcomere 
variants and five published ion-channel disease-causing variants.  
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As a consequence of the above-mentioned large-scale genomic screening projects, rare 
variation in sarcomere genes in the “general” population was also scrutinized, as I did in the 
context of this study (Methods and Results Section) and these data were published 
concomitantly. In one paper, the authors queried the 1000 genomes database for rare exonic 
variants in MYH7, MYBPC3 and TTN and found previously reported and probable pathogenic 
variants in MYH7 and MYBPC3 at a frequency higher than expected for the prevalence of 
cardiomyopathy [246]. Similar findings were reported in other papers, including two that 
analysed the NHLBI exome sequencing population data [330], [245] and another that used the 
Framingham and Jackson Heart Study cohorts [244] to screen for the presence of previously 
reported or likely pathogenic variation in sarcomere genes. Possible explanations for these 
findings are a combination of reduced penetrance for some of these alleles, the possibility of 
digenic and oligogenic models of inheritance and also erroneous attribution of pathogenicity 
to previously reported variants [142]. 
 
The fact that rare variation is cardiomyopathy associated genes has been described in a much 
higher prevalence than expected complicates the interpretation of a given genetic result and 
demonstrates the caution needed when interpreting missense variants, even if they are rare or 
previously described as causal and the need to develop new tools that calculate a probability 
that a given variant is disease causing. If using HTS approaches, as in this study, the potential 
to identify a very large number of rare variants that are also found in the general population 
and which have little or no effect on disease phenotypes could make attribution of causality to 
candidate variants using conventional methods such as co-segregation analysis in large 
pedigrees impractical. The availability of sequencing data from large population cohorts 
allowed the statistically comparison of the distribution of rare variants between controls and 
cases. I compared the sequencing results for the first 223 patients with a set of high depth 
exomes generated by the UK10K sequencing project (www.uk10k.org) and investigated 
whether I could identify an excess of rare variants in cases that would be consistent with a 
pathogenic role. Four sarcomeric genes (MYH7, MYBPC3, TNNI3, TNNT2) showed a significant 
excess of rare nsSNPs compared to controls. Assuming a simple dominant model, we 
estimated that rare nsSNPs in these four genes explained between 13% and 43.7% of HCM 
cases. Additionally, we proposed a statistical approach that estimated the probability that a 
nsSNP candidate variant is causal. While this statistical approach cannot on its own identify a 
variant as causal, it provides insights into the genetic architecture of HCM. 
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I repeated this approach for the larger cohort of 874 patients, using both a 0.2% and 0.5% 
threshold for rarity and incorporating small indels and splice-site variants in the analysis and 
the obtained results were very similar, with the same four sarcomere genes showing a 
statistically significant difference between cases and controls. However, in this second case-
control analysis MYBPC3 showed the highest difference for the frequency of rare variation 
(compared to MYH7 in the previous analysis), which is related to the high prevalence of non-
missense variants in MYBPC3, that were absent from the first comparison. Additionally, rare 
variation in CSRP3 and PLN was significantly higher in HCM cases, which suggests an important 
but incompletely explored role for these genes in HCM genetics. In fact, CSRP3 has been 
questioned as a causal gene, namely due to the unexpectedly high prevalence of the W4R 
variant in the general population [330], but my statistical approach further suggests a 
pathogenic role for this gene in HCM. 
 
I also detected a few number of individual variants, mainly in MYBPC3, to occur at a high 
frequency in this cohort. Taking into account that the cohort is constituted by unrelated 
probands only, the high number of individuals with the same variant could be the result of a 
founder effect. 
 
The case-control comparison for non-sarcomere genes associated with arrhythmogenic right 
ventricular cardiomyopathy or ion-channel disease showed no significant enrichment of rare 
variation in patients compared to controls, either from UK10K project or UCLexome. While 
these data could be interpreted as proving that such variation is purely “background noise”, 
my genotype-phenotype findings seem to suggest otherwise, at least for some of the non-
sarcomere genes, such as ANK2. A modifier effect on phenotype, rather than a causal one, 
could be compatible with an absence of enrichment for these variants, which would only exert 
their effect in the presence of a main and truly causal sarcomere variant. 
 
In conclusion, one approach to the interpretation of variants is purely statistical. Rare genetic 
variation in healthy populations occurs in a much higher prevalence than expected [246], [244], 
[330]. But at least in the case of HCM, I showed that the prevalence of rare variants is 
significantly higher in HCM cases compared to controls for most of the main sarcomeric genes. 
Interpretation of genetic variants might therefore include a probabilistic element, based on 
gene, type of mutation and the proportion of rare variation in cases versus controls; this 
approach was also very recently suggested by other authors [331], [332].  
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Standard approaches to variant interpretation will increasingly need to be complemented by 
other strategies and the novel quantitative methods presented in this study provide one way 
of determining the probability that a variant is disease causing. Additional tools that integrate 
genetic data with high throughput functional analyses and more sophisticated in silico 
prediction models coupled with improved clinical phenotyping will also be required. In the 
scientific setting, corroborative information on pathogenicity is derived from functional assays 
of various kinds but these are expensive, time consuming and difficult to translate into the 
clinical setting. New animal and cellular models are needed to provide accurate (and hopefully 
rapid) data on the consequences of sarcomeric mutations in the clinical diagnostic laboratories. 
Work in iPSCs appears promising [87], as well the use of zebrafish models [333]. 
 
Also, new patterns of oligogenetic or non-mendelian inheritance should be considered, which 
could also justify the high prevalence of rare variants (including published as disease-causing 
ones) in the general population.  
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2. NOVEL GENOTYPE-PHENOTYPE ASSOCIATIONS IN HYPERTROPHIC 
CARDIOMYOPATHY REVEALED BY HIGH-THROUGHPUT SEQUENCING 
 
2.1. INFLUENCE OF SARCOMERIC VARIATION ON PHENOTYPE 
 
In this cohort, the presence of any sarcomere protein (SP) variant was associated with a class-
effect consisting of an asymmetric septal hypertrophy pattern, younger age at presentation, 
family history of HCM and sudden cardiac death (SCD) and higher proportion of female 
individuals. Three studies, published after my data was generated, broadly confirm these 
results [334], [335], [336]. All these data also reproduce part of the results presented in my 
systematic review and meta-analysis (see Introduction) [172]. However, none of these other 
previous or concomitant studies used massively parallel sequencing technology and all 
spanned a period of time where different sequencing technologies and heterogeneous gene 
panels were used, which is a limitation. 
 
I additionally constructed a multivariate regression model based in the variables that 
individually showed a significant association with a SP - positive genotype.  The strongest 
predictors, which showed the highest score values, were family history of HCM and an 
asymmetric septal hypertrophy pattern.  
 
Furthermore, this study also showed that patients with sarcomere protein variants had higher 
cardiovascular and SCD mortality during follow-up. Previous reports have analysed the 
association of genotype and cardiovascular death, but integrated in a composite end-point, 
together with other cardiovascular outcomes, such as an evolution to heart failure or stroke 
[178]. My study was the first to analyse cardiovascular death as an isolated end-point, as well 
as sudden cardiac death. 
 
Patients with more than one sarcomere protein variant had an increased risk profile for SCD, 
confirming the suggestion of a gene dose effect, reported in previously published small series 
[18, 176],[242],[337]. Also, double heterozygotes for MYH7 and MYBPC3 were associated with 
a significantly reduced survival, compared to no variation in these genes or to the presence of 
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a rare variant in either gene in isolation, which further confirms the deleterious prognostic 
effect of multiple SP variation. 
 
With regard to individual sarcomere protein genes, some of the effects seem to reproduce the 
previously mentioned class effect on age, morphology and family history of HCM and SCD, if 
considering the two most prevalently mutated genes, MYBPC3 and MYH7. However, I have 
also demonstrated a number of completely novel associations that provide evidence for gene 
specific effects on clinical phenotype and prognosis. For example, the association between the 
presence of rare variation in TNNI3 and right ventricular hypertrophy, the lower blood 
pressure response to exercise in the presence of MYH7 rare variants and the higher 
percentage of patients submitted to invasive gradient reduction therapies when carrying 
MYBPC3 splicing variants. This last finding is rather interesting, because despite the loss of 
statistical power due to only analysing a subset of variants (splicing but not missense or 
others), an association was discovered with an end-point that is a surrogate to a more severe 
manifestation of the disease – increased symptoms due to left ventricular outflow tract 
obstruction, that are not manageable with pharmacological therapy. This may be a 
consequence of an increased biological effect of these splicing variants, which are particularly 
prevalent in this gene, where haploinsufficiency is probably the predominant mechanism of 
pathogenicity [338]. The association of TNNT2 rare variation and a lower blood pressure 
response to exercise is another relevant finding, already suggested in a previous work, that 
only focused in one mutation (R92W) [234].  
 
The presence of a rare variant in MYBPC3 or MYH7 was associated with reduced survival 
(respectively for SCD and cardiovascular death), but only when modelled for time from birth. 
Interestingly, the presence of rare variation in TNNT2 was related to increased cardiovascular 
death, either modelled for follow-up or for time from birth, but not SCD. Although this is in 
apparent contradiction with earlier reports that associated TNNT2 mutations with an 
increased risk of SCD [172], more recent studies with longitudinal follow-up of large cohorts 
have contested this apparently too simplistic concept [139]. I also compared the survival 
directly between MYH7 and MYBPC3, without finding any difference.  
 
I opted to model all the conducted survival analyses for both follow-up time and time from 
birth, as previous work has suggested that the assessment of the influence of genetic [139] 
and clinical [339] risk factors in mortality can be potentiated by this statistical approach. The 
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rationale is the fact that being a genetic disease, the risk of adverse outcomes is theoretically 
present from birth [339].  
 
However, the low number of outcome events during follow-up may have biased the survival 
analysis and precluded an analysis of other associations, including the effect of carrying 
multiple compared with single variants. The survival from birth is provided for comparison 
with the published literature but also introduces an inherent survivor bias. 
 
I also hypothesized that filtering for putatively biologically more relevant variants, by selecting 
only those that are predicted to be pathogenic in silico, could enhance the discovery of 
genotype-phenotype correlations. However, when the analysis was repeated for only those 
variants, no additional genotype-phenotype correlations were revealed. This is probably 
related to the known limitations of bioinformatic tools, such as Polyphen [160] and SIFT [340], 
that are not directed to a specific phenotype nor validated for clinical use [110].Other possible 
reason for this negative finding was the loss of statistical power, due to the lower number of 
variants analysed. 
 
Finally, the genotype-phenotype analysis was repeated in the sarcomere positive sub-cohort 
alone, with the purpose of limiting the analysis to a more homogeneous population in terms of 
genetic background, which could reveal additional associations, for example related to a 
hypothesized modifier effect of non-SP genes. Again, this approach did not reveal additional 
genotype-phenotype relationships, while reproducing the most significant ones. Again, a loss 
of statistical power occurred in this sub-analysis, as the sample is reduced by half if only 
considering the sarcomere positive individuals. 
 
2.2. CARDIAC MAGNETIC RESONANCE PHENOTYPING SUGGESTED ADDITIONAL GENOTYPE-PHENOTYPE 
ASSOCIATIONS 
 
In the sub-cohort of patients where phenotyping was further refined with cardiac magnetic 
resonance (CMR), the association between the presence of rare sarcomere variation and left 
ventricular wall thickness or the pattern of hypertrophy was confirmed, despite the smaller 
size of the sample. Also, additional genotype-phenotype associations were revealed. Carriers 
of an SP variant showed lower ejection fraction, an association never described before. 
Although in of need of confirmation in other cohorts, this clinically relevant association could 
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prove to be another of the constellation of functional and morphological findings that 
constitute a class-effect of sarcomere variation. The higher reproducibility of left ventricular 
function quantification by CMR [341] can partly explain the fact that this finding was not 
reported in previous echocardiography-based studies of large HCM cohorts. The poorer 
ventricular systolic function might be explained by a common downstream contractility 
impairment, resulting from sarcomere malfunction as a consequence of mutations in any of 
the main sarcomere genes. Interestingly, I have shown that SP genotype-positive patients had 
worse prognosis, which is commonly correlated with lower LVEF in other cardiovascular 
diseases. 
 
Furthermore, sarcomere-negative patients had a significantly higher myocardial mass, for the 
quantification of which CMR is the gold-standard [341]. Again, this is a previously unknown 
correlation, probably revealed by the higher accuracy of CMR, which is much less dependent 
on geometrical assumptions and much more reproducible than echocardiography for the 
calculation of volumes and mass. The increased LV mass observed in the sarcomere-negative 
patients is difficult to explain biologically, as those patients are probably very heterogeneous 
in terms of causality and genetic background. 
 
Another advantage of the more detailed phenotyping provided by CMR is the ability to 
perform tissue characterization [342]. Late-gadolinium enhancement (LGE) has been related to 
an increased prevalence of ventricular arrhythmias and with a higher risk of heart failure in 
HCM, although the association with an increased risk of SCD is more debatable [343]. 
Interestingly, the proportion of individuals with late gadolinium enhancement was increased in 
sarcomere positive individuals, although not reaching statistical significance. 
 
2.3. EFFECTS OF TITIN ON THE PHENOTYPE 
My data on TTN variation provides the first evidence for a possible modifier effect of TTN loss-
of-function variants on the left ventricular systolic function of HCM patients, which showed a 
lower fractional shortening when carrying such variants. This novel finding is biologically 
plausible given the central role of titin in sarcomere biology and structure and the proposed 
position of TTN as the major causal gene in DCM [50]. The results from regression analysis 
demonstrated that right ventricular hypertrophy and maximal LV wall thickness were also 
predictors of the presence of a potentially loss-of-function titin variant.  
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Furthermore, I analysed the phenotype of carriers of candidate titin variants that were 
significantly enriched in this cohort, compared with the 1000 genomes population, and thus 
hypothesized to exert a functional effect. Male sex, increased left ventricular and left atrial 
dimensions and higher maximal wall thickness were predictors for the presence of an enriched 
titin variant. 
The presence of any type of rare TTN variant was significantly associated with a higher 
probability of carrying an implantable cardioverter-defibrillator at baseline or having one 
implanted during follow-up. This suggests an increased SCD risk profile for patients that carry a 
TTN variant, which merits further exploration in future studies. 
2.4. MODIFIER EFFECT OF NON-SARCOMERE VARIANTS 
I have described that many patients with sarcomere mutations also carry rare variants in genes 
coding for desmosomal, ion-channel and other proteins implicated in inherited heart disease, 
but their relevance to disease expression was unknown. Given the phenotypic and genetic 
overlap between different cardiomyopathies, I have hypothesized that variation in non-
sarcomere genes could act as a modifier of the HCM phenotype by acting in common 
downstream pathways and hence contribute at least partially to explain the phenotypic 
heterogeneity that characterizes this disease. This was never tested before my work.  
 
The data in this study suggest that rare ANK2 variants are associated with severe LV 
hypertrophy.  ANK2, or ankyrin B, stabilises membrane ion channels in cardiomyocytes and 
mutations cause long QT syndrome 4, ventricular arrhythmias and sinus node disease [344], 
[345]. I am unaware of any link between ANK2 expression and changes in LV morphology, but 
as ankyrins interact with proteins that influence calcium homeostasis and ß-adrenergic 
signaling, it is conceivable that they eventually affect the cellular expression of sarcomere 
protein gene variants. The strength of association (P = 0.0005) passes a Bonferroni correction 
for the number of tested genes, but further replication in independent cohorts will be 
necessary to confirm these results. 
 
In addition to the association with ANK2 variation, I detected a number of associations of 
lower statistical significance with variation in other non-SP genes. Patients with SCN5A rare 
Section IV- Discussion: 2. Novel genotype-phenotype associations in hypertrophic cardiomyopathy 
 202 
variants were more likely to have LA enlargement at the final evaluation. A link between 
SCN5A disruption and TGF-beta1-mediated fibrosis has recently been demonstrated in a 
murine model of sinus node disease [346] and it is possible that SCN5A variants influence the 
pro-fibrotic milieu associated with sarcomere protein mutations. SCN5A rare variation was also 
associated with a higher proportion of significant left ventricular outflow tract obstruction.  
 
Individuals with rare PLN variants had a significantly increased proportion of NSVT, which is 
interesting considering the recently described arrhythmogenic burden risk of a founder PLN 
mutation [347]. Similarly to the association with ANK2, further replication will be required to 
confirm these findings. 
 
2.5. CLINICAL IMPLICATIONS 
 
If genetic variation is to become a clinically relevant biomarker, it is essential that there is a 
clearer understanding of genotype-phenotype relationships. The associations between 
sarcomere gene variants and the broader phenotype examined in this study contribute to this 
understanding and if confirmed in other populations could inform the counselling of patients 
and relatives who are contemplating predictive genetic testing. The demonstration that non-
sarcomeric variants may influence disease expression is an illustration of the complexity that 
underlies the biology of this genetic disease. New models that incorporate a broad genetic 
profile and deep clinical phenotyping are necessary to use mutation analysis in prognostic 
models. Ultimately, the clarification of genotype-phenotype relationships will require 
collaborative, large-scale research that brings together teams expert in molecular biology, 
clinical medicine, bioinformatics and population science. 
 
 
Section IV- Discussion: 3. Copy number variation in hypertrophic cardiomyopathy 
 203 
 
3. COPY NUMBER VARIATION IN HYPERTROPHIC CARDIOMYOPATHY 
 
Motivated by the fact that approximately 50-60% of HCM patients remain genetically 
undiagnosed [172], a read depth strategy was applied to the targeted high-throughput 
sequence data generated from the first 505 unrelated and consecutive HCM patients. Such 
analysis could be hampered by the limitations of short read sequencing approaches, which 
negatively affect sensitivity/specificity [348]. To avoid false calls, I used an aCGH validation 
strategy and validated 4 out of 12 CNV calls, in line with the previously reported high false 
positive rate across all available algorithms [348]. 
 
Using this two-step approach, I detected and validated potential disease causing CNVs in 0.8% 
of the samples, with direct implications for diagnostic and counselling: some patients without 
mutations on direct sequencing may still have transmissible CNVs in sarcomeric protein genes.  
 
While the limited sensitivity of read depth techniques for CNV detection is an important caveat 
to consider, the read depth methodology applied here provided reliable data for large CNVs 
[349]. Hence, the limited proportion of potential disease causing CNVs in the cohort (< 1%) 
suggests that CNVs are not a major genetic cause of HCM.  While the knowledge of the role of 
CNVs in HCM is scarce, other reports are compatible with this conclusion. These include a 
single family with a large MYH7 deletion as the probable cause [350], which was detected 
using a PCR-based method and more recently a single MYBPC3 deletion [351] in a cohort of 
100 unrelated genotype-negative patients, using multiplex ligation-dependent probe 
amplification (MPLA). A third study, also using MPLA, was unable to detect any large 
rearrangement in MYBPC3 or TNNT2 in a cohort of around 100 unrelated HCM patients [352].  
 
In other cardiomyopathies, two groups [353],[354] reported on three large PKP2 deletions in 
arrhythmogenic right ventricular cardiomyopathy (ARVC) patients, one detected by a SNP 
array [353] in a single family without point mutations in known ARVC genes and the other [354] 
in two unrelated probands (one detected by array methodology and the other by MPLA). 
Another report failed to demonstrate the presence of LMNA CNVs in a cohort of dilated 
cardiomyopathy (DCM) patients [355].  
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Further work to define the pathogenicity of the discovered CNV candidates is required, but the 
two deletions – one in MYBPC3 and the other in PDLIM3 -are likely to be pathogenic.  The large 
deletion in MYBPC3, encompassing 4 exons, is consistent with haploinsufficiency, the most 
commonly accepted pathogenic mechanism for this protein [35, 356]. The large deletion in 
PDLIM3, involving the last 4 exons, is also very likely to cause a truncated protein or RNA 
mediated decay, culminating in haploinsufficiency. Interestingly, although previously reported 
as causal, there are very few data on the association between this gene and HCM (or 
cardiomyopathy in general) [63] and CNVs might prove to be an important cause of pathogenic 
variation in PDLIM3.  PDLIM3 is a conserved human gene: the NHLBI exome sequencing server 
[357][74](24) shows a single loss-of-function (LOF) variant in over 12500 alleles– a frameshift 
insertion (rs199476399; c.178_179insCA; p.(M60Tfs*2))  The observation of a LOF CNV in the 
cohort of HCM cases is consistent with the possibility that PDLIM3 LOF alleles cause HCM. 
However, additional evidence will be necessary to confirm this hypothesis. 
 
The possible causal role of the two large duplications is more difficult to judge. The database 
of genomic variants (http://www.ncbi.nlm.nih.gov/dbvar/, accessed Aug 2014) lists a single 
exonic TNNT2 duplication, (dbVar nsv467961; 218021 bp). This previously reported duplication 
is large and involves 7 genes. It was originally reported in a CNV screening study of a general 
population cohort of 1,500 individuals (no detailed phenotypic data available) [358]. A similar 
dbVar search for exonic LMNA CNVs identified a single duplication (dbVar nsv509513; 246469 
bp), involving 10 genes, and originally published in a technical report of single molecule 
analysis of genome structure in 4 samples [359]. Overall and although a proper estimation of 
control sample size is not possible owing to the heterogeneity of this available database, these 
data suggest that large duplications in these two genes are rare and could be disease causing. 
 
Structural variation has traditionally been studied using hybridization techniques such as 
fluorescent in situ hybridization (FISH), only capable of detecting very large structural changes. 
These approaches have more recently been replaced by aCGH for clinical applications. The 
development of calling algorithms that can detect CNVs from HTS data [273],[348] means that 
for the first time larger patient cohorts can be routinely screened for CNV, as demonstrated in 
this study. Furthermore, while clinically relevant results can be obtained with targeted 
sequencing data, as applied here, such techniques will be radically improved by the 
generalization of whole genome sequencing, for which read depth strategies can be used in 
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combination with read pair and split read methodologies [152] to provide a thorough picture 
of the contribution of CNVs to inherited cardiac disorders. 
Section IV- Discussion: 4. Non-coding sequence data analysis 
 206 
 
4. NON-CODING SEQUENCE DATA ANALYSIS 
 
In this work, I sought to explore, for the first time, the possible contribution of non-coding 
variation to the genetic architecture of HCM, using targeted HTS. I also proposed a pipeline for 
the analysis of non-coding variation, based on open-access bioinformatic tools and public 
databases, which can be used to prioritize candidate variants for future functional studies. 
 
4.1. VARIANTS MAPPING TO TRANSCRIPTION FACTOR BINDING SITES 
 
My results show that a considerable proportion of patients (14%) carry variants that could 
potentially interfere with the binding of cardiac expressed transcription factors (TF). A majority 
of these patients do not carry potentially causal mutations in the exonic regions of these genes.  
 
If only considering those transcription factors in which previous experimental evidence shows 
a role in cardiomyocyte hypertrophy signalling, the proportion of patients without coding 
candidate variants is higher and even higher if only considering the variants that map to 
conserved positions.  
 
SRF (serum response factor) has been established as a mediator of hypertrophic signals and its 
over-expression in transgenic animal models induced cardiac hypertrophy or dilation. Its role 
in the regulation of cardiac development genetic programs has also been demonstrated, as 
well as its effect in the induction of the fetal gene program as part of the cardiac hypertrophy 
response [360],[361],[362]. There is extensive experimental evidence from luciferase reporter 
gene assays, RT-PCR and microarray analysis in cell lines from animal models, that establishes 
SRF as binding to the promoter of ACTC1 and activating the transcription of this 
gene[363],[364],[365],[366],[367]. In this cohort, three variants were predicted to potentially 
interfere with the binding of SRF to regulatory regions of sarcomere genes: two are in 
conserved positions, located in the 5’UTR of ACTC1 and in an intronic region of TPM1. These 
genomic positions also have a high level of evidence for the transcription factor binding, 
reflected by a RegulomeDB score of 2a (datatypes available: TF binding + matched TF motif + 
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matched DNase Footprint + DNase peak).  A third SRF-binding variant is located in the 
upstream region of ACTC1.  
 
C/EBPß (CCAAT/enhancer binding protein beta) has recently been implicated in the 
transcriptional mechanisms and signaling underlying physiological hypertrophy and also 
cardiomyocyte proliferation during development [368]. Data from genetically modified mice 
suggested that C/EBPß inhibits cardiomyocyte hypertrophy in the adult mammalian heart. I 
found three variants that could potentially affect C/EBPß binding to regulatory intronic regions 
of MYBPC3 in four patients that did not carry any candidate coding variants in sarcomere 
genes. All the three positions are conserved. 
 
p300 is a transcription co-activator of GATA4 and myocardin and has histone acetyltransferase 
activity. Overexpression in cardiomyocytes induces hypertrophy [361]. The p300/GATA4 
pathway was also recently suggested to mediate the hypertrophic response to 
aldosterone/mineralocorticoid receptors [369]. Two of the detected variants map to p300 
binding sites, one upstream of MYH7 and the other in an intronic region of TPM1. 
 
STAT3 (signal transducer and activator of transcription 3) over-expression in mice induces 
cardiac hypertrophy. This signaling pathway has also been implicated in cardiomyocyte 
survival (e.g. upon anthracycline toxicity), mitochondrial energy metabolism and extracellular 
matrix composition [370],[371]. I identified two variants potentially affecting the binding of 
STAT3, both in intronic regions of ACTC1. 
 
Activation of HDAC2 (histone deacetylase 2) by hypertrophic stressors has previously been 
demonstrated. Transgenic mice with HDAC2 over-expression exhibit cardiac hypertrophy and 
knock-out mice are resistant to hypertrophy [372]. My analysis identified two variants 
mapping to binding sites for HDAC2. One variant is present in the 3’UTR of TPM1 and another 
in the upstream region of MYH7. 
 
NSRF (neuronrestrictive silencer factor) is a transcription repressor, with a key role in the 
induction of the “fetal gene program” in the presence of hypertrophic stimuli. Knock-in mice 
for a mutant NSRF exhibited a dilated cardiomyopathy phenotype [373]. I detected one variant 
that could interfere with NSRF binding to an intronic region of TNNT2, in a patient without any 
exonic variant in sarcomere genes.  
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YY1 was demonstrated to be an anti-hypertrophic factor. Over-expression of YY1 prevents 
cardiomyocyte hypertrophy and the “fetal gene program” activation in the presence of 
hypertrophic stimuli [374]. A variant that could potentially affect the binding of YY1 to the 
5’UTR of TPM1 was detected in one patient, who did not present any potentially causal variant 
in the coding region of any sarcomere gene. The variant occurred in a conserved position. 
 
One important limitation for this screening is the absence of suitable controls for comparison 
of the frequency of non-coding variation. In fact, most of the available databases, such as 
NHBLI ESP exome sequencing server (http://evs.gs.washington.edu/EVS/) or the 1000 
genomes project browser (http://browser.1000genomes.org/index.html) only include exome 
(coding) sequencing data or in the case of the 1000 genomes, very low read depth data for 
non-coding regions in phase II of the project, which invalidates a meaningful comparison. 
 
Until the completion of the thesis, additional algorithms were published that allow annotation 
of non-coding variants and prediction of pathogenicity, such as Combined Annotation-
Dependent Depletion (CADD) [375], which also allows annotation of coding regions and 
Genome-Wide annotation of Variants (GWAVA), specifically developed to annotate the non-
coding regions [376]. Future work with the use of these algorithms might help the 
prioritization of variants for mechanistic studies, which is outside the scope of the current 
work. 
 
4.2. EXPRESSION COMPARISON BETWEEN CASES AND CONTROLS 
I then sought to understand whether the presence of non-coding variants mapping to TF 
binding sites influenced the expression of the sarcomeric genes where those variants occurred, 
using tissue from two sarcomere-negative individuals previously submitted to miectomy and 
additionally if there was a change in the expression of other sarcomere genes in that tissue.  
The array expression study showed that the RNA levels for the eight main sarcomeric genes 
was not different between these two cases and controls. The most likely explanation is that 
the cause of hypertrophic cardiomyopathy in these two patients resides elsewhere in the 
coding genome. However, as some of these genes also have an important role during cardiac 
development, another explanation can be that the effect of the non-coding variation in the 
expression of these genes could only be verified in earlier stages of development, leading 
years later to the development of HCM. Another open hypothesis is that non-coding variation 
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is a modifier and not a cause of the phenotype, which would require much more complex 
models to evaluate. 
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5. WHOLE-EXOME SEQUENCING 
 
The emergence of high-throughput sequencing technologies has allowed the possibility of 
sequencing the entire coding region of the human genome, the exome, a sequencing process 
called whole-exome sequencing (WES) [377], [107].  
 
In the first few published studies, WES was demonstrated to be useful for new causal gene 
discovery, in Mendelian diseases where the genetic basis was not (partially or completely) 
solved, as an alternative to the more classic linkage studies. This was the case of the initial 
proof-of-concept publications [377],[378] in very rare syndromes such as Miller or Freeman-
Sheldon syndrome. WES was then applied for new gene discovery, and also in the 
cardiovascular setting; one example is the discovery of BAG3 as causal gene for dilated 
cardiomyopathy [379]. 
 
WES has also been used to screen large populations, in the previously mentioned studies that 
have been extremely useful for the understanding of the scope of human variation in health 
and disease, such as the 1000 genomes project [112], the NHBLI ESP [114] and UK10K [380]. 
Those studies, all conducted while my own research was taking place, were very recently 
completed and have provided an extraordinary amount of data, for which one of the most 
useful clinical applications is the ability to filter variants according to their frequency in those 
populations. 
 
More recently and as a consequence of the technological development of sequencing 
platforms and bioinformatic algorithms for variant calling and annotation, the use of WES has 
also been advocated for clinical genetic testing, particularly in diseases characterized by high 
locus heterogeneity (which is the case of HCM), as an alternative to the targeted sequencing of 
a limited panel of genes of interest for the disease being studied [107]. The stated advantages 
are equivalent costs and the gain of extra-information. However, the previously discussed 
challenges of sequence data interpretation are greatly augmented by this approach, because 
variants from more than 20,000 genes are obtained. Other limitations are the lower coverage 
and read depth [109], compared to the more focussed targeted sequencing of a few genes of 
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interest, and the challenging issue of incidental findings, for which recent guidelines have 
recommended a list of genes where variation should be reported [323].  
 
As described previously in this text, around half of the studied HCM probands did not carry any 
candidate variant in a main sarcomere gene. I therefore hypothesized that this could be 
partially due to previously undiscovered genes  - or known genes that were not previously 
associated with HCM. 
 
As such, WES was used as a pilot study for new causal gene discover, in families where I did 
not find any candidate variant in the initial targeted sequencing of known causal genes. I 
selected three of those “genotype-negative” families, where blood was available for two 
affected relatives. After a process of filtering for shared variants between two relatives, rarity 
and relevant disease pathways, a list of between 34-68 candidate variants was obtained. 
 
Based on molecular interactions and data from the literature and databases, the strongest 
candidates obtained were two OBSCN (obscurin) variants – T7800I and A7669T – one in each 
of two families. Furthermore, in one of these families, the phenotype also co-segregates with 
compound heterozigozity for 2 missense TTN variants – R26175Q and T8910S,  both predicted 
to have a functional impact. 
 
Different obscurin isoforms are obtained from differential splicing of the OBSCN gene. Most 
are very large proteins, composed of multiple immunoglobulin domains, a calmodulin/Ca 
interacting domain, a Rho-guanine nucleotide exchange factor (RhoGEF) and in obscurin B, two 
C-terminal kinase domains. This protein interacts with M-band proteins, Z-disc proteins, TTN 
and the sarcoplasmic reticulum through ankyrin [381]. Through these multiple interactions, 
osbcurin is thus believed to exert important roles in myofibrillar and sarcomere organization 
and signaling. The causal role of obscurin variation in cardiomyopathies has not been 
systematically explored. There is only one single report of an association with HCM [75], with 
limited functional data showing impaired interaction with TTN and impaired localization to the 
Z-disc, but co-segregation information is absent. The limited knowledge regarding the 
pathogenicity contribution of obscurin to cardiomyopathies is probably related to factors in 
common with titin. Because of its large dimensions, it has been challenging to sequence the 
gene by previously available conventional sequencing technologies in a significant amount of 
patients. Also, the complex splicing process and multiple isoforms create annotation problems.   
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For my own data, functional studies and sequencing of unaffected relatives has to follow, in 
order to prove pathogenicity and causality for these variants. However it is interesting to 
notice that I detected two possible candidate OBSCN variants in 3 families, suggesting a 
common genetic cause of HCM. More HCM probands should be screeened for variation in this 
gene. For the family with the compound heterozigozity for TTN, I hypothesize that the triple 
variation in these two crucial proteins for sarcomere function is ultimately responsible for the 
phenotype, functioning as an oligogenic mechanism. 
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6. IN SILICO ANALYSIS OF MYH7 MISSENSE VARIANTS – PATHOGENICITY AND 
PHENOTYPE PREDICTION BASED IN THE STRUCTURAL IMPACT OF THE MUTATION  
 
Genotype-phenotype analyses, like the one described in previous sections, do not usually 
account for protein structural data regarding the mutations being analysed, both in terms of 
the location of the mutated residue in a certain domain or the potential impact of the amino 
acid substitution regarding conformational changes, interaction with other domains/regions 
within the same protein, protein-protein interaction or ligand binding.  This limitation is 
probably due to a combination of a still large number of unsolved protein structures and the 
absence of in silico prediction software incorporating structural information. In the 
cardiomyopathy field, only one report has suggested a prognostic influence of the domain 
localization of mutations in beta-myosin heavy chain [169], but this was not the object of 
further studies. 
 
Stimulated by the above limitations and the availability of an in silico software – SAAPpred – 
that predicts the structural impact of an amin oacid change [163], [166] if the residue locates 
to a solved PDB structure, I hypothesized that the integrated use of such a tool would improve 
the ability to predict pathogenicity of missense variants and help in the establishment of 
genotype-phenotype relationships in cardiomyopathy. I used beta-myosin heavy chain as the 
model of this exploratory work, because its structure is mostly solved and almost all causal 
mutations are missense, on the contrary to cardiac myosin binding protein C, where truncating 
mutations are very prevalent. Furthermore, mutations in MYH7 can give rise to two different 
phenotypes – HCM and DCM.  
 
An initial manual analysis showed promising associations between some of the structural 
features and phenotype traits, such as maximal wall thickness or the development of an HCM 
phenotype vs DCM. 
 
This pilot results suggested the possibility that a more sophisticated approach, for example 
using machine-learning methods could generate novel results. When the predictive power of 
the SAAPpred approach was examined by a machine learning approach to discriminate 
between pathogenic and putatively neutral SNPs in MYH7, the dataset gave very reasonable 
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results for accuracy, above 0.90. This was then followed by the creation of a novel predictor, 
which attempts to distinguish between HCM and DCM mutations using SAAP analysis. 
Structural clustering was incorporated as one of the features, because mutations causing HCM 
and DCM were found to cluster in different regions of the beta-myosin heavy chain head. The 
best performance currently achieved for distinguishing HCM and DCM mutations, by removing 
models that perform particularly badly, is an accuracy of 0.79. The reason for removal of the 
badly performing models must be further explored from a protein structural perspective (i.e 
some structures appear to make the performance worse). 
 
In conclusion, the use of a machine learning algorithm based on a structural impact prediction 
tool allowed very reasonable prediction of pathogenicity, at least comparable to the existing 
tools [166], but with the advantage of having been developed for a single protein and disease 
group, which is an often cited limitation of the existing in silico software[110]. These findings 
can now be further validated in additional datasets of MYH7 variants.  
 
Perhaps even more interesting and novel, is the promising ability of predicting phenotype 
(HCM vs DCM) from the structural impact / location of the mutation. Considering that this is 
such a complex biological problem, the accuracy of 0.79 was considered surprisingly good and 
deserves to be further explored for other phenotype traits, such as maximal wall thickness and 
eventually for other sarcomere proteins. The differential clustering of HCM vs DCM mutations 
on the beta-myosin heavy chain head should also be studied in terms of the affected sub-
domains, which may suggest novel hypothesis regarding downstream pathways, mechanisms 














- This study provided the first large-scale quantitative analysis of the prevalence and 
effects of sarcomere protein gene variants in patients with HCM using a targeted HTS 
technology; 
- I identified a large number of nsSNPs in sarcomeric and non-sarcomeric genes. Four 
sarcomeric genes (MYH7, MYBPC3, TNNI3, TNNT2), CSRP3 and PLN showed an excess 
of rare single non-synonymous SNPs (nsSNPs) in cases compared to controls;  
- The frequency of non-sarcomeric variants was similar to the control population but 
some of them are predicted to have functional impact and/or were previously 
published as pathogenic in other inherited cardiac diseases; 
- There is a class effect of sarcomere protein gene variants on the HCM phenotype and I 
detected novel associations with mutations in individual sarcomere protein genes;  
- There is evidence of a modifier effect of variation in non-sarcomere protein genes in 
HCM expression, that could explain some of the characteristic clinical heterogeneity of 
the disease; 
- Copy number variants are apparently a rare genetic cause of hypertrophic 
cardiomyopathy, but patients studied with HTS should be screened for this type of 
variation; 
- Rare non-coding variation is present in a substantial proportion of HCM patients; 
variation in transcription factor binding sites seems to be more important than 
variation in 3’UTR miRNA target regions. 
- Insilico tools that integrate structural features potentially enhance the establishment 
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1 Bringing the data into the R software  
 
We first load the data into R. The numbers below indicate, for each gene, the 
frequencies of candidate variants (i.e. non-synonymous and rare in the 1,000 
genomes dataset) cases and controls. 
 
> n1 <- 1287   
> n2 <- 180   
> genes <- data.frame(gene = c('MYH7', 'TNNT2', 'TNNI3', 'MYBPC3', 'MYL2', 'MYL3', 'ACTC1', 
'TPM1'),   
+   f.controls = c(0.0125, 0.00155, 0.00000, 0.02725, 0.0035, 0.00194, 0.00039, 0.001 
+   f.cases = c(0.086, 0.027, 0.0083, 0.05, 0.011, 0.0055, 0.0027, 0.0027)) 
> genes   
       gene         f.controls  f.cases 
1 MYH7 0.01250 0.0860 
2 TNNT2 0.00155 0.0270 
3 TNNI3 0.00000 0.0083 
4 MYBPC3 0.02725 0.0500 
5 MYL2 0.00350 0.0110 
6 MYL3 0.00194 0.0055 
7 ACTC1 0.00039 0.0027 
8 TPM1 0.00136 0.0027 
 
2 Estimating the proportion of cases explained for each gene  
 
The most difficult question is the following: for a gene of interest, and given 
the estimated frequencies of candidate variants in controls and cases, how can 
we estimate the confidence interval for the proportion of HCM cases explained 
by this class of variants in that gene? Mathematically, we use the following 
notations: x is the frequency of candidate variants in controls and x + y is the 
frequency of candidate variants in cases. The parameter y refers to the 
additional proportion of cases whose disease is caused by mutations in that 
gene. What we are after is a confidence interval for y.  
 
Here, X is a nuisance parameter and we use a profile likelihood argument to 
get rid of this parameter. Precisely, we set up a grid of values for y and for each 
of these we find the value of x that maximizes the lieklihood of the data. The 
function that we use to obtain the cofidence interval for the parameter y is 
below. n1 = 1; is the number of controls and n2 = 180 is the number of cases. 
 
  
> joint.estimate <- function(n1, n2, x1, x2) {  
+ y <- seq(0, 3*x2, x2/100)  ##grid of values for y   
+  
+ ## Now here is the likelihood function   
+ my.fn <- function(x, y) ( -floor(x1*n1)*log(x)   
+ - (n1 - floor(x1*n1))*log(1-x) 
+ - floor(x2*n2)*log(x+y) 
+ - (n2 - floor(x2*n2))*log(1- x - y))  
+ prof <- rep(NA, length(y))  ##profile likelihood   
  255 
+  
+ ## Now loop over all possible values of y and maximise wrt x   
+ for (i in 1:length(y)) {   
+ prof[i] = optim(par = x1, ##here is the maximisation for x   
+ fn = my.fn,   
+ gr = NULL,   
+ y = y[i],   
+ lower = 0.001,   
+ upper = 1 - y - 0.001,   
+ method = 'Brent')$value   
+ }   
+ prof <- ifelse (is.nan(prof), -10^6, prof)   
+ prof <- -prof   
+ prof <- prof - max(prof)   
+  
+ in.CI <- which(2*prof > -qchisq(df = 1, p = 0.95, lower.tail = TRUE))   
+ my.CI <- y[ range( in.CI ) ]   
+ return(my.CI)   
+ }  
 
We can now estimate this confidence interval for each gene in our dataset. Because 
each control/case has 2 chromosomes, if the frequency of candidate variants is f, then 
the proportion of cases with at least one causal variant is f2 + 2f(1 f). 
 
> for  (i in 1:nrow(genes)) {  
+ prop.controls <- 2*genes$f.controls[i]*(1-genes$f.controls[i]) + genes$f.controls[i]^2   
+ prop.cases <- 2*genes$f.cases[i]*(1-genes$f.cases[i]) + genes$f.cases[i]^2   
+  
+ my.CI <- joint.estimate (n1 = n1, n2 = n2, x1 = prop.controls, x2 = prop.cases)   
+ my.CI <- signif(my.CI, 3)   
+ genes$CI.prop.HCM.cases.explained[i] <- paste( '[', my.CI[1], '-', my.CI[2], ']', sep =   ) 
+ }    
> genes    
 gene          f.controls   f.cases      CI.prop.HCM.cases.explained 
1 MYH7 0.01250 0.0860 [0.0889-0.196] 
2 TNNT2 0.00155 0.0270 [0.0218-0.0858] 
3 TNNI3 0.00000 0.0083 [0.000992-0.0329] 
4 MYBPC3 0.02725 0.0500 [0.00195-0.0897] 
5 MYL2 0.00350 0.0110 [0-0.0365] 
6 MYL3 0.00194 0.0055 [0-0.0213] 
7 ACTC1 0.00039 0.0027 [0-0.0106] 
8 TPM1 0.00136 0.0027 [0-0.0106] 
 
     
3 P-values for differences between cases and controls  
 
This computation is done by statistically comparing the number of candidate variants between 
cases and controls. We use a Fisher exact test to quantify this difference. Because we work at 
the allele level the observed number of alleles are 2n1 f1 in controls and 2n1 f2 in cases, where 
f1 and f2 denote the frequency of candidate variants in cases and controls. 
 
> for  (i in 1:nrow(genes)) {  
  256 
+ my.mat <- matrix(data = c(2*n1*(1 - genes$f.controls[ i ]),   
+ 2*n1*genes$f.controls[i],  
+ 2*n2*(1-genes$f.cases[i]),  
+ 2*n2*genes$f.cases[i]),  
+ nrow = 2,  
+ ncol = 2,  
+ byrow = TRUE)  
+  
+ my.mat <- round(my.mat)   
+ genes$P.diff[i] <- fisher.test ( my.mat )$p.value   
+ }   
> genes 
 
 gene f.controls f.cases CI.prop.HCM.cases.explained P.diff 
1 MYH7 0.01250 0.0860 [0.0889-0.196] 3.855666e-13 
2 TNNT2 0.00155 0.0270 [0.0218-0.0858] 4.373726e-07 
3 TNNI3 0.00000 0.0083 [0.000992-0.0329] 1.833766e-03 
4 MYBPC3 0.02725 0.0500 [0.00195-0.0897] 2.987798e-02 
5 MYL2 0.00350 0.0110 [0-0.0365] 6.473193e-02 
6 MYL3 0.00194 0.0055 [0-0.0213] 2.083091e-01 
7 ACTC1 0.00039 0.0027 [0-0.0106] 2.303803e-01 




4 Point estimates for the probability that a candidate variant is causal  
 
 
We want to estimate, for each gene, the probability that a candidate variant in a HCM case is 
causal. This point estimate is straightforward. It is simply: 
 
 
pcausal = Frequency of candidates variants in cases Frequency of candidates variants in 




> genes$prob.causal <- (genes$f.cases - genes$f.controls)/genes$f.cases   
> genes  
 
     gene           f.controls  f.cases     CI.prop.HCM.cases.explained P.diff 
1 MYH7 0.01250 0.0860 [0.0889-0.196] 3.855666e-13 
2 TNNT2 0.00155 0.0270 [0.0218-0.0858] 4.373726e-07 
3 TNNI3 0.00000 0.0083 [0.000992-0.0329] 1.833766e-03 
4 MYBPC3 0.02725 0.0500 [0.00195-0.0897] 2.987798e-02  
5 MYL2 0.00350 0.0110 [0-0.0365] 6.473193e-02 
6 MYL3 0.00194 0.0055 [0-0.0213] 2.083091e-01 
7 ACTC1 0.00039 0.0027 [0-0.0106] 2.303803e-01 
8 TPM1 0.00136 0.0027 [0-0.0106] 4.805606e-01  
prob.causal  
1 0.8546512   
2 0.9425926   
3 1.0000000   
4 0.4550000   
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5 0.6818182   
6 0.6472727   
7 0.8555556  
























































Supplementary table 1. List of distinct rare variants detected (MAF<0.2%; see methods). All variants were detected in heterozygozity. Type of variant: D:  variant 
reported on dbSNP137, not predicted in silico to be pathogenic, not nonsense, frameshift indel or splice-site and not published in the literature; L: novel (or 
reported on dbSNP137) nonsense, frameshift indel or splice-site variant; N: novel variant not predicted in silico to be pathogenic and not nonsense, frameshift 
indel or splice-site; P: published variant in the literature; S: novel (or reported on dbSNP137) missense variant predicted in silico to be pathogenic. MAF: minor 
allele frequency.  
 
ACTC1: actin, alpha, cardiac muscle 1; ANK2: ankyrin 2, neuronal; CASQ2: calsequestrin 2 cardiac muscle; CAV3: caveolin 3; CSRP3: cysteine and glycine-rich 
protein 3 cardiac LIM protein; DES: desmin; DSC2: desmocollin 2; DSG2: desmoglein 2; DSP: desmoplakin; JUP: junction plakoglobin; KCNE1: potassium voltage-
gated channel, Isk-related family, member 1; KCNE2: potassium voltage-gated channel, Isk-related family, member 2; KCNH2: potassium voltage-gated channel, 
subfamily H eag-related, member 2; KCNJ2: potassium inwardly-rectifying channel, subfamily J, member 2; KCNQ1: potassium voltage-gated channel, KQT-like 
subfamily, member 1; LDB3: LIM domain binding 3; LMNA: lamin A/C; MYBPC3: myosin binding protein C, cardiac; MYH6: myosin, heavy chain 6, cardiac muscle, 
alpha; MYH7: myosin, heavy chain 7, cardiac muscle, beta; MYL2: myosin, light chain 2, regulatory, cardiac, slow; MYL3: myosin, light chain 3, alkali; PDLIM3: PDZ 
and LIM domain 3; PKP2: plakophilin 2; PLN, phospholamban; RBM20: RNA binding motif protein 20; RYR2: ryanodine receptor 2 cardiac; SCN5A: sodium channel, 
voltage-gated, type V, alpha subunit; TCAP: titin-cap; TGFbeta3: transforming growth factor, beta 3; TMEM43: transmembrane protein 43; TNNC1: troponin C type 
1 slow; TNNI3: troponin I type 3 cardiac; TNNT2: troponin T type 2 cardiac; TPM1: tropomyosin 1 alpha; VCL: vinculin. 
 
 
Gene Genomic signature Transcript / Amino acid change dbSNP137 ID 
Type of 
variant MAF- cases 
ACTC1 15_35084398_G_A ENSG00000159251:ENST00000290378:exon5:c.C701T:p.S234F   N 0,00057 
ACTC1 15_35085539_T_C ENSG00000159251:ENST00000290378:exon3:c.A361G:p.M121V   S 0,00058 




45362:ENST00000504454:exon1:c.G56A:p.S19N   N 0,00057 
ANK2 4_114067089_T_A ENSG00000145362:ENST00000511380:exon1:c.T65A:p.M22K rs116338686 D 0,00115 



































0506722:exon27:c.C2756G:p.A919G   S 0,00115 
ANK2 4_114244911_G_A ENST00000506722:exon28:-4G>A rs139641776 L 0,00057 



































































78K,ENSG00000145362:ENST00000504454:exon39:c.G5077A:p.E1693K   N 0,00057 
ANK2 4_114275005_C_A 
ENSG00000145362:ENST00000264366:exon37:c.C5132A:p.A1711D,ENSG00000145362:ENST00000
357077:exon38:c.C5231A:p.A1744D rs147706514 D 0,00057 
ANK2 4_114275005_C_T 
ENSG00000145362:ENST00000264366:exon37:c.C5132T:p.A1711V,ENSG00000145362:ENST00000
357077:exon38:c.C5231T:p.A1744V   N 0,00057 
ANK2 4_114275096_G_T 
ENSG00000145362:ENST00000264366:exon37:c.G5223T:p.Q1741H,ENSG00000145362:ENST00000
357077:exon38:c.G5322T:p.Q1774H   S 0,00057 
ANK2 4_114275262_C_T 
ENSG00000145362:ENST00000264366:exon37:c.C5389T:p.H1797Y,ENSG00000145362:ENST00000
357077:exon38:c.C5488T:p.H1830Y   N 0,00057 
ANK2 4_114275344_T_A 
ENSG00000145362:ENST00000264366:exon37:c.T5471A:p.V1824E,ENSG00000145362:ENST00000
357077:exon38:c.T5570A:p.V1857E rs141212932 D 0,00057 
ANK2 4_114275425_C_T 
ENSG00000145362:ENST00000264366:exon37:c.C5552T:p.S1851L,ENSG00000145362:ENST000003
57077:exon38:c.C5651T:p.S1884L rs150737736 D 0,00057 
ANK2 4_114275688_C_A 
ENSG00000145362:ENST00000264366:exon37:c.C5815A:p.Q1939K,ENSG00000145362:ENST00000
357077:exon38:c.C5914A:p.Q1972K   N 0,00057 
ANK2 4_114275852_A_T 
ENSG00000145362:ENST00000264366:exon37:c.A5979T:p.K1993N,ENSG00000145362:ENST00000
357077:exon38:c.A6078T:p.K2026N   N 0,00115 
ANK2 4_114275950_C_T 
ENSG00000145362:ENST00000264366:exon37:c.C6077T:p.T2026M,ENSG00000145362:ENST00000
357077:exon38:c.C6176T:p.T2059M rs200765866 S 0,00058 
ANK2 4_114275980_G_A 
ENSG00000145362:ENST00000264366:exon37:c.G6107A:p.R2036H,ENSG00000145362:ENST00000
357077:exon38:c.G6206A:p.R2069H rs149645600 S 0,00058 
ANK2 4_114276279_G_A 
ENSG00000145362:ENST00000264366:exon37:c.G6406A:p.V2136I,ENSG00000145362:ENST000003
57077:exon38:c.G6505A:p.V2169I rs149292242 S 0,00057 
ANK2 4_114276360_G_A 
ENSG00000145362:ENST00000264366:exon37:c.G6487A:p.G2163S,ENSG00000145362:ENST00000
357077:exon38:c.G6586A:p.G2196S   N 0,00057 
ANK2 4_114276657_A_G 
ENSG00000145362:ENST00000264366:exon37:c.A6784G:p.T2262A,ENSG00000145362:ENST00000
357077:exon38:c.A6883G:p.T2295A   N 0,00058 
ANK2 4_114276879_G_T 
ENSG00000145362:ENST00000264366:exon37:c.G7006T:p.V2336F,ENSG00000145362:ENST00000






357077:exon38:c.A7117G:p.T2373A rs184514058 D 0,00066 
ANK2 4_114276922_C_T 
ENSG00000145362:ENST00000264366:exon37:c.C7049T:p.P2350L,ENSG00000145362:ENST000003
57077:exon38:c.C7148T:p.P2383L rs35960628 D 0,00066 
ANK2 4_114276957_A_C 
ENSG00000145362:ENST00000264366:exon37:c.A7084C:p.T2362P,ENSG00000145362:ENST00000
357077:exon38:c.A7183C:p.T2395P rs201693280 D 0,00133 
ANK2 4_114277041_G_A 
ENSG00000145362:ENST00000264366:exon37:c.G7168A:p.A2390T,ENSG00000145362:ENST00000
357077:exon38:c.G7267A:p.A2423T rs3733616 D 0,00062 
ANK2 4_114277108_A_G 
ENSG00000145362:ENST00000264366:exon37:c.A7235G:p.D2412G,ENSG00000145362:ENST00000
357077:exon38:c.A7334G:p.D2445G   S 0,00059 
ANK2 4_114277642_C_G 
ENSG00000145362:ENST00000264366:exon37:c.C7769G:p.S2590C,ENSG00000145362:ENST00000
357077:exon38:c.C7868G:p.S2623C rs116253689 D 0,00057 
ANK2 4_114277871_G_A 
ENSG00000145362:ENST00000264366:exon37:c.G7998A:p.M2666I,ENSG00000145362:ENST00000
357077:exon38:c.G8097A:p.M2699I rs148904454 D 0,00058 
ANK2 4_114278014_G_A 
ENSG00000145362:ENST00000264366:exon37:c.G8141A:p.R2714H,ENSG00000145362:ENST00000
357077:exon38:c.G8240A:p.R2747H rs142137451 D 0,00057 
ANK2 4_114278542_A_G 
ENSG00000145362:ENST00000264366:exon37:c.A8669G:p.Q2890R,ENSG00000145362:ENST00000
357077:exon38:c.A8768G:p.Q2923R   S 0,00057 
ANK2 4_114278701_C_G 
ENSG00000145362:ENST00000264366:exon37:c.C8828G:p.S2943C,ENSG00000145362:ENST00000
357077:exon38:c.C8927G:p.S2976C   S 0,00057 
ANK2 4_114278820_G_A 
ENSG00000145362:ENST00000505342:exon1:c.G76A:p.E26K,ENSG00000145362:ENST0000026436



























































.R3842W,ENSG00000145362:ENST00000506722:exon44:c.C5242T:p.R1748W rs139797180 S 0,00057 





















p.E3914D,ENSG00000145362:ENST00000506722:exon46:c.G5460C:p.E1820D   S 0,00057 
ANK2 4_114295915_A_G 
ENST00000514960:exon19:c.2702-5A>G,ENST00000505342:exon9:c.2890-
5A>G,ENST00000506344:exon2:c.134-5A>G   L 0,00057 
ANK2 4_114296105_A_G 
ENST00000514960:exon19:c.2884+3A>G,ENST00000505342:exon9:c.3072+3A>G,ENST0000050634
4:exon2:c.316+3A>G   L 0,00057 
ANK2 4_114299338_G_A ENST00000506344:exon3:c.408+1G>A,ENST00000514167:exon2:c.183+1G>A rs180914830 L 0,00057 
CASQ2 1_116243897_C_A 
ENSG00000118729:ENST00000456138:exon9:c.G952T:p.D318Y,ENSG00000118729:ENST00000261
448:exon11:c.G1165T:p.D389Y   N 0,00061 
CASQ2 1_116243928_ATC_- 
ENSG00000118729:ENST00000456138:exon9:c.919_921del:p.307_307del,ENSG00000118729:ENST
00000261448:exon11:c.1132_1134del:p.378_378del   N 0,00060 
CASQ2 1_116247824_C_T 
ENSG00000118729:ENST00000456138:exon7:c.G715A:p.D239N,ENSG00000118729:ENST00000261
448:exon9:c.G928A:p.D310N rs141314684 D 0,00057 
CASQ2 1_116269737_T_C 
ENSG00000118729:ENST00000456138:exon4:c.A400G:p.K134E,ENSG00000118729:ENST00000261
448:exon6:c.A613G:p.K205E   S 0,00057 
CASQ2 1_116275587_C_G 
ENSG00000118729:ENST00000456138:exon3:c.G328C:p.A110P,ENSG00000118729:ENST00000261
448:exon5:c.G541C:p.A181P   N 0,00057 
CASQ2 1_116283431_C_T ENSG00000118729:ENST00000261448:exon3:c.G338A:p.S113N rs199750975 D 0,00057 
CASQ2 1_116287470_C_T 
ENSG00000118729:ENST00000261448:exon2:c.G298A:p.A100T,ENSG00000118729:ENST00000456
138:exon2:c.G298A:p.A100T   N 0,00057 
CASQ2 1_116310926_T_C ENST00000261448:exon2:c.234+3A>G,ENST00000456138:exon2:c.234+3A>G   L 0,00057 
CAV3 3_8775602_G_A 
ENSG00000182533:ENST00000343849:exon1:c.G40A:p.V14I,ENSG00000182533:ENST00000397368
:exon1:c.G40A:p.V14I rs121909281 D 0,00115 
CAV3 3_8787374_G_A 
ENSG00000182533:ENST00000343849:exon2:c.G277A:p.A93T,ENSG00000182533:ENST000003973
68:exon2:c.G277A:p.A93T rs28936686 P 0,00063 
CSRP3 11_19204270_G_A 
ENSG00000129170:ENST00000265968:exon6:c.C532T:p.P178S,ENSG00000129170:ENST000005337






783:exon6:c.G449A:p.C150Y   S 0,00172 
CSRP3 11_19206593_C_A ENST00000265968:exon6:c.415-1G>T,ENST00000533783:exon7:c.415-1G>T   L 0,00115 
CSRP3 11_19209682_C_G ENST00000265968:exon4:c.281+1G>C,ENST00000533783:exon5:c.281+1G>C   L 0,00057 
CSRP3 11_19209752_A_G 
ENSG00000129170:ENST00000265968:exon3:c.T212C:p.I71T,ENSG00000129170:ENST0000053378
3:exon4:c.T212C:p.I71T   N 0,00057 
CSRP3 11_19209773_C_T 
ENSG00000129170:ENST00000265968:exon3:c.G191A:p.R64H,ENSG00000129170:ENST000005337
83:exon4:c.G191A:p.R64H   S 0,00057 
CSRP3 11_19209833_A_G 
ENSG00000129170:ENST00000265968:exon3:c.T131C:p.L44P,ENSG00000129170:ENST0000053378
3:exon4:c.T131C:p.L44P rs104894205 P 0,00172 
CSRP3 11_19213968_A_G 
ENSG00000129170:ENST00000265968:exon2:c.T28C:p.C10R,ENSG00000129170:ENST0000053378
3:exon3:c.T28C:p.C10R   S 0,00057 
CSRP3 11_19213974_C_T 
ENSG00000129170:ENST00000265968:exon2:c.G22A:p.A8T,ENSG00000129170:ENST00000533783:
exon3:c.G22A:p.A8T rs45531937 D 0,00057 
DES 2_220284854_A_G ENSG00000175084:ENST00000373960:exon2:c.A616G:p.N206D   N 0,00058 
DES 2_220285382_GG_-     L 0,00059 
DES 2_220288540_G_A ENSG00000175084:ENST00000373960:exon7:c.G1286A:p.R429Q rs200580581 D 0,00059 
DSC2 18_28648063_C_T ENSG00000134755:ENST00000280904:exon16:c.G2624A:p.R875Q   N 0,00057 
DSC2 18_28648870_C_T 
ENSG00000134755:ENST00000251081:exon15:c.G2498A:p.R833H,ENSG00000134755:ENST000002
80904:exon15:c.G2498A:p.R833H   P 0,00058 
DSC2 18_28648998_TCC_- 
ENSG00000134755:ENST00000251081:exon15:c.2368_2370del:p.790_790del,ENSG00000134755:E
NST00000280904:exon15:c.2368_2370del:p.790_790del   N 0,00058 
DSC2 18_28649002_CCT_- 
ENSG00000134755:ENST00000251081:exon15:c.2364_2366del:p.788_789del,ENSG00000134755:E
NST00000280904:exon15:c.2364_2366del:p.788_789del   P 0,00058 
DSC2 18_28649033_C_T 
ENSG00000134755:ENST00000251081:exon15:c.G2335A:p.G779R,ENSG00000134755:ENST000002
80904:exon15:c.G2335A:p.G779R rs139290300 S 0,00058 
DSC2 18_28649081_C_T 
ENSG00000134755:ENST00000251081:exon15:c.G2287A:p.A763T,ENSG00000134755:ENST000002
80904:exon15:c.G2287A:p.A763T   N 0,00057 
DSC2 18_28650748_A_C 
ENSG00000134755:ENST00000251081:exon14:c.T2194G:p.L732V,ENSG00000134755:ENST000002
80904:exon14:c.T2194G:p.L732V rs151024019 P 0,00458 
DSC2 18_28651640_C_T 
ENSG00000134755:ENST00000251081:exon13:c.G2056A:p.G686S,ENSG00000134755:ENST000002
80904:exon13:c.G2056A:p.G686S   N 0,00057 
DSC2 18_28654750_G_A 
ENSG00000134755:ENST00000251081:exon12:c.C1787T:p.A596V,ENSG00000134755:ENST000002
80904:exon12:c.C1787T:p.A596V rs148185335 P 0,00115 






904:exon8:c.C1073T:p.T358I rs139399951 D 0,00057 
DSC2 18_28666574_C_T 
ENSG00000134755:ENST00000251081:exon7:c.G907A:p.V303M,ENSG00000134755:ENST0000028
0904:exon7:c.G907A:p.V303M rs145560678 P 0,00229 
DSC2 18_28666624_C_A 
ENSG00000134755:ENST00000251081:exon7:c.G857T:p.G286V,ENSG00000134755:ENST00000280
904:exon7:c.G857T:p.G286V rs199682735 D 0,00057 
DSC2 18_28666627_A_G 
ENSG00000134755:ENST00000251081:exon7:c.T854C:p.I285T,ENSG00000134755:ENST000002809
04:exon7:c.T854C:p.I285T rs199918720 D 0,00057 
DSC2 18_28666657_G_A 
ENSG00000134755:ENST00000251081:exon7:c.C824T:p.T275M,ENSG00000134755:ENST00000280
904:exon7:c.C824T:p.T275M   P 0,00057 
DSC2 18_28671095_G_A 
ENSG00000134755:ENST00000251081:exon4:c.C370T:p.H124Y,ENSG00000134755:ENST00000280
904:exon4:c.C370T:p.H124Y   N 0,00057 
DSC2 18_28672152_G_A 
ENSG00000134755:ENST00000251081:exon3:c.C266T:p.S89L,ENSG00000134755:ENST0000028090
4:exon3:c.C266T:p.S89L rs141379407 P 0,00057 
DSC2 18_28672246_A_C 
ENSG00000134755:ENST00000251081:exon3:c.T172G:p.F58V,ENSG00000134755:ENST000002809
04:exon3:c.T172G:p.F58V rs138749562 P 0,00057 
DSC2 18_28681901_C_T 
ENSG00000134755:ENST00000251081:exon1:c.G34A:p.G12R,ENSG00000134755:ENST0000028090
4:exon1:c.G34A:p.G12R   N 0,00127 
DSC2 18_28681932_C_A 
ENSG00000134755:ENST00000251081:exon1:c.G3T:p.M1I,ENSG00000134755:ENST00000280904:e
xon1:c.G3T:p.M1I   S 0,00153 
DSG2 18_29099805_C_A 
ENSG00000046604:ENST00000261590:exon3:c.C121A:p.H41N,ENSG00000046604:ENST000005852
06:exon3:c.C121A:p.H41N rs201499704 P 0,00114 
DSG2 18_29101120_G_A 
ENSG00000046604:ENST00000261590:exon5:c.G437A:p.R146H,ENSG00000046604:ENST00000585
206:exon5:c.G437A:p.R146H   P 0,00058 
DSG2 18_29102067_A_G 
ENSG00000046604:ENST00000261590:exon6:c.A545G:p.N182S,ENSG00000046604:ENST00000585
206:exon6:c.A545G:p.N182S   N 0,00057 
DSG2 18_29104717_A_G ENSG00000046604:ENST00000261590:exon8:c.A880G:p.K294E   P 0,00057 
DSG2 18_29104798_T_A ENSG00000046604:ENST00000261590:exon8:c.T961A:p.F321I rs201040643 P 0,00057 
DSG2 18_29104840_A_G ENSG00000046604:ENST00000261590:exon8:c.A1003G:p.T335A rs191564916 P 0,00057 
DSG2 18_29110986_-_C ENSG00000046604:ENST00000261590:exon9:c.1051_1052insC:p.S351fs   L 0,00057 
DSG2 18_29110986_A_C ENSG00000046604:ENST00000261590:exon9:c.A1051C:p.S351R   N 0,00057 
DSG2 18_29115255_G_A ENSG00000046604:ENST00000261590:exon10:c.G1303A:p.D435N   P 0,00057 
DSG2 18_29115328_A_G ENSG00000046604:ENST00000261590:exon10:c.A1376G:p.Y459C   S 0,00057 




DSG2 18_29122696_A_T ENSG00000046604:ENST00000261590:exon14:c.A2215T:p.I739F   N 0,00059 
DSG2 18_29126099_C_T ENSG00000046604:ENST00000261590:exon15:c.C2750T:p.A917V   P 0,00057 
DSG2 18_29126255_C_T ENSG00000046604:ENST00000261590:exon15:c.C2906T:p.A969V   S 0,00057 
DSG2 18_29126389_G_A ENSG00000046604:ENST00000261590:exon15:c.G3040A:p.V1014I rs200830807 P 0,00057 
DSG2 18_29126426_G_A ENSG00000046604:ENST00000261590:exon15:c.G3077A:p.S1026N   S 0,00057 
DSG2 18_29126458_A_G ENSG00000046604:ENST00000261590:exon15:c.A3109G:p.N1037D   N 0,00057 
DSG2 18_29126475_G_C ENSG00000046604:ENST00000261590:exon15:c.G3126C:p.Q1042H   S 0,00057 
DSG2 18_29126516_C_T ENSG00000046604:ENST00000261590:exon15:c.C3167T:p.T1056I   P 0,00057 
DSP 6_7562969_A_G 
ENSG00000096696:ENST00000379802:exon5:c.A682G:p.I228V,ENSG00000096696:ENST000004186
64:exon5:c.A682G:p.I228V   N 0,00058 
DSP 6_7562975_G_A 
ENSG00000096696:ENST00000379802:exon5:c.G688A:p.D230N,ENSG00000096696:ENST00000418
664:exon5:c.G688A:p.D230N rs147315869 P 0,00172 
DSP 6_7564006_A_T 
ENSG00000096696:ENST00000379802:exon6:c.A764T:p.Y255F,ENSG00000096696:ENST000004186
64:exon6:c.A764T:p.Y255F   S 0,00057 
DSP 6_7565758_G_T ENST00000379802:exon7:c.939+5G>T,ENST00000418664:exon7:c.939+5G>T   L 0,00058 
DSP 6_7569444_G_A 
ENSG00000096696:ENST00000379802:exon12:c.G1445A:p.C482Y,ENSG00000096696:ENST000004
18664:exon12:c.G1445A:p.C482Y   S 0,00058 
DSP 6_7569482_G_A 
ENSG00000096696:ENST00000379802:exon12:c.G1483A:p.V495M,ENSG00000096696:ENST00000
418664:exon12:c.G1483A:p.V495M   N 0,00058 
DSP 6_7570791_G_A 
ENSG00000096696:ENST00000379802:exon13:c.G1696A:p.A566T,ENSG00000096696:ENST000004
18664:exon13:c.G1696A:p.A566T rs148147581 P 0,00059 
DSP 6_7571692_A_G 
ENSG00000096696:ENST00000379802:exon14:c.A1778G:p.N593S,ENSG00000096696:ENST000004
18664:exon14:c.A1778G:p.N593S rs34239595 D 0,00057 
DSP 6_7574937_A_G 
ENSG00000096696:ENST00000379802:exon17:c.A2345G:p.D782G,ENSG00000096696:ENST000004
18664:exon17:c.A2345G:p.D782G   S 0,00057 
DSP 6_7575014_C_T 
ENSG00000096696:ENST00000379802:exon17:c.C2422T:p.R808C,ENSG00000096696:ENST000004
18664:exon17:c.C2422T:p.R808C rs150339369 S 0,00172 
DSP 6_7576669_C_T 
ENSG00000096696:ENST00000379802:exon19:c.C2773T:p.R925W,ENSG00000096696:ENST000004
18664:exon19:c.C2773T:p.R925W rs145933612 S 0,00057 
DSP 6_7578770_T_C 
ENSG00000096696:ENST00000379802:exon22:c.T3059C:p.M1020T,ENSG00000096696:ENST00000
418664:exon22:c.T3059C:p.M1020T   N 0,00057 
DSP 6_7580129_A_G ENSG00000096696:ENST00000379802:exon23:c.A3706G:p.R1236G   S 0,00115 




DSP 6_7580810_G_A ENSG00000096696:ENST00000379802:exon23:c.G4387A:p.V1463I   N 0,00058 
DSP 6_7580912_C_T ENSG00000096696:ENST00000379802:exon23:c.C4489T:p.R1497W rs148041814 D 0,00057 
DSP 6_7580913_G_A ENSG00000096696:ENST00000379802:exon23:c.G4490A:p.R1497Q   N 0,00057 
DSP 6_7580981_A_T ENSG00000096696:ENST00000379802:exon23:c.A4558T:p.S1520C   S 0,00058 
DSP 6_7581198_A_G ENSG00000096696:ENST00000379802:exon23:c.A4775G:p.K1592R rs200421954 P 0,00120 
DSP 6_7581420_G_A ENSG00000096696:ENST00000379802:exon23:c.G4997A:p.R1666Q   N 0,00058 
DSP 6_7581543_A_G ENSG00000096696:ENST00000379802:exon23:c.A5120G:p.Q1707R   S 0,00057 
DSP 6_7581601_C_A ENSG00000096696:ENST00000379802:exon23:c.C5178A:p.N1726K rs147415451 P 0,00057 
DSP 6_7581644_G_A ENSG00000096696:ENST00000379802:exon23:c.G5221A:p.A1741T   N 0,00057 
DSP 6_7581786_A_G ENSG00000096696:ENST00000379802:exon23:c.A5363G:p.Q1788R rs139673146 D 0,00057 
DSP 6_7583299_A_G 
ENSG00000096696:ENST00000379802:exon24:c.A5804G:p.Y1935C,ENSG00000096696:ENST00000
418664:exon24:c.A4007G:p.Y1336C   N 0,00058 
DSP 6_7583347_G_A 
ENSG00000096696:ENST00000379802:exon24:c.G5852A:p.R1951Q,ENSG00000096696:ENST00000
418664:exon24:c.G4055A:p.R1352Q   N 0,00058 
DSP 6_7583376_G_A 
ENSG00000096696:ENST00000379802:exon24:c.G5881A:p.V1961I,ENSG00000096696:ENST000004
18664:exon24:c.G4084A:p.V1362I   N 0,00058 
DSP 6_7584376_C_G 
ENSG00000096696:ENST00000379802:exon24:c.C6881G:p.A2294G,ENSG00000096696:ENST00000
418664:exon24:c.C5084G:p.A1695G rs147000526 P 0,00115 
DSP 6_7584845_G_C 
ENSG00000096696:ENST00000379802:exon24:c.G7350C:p.K2450N,ENSG00000096696:ENST00000
418664:exon24:c.G5553C:p.K1851N   S 0,00057 
DSP 6_7584922_A_T 
ENSG00000096696:ENST00000379802:exon24:c.A7427T:p.E2476V,ENSG00000096696:ENST00000
418664:exon24:c.A5630T:p.E1877V   S 0,00057 
DSP 6_7585127_T_G 
ENSG00000096696:ENST00000379802:exon24:c.T7632G:p.F2544L,ENSG00000096696:ENST000004
18664:exon24:c.T5835G:p.F1945L   N 0,00057 
DSP 6_7585233_G_T 
ENSG00000096696:ENST00000379802:exon24:c.G7738T:p.D2580Y,ENSG00000096696:ENST00000
418664:exon24:c.G5941T:p.D1981Y   N 0,00057 
DSP 6_7585612_A_T 
ENSG00000096696:ENST00000379802:exon24:c.A8117T:p.K2706M,ENSG00000096696:ENST00000
418664:exon24:c.A6320T:p.K2107M   N 0,00059 
DSP 6_7585686_T_C 
ENSG00000096696:ENST00000379802:exon24:c.T8191C:p.Y2731H,ENSG00000096696:ENST00000
418664:exon24:c.T6394C:p.Y2132H rs201397978 D 0,00240 
DSP 6_7585774_C_T 
ENSG00000096696:ENST00000379802:exon24:c.C8279T:p.A2760V,ENSG00000096696:ENST00000






18664:exon24:c.C6629T:p.S2210L   N 0,00058 
DSP 6_7585962_C_G 
ENSG00000096696:ENST00000379802:exon24:c.C8467G:p.P2823A,ENSG00000096696:ENST00000
418664:exon24:c.C6670G:p.P2224A rs142717240 S 0,00115 
DSP 6_7586019_C_T 
ENSG00000096696:ENST00000379802:exon24:c.C8524T:p.R2842C,ENSG00000096696:ENST00000








S rs147628503 D 0,00070 
JUP 17_39919360_C_T 
ENSG00000173801:ENST00000310706:exon8:c.G1372A:p.A458T,ENSG00000173801:ENST0000039
3930:exon8:c.G1372A:p.A458T,ENSG00000173801:ENST00000393931:exon8:c.G1372A:p.A458T rs139559495 D 0,00080 
JUP 17_39919408_T_A 
ENSG00000173801:ENST00000310706:exon8:c.A1324T:p.I442F,ENSG00000173801:ENST00000393
930:exon8:c.A1324T:p.I442F,ENSG00000173801:ENST00000393931:exon8:c.A1324T:p.I442F rs142213474 S 0,00064 
JUP 17_39921027_G_C 
ENSG00000173801:ENST00000310706:exon7:c.C1096G:p.P366A,ENSG00000173801:ENST0000039





































6N,ENSG00000180509:ENST00000399286:exon4:c.C17A:p.T6N   N 0,00058 
KCNE2 21_35736455_G_A     L 0,00057 
KCNE2 21_35742806_C_T ENSG00000159197:ENST00000290310:exon2:c.C29T:p.T10M rs199473648 P 0,00057 
KCNE2 21_35742817_G_A ENSG00000159197:ENST00000290310:exon2:c.G40A:p.V14I rs142153692 P 0,00115 
KCNE2 21_35742938_T_C ENSG00000159197:ENST00000290310:exon2:c.T161C:p.M54T rs74315447 P 0,00057 
KCNE2 21_35742947_T_C ENSG00000159197:ENST00000290310:exon2:c.T170C:p.I57T rs74315448 P 0,00057 
KCNE2 21_35743134_C_A ENSG00000159197:ENST00000290310:exon2:c.C357A:p.F119L rs139202426 D 0,00058 
KCNH2 7_150642517_G_A 
ENSG00000055118:ENST00000330883:exon11:c.C2396T:p.P799L,ENSG00000055118:ENST0000039




5Q rs41307270 S 0,00063 
KCNH2 7_150644718_T_C 
ENSG00000055118:ENST00000330883:exon8:c.A1921G:p.S641G,ENSG00000055118:ENST0000039
2968:exon10:c.A2653G:p.S885G,ENSG00000055118:ENST00000262186:exon12:c.A2941G:p.S981G rs76649554 D 0,00111 
KCNH2 7_150645607_C_T 
ENSG00000055118:ENST00000330883:exon7:c.G1597A:p.G533S,ENSG00000055118:ENST0000039
2968:exon9:c.G2329A:p.G777S,ENSG00000055118:ENST00000262186:exon11:c.G2617A:p.G873S rs41314354 D 0,00117 
KCNH2 7_150647078_G_A ENSG00000055118:ENST00000430723:exon9:c.C2576T:p.T859M rs41314366 S 0,00059 





67_767del   N 0,00073 
KCNH2 7_150654468_G_A 
ENSG00000055118:ENST00000392968:exon3:c.C751T:p.P251S,ENSG00000055118:ENST000002621
86:exon5:c.C1039T:p.P347S,ENSG00000055118:ENST00000430723:exon5:c.C1039T:p.P347S rs138776684 P 0,00118 
KCNH2 7_150655425_T_C 
ENSG00000055118:ENST00000392968:exon2:c.A350G:p.D117G,ENSG00000055118:ENST00000262















_553del:p.182_185del   N 0,01124 
KCNH2 7_150655521_C_T 
ENSG00000055118:ENST00000392968:exon2:c.G254A:p.R85Q,ENSG00000055118:ENST000002621
86:exon4:c.G542A:p.R181Q,ENSG00000055118:ENST00000430723:exon4:c.G542A:p.R181Q rs41308954 D 0,01099 
KCNH2 7_150655537_G_A 
ENSG00000055118:ENST00000392968:exon2:c.C238T:p.R80W,ENSG00000055118:ENST000002621
86:exon4:c.C526T:p.R176W,ENSG00000055118:ENST00000430723:exon4:c.C526T:p.R176W rs36210422 S 0,00543 
KCNH2 7_150656690_G_A 
ENSG00000055118:ENST00000392968:exon1:c.C154T:p.R52W,ENSG00000055118:ENST000002621
86:exon3:c.C442T:p.R148W,ENSG00000055118:ENST00000430723:exon3:c.C442T:p.R148W rs139544114 D 0,00140 
KCNH2 7_150674983_G_A 
ENSG00000055118:ENST00000262186:exon1:c.C19T:p.H7Y,ENSG00000055118:ENST00000430723:
exon1:c.C19T:p.H7Y   S 0,00175 
KCNJ2 17_68172133_A_G 
ENSG00000123700:ENST00000243457:exon2:c.A953G:p.N318S,ENSG00000123700:ENST00000535
240:exon2:c.A953G:p.N318S   N 0,00057 
KCNQ1 
11_2466480_-
_CGCGCCCAT ENSG00000053918:ENST00000155840:exon1:c.152_153insCGCGCCCAT:p.Y51delinsYAPI   N 0,01376 
KCNQ1 11_2466545_C_A ENSG00000053918:ENST00000155840:exon1:c.C217A:p.P73T rs199472676 P 0,00110 
KCNQ1 11_2542757_C_T ENSG00000053918:ENST00000380776:exon2:c.C133T:p.R45C rs80269976 D 0,00058 
KCNQ1 11_2542793_G_A ENSG00000053918:ENST00000380776:exon2:c.G169A:p.D57N rs10400212 D 0,00059 
KCNQ1 11_2549229_C_T 
ENSG00000053918:ENST00000155840:exon2:c.C458T:p.T153M,ENSG00000053918:ENST00000335
475:exon2:c.C77T:p.T26M,ENSG00000053918:ENST00000496887:exon3:c.C197T:p.T66M rs143709408 P 0,00068 
KCNQ1 11_2591921_C_T 
ENSG00000053918:ENST00000155840:exon3:c.C541T:p.R181C,ENSG00000053918:ENST00000335
475:exon3:c.C160T:p.R54C,ENSG00000053918:ENST00000496887:exon4:c.C280T:p.R94C rs199473395 P 0,00094 
KCNQ1 11_2594092_T_G 
ENSG00000053918:ENST00000155840:exon6:c.T797G:p.L266R,ENSG00000053918:ENST00000335
475:exon6:c.T416G:p.L139R,ENSG00000053918:ENST00000496887:exon7:c.T536G:p.L179R   S 0,00062 
KCNQ1 11_2604687_A_T 
ENSG00000053918:ENST00000155840:exon7:c.A944T:p.Y315F,ENSG00000053918:ENST000003354
75:exon7:c.A563T:p.Y188F rs74462309 P 0,00074 
KCNQ1 11_2608850_G_T 
ENSG00000053918:ENST00000155840:exon9:c.G1179T:p.K393N,ENSG00000053918:ENST0000033
5475:exon9:c.G798T:p.K266N rs12720457 D 0,00158 
KCNQ1 11_2790079_G_A 
ENSG00000053918:ENST00000155840:exon12:c.G1520A:p.R507Q,ENSG00000053918:ENST000003
35475:exon12:c.G1139A:p.R380Q   N 0,00058 
KCNQ1 11_2797186_G_A ENST00000155840:exon13:c.1591-4G>A,ENST00000335475:exon13:c.1210-4G>A   L 0,00085 
KCNQ1 11_2869087_G_A 
ENSG00000053918:ENST00000155840:exon16:c.G1885A:p.G629S,ENSG00000053918:ENST000003






35475:exon16:c.G1522A:p.G508R rs199473484 P 0,00097 
KCNQ1 11_2869127_G_T 
ENSG00000053918:ENST00000155840:exon16:c.G1925T:p.C642F,ENSG00000053918:ENST000003
35475:exon16:c.G1544T:p.C515F   N 0,00096 



























xon6:c.G511A:p.A171T   N 0,00066 
LDB3 10_88466427_G_A ENSG00000122367:ENST00000361373:exon7:c.G1036A:p.A346T rs201968775 D 0,00094 




























:exon10:c.A1342G:p.I448V   P 0,00079 
LMNA 1_156096679_G_A 
ENSG00000160789:ENST00000392353:exon1:c.G86A:p.R29K,ENSG00000160789:ENST0000036829
7:exon2:c.G86A:p.R29K,ENSG00000160789:ENST00000515459:exon2:c.G86A:p.R29K   N 0,00123 






















































































28C rs201312636 S 0,00057 
MYBPC3 11_47354116_C_T 
ENST00000256993:exon31:c.3624+1G>A,ENST00000399249:exon32:c.3627+1G>A,ENST000005459
























79K rs199669878 P 0,00059 
MYBPC3 11_47354256_G_C 
ENST00000256993:exon31:c.3488-3C>G,ENST00000399249:exon32:c.3491-





















0000545968:exon31:c.3333_3334insGTG:p.E1111delinsEW   N 0,00062 
MYBPC3 11_47354740_C_G 
ENST00000256993:exon29:c.3327+5G>C,ENST00000399249:exon30:c.3330+5G>C,ENST000005459
















c.3227_3228insT:p.D1076fs   P 0,00378 
MYBPC3 11_47355103_C_T 
ENST00000256993:exon28:c.3187+5G>A,ENST00000399249:exon29:c.3190+5G>A,ENST000005459
















002W rs3729799 D 0,00065 
MYBPC3 11_47355304_C_T 
ENST00000256993:exon28:c.2992-1G>A,ENST00000399249:exon29:c.2995-
1G>A,ENST00000545968:exon30:c.2995-1G>A   L 0,00066 
MYBPC3 11_47355514_T_A 
ENSG00000134571:ENST00000256993:exon26:c.A2950T:p.K984X,ENSG00000134571:ENST000003
99249:exon27:c.A2953T:p.K985X,ENSG00000134571:ENST00000545968:exon28:c.A2953T:p.K985X   L 0,00068 
MYBPC3 11_47356588_C_A 
ENST00000256993:exon26:c.2902+5G>T,ENST00000399249:exon27:c.2905+5G>T,ENST000005459










on27:c.2864_2865del:p.955_955del   L 0,00156 
MYBPC3 11_47356671_G_A 
ENSG00000134571:ENST00000256993:exon25:c.C2824T:p.R942X,ENSG00000134571:ENST000003
99249:exon26:c.C2827T:p.R943X,ENSG00000134571:ENST00000545968:exon27:c.C2827T:p.R943X   P 0,00312 
MYBPC3 11_47356710_G_C 
ENSG00000134571:ENST00000256993:exon25:c.C2785G:p.L929V,ENSG00000134571:ENST000003
99249:exon26:c.C2788G:p.L930V,ENSG00000134571:ENST00000545968:exon27:c.C2788G:p.L930V   N 0,00082 
MYBPC3 11_47357425_CA_-     P 0,00061 
MYBPC3 11_47357437_G_T 
ENSG00000134571:ENST00000256993:exon24:c.C2725A:p.P909T,ENSG00000134571:ENST000003








870fs   P 0,00252 
MYBPC3 11_47357560_G_T 
ENSG00000134571:ENST00000256993:exon24:c.C2602A:p.P868T,ENSG00000134571:ENST000003
99249:exon25:c.C2605A:p.P869T,ENSG00000134571:ENST00000545968:exon26:c.C2605A:p.P869T   P 0,00188 
MYBPC3 11_47357560_GA_GGA 
ENSG00000134571:ENST00000256993:exon24:c.2601_2602TCC,ENSG00000134571:ENST00000399




868fs   P 0,00253 
MYBPC3 11_47357563_C_G 
ENST00000256993:exon25:c.2600-1G>C,ENST00000399249:exon26:c.2603-
1G>C,ENST00000545968:exon27:c.2603-1G>C,ENST00000544791:exon27:c.2535-1G>C   L 0,00062 
MYBPC3 11_47357564_T_C 
ENST00000256993:exon25:c.2600-2A>G,ENST00000399249:exon26:c.2603-











































H   P 0,00218 
MYBPC3 11_47359116_G_A 
ENSG00000134571:ENST00000256993:exon23:c.C2425T:p.R809C,ENSG00000134571:ENST000003




































7M,ENSG00000134571:ENST00000545968:exon23:c.G2179A:p.V727M   S 0,00066 
MYBPC3 11_47360235_G_A 
ENST00000256993:exon22:c.2146-5C>T,ENST00000399249:exon23:c.2149-












,ENSG00000134571:ENST00000545968:exon21:c.C1960T:p.R654C   P 0,00059 
MYBPC3 11_47361343_T_C 
ENST00000256993:exon20:c.1925-2A>G,ENST00000399249:exon21:c.1928-



















543fs,ENSG00000134571:ENST00000545968:exon18:c.1628delA:p.K543fs   L 0,00058 
MYBPC3 11_47364125_T_A 
ENST00000256993:exon16:c.1621+4A>T,ENST00000399249:exon17:c.1624+4A>T,ENST000005459


















































68:exon17:c.1457+5G>C,ENST00000544791:exon17:c.1457+5G>C   L 0,00060 
MYBPC3 11_47364377_T_C 
ENST00000256993:exon15:c.1454+4A>G,ENST00000399249:exon16:c.1457+4A>G,ENST000005459





































234_1235insT:p.F412fs,ENSG00000134571:ENST00000545968:exon15:c.1234_1235insT:p.F412fs   P 0,00137 
MYBPC3 11_47364698_T_C 
ENST00000256993:exon14:c.1224-2A>G,ENST00000399249:exon15:c.1227-










68:exon13:c.1090+1G>T,ENST00000544791:exon13:c.1090+1G>T   P 0,00231 
MYBPC3 11_47367757_C_T 
ENST00000256993:exon12:c.1090+1G>A,ENST00000399249:exon12:c.1090+1G>A,ENST000005459



























,ENSG00000134571:ENST00000545968:exon12:c.G961A:p.V321M rs200119454 P 0,00187 
MYBPC3 11_47367923_T_C 
ENST00000256993:exon12:c.927-2A>G,ENST00000399249:exon12:c.927-




NSG00000134571:ENST00000545968:exon11:c.G917A:p.R306Q   N 0,00059 




0000134571:ENST00000545968:exon9:c.C859T:p.H287Y   P 0,00066 
MYBPC3 11_47369406_A_G 
ENST00000256993:exon8:c.821+2T>C,ENST00000399249:exon8:c.821+2T>C,ENST00000545968:ex





























82_589del:p.194_197del,ENSG00000134571:ENST00000545968:exon5:c.582_589del:p.194_197del   L 0,00071 
MYBPC3 11_47371560_C_T 
ENST00000256993:exon5:c.505+5G>A,ENST00000399249:exon5:c.505+5G>A,ENST00000545968:ex




































405093:exon37:c.C5644A:p.R1882S   S 0,00058 
MYH6 14_23852501_C_T 
ENSG00000197616:ENST00000356287:exon36:c.G5594A:p.R1865Q,ENSG00000197616:ENST00000
405093:exon37:c.G5594A:p.R1865Q rs138720701 P 0,00059 
MYH6 14_23852520_C_T 
ENSG00000197616:ENST00000356287:exon36:c.G5575A:p.D1859N,ENSG00000197616:ENST00000
405093:exon37:c.G5575A:p.D1859N   S 0,00069 
MYH6 14_23853739_C_T 
ENSG00000197616:ENST00000356287:exon35:c.G5477A:p.G1826D,ENSG00000197616:ENST00000
405093:exon36:c.G5477A:p.G1826D rs200260229 D 0,00119 
MYH6 14_23853740_C_T 
ENSG00000197616:ENST00000356287:exon35:c.G5476A:p.G1826S,ENSG00000197616:ENST00000
405093:exon36:c.G5476A:p.G1826S rs202141059 D 0,00119 
MYH6 14_23853806_G_T 
ENSG00000197616:ENST00000356287:exon35:c.C5410A:p.Q1804K,ENSG00000197616:ENST00000
405093:exon36:c.C5410A:p.Q1804K rs144571463 D 0,00060 
MYH6 14_23854220_TCT_- 
ENSG00000197616:ENST00000356287:exon34:c.5192_5194del:p.1731_1732del,ENSG0000019761
6:ENST00000405093:exon35:c.5192_5194del:p.1731_1732del   N 0,00057 
MYH6 14_23855136_C_A ENST00000405093:exon35:c.5163+1G>T,ENST00000356287:exon34:c.5163+1G>T   L 0,00058 
MYH6 14_23855160_G_A 
ENSG00000197616:ENST00000356287:exon33:c.C5140T:p.R1714W,ENSG00000197616:ENST00000
405093:exon34:c.C5140T:p.R1714W rs140651265 S 0,00058 
MYH6 14_23855228_C_T 
ENSG00000197616:ENST00000356287:exon33:c.G5072A:p.R1691H,ENSG00000197616:ENST00000
405093:exon34:c.G5072A:p.R1691H   S 0,00060 
MYH6 14_23855609_T_C 
ENSG00000197616:ENST00000356287:exon32:c.A4874G:p.N1625S,ENSG00000197616:ENST00000
405093:exon33:c.A4874G:p.N1625S   S 0,00058 
MYH6 14_23855779_G_T 
ENSG00000197616:ENST00000356287:exon32:c.C4704A:p.N1568K,ENSG00000197616:ENST00000
405093:exon33:c.C4704A:p.N1568K rs149771264 S 0,00058 
MYH6 14_23856786_C_G 
ENSG00000197616:ENST00000356287:exon31:c.G4602C:p.Q1534H,ENSG00000197616:ENST00000
405093:exon32:c.G4602C:p.Q1534H rs199600772 S 0,00057 
MYH6 14_23856987_C_T 
ENSG00000197616:ENST00000356287:exon30:c.G4505A:p.R1502Q,ENSG00000197616:ENST00000
405093:exon31:c.G4505A:p.R1502Q rs199936506 D 0,00115 
MYH6 14_23857371_A_T 
ENSG00000197616:ENST00000356287:exon29:c.T4352A:p.F1451Y,ENSG00000197616:ENST000004
05093:exon30:c.T4352A:p.F1451Y   N 0,00058 
MYH6 14_23857395_G_T 
ENSG00000197616:ENST00000356287:exon29:c.C4328A:p.A1443D,ENSG00000197616:ENST00000
405093:exon30:c.C4328A:p.A1443D   P 0,00058 
MYH6 14_23857530_C_T 
ENSG00000197616:ENST00000356287:exon29:c.G4193A:p.R1398Q,ENSG00000197616:ENST00000
405093:exon30:c.G4193A:p.R1398Q rs150815925 D 0,00058 
MYH6 14_23858107_G_A 
ENSG00000197616:ENST00000356287:exon28:c.C4136T:p.T1379M,ENSG00000197616:ENST00000
405093:exon29:c.C4136T:p.T1379M rs145611185 P 0,00058 
MYH6 14_23858161_C_T 
ENSG00000197616:ENST00000356287:exon28:c.G4082A:p.R1361H,ENSG00000197616:ENST00000






05093:exon28:c.C3932T:p.T1311I   S 0,00058 
MYH6 14_23858687_G_A 
ENSG00000197616:ENST00000356287:exon27:c.C3893T:p.A1298V,ENSG00000197616:ENST00000
405093:exon28:c.C3893T:p.A1298V   N 0,00058 
MYH6 14_23858720_C_T 
ENSG00000197616:ENST00000356287:exon27:c.G3860A:p.G1287E,ENSG00000197616:ENST00000
405093:exon28:c.G3860A:p.G1287E   N 0,00058 
MYH6 14_23859370_C_T 
ENSG00000197616:ENST00000356287:exon25:c.G3628A:p.D1210N,ENSG00000197616:ENST00000
405093:exon26:c.G3628A:p.D1210N   S 0,00065 
MYH6 14_23859484_C_T 
ENSG00000197616:ENST00000356287:exon25:c.G3514A:p.E1172K,ENSG00000197616:ENST00000
405093:exon26:c.G3514A:p.E1172K   S 0,00092 
MYH6 14_23859571_G_A 
ENSG00000197616:ENST00000356287:exon25:c.C3427T:p.R1143W,ENSG00000197616:ENST00000
405093:exon26:c.C3427T:p.R1143W   S 0,00093 
MYH6 14_23859652_G_T 
ENSG00000197616:ENST00000356287:exon25:c.C3346A:p.R1116S,ENSG00000197616:ENST00000
405093:exon26:c.C3346A:p.R1116S   P 0,00080 
MYH6 14_23861814_T_A 
ENSG00000197616:ENST00000356287:exon24:c.A3299T:p.Q1100L,ENSG00000197616:ENST00000
405093:exon25:c.A3299T:p.Q1100L   S 0,00057 
MYH6 14_23862208_C_T 
ENSG00000197616:ENST00000356287:exon23:c.G3164A:p.R1055Q,ENSG00000197616:ENST00000
405093:exon24:c.G3164A:p.R1055Q   N 0,00057 
MYH6 14_23862646_C_A 
ENSG00000197616:ENST00000356287:exon22:c.G3010T:p.A1004S,ENSG00000197616:ENST00000
405093:exon23:c.G3010T:p.A1004S rs143978652 P 0,00057 
MYH6 14_23862870_C_T ENST00000405093:exon23:c.2928+5G>A,ENST00000356287:exon22:c.2928+5G>A rs28730772 L 0,00400 
MYH6 14_23863087_G_A 
ENSG00000197616:ENST00000356287:exon21:c.C2716T:p.R906C,ENSG00000197616:ENST000004
05093:exon22:c.C2716T:p.R906C rs143928061 S 0,00057 
MYH6 14_23863348_G_A 
ENSG00000197616:ENST00000356287:exon20:c.C2614T:p.R872C,ENSG00000197616:ENST000004
05093:exon21:c.C2614T:p.R872C rs201193346 S 0,00058 
MYH6 14_23863384_G_A 
ENSG00000197616:ENST00000356287:exon20:c.C2578T:p.R860C,ENSG00000197616:ENST000004
05093:exon21:c.C2578T:p.R860C   S 0,00057 
MYH6 14_23865497_G_A 
ENSG00000197616:ENST00000356287:exon19:c.C2425T:p.R809C,ENSG00000197616:ENST000004
05093:exon20:c.C2425T:p.R809C   S 0,00057 
MYH6 14_23865569_G_A 
ENSG00000197616:ENST00000356287:exon19:c.C2353T:p.R785C,ENSG00000197616:ENST000004
05093:exon20:c.C2353T:p.R785C   S 0,00058 
MYH6 14_23866275_G_T 
ENSG00000197616:ENST00000356287:exon17:c.C2065A:p.P689T,ENSG00000197616:ENST000004
05093:exon18:c.C2065A:p.P689T   N 0,00060 
MYH6 14_23868065_T_G 
ENSG00000197616:ENST00000356287:exon14:c.A1763C:p.D588A,ENSG00000197616:ENST000004
05093:exon15:c.A1763C:p.D588A rs142992009 D 0,00057 






05093:exon13:c.G1361T:p.R454L   S 0,00058 
MYH6 14_23870001_G_A 
ENSG00000197616:ENST00000356287:exon12:c.C1327T:p.R443C,ENSG00000197616:ENST000004
05093:exon13:c.C1327T:p.R443C rs182373896 S 0,00058 
MYH6 14_23870012_C_T 
ENSG00000197616:ENST00000356287:exon12:c.G1316A:p.W439X,ENSG00000197616:ENST00000
405093:exon13:c.G1316A:p.W439X   L 0,00058 
MYH6 14_23870034_C_G 
ENSG00000197616:ENST00000356287:exon12:c.G1294C:p.V432L,ENSG00000197616:ENST000004
05093:exon13:c.G1294C:p.V432L   N 0,00057 
MYH6 14_23870151_A_C 
ENSG00000197616:ENST00000356287:exon12:c.T1177G:p.S393A,ENSG00000197616:ENST000004
05093:exon13:c.T1177G:p.S393A rs199877580 D 0,00057 
MYH6 14_23871758_C_G 
ENSG00000197616:ENST00000356287:exon11:c.G1056C:p.K352N,ENSG00000197616:ENST000004
05093:exon12:c.G1056C:p.K352N   S 0,00058 
MYH6 14_23871766_C_T 
ENSG00000197616:ENST00000356287:exon11:c.G1048A:p.V350I,ENSG00000197616:ENST0000040
5093:exon12:c.G1048A:p.V350I rs200260629 D 0,00058 
MYH6 14_23872631_A_T 
ENSG00000197616:ENST00000356287:exon9:c.T824A:p.I275N,ENSG00000197616:ENST000004050
93:exon10:c.T824A:p.I275N rs201327273 P 0,00120 
MYH6 14_23874309_G_A 
ENSG00000197616:ENST00000356287:exon5:c.C530T:p.T177M,ENSG00000197616:ENST00000405
093:exon6:c.C530T:p.T177M   S 0,00058 
MYH6 14_23874525_C_T 
ENSG00000197616:ENST00000356287:exon4:c.G409A:p.E137K,ENSG00000197616:ENST00000405
093:exon5:c.G409A:p.E137K   N 0,00061 
MYH6 14_23874889_C_T 
ENSG00000197616:ENST00000356287:exon3:c.G292A:p.E98K,ENSG00000197616:ENST000004050
93:exon4:c.G292A:p.E98K rs140596256 D 0,00059 
MYH6 14_23874936_G_A 
ENSG00000197616:ENST00000356287:exon3:c.C245T:p.P82L,ENSG00000197616:ENST0000040509
3:exon4:c.C245T:p.P82L   S 0,00058 
MYH6 14_23876352_C_G 
ENSG00000197616:ENST00000356287:exon2:c.G81C:p.Q27H,ENSG00000197616:ENST0000040509
3:exon3:c.G81C:p.Q27H   N 0,00058 
MYH6 14_23876363_G_T 
ENSG00000197616:ENST00000356287:exon2:c.C70A:p.L24I,ENSG00000197616:ENST00000405093:
exon3:c.C70A:p.L24I   N 0,00115 
MYH6 14_23876785_C_T     L 0,00059 
MYH7 14_23882979_T_A ENSG00000092054:ENST00000355349:exon39:c.A5779T:p.I1927F   P 0,00058 
MYH7 14_23883068_C_T ENSG00000092054:ENST00000355349:exon39:c.G5690A:p.R1897H   S 0,00058 
MYH7 14_23883217_G_A ENSG00000092054:ENST00000355349:exon38:c.C5654T:p.A1885V   N 0,00059 
MYH7 14_23884200_G_A ENST00000355349:exon38:c.5559+4C>T   L 0,00058 
MYH7 14_23884421_C_T ENSG00000092054:ENST00000355349:exon37:c.G5342A:p.R1781H   P 0,00058 




MYH7 14_23884860_C_T ENSG00000092054:ENST00000355349:exon35:c.G5135A:p.R1712Q rs193922390 P 0,00063 
MYH7 14_23885349_C_T ENSG00000092054:ENST00000355349:exon34:c.G4817A:p.R1606H   N 0,00058 
MYH7 14_23885502_T_C ENSG00000092054:ENST00000355349:exon34:c.A4664G:p.E1555G   P 0,00058 
MYH7 14_23886806_C_T ENSG00000092054:ENST00000355349:exon31:c.G4259A:p.R1420Q   P 0,00058 
MYH7 14_23886815_G_A ENSG00000092054:ENST00000355349:exon31:c.C4250T:p.T1417I   S 0,00058 
MYH7 14_23887522_C_T ENSG00000092054:ENST00000355349:exon30:c.G4066A:p.E1356K   P 0,00296 
MYH7 14_23887607_G_T ENSG00000092054:ENST00000355349:exon30:c.C3981A:p.N1327K rs141764279 D 0,00058 
MYH7 14_23888775_T_C ENSG00000092054:ENST00000355349:exon28:c.A3770G:p.N1257S   N 0,00058 
MYH7 14_23889158_C_T ENSG00000092054:ENST00000355349:exon27:c.G3622A:p.D1208N   S 0,00062 
MYH7 14_23889187_T_C ENSG00000092054:ENST00000355349:exon27:c.A3593G:p.D1198G   S 0,00070 
MYH7 14_23892910_A_G ENSG00000092054:ENST00000355349:exon24:c.T2945C:p.M982T rs145532615 P 0,00057 
MYH7 14_23893148_C_G ENSG00000092054:ENST00000355349:exon23:c.G2890C:p.V964L rs45496496 P 0,00344 
MYH7 14_23893192_T_A ENSG00000092054:ENST00000355349:exon23:c.A2846T:p.E949V   S 0,00057 
MYH7 14_23893246_T_C ENSG00000092054:ENST00000355349:exon23:c.A2792G:p.E931G   S 0,00057 
MYH7 14_23893255_T_C ENSG00000092054:ENST00000355349:exon23:c.A2783G:p.D928G   S 0,00057 
MYH7 14_23893268_C_G ENSG00000092054:ENST00000355349:exon23:c.G2770C:p.E924Q   P 0,00057 
MYH7 14_23893268_C_T ENSG00000092054:ENST00000355349:exon23:c.G2770A:p.E924K rs121913628 P 0,00057 
MYH7 14_23893316_G_C ENSG00000092054:ENST00000355349:exon23:c.C2722G:p.L908V rs121913631 P 0,00057 
MYH7 14_23893321_T_C ENSG00000092054:ENST00000355349:exon23:c.A2717G:p.D906G   P 0,00286 
MYH7 14_23893357_T_C ENSG00000092054:ENST00000355349:exon23:c.A2681G:p.E894G   P 0,00172 
MYH7 14_23893988_T_G ENSG00000092054:ENST00000355349:exon22:c.A2669C:p.Q890P   S 0,00060 
MYH7 14_23894048_C_T ENSG00000092054:ENST00000355349:exon22:c.G2609A:p.R870H rs36211715 P 0,00293 
MYH7 14_23894051_C_G ENSG00000092054:ENST00000355349:exon22:c.G2606C:p.R869P   N 0,00117 
MYH7 14_23894051_C_T ENSG00000092054:ENST00000355349:exon22:c.G2606A:p.R869H rs202141173 P 0,00058 
MYH7 14_23894052_G_A ENSG00000092054:ENST00000355349:exon22:c.C2605T:p.R869C   P 0,00117 
MYH7 14_23894052_G_T ENSG00000092054:ENST00000355349:exon22:c.C2605A:p.R869S   N 0,00058 




MYH7 14_23894118_T_C ENSG00000092054:ENST00000355349:exon22:c.A2539G:p.K847E   P 0,00116 
MYH7 14_23894118_TCT_- ENSG00000092054:ENST00000355349:exon22:c.2537_2539del:p.846_847del   N 0,00058 
MYH7 14_23894123_C_T ENSG00000092054:ENST00000355349:exon22:c.G2534A:p.R845K   N 0,00058 
MYH7 14_23894193_T_A ENSG00000092054:ENST00000355349:exon22:c.A2464T:p.M822L   P 0,00058 
MYH7 14_23894525_C_T ENSG00000092054:ENST00000355349:exon21:c.G2389A:p.A797T rs3218716 P 0,00172 
MYH7 14_23894539_G_T ENSG00000092054:ENST00000355349:exon21:c.C2375A:p.S792Y   N 0,00058 
MYH7 14_23894554_C_T ENSG00000092054:ENST00000355349:exon21:c.G2360A:p.R787H   P 0,00173 
MYH7 14_23894566_C_T ENSG00000092054:ENST00000355349:exon21:c.G2348A:p.R783H   P 0,00058 
MYH7 14_23894969_C_A ENSG00000092054:ENST00000355349:exon20:c.G2221T:p.G741W   P 0,00057 
MYH7 14_23894969_C_G ENSG00000092054:ENST00000355349:exon20:c.G2221C:p.G741R rs121913632 P 0,00057 
MYH7 14_23895023_G_A ENSG00000092054:ENST00000355349:exon20:c.C2167T:p.R723C rs121913630 P 0,00230 
MYH7 14_23895023_G_C ENSG00000092054:ENST00000355349:exon20:c.C2167G:p.R723G   P 0,00057 
MYH7 14_23895179_C_T ENSG00000092054:ENST00000355349:exon19:c.G2156A:p.R719Q rs121913641 P 0,00118 
MYH7 14_23895180_G_A ENSG00000092054:ENST00000355349:exon19:c.C2155T:p.R719W rs121913637 P 0,00059 
MYH7 14_23895243_C_G ENSG00000092054:ENST00000355349:exon19:c.G2092C:p.V698L   N 0,00065 
MYH7 14_23895254_C_T ENSG00000092054:ENST00000355349:exon19:c.G2081A:p.R694H   P 0,00065 
MYH7 14_23896042_C_T ENSG00000092054:ENST00000355349:exon18:c.G1988A:p.R663H   P 0,00287 
MYH7 14_23896043_G_A ENSG00000092054:ENST00000355349:exon18:c.C1987T:p.R663C   P 0,00172 
MYH7 14_23896812_A_T ENSG00000092054:ENST00000355349:exon16:c.T1870A:p.Y624N   P 0,00057 
MYH7 14_23896866_C_T ENSG00000092054:ENST00000355349:exon16:c.G1816A:p.V606M rs121913627 P 0,00229 
MYH7 14_23897796_C_A ENSG00000092054:ENST00000355349:exon15:c.G1491T:p.E497D   P 0,00057 
MYH7 14_23897840_C_T ENSG00000092054:ENST00000355349:exon15:c.G1447A:p.E483K rs121913651 P 0,00057 
MYH7 14_23897854_A_T ENSG00000092054:ENST00000355349:exon15:c.T1433A:p.I478N   S 0,00057 
MYH7 14_23898213_C_A ENSG00000092054:ENST00000355349:exon14:c.G1358T:p.R453L   S 0,00057 
MYH7 14_23898240_T_C ENSG00000092054:ENST00000355349:exon14:c.A1331G:p.N444S   P 0,00057 
MYH7 14_23898292_G_T ENSG00000092054:ENST00000355349:exon14:c.C1279A:p.L427M   P 0,00230 




MYH7 14_23898487_C_T ENSG00000092054:ENST00000355349:exon13:c.G1208A:p.R403Q rs121913624 P 0,00057 
MYH7 14_23898488_G_A ENSG00000092054:ENST00000355349:exon13:c.C1207T:p.R403W rs3218714 P 0,00172 
MYH7 14_23898551_C_A ENSG00000092054:ENST00000355349:exon13:c.G1144T:p.D382Y   P 0,00115 
MYH7 14_23899059_C_A ENSG00000092054:ENST00000355349:exon12:c.G1063T:p.A355S   N 0,00115 
MYH7 14_23899059_C_T ENSG00000092054:ENST00000355349:exon12:c.G1063A:p.A355T   P 0,00229 
MYH7 14_23899071_T_C ENSG00000092054:ENST00000355349:exon12:c.A1051G:p.K351E   P 0,00115 
MYH7 14_23899101_A_G ENSG00000092054:ENST00000355349:exon12:c.T1021C:p.F341L   S 0,00057 
MYH7 14_23899864_G_T ENSG00000092054:ENST00000355349:exon11:c.C904A:p.L302M   S 0,00057 
MYH7 14_23900635_A_G ENSG00000092054:ENST00000355349:exon9:c.T788C:p.I263T   P 0,00057 
MYH7 14_23900656_C_T ENSG00000092054:ENST00000355349:exon9:c.G767A:p.G256E rs121913633 P 0,00057 
MYH7 14_23900677_C_T ENSG00000092054:ENST00000355349:exon9:c.G746A:p.R249Q rs3218713 P 0,00057 
MYH7 14_23900811_C_T ENSG00000092054:ENST00000355349:exon8:c.G715A:p.D239N   P 0,00058 
MYH7 14_23901712_C_T ENSG00000092054:ENST00000355349:exon6:c.G506A:p.R169K   N 0,00058 
MYH7 14_23901922_C_T ENSG00000092054:ENST00000355349:exon5:c.G428A:p.R143Q   P 0,00059 
MYH7 14_23902293_G_T ENSG00000092054:ENST00000355349:exon4:c.C345A:p.Y115X   L 0,00058 
MYH7 14_23902340_C_T ENSG00000092054:ENST00000355349:exon4:c.G298A:p.A100T   S 0,00058 
MYH7 14_23902892_C_T ENSG00000092054:ENST00000355349:exon3:c.G50A:p.R17H   S 0,00058 
MYH7 14_23903456_G_A   rs45566639 L 0,00401 
MYL2 12_111350901_T_G 
ENSG00000111245:ENST00000548438:exon5:c.A359C:p.E120A,ENSG00000111245:ENST00000228
841:exon6:c.A401C:p.E134A rs143139258 S 0,00115 
MYL2 12_111350926_G_C 
ENSG00000111245:ENST00000548438:exon5:c.C334G:p.Q112E,ENSG00000111245:ENST00000550
439:exon5:c.C319G:p.Q107E,ENSG00000111245:ENST00000228841:exon6:c.C376G:p.Q126E   S 0,00058 
MYL2 12_111352004_C_G 
ENSG00000111245:ENST00000548438:exon3:c.G218C:p.G73A,ENSG00000111245:ENST000005504
39:exon3:c.G203C:p.G68A,ENSG00000111245:ENST00000228841:exon4:c.G260C:p.G87A   S 0,00058 
MYL2 12_111352091_C_T 
ENSG00000111245:ENST00000548438:exon3:c.G131A:p.R44Q,ENSG00000111245:ENST000005504
39:exon3:c.G116A:p.R39Q,ENSG00000111245:ENST00000228841:exon4:c.G173A:p.R58Q rs104894369 P 0,00057 
MYL2 12_111353547_G_T 
ENSG00000111245:ENST00000550439:exon2:c.C84A:p.N28K,ENSG00000111245:ENST0000022884
1:exon3:c.C141A:p.N47K rs199474808 P 0,00057 
MYL2 12_111356937_C_T 
ENSG00000111245:ENST00000550439:exon1:c.G7A:p.E3K,ENSG00000111245:ENST00000228841:e






8:exon2:c.G37A:p.A13T rs104894363 P 0,00115 
MYL3 3_46899903_T_C 
ENSG00000160808:ENST00000292327:exon5:c.A530G:p.E177G,ENSG00000160808:ENST00000395
869:exon5:c.A530G:p.E177G rs193922391 S 0,00058 
MYL3 3_46900970_G_A 
ENSG00000160808:ENST00000292327:exon4:c.C476T:p.T159M,ENSG00000160808:ENST00000395
869:exon4:c.C476T:p.T159M   S 0,00058 
MYL3 3_46900986_G_A 
ENSG00000160808:ENST00000292327:exon4:c.C460T:p.R154C,ENSG00000160808:ENST00000395
869:exon4:c.C460T:p.R154C rs143852164 S 0,00115 
MYL3 3_46901009_C_T 
ENSG00000160808:ENST00000292327:exon4:c.G437A:p.G146D,ENSG00000160808:ENST00000395
869:exon4:c.G437A:p.G146D   S 0,00058 
MYL3 3_46902285_C_T 
ENSG00000160808:ENST00000292327:exon3:c.G188A:p.R63H,ENSG00000160808:ENST000003958
69:exon3:c.G188A:p.R63H rs139354105 S 0,00058 
PDLIM3 4_186423516_T_C 
ENSG00000154553:ENST00000284771:exon7:c.A883G:p.T295A,ENSG00000154553:ENST00000284
770:exon8:c.A1027G:p.T343A   N 0,00172 
PDLIM3 4_186423579_C_T 
ENSG00000154553:ENST00000284771:exon7:c.G820A:p.D274N,ENSG00000154553:ENST00000284
770:exon8:c.G964A:p.D322N   S 0,00057 
PDLIM3 4_186427754_C_T 
ENSG00000154553:ENST00000284771:exon5:c.G571A:p.D191N,ENSG00000154553:ENST00000284
770:exon6:c.G715A:p.D239N rs142143310 D 0,00058 
PDLIM3 4_186427786_G_A 
ENSG00000154553:ENST00000284771:exon5:c.C539T:p.P180L,ENSG00000154553:ENST000002847
70:exon6:c.C683T:p.P228L rs201185673 D 0,00115 
PDLIM3 4_186429568_C_A ENSG00000154553:ENST00000284770:exon5:c.G547T:p.V183L   N 0,00057 
PDLIM3 4_186435447_A_G ENSG00000154553:ENST00000284767:exon5:c.T563C:p.L188P   N 0,00057 
PDLIM3 4_186435483_G_C 
ENSG00000154553:ENST00000284770:exon4:c.C339G:p.N113K,ENSG00000154553:ENST00000284
767:exon5:c.C527G:p.T176S   N 0,00057 
PDLIM3 4_186444600_C_T 
ENSG00000154553:ENST00000505886:exon2:c.G94A:p.G32R,ENSG00000154553:ENST0000051229
3:exon2:c.G94A:p.G32R rs200354645 D 0,00115 
PDLIM3 4_186446250_T_C 
ENSG00000154553:ENST00000284767:exon2:c.A169G:p.T57A,ENSG00000154553:ENST000002847
70:exon2:c.A169G:p.T57A,ENSG00000154553:ENST00000284771:exon2:c.A169G:p.T57A rs142951316 D 0,00115 
PKP2 12_32949101_G_T 
ENSG00000057294:ENST00000340811:exon11:c.C2299A:p.R767S,ENSG00000057294:ENST000000
70846:exon12:c.C2431A:p.R811S rs139734328 D 0,00058 
PKP2 12_32955491_C_G ENST00000340811:exon11:c.2014-1G>C,ENST00000070846:exon12:c.2146-1G>C rs193922674 P 0,00057 
PKP2 12_32975431_A_C 
ENSG00000057294:ENST00000340811:exon8:c.T1809G:p.C603W,ENSG00000057294:ENST0000007
0846:exon9:c.T1941G:p.C647W rs149392678 S 0,00114 
PKP2 12_32994007_C_- 
ENSG00000057294:ENST00000340811:exon6:c.1511delG:p.G504fs,ENSG00000057294:ENST00000






0846:exon7:c.A1550G:p.N517S rs144536197 D 0,00115 
PKP2 12_32996206_C_T ENSG00000057294:ENST00000070846:exon6:c.G1420A:p.A474T rs138538072 D 0,00193 
PKP2 12_33021936_C_T 
ENSG00000057294:ENST00000070846:exon4:c.G1095A:p.M365I,ENSG00000057294:ENST0000034
0811:exon4:c.G1095A:p.M365I   N 0,00058 
PKP2 12_33021997_C_G ENST00000340811:exon5:c.1035-1G>C,ENST00000070846:exon5:c.1035-1G>C   L 0,00057 
PKP2 12_33030850_C_A 
ENSG00000057294:ENST00000070846:exon3:c.G964T:p.G322C,ENSG00000057294:ENST00000340
811:exon3:c.G964T:p.G322C   S 0,00064 
PKP2 12_33031039_C_A 
ENSG00000057294:ENST00000070846:exon3:c.G775T:p.E259X,ENSG00000057294:ENST00000340
811:exon3:c.G775T:p.E259X   P 0,00062 
PKP2 12_33031321_C_T 
ENSG00000057294:ENST00000070846:exon3:c.G493A:p.D165N,ENSG00000057294:ENST00000340
811:exon3:c.G493A:p.D165N   S 0,00118 
PKP2 12_33031329_G_A 
ENSG00000057294:ENST00000070846:exon3:c.C485T:p.T162M,ENSG00000057294:ENST00000340
811:exon3:c.C485T:p.T162M   N 0,00059 
PKP2 12_33031468_T_C 
ENSG00000057294:ENST00000070846:exon3:c.A346G:p.T116A,ENSG00000057294:ENST00000340
811:exon3:c.A346G:p.T116A   N 0,00057 
PKP2 12_33031883_G_C 
ENSG00000057294:ENST00000070846:exon2:c.C307G:p.P103A,ENSG00000057294:ENST00000340
811:exon2:c.C307G:p.P103A   N 0,00057 
PKP2 12_33031883_G_T 
ENSG00000057294:ENST00000070846:exon2:c.C307A:p.P103T,ENSG00000057294:ENST00000340
811:exon2:c.C307A:p.P103T rs139215336 D 0,00057 
PKP2 12_33031888_C_T 
ENSG00000057294:ENST00000070846:exon2:c.G302A:p.R101H,ENSG00000057294:ENST00000340
811:exon2:c.G302A:p.R101H rs149542398 P 0,00115 
PKP2 12_33031931_C_G 
ENSG00000057294:ENST00000070846:exon2:c.G259C:p.V87L,ENSG00000057294:ENST000003408
11:exon2:c.G259C:p.V87L   P 0,00057 
PKP2 12_33049492_C_A 
ENSG00000057294:ENST00000070846:exon1:c.G174T:p.E58D,ENSG00000057294:ENST000003408
11:exon1:c.G174T:p.E58D rs146708884 P 0,00771 



















0000144283:ENST00000426248:exon5:c.A377G:p.Y126C   S 0,00114 
PKP4 2_159481523_G_C 
ENSG00000144283:ENST00000389757:exon7:c.G737C:p.G246A,ENSG00000144283:ENST00000389
759:exon7:c.G737C:p.G246A   N 0,00058 
PKP4 2_159481526_C_T 
ENSG00000144283:ENST00000389757:exon7:c.C740T:p.S247F,ENSG00000144283:ENST000003897
59:exon7:c.C740T:p.S247F   N 0,00058 
PKP4 2_159481840_C_A 
ENSG00000144283:ENST00000389757:exon7:c.C1054A:p.P352T,ENSG00000144283:ENST0000038
9759:exon7:c.C1054A:p.P352T   N 0,00058 
PKP4 2_159481864_G_T 
ENSG00000144283:ENST00000389757:exon7:c.G1078T:p.D360Y,ENSG00000144283:ENST0000038
9759:exon7:c.G1078T:p.D360Y rs147567711 S 0,00058 
PKP4 2_159481865_A_G 
ENSG00000144283:ENST00000389757:exon7:c.A1079G:p.D360G,ENSG00000144283:ENST0000038
9759:exon7:c.A1079G:p.D360G rs147809285 D 0,00058 
PKP4 2_159497153_G_A 
ENSG00000144283:ENST00000389757:exon10:c.G1577A:p.R526H,ENSG00000144283:ENST000003
89759:exon10:c.G1577A:p.R526H rs144253065 S 0,00057 
PKP4 2_159499094_G_A 
ENSG00000144283:ENST00000389757:exon11:c.G1792A:p.V598I,ENSG00000144283:ENST0000038
9759:exon11:c.G1792A:p.V598I   N 0,00057 
PKP4 2_159499181_A_G 
ENSG00000144283:ENST00000389757:exon11:c.A1879G:p.I627V,ENSG00000144283:ENST0000038
9759:exon11:c.A1879G:p.I627V   N 0,00057 
PKP4 2_159517919_A_G 
ENSG00000144283:ENST00000389757:exon13:c.A2168G:p.Y723C,ENSG00000144283:ENST000003
89759:exon13:c.A2168G:p.Y723C rs150425961 S 0,00057 
PKP4 2_159519410_C_T 
ENSG00000144283:ENST00000389757:exon14:c.C2213T:p.T738M,ENSG00000144283:ENST000003
89759:exon14:c.C2213T:p.T738M rs201257617 S 0,00058 
PKP4 2_159519557_G_A 
ENSG00000144283:ENST00000389757:exon14:c.G2360A:p.G787E,ENSG00000144283:ENST000003
89759:exon14:c.G2360A:p.G787E   S 0,00057 
PKP4 2_159519581_G_A 
ENSG00000144283:ENST00000389757:exon14:c.G2384A:p.R795K,ENSG00000144283:ENST000003
89759:exon14:c.G2384A:p.R795K rs139221917 D 0,00115 
PKP4 2_159519846_G_T 
ENSG00000144283:ENST00000389757:exon15:c.G2466T:p.W822C,ENSG00000144283:ENST000003
89759:exon15:c.G2466T:p.W822C   S 0,00058 
PKP4 2_159523058_G_A 
ENSG00000144283:ENST00000389757:exon16:c.G2711A:p.R904H,ENSG00000144283:ENST000003








89759:exon18:c.G2993A:p.R998Q   S 0,00057 
PKP4 2_159536972_C_G 
ENSG00000144283:ENST00000389757:exon21:c.C3233G:p.S1078C,ENSG00000144283:ENST00000






389759:exon22:c.G3440A:p.R1147Q   N 0,00057 
PLN 6_118879986_A_T     L 0,00057 
PLN 6_118880110_G_A ENSG00000198523:ENST00000357525:exon2:c.G26A:p.R9H   S 0,00057 
PLN 6_118880137_T_C ENSG00000198523:ENST00000357525:exon2:c.T53C:p.I18T   N 0,00057 
PLN 6_118880145_-_CT ENSG00000198523:ENST00000357525:exon2:c.61_62insCT:p.P21fs   L 0,00057 
PLN 6_118880157_C_T ENSG00000198523:ENST00000357525:exon2:c.C73T:p.R25C   N 0,00057 
PLN 6_118880158_G_A ENSG00000198523:ENST00000357525:exon2:c.G74A:p.R25H   N 0,00057 
PLN 6_118880236_T_C ENSG00000198523:ENST00000357525:exon2:c.T152C:p.L51P   S 0,00057 
PNN 14_39646638_A_G 
ENSG00000100941:ENST00000216832:exon4:c.A277G:p.R93G,ENSG00000100941:ENST000005533
31:exon4:c.A277G:p.R93G,ENSG00000100941:ENST00000556530:exon4:c.A277G:p.R93G   N 0,00058 
PNN 14_39649827_C_T ENSG00000100941:ENST00000216832:exon9:c.C914T:p.A305V rs140529795 D 0,00057 
PNN 14_39650139_A_G ENSG00000100941:ENST00000216832:exon9:c.A1226G:p.N409S rs143201887 D 0,00057 
PNN 14_39650169_A_G ENSG00000100941:ENST00000216832:exon9:c.A1256G:p.N419S rs145173115 D 0,00057 
PNN 14_39650261_A_G ENSG00000100941:ENST00000216832:exon9:c.A1348G:p.S450G rs145827544 D 0,00057 
PNN 14_39650320_A_T ENSG00000100941:ENST00000216832:exon9:c.A1407T:p.Q469H rs148193612 D 0,00058 
PNN 14_39650334_CTCAAC_- ENSG00000100941:ENST00000216832:exon9:c.1421_1426del:p.474_476del   N 0,00058 
PNN 14_39650338_ACCTCA_- ENSG00000100941:ENST00000216832:exon9:c.1425_1430del:p.475_477del   N 0,00058 
PNN 14_39650559_A_C ENSG00000100941:ENST00000216832:exon9:c.A1646C:p.H549P   N 0,00057 
PNN 14_39650883_C_G ENSG00000100941:ENST00000216832:exon9:c.C1970G:p.T657S   N 0,00057 
RBM20 10_112404334_-_GCA ENSG00000203867:ENST00000369519:exon1:c.122_123insGCA:p.M41delinsMQ   N 0,01980 
RBM20 10_112404342_-_AGC ENSG00000203867:ENST00000369519:exon1:c.130_131insAGC:p.P44delinsQP   N 0,01754 
RBM20 10_112541047_G_T ENSG00000203867:ENST00000369519:exon2:c.G680T:p.G227V rs202238753 D 0,00058 
RBM20 10_112541290_T_C ENSG00000203867:ENST00000369519:exon2:c.T923C:p.V308A   N 0,00059 
RBM20 10_112541394_C_T ENSG00000203867:ENST00000369519:exon2:c.C1027T:p.H343Y rs112226602 D 0,00058 
RBM20 10_112541424_G_A ENSG00000203867:ENST00000369519:exon2:c.G1057A:p.E353K   S 0,00058 
RBM20 10_112541460_G_A ENSG00000203867:ENST00000369519:exon2:c.G1093A:p.G365R rs201047984 S 0,00058 




RBM20 10_112541511_G_T ENSG00000203867:ENST00000369519:exon2:c.G1144T:p.A382S   N 0,00057 
RBM20 10_112541568_G_A ENSG00000203867:ENST00000369519:exon2:c.G1201A:p.D401N   S 0,00057 
RBM20 10_112541632_T_C ENSG00000203867:ENST00000369519:exon2:c.T1265C:p.F422S   S 0,00057 
RBM20 10_112544571_C_T ENSG00000203867:ENST00000369519:exon5:c.C1451T:p.T484I rs116442272 D 0,00057 
RBM20 10_112557371_G_A ENSG00000203867:ENST00000369519:exon6:c.G1633A:p.V545I   N 0,00057 
RBM20 10_112559642_G_A ENSG00000203867:ENST00000369519:exon7:c.G1766A:p.R589Q   N 0,00115 
RBM20 10_112572113_C_T ENSG00000203867:ENST00000369519:exon9:c.C1958T:p.T653I   S 0,00060 
RBM20 10_112572169_G_A ENSG00000203867:ENST00000369519:exon9:c.G2014A:p.G672S   N 0,00061 
RBM20 10_112572271_C_A ENSG00000203867:ENST00000369519:exon9:c.C2116A:p.P706T   N 0,00059 
RBM20 10_112572356_G_A ENSG00000203867:ENST00000369519:exon9:c.G2201A:p.R734Q   S 0,00059 
RBM20 10_112572368_C_T ENSG00000203867:ENST00000369519:exon9:c.C2213T:p.P738L   N 0,00059 
RBM20 10_112572394_C_T ENSG00000203867:ENST00000369519:exon9:c.C2239T:p.H747Y   S 0,00059 
RBM20 10_112572419_G_A ENSG00000203867:ENST00000369519:exon9:c.G2264A:p.R755H   S 0,00058 
RBM20 10_112572473_A_G ENSG00000203867:ENST00000369519:exon9:c.A2318G:p.K773R rs181769913 D 0,00058 
RBM20 10_112572488_C_T ENSG00000203867:ENST00000369519:exon9:c.C2333T:p.A778V   N 0,00058 
RBM20 10_112581039_G_A ENSG00000203867:ENST00000369519:exon11:c.G2662A:p.D888N rs201370621 P 0,00344 
RBM20 10_112581264_A_G ENSG00000203867:ENST00000369519:exon11:c.A2887G:p.K963E   N 0,00057 
RBM20 10_112581282_G_A ENSG00000203867:ENST00000369519:exon11:c.G2905A:p.V969I   N 0,00057 
RBM20 10_112581381_C_G ENSG00000203867:ENST00000369519:exon11:c.C3004G:p.L1002V   N 0,00115 
RBM20 10_112581391_A_G ENSG00000203867:ENST00000369519:exon11:c.A3014G:p.D1005G   S 0,00057 
RBM20 10_112581400_G_A ENSG00000203867:ENST00000369519:exon11:c.G3023A:p.R1008Q   N 0,00115 
RBM20 10_112581424_G_C ENSG00000203867:ENST00000369519:exon11:c.G3047C:p.G1016A   S 0,00057 
RBM20 10_112581492_C_T ENSG00000203867:ENST00000369519:exon11:c.C3115T:p.P1039S   N 0,00057 
RBM20 10_112581642_C_G ENSG00000203867:ENST00000369519:exon11:c.C3265G:p.P1089A rs147356378 D 0,00058 
RBM20 10_112581643_C_G ENSG00000203867:ENST00000369519:exon11:c.C3266G:p.P1089R   N 0,00057 
RYR2 1_237538086_G_A 
ENSG00000198626:ENST00000542537:exon6:c.G406A:p.D136N,ENSG00000198626:ENST00000366











G   S 0,00057 
RYR2 1_237619982_G_T 
ENSG00000198626:ENST00000542537:exon15:c.G1511T:p.R504L,ENSG00000198626:ENST000003
66574:exon16:c.G1559T:p.R520L,ENSG00000198626:ENST00000360064:exon17:c.G1553T:p.R518L   N 0,00057 
RYR2 1_237659825_T_G 
ENSG00000198626:ENST00000542537:exon19:c.T1928G:p.I643S,ENSG00000198626:ENST0000036
6574:exon20:c.T1976G:p.I659S,ENSG00000198626:ENST00000360064:exon21:c.T1970G:p.I657S   S 0,00057 
RYR2 1_237659929_C_T 
ENSG00000198626:ENST00000542537:exon19:c.C2032T:p.R678X,ENSG00000198626:ENST000003




R   S 0,00057 
RYR2 1_237660057_G_A 
ENST00000366574:exon20:c.2203+5G>A,ENST00000360064:exon21:c.2197+5G>A,ENST000005425












S   S 0,00057 
RYR2 1_237666593_C_T 
ENSG00000198626:ENST00000542537:exon21:c.C2353T:p.R785C,ENSG00000198626:ENST000003








A   S 0,00057 
RYR2 1_237693732_T_C 
ENSG00000198626:ENST00000542537:exon24:c.T2780C:p.L927S,ENSG00000198626:ENST0000036





























































I   S 0,00057 
RYR2 1_237787064_G_C 
ENST00000366574:exon39:c.5917-1G>C,ENST00000360064:exon40:c.5911-






















































D4365N,ENSG00000198626:ENST00000360064:exon92:c.G13111A:p.D4371N   N 0,00058 
RYR2 1_237948273_-_TAAT 
ENST00000366574:exon90:c.13260+1->TAAT,ENST00000360064:exon92:c.13278+1-




88A,ENSG00000198626:ENST00000360064:exon99:c.C14080G:p.P4694A   N 0,00057 
RYR2 1_237969434_T_C 
ENST00000366574:exon99:c.14152-3T>C,ENST00000360064:exon101:c.14170-
















































































































































































































































































1:exon2:c.C52T:p.R18W,ENSG00000183873:ENST00000451551:exon2:c.C52T:p.R18W rs199473044 P 0,00128 
TCAP 17_37821616_G_A 
ENSG00000173991:ENST00000309889:exon1:c.G4A:p.A2T,ENSG00000173991:ENST00000578283:e
xon1:c.G4A:p.A2T   N 0,00062 
TCAP 17_37821644_C_T 
ENSG00000173991:ENST00000309889:exon1:c.C32T:p.S11L,ENSG00000173991:ENST00000578283
:exon1:c.C32T:p.S11L rs45495192 D 0,00126 
TCAP 17_37821645_GGA_- 
ENSG00000173991:ENST00000309889:exon1:c.33_35del:p.11_12del,ENSG00000173991:ENST0000
0578283:exon1:c.33_35del:p.11_12del   N 0,00063 
TCAP 17_37821649_GAG_- 
ENSG00000173991:ENST00000309889:exon1:c.37_39del:p.13_13del,ENSG00000173991:ENST0000
0578283:exon1:c.37_39del:p.13_13del   P 0,00063 
TCAP 17_37822175_G_T 
ENSG00000173991:ENST00000309889:exon2:c.G317T:p.R106L,ENSG00000173991:ENST00000578






83:exon3:c.C265T:p.L89F   N 0,00091 
TCAP 17_37822211_C_T 
ENSG00000173991:ENST00000309889:exon2:c.C353T:p.A118V,ENSG00000173991:ENST00000578
283:exon3:c.C281T:p.A94V rs143233087 D 0,00090 
TGFB3 14_76429772_C_G 
ENSG00000119699:ENST00000238682:exon5:c.G813C:p.K271N,ENSG00000119699:ENST00000556
285:exon5:c.G813C:p.K271N rs147601018 D 0,00058 
TGFB3 14_76437523_C_T 
ENSG00000119699:ENST00000238682:exon3:c.G592A:p.E198K,ENSG00000119699:ENST00000556
285:exon3:c.G592A:p.E198K   N 0,00058 
TGFB3 14_76437535_G_A 
ENSG00000119699:ENST00000238682:exon3:c.C580T:p.R194W,ENSG00000119699:ENST00000556
285:exon3:c.C580T:p.R194W   S 0,00058 
TGFB3 14_76438059_C_T 
ENSG00000119699:ENST00000238682:exon2:c.G355A:p.E119K,ENSG00000119699:ENST00000556
285:exon2:c.G355A:p.E119K   N 0,00059 
TGFB3 14_76446944_G_A 
ENSG00000119699:ENST00000238682:exon1:c.C293T:p.S98L,ENSG00000119699:ENST0000055628
5:exon1:c.C293T:p.S98L rs142047577 D 0,00059 
TMEM43 3_14170982_G_A ENSG00000170876:ENST00000306077:exon2:c.G83A:p.R28Q   S 0,00058 
TMEM43 3_14170990_G_A ENSG00000170876:ENST00000306077:exon2:c.G91A:p.E31K   N 0,00058 
TMEM43 3_14172439_G_A ENSG00000170876:ENST00000306077:exon3:c.G280A:p.A94T   N 0,00088 
TMEM43 3_14175244_T_C ENSG00000170876:ENST00000306077:exon7:c.T518C:p.M173T   S 0,00093 
TMEM43 3_14176287_G_A ENSG00000170876:ENST00000306077:exon8:c.G601A:p.D201N rs138182276 D 0,00063 
TMEM43 3_14177355_A_T ENSG00000170876:ENST00000306077:exon10:c.A829T:p.T277S   N 0,00059 
TNNC1 3_52485431_T_C ENSG00000114854:ENST00000232975:exon5:c.A430G:p.N144D   N 0,00060 
TNNC1 3_52485805_C_T 
ENSG00000114854:ENST00000496590:exon3:c.G140A:p.G47E,ENSG00000114854:ENST000002329
75:exon4:c.G272A:p.G91E   S 0,00057 
TNNC1 3_52485879_G_A ENST00000232975:exon5:c.203-5C>T,ENST00000496590:exon4:c.71-5C>T rs142519988 L 0,00058 
TNNC1 3_52486194_C_T ENSG00000114854:ENST00000232975:exon3:c.G130A:p.V44M   S 0,00063 
TNNI3 19_55663243_G_C 
ENSG00000129991:ENST00000588882:exon5:c.C517G:p.L173V,ENSG00000129991:ENST00000344
887:exon8:c.C592G:p.L198V   P 0,00057 
TNNI3 19_55663249_C_T 
ENSG00000129991:ENST00000588882:exon5:c.G511A:p.D171N,ENSG00000129991:ENST00000344
887:exon8:c.G586A:p.D196N rs104894727 P 0,00115 
TNNI3 19_55663278_C_T 
ENSG00000129991:ENST00000588882:exon5:c.G482A:p.R161Q,ENSG00000129991:ENST00000344
887:exon8:c.G557A:p.R186Q   P 0,00057 
TNNI3 19_55665421_C_T 
ENSG00000129991:ENST00000588882:exon4:c.G451A:p.V151M,ENSG00000129991:ENST0000034






887:exon7:c.G511A:p.A171T rs121917761 P 0,00057 
TNNI3 19_55665462_C_T 
ENSG00000129991:ENST00000588882:exon4:c.G410A:p.R137Q,ENSG00000129991:ENST00000344
887:exon7:c.G485A:p.R162Q   P 0,00173 
TNNI3 19_55665463_G_A 
ENSG00000129991:ENST00000588882:exon4:c.C409T:p.R137W,ENSG00000129991:ENST00000344
887:exon7:c.C484T:p.R162W   P 0,00115 
TNNI3 19_55665477_G_A 
ENSG00000129991:ENST00000588882:exon4:c.C395T:p.A132V,ENSG00000129991:ENST00000344
887:exon7:c.C470T:p.A157V   P 0,00057 
TNNI3 19_55665514_G_A 
ENSG00000129991:ENST00000588882:exon4:c.C358T:p.R120W,ENSG00000129991:ENST00000344
887:exon7:c.C433T:p.R145W rs104894724 P 0,00229 
TNNI3 19_55665525_C_T 
ENSG00000129991:ENST00000588882:exon4:c.G347A:p.R116Q,ENSG00000129991:ENST00000344
887:exon7:c.G422A:p.R141Q   P 0,00057 
TNNI3 19_55667616_G_A 
ENSG00000129991:ENST00000588882:exon2:c.C160T:p.R54C,ENSG00000129991:ENST000003448
87:exon5:c.C235T:p.R79C rs3729712 D 0,00082 
TNNI3 19_55668007_T_A 
ENSG00000129991:ENST00000586858:exon1:c.A39T:p.K13N,ENSG00000129991:ENST0000058888
2:exon1:c.A39T:p.K13N,ENSG00000129991:ENST00000344887:exon4:c.A114T:p.K38N   S 0,00062 
TNNI3 19_55668029_G_T 
ENSG00000129991:ENST00000586858:exon1:c.C17A:p.S6Y,ENSG00000129991:ENST00000588882:








































































































































































A38V,ENSG00000118194:ENST00000458432:exon6:c.C119T:p.A40V rs200754249 P 0,00058 












5C>T,ENST00000422165:exon5:c.53-5C>T   L 0,00061 









































































61G:p.D254G,ENSG00000140416:ENST00000357980:exon9:c.A887G:p.D296G   S 0,00057 
TPM1 15_63354907_A_G ENSG00000140416:ENST00000560959:exon7:c.A727G:p.I243V   N 0,00057 
TPM1 15_63354938_CGCT_- ENSG00000140416:ENST00000560959:exon7:c.758_761del:p.253_254del   L 0,00114 
TPM1 15_63354943_C_T ENSG00000140416:ENST00000560959:exon7:c.C763T:p.L255F rs56054026 D 0,00114 
TPM1 15_63356281_A_G 
ENSG00000140416:ENST00000559281:exon8:c.A683G:p.K228R,ENSG00000140416:ENST00000288
398:exon9:c.A791G:p.K264R,ENSG00000140416:ENST00000403994:exon9:c.A791G:p.K264R   S 0,00057 
TPM1 15_63358166_A_G ENSG00000140416:ENST00000560445:exon3:c.A193G:p.I65V   N 0,00057 
VCL 10_75832551_G_A 
ENSG00000035403:ENST00000211998:exon5:c.G563A:p.R188Q,ENSG00000035403:ENST00000372
755:exon5:c.G563A:p.R188Q   N 0,00057 
VCL 10_75832578_C_T 
ENSG00000035403:ENST00000211998:exon5:c.C590T:p.T197I,ENSG00000035403:ENST000003727
55:exon5:c.C590T:p.T197I rs189242810 S 0,00057 
VCL 10_75834522_C_T 
ENSG00000035403:ENST00000211998:exon6:c.C644T:p.T215I,ENSG00000035403:ENST000003727
55:exon6:c.C644T:p.T215I   N 0,00057 
VCL 10_75849088_A_G 
ENSG00000035403:ENST00000436396:exon2:c.A173G:p.K58R,ENSG00000035403:ENST000002119
98:exon9:c.A1157G:p.K386R,ENSG00000035403:ENST00000372755:exon9:c.A1157G:p.K386R rs200342284 D 0,00115 
VCL 10_75849097_A_G 
ENSG00000035403:ENST00000436396:exon2:c.A182G:p.D61G,ENSG00000035403:ENST000002119
98:exon9:c.A1166G:p.D389G,ENSG00000035403:ENST00000372755:exon9:c.A1166G:p.D389G   N 0,00115 
VCL 10_75849776_T_C 
ENST00000211998:exon10:c.1177-5T>C,ENST00000372755:exon10:c.1177-
5T>C,ENST00000436396:exon3:c.193-5T>C   L 0,00057 
VCL 10_75849841_G_A 
ENSG00000035403:ENST00000436396:exon3:c.G253A:p.A85T,ENSG00000035403:ENST000002119






98:exon12:c.A1555C:p.I519L,ENSG00000035403:ENST00000372755:exon12:c.A1555C:p.I519L rs141033098 S 0,00173 
VCL 10_75855491_C_G 
ENSG00000035403:ENST00000436396:exon5:c.C637G:p.L213V,ENSG00000035403:ENST00000211
998:exon12:c.C1621G:p.L541V,ENSG00000035403:ENST00000372755:exon12:c.C1621G:p.L541V   N 0,00058 
VCL 10_75857050_T_C 
ENSG00000035403:ENST00000436396:exon6:c.T848C:p.V283A,ENSG00000035403:ENST00000211
998:exon13:c.T1832C:p.V611A,ENSG00000035403:ENST00000372755:exon13:c.T1832C:p.V611A   N 0,00057 
VCL 10_75857059_C_T 
ENSG00000035403:ENST00000436396:exon6:c.C857T:p.T286M,ENSG00000035403:ENST00000211
998:exon13:c.C1841T:p.T614M,ENSG00000035403:ENST00000372755:exon13:c.C1841T:p.T614M   S 0,00057 
VCL 10_75860740_A_G 
ENSG00000035403:ENST00000436396:exon7:c.A923G:p.H308R,ENSG00000035403:ENST00000211
998:exon14:c.A1907G:p.H636R,ENSG00000035403:ENST00000372755:exon14:c.A1907G:p.H636R rs71579374 D 0,00057 
VCL 10_75860750_G_T 
ENSG00000035403:ENST00000436396:exon7:c.G933T:p.K311N,ENSG00000035403:ENST00000211
998:exon14:c.G1917T:p.K639N,ENSG00000035403:ENST00000372755:exon14:c.G1917T:p.K639N   S 0,00057 
VCL 10_75860773_C_T 
ENSG00000035403:ENST00000436396:exon7:c.C956T:p.A319V,ENSG00000035403:ENST00000211
998:exon14:c.C1940T:p.A647V,ENSG00000035403:ENST00000372755:exon14:c.C1940T:p.A647V   N 0,00057 
VCL 10_75860806_T_C 
ENSG00000035403:ENST00000436396:exon7:c.T989C:p.V330A,ENSG00000035403:ENST00000211
998:exon14:c.T1973C:p.V658A,ENSG00000035403:ENST00000372755:exon14:c.T1973C:p.V658A   N 0,00172 
VCL 10_75871695_TAGGTG_- 
ENSG00000035403:ENST00000436396:exon12:c.1790_1795del:p.597_599del,ENSG00000035403:E
NST00000211998:exon19:c.2774_2779del:p.925_927del   N 0,00057 
VCL 10_75871722_C_T 
ENSG00000035403:ENST00000436396:exon12:c.C1817T:p.A606V,ENSG00000035403:ENST000002
11998:exon19:c.C2801T:p.A934V rs16931179 P 0,00057 
VCL 10_75871748_C_G 
ENSG00000035403:ENST00000436396:exon12:c.C1843G:p.P615A,ENSG00000035403:ENST000002
11998:exon19:c.C2827G:p.P943A rs71579375 P 0,00057 
VCL 10_75871782_TGT_- 
ENSG00000035403:ENST00000436396:exon12:c.1877_1879del:p.626_627del,ENSG00000035403:E




























































Supplementary table 2. List of candidate titin variants L : predicted loss-of-function variant; E: enriched variant; P: published in the literature as associated with 
hypertrophic cardiomyopathy. All the types of variants are defined in the Methods Section, chapter 3.3. 
 
Genomic signature Transcript / Amino acid change 
Type of 













p.P34061L,ENSG00000155657:ENST00000589042:exon360:c.C107105T:p.P35702L     






7T:p.E33886V,ENSG00000155657:ENST00000589042:exon360:c.A106580T:p.E35527V   rs55725279 
2_179394779_T_C NM_003319:c.A79244G:p.H26415R   






















_35172del     
2_179395930_T_C NM_003319:c.A78217G:p.M26073V   
 
2_179395936_G_A NM_003319:c.C19652T:p.T6551M   
 
2_179395959_G_A NM_003319:c.C78188T:p.A26063V   
 2_179396215_G_A NM_003319:c.C77932T:p.R25978C   
 2_179396479_A_C NM_003319:c.T77668G:p.C25890G   
 2_179396496_C_T NM_003319:c.G77651A:p.R25884H   
 




















A     
2_179397081_G_A NM_003319:c.G60895A:p.G20299S   












4642del     
2_179397654_A_G NM_003319:c.T76493C:p.V25498A   rs55945684 
2_179397706_G_A NM_003319:c.C76441T:p.R25481C   
 







T:p.R32814C,ENSG00000155657:ENST00000589042:exon358:c.C103363T:p.R34455C   rs72629785 
2_179398050_G_A NM_003319:c.C76097T:p.T25366M   
 2_179398186_C_T NM_003319:c.G75961A:p.V25321M   
 2_179398386_G_A NM_003319:c.C75761T:p.T25254I   
 







4251V   rs56173891 







W   rs140319117 
2_179399406_G_C NM_003319:c.A58496T:p.K19499I   
 




2_179399687_C_T NM_003319:c.G74460A:p.M24820I   
 
2_179400016_-_ATCTGAAGG NM_003319:c.74131_74132insCCTTCAGAT:p.P24711delinsPSDP   
 
2_179400027_-_CTGAAGGCT NM_003319:c.74120_74121insAGCCTTCAG:p.K24707delinsKPSE   
 
2_179400097_C_T NM_003319:c.G74050A:p.V24684M   








K   rs201857158 








K     
2_179401935_C_T NM_003319:c.G72706A:p.E24236K   rs72648278 
2_179402104_C_T NM_003319:c.G72635A:p.G24212E   
 







p.S31370T,ENSG00000155657:ENST00000589042:exon354:c.T99031A:p.S33011T   rs78814506 






















.P31240S,ENSG00000155657:ENST00000589042:exon352:c.C98641T:p.P32881S     
2_179404361_G_A NM_003319:c.C71236T:p.R23746C   
 



































2_179406044_C_T NM_003319:c.G70565A:p.R23522H   rs55704830 
2_179406131_C_T NM_003319:c.G70478A:p.R23493Q   
 
2_179406177_C_T NM_003319:c.G70432A:p.A23478T   
 
2_179406266_C_T NM_003319:c.G70343A:p.R23448H   
 2_179406993_A_G NM_003319:c.T70295C:p.I23432TTTN;TTN   rs55660660 
2_179407041_C_T NM_003319:c.G70247A:p.G23416E   
 

















T:p.R30726C,ENSG00000155657:ENST00000589042:exon348:c.C97099T:p.R32367C   rs202064385 
2_179407592_A_G NM_003319:c.T69794C:p.I23265T   
 







.L30598P,ENSG00000155657:ENST00000589042:exon347:c.T96716C:p.L32239P     















N     
2_179408731_G_A NM_003319:c.C68945T:p.T22982M   
 2_179408940_C_T NM_003319:c.G68821A:p.V22941M   rs191786700 
2_179408964_C_T NM_003319:c.G68797A:p.E22933K   
 





















51del   
 
2_179410548_G_T NM_003319:c.C68220A:p.F22740LTTN;TTN   
 
2_179410568_T_C NM_003319:c.A68200G:p.I22734V   
 
2_179410666_G_A NM_003319:c.G64570A:p.A21524T   






















C:p.E30003D,ENSG00000155657:ENST00000589042:exon342:c.A94932C:p.E31644D     













T:p.R29904C,ENSG00000155657:ENST00000589042:exon341:c.C94633T:p.R31545C   rs202187398 
2_179411602_A_G NM_003319:c.A3557T:p.D1186V   







29584T,ENSG00000155657:ENST00000589042:exon339:c.T93674C:p.I31225T     
2_179413138_C_T NM_003319:c.G66020A:p.R22007H   rs141817409 











29286K,ENSG00000155657:ENST00000589042:exon339:c.T92780A:p.I30927K   
 







1T:p.G29214V,ENSG00000155657:ENST00000589042:exon339:c.G92564T:p.G30855V   
 







C:p.V29154L,ENSG00000155657:ENST00000589042:exon339:c.G92383C:p.V30795L     
2_179414059_C_G NM_003319:c.G65099C:p.R21700T   
 







N   
 
2_179414800_C_T NM_003319:c.C20350A:p.P6784T   
 
2_179414955_A_T NM_003319:c.T64415A:p.I21472N   
 
























A:p.S28667R,ENSG00000155657:ENST00000589042:exon335:c.C90924A:p.S30308R     
















2A:p.A28598T,ENSG00000155657:ENST00000589042:exon335:c.G90715A:p.A30239T     
2_179417033_A_T NM_003319:c.T63399A:p.H21133Q   
 
2_179417043_T_C NM_003319:c.A63389G:p.K21130R   
 
2_179417091_C_T NM_133378:c.A16443G:p.I5481M   







p.V28426I,ENSG00000155657:ENST00000589042:exon335:c.G90199A:p.V30067I     










8A:p.G28373E,ENSG00000155657:ENST00000589042:exon335:c.G90041A:p.G30014E     
2_179417638_A_T NM_003319:c.T62794A:p.L20932M   
 
2_179417643_A_G NM_003319:c.T62789C:p.I20930T   
 
2_179417703_G_A NM_003319:c.C62729T:p.A20910V   rs117097948 







796M E rs72648237 







T:p.R27933C,ENSG00000155657:ENST00000589042:exon332:c.C88720T:p.R29574C   rs200513274 
2_179419366_T_C NM_003319:c.A61513G:p.I20505V   rs139506970 








D   rs72648235 

















4A:p.A27862T,ENSG00000155657:ENST00000589042:exon331:c.G88507A:p.A29503T   
 
2_179419792_G_A NM_003319:c.C61199T:p.S20400F   rs146181116 
2_179421596_T_C NM_003319:c.A61090G:p.I20364V   
 
2_179421791_C_T NM_003319:c.C77066T:p.A25689V   
 
2_179422112_G_A NM_003319:c.C60682T:p.R20228C   rs191482653 
2_179422181_C_T NM_003319:c.G60613A:p.V20205I   rs141624266 
2_179422286_C_A NA L rs201770959 
2_179422450_G_A NM_003319:c.C60436T:p.R20146C   
 
2_179422470_G_C NM_003319:c.C60416G:p.T20139R   rs72648228 
2_179422612_G_A NM_003319:c.A31229G:p.N10410S   
 
2_179422669_G_T NM_133378:c.G17911A:p.A5971T   rs72648227 







T:p.A27250S,ENSG00000155657:ENST00000589042:exon326:c.G86671T:p.A28891S     
2_179424363_A_T NM_003319:c.T59301A:p.S19767R   
 2_179424625_G_A NM_003319:c.C59039T:p.A19680V   
 
2_179425063_C_T NM_003319:c.G19060T:p.A6354S   
 























2A:p.R26681H,ENSG00000155657:ENST00000589042:exon326:c.G84965A:p.R28322H     
2_179425895_G_A NM_003319:c.C57769T:p.R19257C   
 
2_179425988_G_A NM_003319:c.C57676T:p.R19226C   rs192152102 
2_179426020_C_A NM_003319:c.G13480A:p.V4494I   
 






C:p.T26571P,ENSG00000155657:ENST00000589042:exon326:c.A84634C:p.T28212P     
2_179426596_C_T NM_133378:c.G17066C:p.G5689A   
 2_179426702_G_A NM_003319:c.C56962T:p.L18988F   







C:p.E26383D,ENSG00000155657:ENST00000589042:exon326:c.A84072C:p.E28024D     
2_179427119_T_C NM_003319:c.A56545G:p.T18849A   rs188370772 


















1A:p.G25984E,ENSG00000155657:ENST00000589042:exon326:c.G82874A:p.G27625E     













C:p.Y25921H,ENSG00000155657:ENST00000589042:exon326:c.T82684C:p.Y27562H     












G:p.P25720A,ENSG00000155657:ENST00000589042:exon326:c.C82081G:p.P27361A   rs56137800 
2_179428921_C_T NM_003319:c.G54743A:p.G18248E   
 
2_179429015_T_C NM_003319:c.A54649G:p.K18217E   
 
2_179429017_T_C NM_003319:c.A54647G:p.Y18216C   
 2_179429320_A_G NM_003319:c.T54344C:p.I18115T   rs182126530 
2_179429356_C_T NM_003319:c.G54308A:p.R18103H   
 





2_179429577_A_C NM_003319:c.T54087G:p.H18029Q   
 







3T:p.K25371N,ENSG00000155657:ENST00000589042:exon326:c.G81036T:p.K27012N     







5T:p.T25312M,ENSG00000155657:ENST00000589042:exon326:c.C80858T:p.T26953M   
 













2A:p.G25168S,ENSG00000155657:ENST00000589042:exon326:c.G80425A:p.G26809S     
















2_179430976_C_T NM_003319:c.G52688A:p.R17563Q   
 


















T:p.A24697S,ENSG00000155657:ENST00000589042:exon326:c.G79012T:p.A26338S     
2_179431871_T_C NM_003319:c.A51793G:p.S17265G   
 






8A:p.R24493H,ENSG00000155657:ENST00000589042:exon326:c.G78401A:p.R26134H     







p.V24381I,ENSG00000155657:ENST00000589042:exon326:c.G78064A:p.V26022I     
2_179433557_G_T NM_003319:c.C50107A:p.L16703I   
 2_179433672_T_A NM_003319:c.A49992T:p.K16664N   

















A:p.T23939K,ENSG00000155657:ENST00000589042:exon326:c.C76739A:p.T25580K   rs56372592 












p.I23800V,ENSG00000155657:ENST00000589042:exon326:c.A76321G:p.I25441V     
2_179434840_A_T NM_003319:c.T48824A:p.V16275D   
 
2_179435114_G_A NM_003319:c.C48550T:p.R16184C   
 
2_179435332_C_T NM_003319:c.G48332A:p.R16111H   
 
2_179435401_G_A NM_003319:c.C48263T:p.S16088L   








W     
2_179435894_C_T NM_003319:c.G47770A:p.V15924M   
 










.P23323L,ENSG00000155657:ENST00000589042:exon326:c.C74891T:p.P24964L   rs72646899 








68del   
 















2C:p.E22968Q,ENSG00000155657:ENST00000589042:exon326:c.G73825C:p.E24609Q   rs55762754 







5G:p.T22749A,ENSG00000155657:ENST00000589042:exon326:c.A73168G:p.T24390A   rs182491843 
2_179437868_G_A NM_003319:c.C45796T:p.R15266C   
 
2_179437928_T_C NM_003319:c.A45736G:p.T15246A   rs56201325 











D   rs187868672 
2_179438252_A_G NM_003319:c.T45412C:p.Y15138H   
 2_179438557_G_T NM_003319:c.C45107A:p.T15036N   rs192962624 
2_179438710_T_C NM_003319:c.A44954G:p.E14985G   
 
2_179438713_A_G NM_003319:c.T44951C:p.L14984P   rs56399205 







8A:p.A22360T,ENSG00000155657:ENST00000589042:exon326:c.G72001A:p.A24001T   rs180828370 
2_179439151_G_C NM_003319:c.G38281A:p.E12761K   
 





























02W   
 







T:p.A21970V,ENSG00000155657:ENST00000589042:exon326:c.C70832T:p.A23611V   rs72646891 
2_179440028_C_T NM_003319:c.G43636A:p.A14546T   













1G:p.I21647M,ENSG00000155657:ENST00000589042:exon326:c.A69864G:p.I23288M     











5A:p.R21472Q,ENSG00000155657:ENST00000589042:exon324:c.G69338A:p.R23113Q   
 
2_179441932_G_A NM_003319:c.C41935T:p.P13979S   rs55980498 
2_179442329_C_T NM_003319:c.G41629A:p.E13877KTTN;TTN   
 




2_179442825_G_A NM_003319:c.C41222T:p.T13741I   
 
2_179443533_C_T NM_003319:c.G41029A:p.D13677NTTN;TTN   
 







0A:p.M20860I,ENSG00000155657:ENST00000589042:exon319:c.G67503A:p.M22501I   
 








W   
 
2_179444915_A_G NM_003319:c.T39904C:p.S13302P   rs72646873 
2_179446322_C_T NM_003319:c.G39478A:p.D13160N   rs72646870 
2_179446418_C_T NM_003319:c.G39382A:p.V13128I   
 2_179446770_G_A NM_003319:c.C39131T:p.P13044L   
 2_179446813_G_A NM_003319:c.C39088T:p.R13030W   
 













20347T,ENSG00000155657:ENST00000589042:exon314:c.T65963C:p.I21988T   
 
2_179447261_C_T NM_003319:c.G38727A:p.M12909I   
 










.P20250L,ENSG00000155657:ENST00000589042:exon313:c.C65672T:p.P21891L     
2_179447940_C_G NM_003319:c.G38395C:p.D12799H   
 
2_179448375_G_A NM_003319:c.C38339T:p.P12780L   
 







20179I,ENSG00000155657:ENST00000589042:exon312:c.C65459T:p.T21820I   rs56130023 













F20091L,ENSG00000155657:ENST00000589042:exon311:c.T65194C:p.F21732L   
 
2_179449231_G_T NM_003319:c.C37852A:p.P12618T   
 2_179449452_C_T NM_003319:c.G37721A:p.R12574Q   
 2_179449606_C_T NM_003319:c.G37567A:p.G12523R   rs181717727 
2_179451454_G_A NM_003319:c.C36979T:p.R12327C   rs72646859 
2_179452021_C_T NM_003319:c.G36722A:p.R12241H   
 










3A:p.R19568Q,ENSG00000155657:ENST00000589042:exon306:c.G63626A:p.R21209Q   rs148684589 
2_179452447_T_C NM_003319:c.A36394G:p.I12132V   rs72646855 














W   rs200726948 
2_179452853_G_C NM_003319:c.C36086G:p.A12029G   
 2_179453771_C_A NM_003319:c.G35486T:p.C11829F   
 
2_179453841_G_C NM_003319:c.C35416G:p.L11806V   
 
2_179453997_T_C NM_003319:c.A35260G:p.K11754E   
 






4A:p.L19132M,ENSG00000155657:ENST00000589042:exon304:c.C62317A:p.L20773M     
2_179454263_A_G NM_003319:c.T34994C:p.V11665A   
 2_179454383_C_T NM_003319:c.G34874A:p.R11625Q   










18829T,ENSG00000155657:ENST00000589042:exon304:c.T61409C:p.I20470T   rs202012910 
2_179455133_C_T NM_003319:c.G34124A:p.G11375E   
 






9A:p.R18670Q,ENSG00000155657:ENST00000589042:exon304:c.G60932A:p.R20311Q     
2_179455631_G_A NM_003319:c.C33626T:p.P11209L E rs72646845 







.P18425L,ENSG00000155657:ENST00000589042:exon303:c.C60197T:p.P20066L     
2_179456491_C_T NM_003319:c.G32860A:p.E10954K   







T:p.R18318C,ENSG00000155657:ENST00000589042:exon302:c.C59875T:p.R19959C     







.P18131L,ENSG00000155657:ENST00000589042:exon300:c.C59315T:p.P19772L   rs72646840 










5A:p.R17912Q,ENSG00000155657:ENST00000589042:exon298:c.G58658A:p.R19553Q     







p.V17835I,ENSG00000155657:ENST00000589042:exon297:c.G58426A:p.V19476I   
 
2_179458696_T_C NM_133378:c.A17270G:p.K5757R   
 

























G:p.V17643G,ENSG00000155657:ENST00000589042:exon296:c.T57851G:p.V19284G   
 










L17635F,ENSG00000155657:ENST00000589042:exon295:c.C57826T:p.L19276F     













p.Y17578F,ENSG00000155657:ENST00000589042:exon295:c.A57656T:p.Y19219F   rs201541213 
2_179460488_T_C NM_003319:c.A30398G:p.N10133S   
 







17440T,ENSG00000155657:ENST00000589042:exon293:c.T57242C:p.I19081T   rs78509062 
2_179462685_A_G NM_003319:c.T30017C:p.I10006T   
 








71M     
2_179465706_A_T NM_003319:c.T28730A:p.L9577Q   rs140714512 
2_179465721_C_T NM_003319:c.G28715A:p.R9572H   
 
















6811P,ENSG00000155657:ENST00000589042:exon286:c.T55354C:p.S18452P     
2_179467275_G_A NM_003319:c.C27659T:p.T9220M   
 
2_179468618_C_A NM_003319:c.G27601T:p.A9201S   
 
2_179469013_T_C NM_003319:c.A27206G:p.N9069S   
 
2_179469756_G_A NM_003319:c.C26953T:p.R8985C   rs55734111 
2_179469764_G_A NM_003319:c.C26945T:p.A8982V   
 2_179469960_C_T NM_003319:c.G26749A:p.E8917K   







p.R16327H,ENSG00000155657:ENST00000589042:exon280:c.G53903A:p.R17968H   rs200100660 







113L,ENSG00000155657:ENST00000589042:exon277:c.T53260C:p.F17754L   
 










2_179472662_G_A NM_003319:c.G11659A:p.V3887M   
 




















p.R15700Q,ENSG00000155657:ENST00000589042:exon273:c.G52022A:p.R17341Q     







p.R15655H,ENSG00000155657:ENST00000589042:exon273:c.G51887A:p.R17296H   rs200456782 














.A15568T,ENSG00000155657:ENST00000589042:exon272:c.G51625A:p.A17209T     











5309E,ENSG00000155657:ENST00000589042:exon269:c.C50850A:p.D16950E   rs200700386 
2_179476342_C_G NM_003319:c.G23419C:p.A7807P   
 
2_179476619_C_T NM_003319:c.G23222A:p.G7741E   
 







,ENSG00000155657:ENST00000589042:exon268:c.T50363C:p.I16788T   
 2_179477040_C_T NM_003319:c.G23017A:p.E7673K   rs148018042 







5015S,ENSG00000155657:ENST00000589042:exon266:c.C49966A:p.R16656S     
2_179477529_C_G NM_003319:c.G12770A:p.G4257D   rs55663050 
2_179477577_C_T NM_003319:c.C60274T:p.L20092F   
 







4814A,ENSG00000155657:ENST00000589042:exon263:c.A49363G:p.T16455A     






















2S,ENSG00000155657:ENST00000589042:exon260:c.C48727T:p.P16243S   rs72677242 






14477G,ENSG00000155657:ENST00000589042:exon258:c.A48353G:p.D16118G     
2_179481223_G_A NM_003319:c.C21100T:p.R7034W   
 
2_179481467_A_C NM_003319:c.T20954G:p.V6985G   
 







4343L,ENSG00000155657:ENST00000589042:exon256:c.G47950C:p.V15984L   
 
2_179482089_C_T NM_003319:c.G62191A:p.V20731M   rs72677237 
2_179482533_G_T NM_133379:c.G14492A:p.C4831Y   










4131Q,ENSG00000155657:ENST00000589042:exon253:c.G47315A:p.R15772Q   rs72677233 












52I,ENSG00000155657:ENST00000589042:exon252:c.G47077A:p.V15693I   rs201717871 
2_179483349_T_C NM_003319:c.A19733G:p.H6578R   
 
2_179483375_C_A NM_003319:c.G19707T:p.R6569S   
 
2_179483384_G_C NM_003319:c.C19698G:p.D6566E   
 








00000155657:ENST00000589042:exon250:c.46666_46668del:p.15556_15556del     
2_179484555_C_A NM_003319:c.G19294T:p.V6432F   
 







3822R,ENSG00000155657:ENST00000589042:exon249:c.G46387A:p.G15463R   rs200042932 










3767T,ENSG00000155657:ENST00000589042:exon248:c.G46222A:p.A15408T     
2_179485196_A_C NM_003319:c.T18857G:p.V6286G   
 
2_179485268_C_T NM_003319:c.G18785A:p.R6262H   
 
2_179485304_T_C NM_003319:c.A18749G:p.E6250G   
 
2_179485589_T_A NM_003319:c.A18553T:p.S6185C   
 2_179485846_G_C NM_003319:c.C18404G:p.A6135G   
 2_179486037_C_A NM_003319:c.G18213T:p.K6071N   rs72677225 






3343R,ENSG00000155657:ENST00000589042:exon244:c.G44950C:p.G14984R     






3052H,ENSG00000155657:ENST00000589042:exon238:c.G44078A:p.R14693H     
2_179495936_ATCTGC_- NM_003319:c.16639_16644del:p.5547_5548del   
 
2_179497042_C_T NM_003319:c.G16384A:p.V5462I   
 
2_179497134_C_T NM_003319:c.G16292A:p.R5431Q   
 2_179497457_T_C NM_003319:c.A16081G:p.K5361E   


















2378H,ENSG00000155657:ENST00000589042:exon229:c.G42056A:p.R14019H   
 







2296V,ENSG00000155657:ENST00000589042:exon227:c.C41810T:p.A13937V   
 













2124E,ENSG00000155657:ENST00000589042:exon225:c.A41293G:p.K13765E     
2_179501481_T_C NM_003319:c.A13778G:p.K4593R   rs184713215 


















5657:ENST00000589042:exon219:c.G40498T:p.V13500F   rs201944202 
2_179511286_T_C 
ENSG00000155657:ENST00000446966:exon10:c.A740G:p.E247G,ENSG00000155657:E
NST00000589042:exon216:c.A40223G:p.E13408G   rs183950862 
2_179514582_A_G NM_133378:c.T32555C:p.V10852A   
 
2_179515498_G_A NM_133378:c.C32387T:p.A10796V   
 





00589042:exon202:c.C39085A:p.P13029T   
 
2_179517425_C_T ENSG00000155657:ENST00000589042:exon201:c.G38998A:p.V13000M     
2_179518992_G_A ENSG00000155657:ENST00000589042:exon193:c.C38323T:p.L12775F   rs186232617 
2_179518994_A_G ENSG00000155657:ENST00000589042:exon193:c.T38321C:p.V12774A     
2_179527707_G_A 
ENSG00000155657:ENST00000342992:exon153:c.C31559T:p.A10520V,ENSG0000015
5657:ENST00000589042:exon174:c.C36776T:p.A12259V   
 2_179527775_T_A NM_133378:c.A31491T:p.E10497D   rs1883088 
2_179528017_T_C ENSG00000155657:ENST00000589042:exon173:c.A36676G:p.K12226E   rs200815663 
2_179528377_T_A ENSG00000155657:ENST00000589042:exon171:c.A36509T:p.E12170V   rs200840285 
2_179528759_T_C ENSG00000155657:ENST00000589042:exon169:c.A36347G:p.E12116G   rs200513156 
2_179528793_T_C ENSG00000155657:ENST00000589042:exon169:c.A36313G:p.K12105E   




00589042:exon156:c.A35264C:p.K11755T   rs189966800 
2_179537200_C_T NM_133378:c.G30961A:p.V10321I   
 2_179537434_T_C NM_133378:exon149:c.30884-4A>G L 
 





2_179538378_C_G NM_133378:c.G30865C:p.E10289Q   
 
2_179538425_A_G NM_133378:c.T30818C:p.I10273T   
 
2_179539812_T_G NM_133378:c.A30663C:p.E10221D   
 
2_179540461_G_T ENSG00000155657:ENST00000589042:exon149:c.C34474A:p.P11492T   rs182428755 










el   
 
2_179542397_TTC_- NM_133378:c.30508_30510del:p.10170_10170del   
 
2_179542423_G_T NM_133378:c.C30484A:p.P10162T   
 
2_179544077_G_A NM_133378:c.C29999T:p.P10000L   
 2_179544685_-_CCT NM_133378:c.29784_29785insAGG:p.E9928delinsEG   
 2_179544689_-_ATT NM_133378:c.29780_29781insAAT:p.E9927delinsEX L 
 2_179544700_-_TCT NM_133378:c.29769_29770insAGA:p.V9923delinsVE   
 




0589042:exon138:c.G33305A:p.R11102H     

















2_179548809_A_T NM_133378:c.T28991A:p.V9664ETTN;TTN   
 








589042:exon131:c.C32557T:p.P10853S   rs201738153 
2_179549707_G_A NM_133378:c.C28748T:p.A9583V   rs72650030 




89042:exon126:c.T32158C:p.F10720L     






.C31837G:p.P10613A   rs200213832 

















31645G:p.I10549V     









G31399A:p.V10467I   rs72650019 
2_179560717_T_C NM_133378:c.A27350G:p.E9117G   






30742G:p.T10248A     
2_179563611_T_C NM_133378:c.A26981G:p.K8994R   
 
2_179566792_T_A NM_133378:c.A26781T:p.E8927DTTN;TTN   
 













589042:exon103:c.G29457T:p.E9819D   
 
2_179571284_C_T NM_133378:c.G25585A:p.A8529T   
 
2_179571370_C_T NM_133378:c.G25499A:p.R8500H P 
 
2_179571661_C_G NM_133378:c.G25330C:p.A8444P   
 2_179571683_T_G NM_133378:exon99:c.25310-2A>C L rs6716782 
2_179572324_G_A NM_133378:c.C25238T:p.S8413L   
 
2_179574313_G_A NM_133378:c.C25001T:p.T8334M   rs184923756 





9042:exon96:c.T27676C:p.C9226R     







42:exon95:c.T27368C:p.I9123T     





















9042:exon92:c.C26528T:p.T8843M   rs72648990 




042:exon92:c.C26485T:p.P8829S     






















2_179581897_C_T NM_133378:c.G21832A:p.D7278N   
 





9042:exon86:c.C25046G:p.A8349G     




9042:exon86:c.G24964T:p.V8322L   rs201571580 




9042:exon85:c.A24681G:p.I8227M     
2_179583960_C_T NM_133378:c.G20425A:p.G6809S   
 





9042:exon82:c.A23917G:p.T7973A     





89042:exon81:c.G23617A:p.D7873N     
2_179584831_G_C NM_003319:c.G37594A:p.V12532M   
 
2_179585187_C_T NM_133378:c.G19570A:p.D6524N   rs72648973 








9042:exon78:c.G22667A:p.R7556H     







9042:exon75:c.G21800A:p.G7267D   
 2_179587955_G_T NM_133378:c.C18047A:p.S6016Y   rs187925021 
2_179588184_C_T NM_003319:c.C60217A:p.P20073T   
 
2_179588279_C_T NM_133378:c.G17816A:p.C5939Y   rs189951108 
2_179588622_C_T NM_133378:c.G17632A:p.A5878T   
 
2_179589100_T_C NM_003319:c.G31441C:p.E10481Q   
 2_179589103_T_C NM_133378:c.A17267G:p.N5756S   
 2_179590133_C_G NM_003319:c.A5126G:p.N1709S   
 
2_179590695_G_A NM_133378:c.C16622T:p.S5541L   
 




042:exon70:c.A20335T:p.S6779C   rs149470241 





042:exon70:c.A20293T:p.S6765C     



























9042:exon67:c.A19547T:p.K6516M   rs199796249 
2_179593110_G_T NM_133378:c.C15709A:p.P5237T   
 
2_179593503_G_T NM_133378:c.C15418A:p.P5140T   rs72648953 
2_179593702_C_A NM_133378:c.G15331T:p.D5111Y   rs188878341 





042:exon65:c.A18961G:p.I6321V   rs145204073 





9042:exon64:c.C18776G:p.T6259S   rs72648949 
2_179594164_C_T NM_133378:c.G14987A:p.R4996Q   
 
2_179594220_T_G NM_133378:c.A14931C:p.E4977D   




9042:exon63:c.A18325G:p.K6109E   rs73973139 





042:exon60:c.G17500A:p.V5834I     
2_179596269_G_A NM_133378:c.C13492T:p.L4498F   rs72648943 









042:exon58:c.C16934T:p.P5645L     














9042:exon53:c.A15584G:p.E5195G   rs72648931 
2_179598553_T_G NM_133378:c.A11831C:p.Q3944P   rs72648930 














042:exon51:c.G15178A:p.V5060I   rs72648929 
2_179599565_C_T NM_133378:c.G11354A:p.R3785Q   
 2_179599697_T_G NM_133378:c.A11222C:p.K3741T   
 
2_179600303_G_A NM_133378:c.C11138T:p.T3713I   
 




42:exon50:c.T14813C:p.F4938S     





9042:exon50:c.G14698A:p.A4900T   rs72648923 

















NSG00000155657:ENST00000589042:exon49:c.C14179T:p.P4727S     







C   rs34706803 
2_179603991_T_G NM_003319:c.A12880C:p.N4294H   
 
2_179604063_T_C NM_003319:c.A12808G:p.K4270E   
 
2_179604101_C_T NM_003319:c.G22724C:p.S7575T   rs55857742 























2_179605139_C_T NM_003319:c.G11732A:p.S3911N   
 


















S   rs199844346 






10885A:p.P3629T,ENSG00000155657:ENST00000589042:exon48:c.C11836A:p.P3946T     
2_179610391_C_G NM_133379:c.G16736C:p.S5579T   
 
2_179610514_C_T ENSG00000155657:ENST00000360870:exon46:c.G16613A:p.R5538H   rs145932311 
2_179610658_A_G NM_133379:c.T16469C:p.L5490S   
 2_179610806_G_A NM_133379:c.C16321T:p.R5441X L 
 2_179610967_C_T NM_133379:c.G16160A:p.C5387Y   rs72648913 
2_179610985_C_T NM_133379:c.G16142A:p.R5381H   
 
2_179611046_AATCCATATTTG_- NM_133379:c.16070_16081del:p.5357_5361del   
 
2_179611126_G_A NM_133379:c.C16001T:p.P5334L   rs151253841 
2_179611340_C_T NM_133379:c.G15787A:p.E5263K   
 2_179611825_T_C NM_133379:c.A15302G:p.E5101G   rs142973956 





2_179612313_C_T NM_133379:c.G14814A:p.M4938I   
 
2_179612315_T_C NM_133379:c.A14812G:p.M4938V   rs145581345 
2_179612321_T_A NM_133379:c.A14806T:p.T4936S   rs72648909 
2_179612414_G_C NM_133379:c.C14713G:p.L4905V   
 2_179612521_G_T ENSG00000155657:ENST00000360870:exon46:c.C14606A:p.A4869D     
2_179612635_C_T NM_003319:c.T63631G:p.C21211G   
 
2_179612678_G_A ENSG00000155657:ENST00000360870:exon46:c.C14449T:p.Q4817X L   
2_179613049_A_G NM_133379:c.T14078C:p.I4693T   rs139486133 
2_179613264_C_T ENSG00000155657:ENST00000360870:exon46:c.G13863A:p.M4621I   rs77419653 
2_179613268_T_G NM_133379:c.A13859C:p.Q4620P   rs139172299 
2_179613376_T_C ENSG00000155657:ENST00000360870:exon46:c.A13751G:p.K4584R     
2_179613494_C_T ENSG00000155657:ENST00000360870:exon46:c.G13633A:p.A4545T   rs147884688 
2_179613541_G_C NM_133379:c.C13586G:p.A4529G   rs138927584 
2_179613763_T_C NM_133379:c.A13364G:p.K4455R   rs142304137 
2_179613780_T_C NM_133379:c.A13347G:p.I4449M   rs144539321 
2_179614099_G_T NM_133379:c.C13028A:p.T4343N   
 2_179614148_T_C NM_133379:c.A12979G:p.I4327V   rs144226338 
2_179614901_C_T NM_133379:c.G12226A:p.E4076K   rs144690298 
2_179615024_C_T NM_133379:c.G12103A:p.A4035T   
 
2_179615318_T_G ENSG00000155657:ENST00000360870:exon46:c.A11809C:p.K3937Q     
2_179615844_C_G ENSG00000155657:ENST00000360870:exon46:c.G11283C:p.K3761N   rs200816462 
2_179616052_C_G ENSG00000155657:ENST00000360870:exon46:c.G11075C:p.S3692T   rs147314430 
2_179616073_C_A ENSG00000155657:ENST00000360870:exon46:c.G11054T:p.G3685V   
 2_179616248_C_T NM_133379:c.G10879A:p.G3627R   
 
2_179616296_T_C NM_133379:c.A10831G:p.K3611E   
 
2_179616345_T_- ENSG00000155657:ENST00000360870:exon46:c.10782delA:p.S3594fs L   





2_179616481_C_T NM_133379:c.G10646A:p.R3549H   rs148115514 
2_179616490_G_A ENSG00000155657:ENST00000360870:exon46:c.C10637T:p.T3546I     
2_179616716_C_T NM_133379:c.G10411A:p.A3471T   rs149878929 




57:ENST00000589042:exon45:c.C10507A:p.Q3503K     
2_179622508_T_A 
ENSG00000155657:ENST00000359218:exon44:c.A10301T:p.E3434V,ENSG000001556
57:ENST00000589042:exon45:c.A10439T:p.E3480V     
2_179622577_T_C NM_133432:c.A10232G:p.K3411R   
 














7:ENST00000591111:exon43:c.G10088A:p.R3363H   rs148169214 
2_179629385_T_C NM_003319:c.A9719G:p.K3240R   
 

























NST00000591111:exon40:c.G9338A:p.R3113H   rs141258018 
2_179634955_C_G NM_003319:c.G8335C:p.V2779L   








NST00000591111:exon34:c.A7871G:p.K2624R   
 
2_179637933_T_C NM_003319:c.A7620G:p.I2540M   
 
2_179638249_C_T NM_003319:c.G7396A:p.E2466K   rs116049561 
2_179638672_T_C NM_003319:c.G73852A:p.E24618K   
 2_179638750_T_C NM_003319:c.A7007G:p.E2336G   
 
2_179639020_G_A NM_003319:c.C6833T:p.T2278M   
 
2_179639042_G_A NM_003319:c.C6811T:p.R2271C   
 
2_179640101_C_T NM_003319:c.G6352A:p.A2118T   rs56285559 








NST00000591111:exon28:c.A6195C:p.K2065N     
2_179640598_C_A NM_003319:c.G5855T:p.R1952L   
 
2_179640716_A_T NM_003319:c.T5737A:p.F1913I   
 


















0000591111:exon28:c.G5418T:p.L1806F     
2_179641226_A_C NM_003319:c.G57644T:p.G19215V   
 
2_179641327_T_C NM_003319:c.G57068A:p.S19023N   
 
2_179641518_T_A NM_003319:c.A4935T:p.E1645D   
 
2_179641646_C_T NM_003319:c.G4807A:p.V1603I   rs138931943 







00591111:exon26:c.C4619T:p.S1540L     
2_179642260_C_T NM_003319:c.G4394A:p.G1465D   
 
2_179642515_A_G NM_003319:c.T4258C:p.F1420L   









591111:exon25:c.4276_4290del:p.1426_1430del     





2_179643601_C_G NM_003319:c.G4070C:p.R1357TTTN;TTN   
 







0000591111:exon24:c.T4160C:p.L1387P   rs115303497 
2_179643761_G_A NM_003319:c.C3910T:p.R1304C   
 








T00000591111:exon22:c.C3668T:p.A1223V   rs78269740 
2_179644851_A_G NM_003319:c.T3467C:p.V1156A   rs150667217 
2_179645857_G_T NM_003319:c.C3376A:p.L1126I   
 
2_179645962_C_G NM_003319:c.G3271C:p.G1091R   rs72647870 















NST00000591111:exon20:c.G3241A:p.A1081T   rs55914517 
2_179647533_C_T NM_003319:c.A64406T:p.D21469V   
 





2_179648807_C_T NM_003319:c.G2627A:p.R876H   rs56046320 















91111:exon16:c.G2731A:p.V911I   rs141961878 
2_179648886_C_A NM_003319:c.G2548T:p.V850F   
 
2_179648967_T_A NM_003319:c.A2467T:p.T823S   
 2_179650635_C_A NM_003319:c.G2172T:p.Q724H   























































n6:c.C835T:p.R279W   rs138060032 












4:c.A535G:p.T179A     
 
 

















































Supplementary table 3. List of candidate variants for family 1. In silico prediction of pathogenicity as descibed in the Methods Section, chapter 3.2. 
 
Chromosome Genomic position Gene name Type of variant Amino acid change In silico prediction of pathogenicity 
1 179095724 ABL2 missense S159G Damaging 
2 21266783 APOB missense L4198P Damaging 
17 1933455 DPH1 missense R417W Damaging 
1 157667701 FCRL3 missense I103V Damaging 
6 26234977 HIST1H2APS3 missense A62E 
 6 160390393 IGF2R missense Q39E 
 
6 52130931 MCM3 missense K724E Tolerated 
1 1563501 MIB2 missense A706T Tolerated 
17 36873726 MLLT6 missense G565R Damaging 
13 33110187 N4BP2L2 missense W326C Damaging 
17 45699167 NPEPPS missense E877K Damaging 
4 129793236 PHF17 missense R783Q Tolerated 
17 4714242 PLD2 missense R336G Tolerated 
1 204199701 PLEKHA6 missense S808T Damaging 
2 209308218 PTH2R missense P219S   
5 53815614 SNX18 missense E611A   
2 179600301 TTN-AS1 missense T3713I   
3 151545773 AADAC missense I338T Damaging 
2 37428927 CEBPZ in-frame 1048delK   
1 26510311 CNKSR1 frameshift P284fs   
6 151627014 AKAP12 in-frame 99delE   
18 9258690 ANKRD12 missense T1809A Tolerated 
17 42988667 GFAP frameshift L346fs   
6 26234977 HIST1H1D missense A62E Damaging 




8 41790762 KAT6A in-frame 
1652_1659delPPPPPQQ
P   
7 138665900 KIAA1549 missense R39H Tolerated 
5 56177849 MAP3K1 in-frame 942_943insT   
15 31775991 OTUD7A missense P763S Tolerated 
3 126733201 PLXNA1 missense D863N Damaging 
3 157823589 SHOX2 in-frame 75_76insGGG   
22 38121208 TRIOBP missense S882Y Damaging 
8 37555624 ZNF703 frameshift H402fs   
























Supplementary table 4. List of candidate variants for family 2. In silico prediction of pathogenicity as descibed in the Methods Section, chapter 3.2. 
 
Chromosome Genomic position Gene name Type of variant Amino acid change In silico prediction of pathogenicity 
5 125930883 ALDH7A1 missense R3H Damaging 
2 29420448 ALK missense G1345R   
1 3390007 ARHGEF16 missense P409L Damaging 
15 73009153 BBS4 missense V123I Tolerated 
7 34118681 BMPER missense S431G Tolerated 
19 13318208 CACNA1A missense H2480Q Tolerated 
19 13409923 CACNA1A missense E842K Tolerated 
2 109421373 CCDC138 missense T255I Damaging 
1 180062301 CEP350 missense K2354R Tolerated 
6 39851777 DAAM2 missense M629V Tolerated 
3 52430697 DNAH1 missense H3832N   
17 62122829 ERN1 missense R848T   
19 8137051 FBN3 missense G2657R   
6 89891741 GABRR1 missense R278C Damaging 
15 101567966 LRRK1 missense D884N Tolerated 
15 101602891 LRRK1 missense K1637R Tolerated 
3 47912584 MAP4 missense R588C Damaging 
3 195510085 MUC4 missense S2789I   
11 73914789 PPME1 missense D40N Damaging 
1 156756827 PRCC missense D315V Tolerated 
6 7231679 RREB1 missense T1116I Tolerated 
2 65571917 SPRED2 missense M47K Tolerated 
2 179447849 TTN-AS1 missense T19326R   
11 124012430 VWA5A missense K669E Tolerated 
12 7045892 ATN1 in-frame 494_495insQQQ   
2 201683051 BZW1 missense G256R Tolerated 
17 5389469 DERL2; MIS12 missense S5G Tolerated 
16 12009531 GSPT1 in-frame 16_17insG   
12 108956408 ISCU missense A4P Tolerated 




1 156641755 NES missense K742T Tolerated 
1 228559007 OBSCN missense T7800I Tolerated 
20 1895825 SIRPA missense R54C Damaging 
15 90144561 TICRR missense M729T Damaging 
2 179647666 TTN missense F943L   
11 46726193 ZNF408 missense Q307E Damaging 
3 52430697 DNAH1 missense R3832S   
1 156707446 MRPL24 missense T169M Tolerated 
1 114523963 OLFML3 missense P265S Tolerated 


























Supplementary table 5. List of candidate variants for family 3. In silico prediction of pathogenicity as descibed in the Methods Section, chapter 3.2. 
 
Chromosome Genomic position  Gene name Type of variant Amino acid change In silico prediction of pathogenicity 
4 657634 PDE6B missense A666T Damaging 
16 1129292 SSTR5-AS1 missense V142M Damaging 
12 1192430 ERC1 missense P257L Tolerated 
7 1510287 INTS1 missense M2167L Tolerated 
6 7727612 BMP6 missense A142T 
 20 8639220 PLCB1  missense Q244R Tolerated 
12 9227259 A2M missense T1218M 
 19 15278138 NOTCH3 missense V1762M 
 19 18879577 CRTC1 missense P448S Tolerated 
13 25671834 PABPC3 missense V500M 
 8 28574330 EXTL3 missense R252W 
 2 32445307 SLC30A6 missense R344Q Damaging 
20 35060823 DLGAP4 missense E235Q Tolerated 
22 43026923 CYB5R3 missense D133N Damaging 
15 43815184 MAP1A missense P743S 
 11 46388005 DGKZ missense A67P 
 3 47125674 SETD2 missense T1866A 
 3 47787459 SMARCC1 missense A114T 
 17 48602268 MYCBPAP missense V599I Tolerated 
3 48610326 COL7A1 missense K2267R 
 2 48698319 PPP1R21 missense T331S Tolerated 
15 48755314 FBN1 missense N1730T 
 12 56333949 DGKA missense I265V Tolerated 
10 64952781 JMJD1C missense N1998T Tolerated 
17 67302933 ABCA5 missense V241I Tolerated 
16 69748946 NQO1 missense L113P Damaging 
17 73969720 ACOX1 missense T139M Damaging 
2 101096985 NMS missense T122P 
 3 119256163 CD80 missense S174F Tolerated 




2 152520109 NEB missense A1906T Tolerated 
2 153003680 STAM2 missense S148C 
 7 158902557 VIPR2 missense E69K Tolerated 
5 171766091 SH3PXD2B missense A673V 
 2 179395623 TTN-AS1 missense R32672Q 
 2 179469980 TTN-AS1 missense T15407S 
 3 183469964 YEATS2 missense T358S Tolerated 
4 184615778 TRAPPC11 missense R844C Damaging 
4 186533089 SORBS2 missense E977Q Damaging 
2 215593705 BARD1 missense F677L Damaging 
1 228559348 OBSCN missense A7669T Tolerated 
1 229477857 CCSAP missense A119G Tolerated 
2 233714978 GIGYF2 missense V1253L Tolerated 
1 240256439 FMN2 missense D344N 
 2 242072365 PASK missense I463V Tolerated 
9 35660840 
ARHGEF39; 
CCDC107 missense E170K Tolerated 
19 58864466 A1BG frameshift P56fs   
6 157527493 ARID1B in-frame 1740delD   
1 176934357 ASTN1 missense I514V Tolerated 
4 42588463 ATP8A1 missense V209I Tolerated 
7 122526234 CADPS2 in-frame 52_53insV   
8 2976054 CSMD1 missense I2099M Tolerated 
1 85029497 CTBS missense K239R Tolerated 
2 240056115 HDAC4 missense E374K Tolerated 
16 30004967 HIRIP3 missense M155L Tolerated 
1 186101518 HMCN1 missense R4430H   
2 201756818 NIF3L1 missense N24S Damaging 
22 36157297 RBFOX2 missense V306M Tolerated 
22 31957335 SFI1 missense H217R Tolerated 
9 71835968 TJP2 missense S147G Tolerated 
4 69202912 YTHDC1 in-frame 239delE   
16 72821594 ZFHX3 in-frame 
2605_2613delGGGGGGG




11 6422635 APBB1 missense R251C Damaging 
1 151288179 PI4KB missense A272G Tolerated 
3 127339941 MCM2 missense R825Q Tolerated 
22 30069405 NF2 missense R424C Tolerated 
1 14105122 PRDM2 in-frame 282_283insE   
1 14105137 PRDM2 in-frame 287_288insD   
 
 























APPENDIX G –  LIST OF MYH7 VARIANTS USED FOR PATHOGENICITY AND 
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Supplementary table 6. List of MYH7 missense variants used for pathogenicity and phenotype 
prediction based in the structural impact of the mutation. AA1 – reference amino acid; AA2: 
observed amino acid. 
 
 
Position AA1 AA2 
4 S L 
13 A T 
17 R H 
26 A V 
39 V M 
59 V I 
81 P S 
100 A T 
115 Y H 
124 T I 
142 Y H 
143 R Q 
143 R G 
143 R W 
146 K N 
148 S I 
162 Y C 
162 Y H 
169 R K 
177 T I 
178 G R 
181 G R 
185 T S 
186 V L 
187 N K 
188 T N 
190 R T 
194 Y S 
196 A T 
201 I T 
204 R H 
207 K Q 
211 P L 
214 G D 
216 L V 
219 Q E 
219 Q L 
222 Q K 
223 A T 
  377 
227 L V 
232 N S 
233 A S 
237 R W 
239 D N 
243 R C 
243 R H 
244 F L 
246 K Q 
247 F L 
249 R Q 
251 H N 
252 F L 
256 G E 
259 A E 
263 I T 
266 Y C 
270 K R 
272 R T 
281 R T 
283 Y D 
291 S F 
301 L Q 
312 F C 
320 V M 
322 S F 
325 D G 
326 A P 
328 E G 
338 V M 
349 M T 
350 Y N 
351 K E 
355 A T 
355 A T 
369 R Q 
377 G R 
377 G S 
382 D Y 
383 K N 
385 A V 
386 Y H 
388 M T 
390 L P 
  378 
390 L V 
398 G E 
403 R W 
403 R W 
403 R Q 
403 R L 
404 V L 
404 V M 
406 V M 
407 G V 
411 V I 
412 T N 
425 G R 
427 L M 
427 L M 
428 A V 
430 A E 
435 M T 
440 V M 
441 T M 
442 R H 
442 R C 
443 I T 
444 N S 
450 K E 
450 K T 
453 R C 
453 R H 
453 R L 
453 R S 
457 I T 
467 I T 
475 Q H 
475 Q K 
478 I N 
479 N S 
483 E K 
484 K N 
489 F I 
493 M L 
497 E D 
499 E K 
500 E A 
501 Y H 
  379 
501 Y C 
511 I F 
511 I T 
513 F C 
515 M R 
515 M T 
516 D E 
517 L M 
525 E K 
528 M I 
529 G D 
531 M R 
532 S P 
539 M L 
540 F L 
542 K R 
543 A T 
545 D N 
550 A V 
561 A T 
564 Q E 
576 H R 
583 A V 
584 G R 
584 G S 
587 D H 
587 D V 
591 I T 
601 L V 
601 L F 
602 N S 
606 V M 
609 Y C 
615 K N 
615 K Q 
624 Y N 
637 K E 
642 S L 
652 R K 
652 R G 
658 L V 
659 M I 
663 R H 
663 R S 
  380 
671 R C 
694 R H 
694 R C 
694 R L 
695 N S 
698 V A 
705 C W 
710 P R 
712 R L 
716 G R 
719 R Q 
719 R W 
719 R P 
721 R K 
723 R C 
723 R G 
723 R H 
728 A V 
729 A P 
730 I N 
731 P L 
733 G R 
733 G E 
734 Q E 
734 Q P 
736 I M 
736 I T 
736 I L 
738 R H 
741 G R 
741 G W 
741 G A 
742 A E 
743 E D 
763 V G 
763 V M 
764 F L 
768 G R 
771 G A 
774 E V 
778 D E 
778 D G 
778 D V 
779 E D 
  381 
782 S R 
782 S N 
783 R H 
783 R P 
787 R H 
787 R C 
793 R Q 
796 L F 
797 A T 
797 A P 
814 I S 
818 I N 
822 M L 
822 M T 
822 M V 
823 G E 
824 V I 
835 K T 
838 P L 
844 E K 
845 R K 
845 R G 
846 E Q 
846 E K 
847 K E 
849 M T 
850 A D 
850 A T 
852 M T 
858 R C 
858 R H 
858 R P 
865 K R 
866 S Y 
868 A P 
869 R H 
869 R C 
869 R G 
870 R H 
870 R C 
877 M K 
878 V A 
878 V G 
882 Q E 
  382 
889 L H 
890 Q P 
894 E G 
901 A P 
901 A G 
903 E K 
903 E G 
903 E K 
904 R H 
904 R C 
905 C F 
906 D G 
906 D G 
908 L V 
909 I M 
910 K Q 
921 E K 
924 E K 
924 E Q 
927 E K 
927 W C 
928 D G 
928 D N 
928 D V 
930 E Q 
930 E K 
931 E G 
932 M K 
935 E K 
949 E K 
949 E V 
953 D H 
955 D N 
961 L R 
964 V L 
965 E K 
970 A V 
982 M T 
1019 T N 
1027 L P 
1038 L P 
1042 K N 
1044 V L 
1044 V A 
  383 
1045 R H 
1045 R C 
1053 R Q 
1057 G D 
1057 G S 
1067 M T 
1069 D Y 
1079 R Q 
1101 G S 
1116 E K 
1128 A T 
1135 L R 
1169 A S 
1193 R C 
1193 R S 
1205 E K 
1208 D N 
1218 E Q 
1223 E Q 
1250 R W 
1263 A E 
1327 N K 
1332 A T 
1351 T M 
1352 E Q 
1356 E K 
1359 R C 
1377 T M 
1378 D H 
1379 A T 
1382 R Q 
1382 R W 
1414 L M 
1420 R Q 
1420 R W 
1426 E K 
1434 R C 
1454 A T 
1459 K N 
1465 S L 
1474 A D 
1475 R C 
1481 L P 
1488 Y C 
  384 
1490 E K 
1491 S C 
1496 E A 
1500 R W 
1500 R P 
1513 T S 
1536 E K 
1555 E G 
1555 E K 
1573 E K 
1619 E K 
1634 R C 
1637 A T 
1652 D Y 
1660 A E 
1662 R H 
1663 A P 
1677 R C 
1677 R H 
1691 V M 
1706 L P 
1712 R Q 
1712 R W 
1751 A D 
1752 E V 
1753 E K 
1760 T M 
1764 M K 
1766 A T 
1768 E K 
1769 L M 
1776 S G 
1777 A T 
1781 R H 
1792 D G 
1793 L P 
1801 E K 
1801 E G 
1808 G A 
1832 R C 
1836 S L 
1838 K R 
1845 R W 
1846 R C 
  385 
1854 T M 
1863 R Q 
1883 E K 
1901 H Q 
1901 H L 
1918 N K 
1925 R G 
1927 I F 
1929 T M 
1931 G C 
 
 
 
